paroxetine profile

Paroxetine is a selective serotonin reuptake inhibitor (SSRI) antidepressant. It was first synthesized in the 1980s by a team of scientists at SmithKline Beecham (now GlaxoSmithKline). Paroxetine is thought to work by increasing the levels of serotonin in the brain, a neurotransmitter that plays a role in mood regulation. It is used to treat major depressive disorder, generalized anxiety disorder, obsessive-compulsive disorder, panic disorder, social anxiety disorder, and premenstrual dysphoric disorder. Paroxetine has been studied extensively for its efficacy and safety in treating these conditions. It is generally well-tolerated, but common side effects include nausea, headache, and sexual dysfunction. Paroxetine is a widely prescribed medication, and it has been a subject of much research to understand its mechanisms of action, efficacy, and safety. The development of paroxetine has had a significant impact on the treatment of mental health disorders, providing a valuable therapeutic option for many patients.'

Paroxetine: A serotonin uptake inhibitor that is effective in the treatment of depression. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

paroxetine : A benzodioxole that consists of piperidine bearing 1,3-benzodioxol-5-yloxy)methyl and 4-fluorophenyl substituents at positions 3 and 4 respectively; the (3S,4R)-diastereomer. Highly potent and selective 5-HT uptake inhibitor that binds with high affinity to the serotonin transporter (Ki = 0.05 nM). Ki values are 1.1, 350 and 1100 nM for inhibition of [3H]-5-HT, [3H]-l-NA and [3H]-DA uptake respectively. Displays minimal affinity for alpha1-, alpha2- or beta-adrenoceptors, 5-HT2A, 5-HT1A, D2 or H1 receptors at concentrations below 1000 nM, however displays weak affinity for muscarinic ACh receptors (Ki = 42 nM). Antidepressant and anxiolytic in vivo. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	43815
CHEMBL ID	490
CHEBI ID	7936
SCHEMBL ID	27799
MeSH ID	M0026386

Synonym
BIDD:GT0673
AB00053704-21
BRD-K37991163-003-02-7
arotin
daparox
(-)3s,4r-paroxetine
besitram
parogen
arketis
xetanor
DIVK1C_006884
nnc-20-7051
brl-29060
fg-7051
(3s,4r)-3-[(2h-1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine
chembl490 ,
bdbm22416
(3s,4r)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine
(3s,4r)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine
paroxetina
CHEBI:7936 ,
paroxetinum
(3s-trans)-3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine
SPECTRUM_001752
PRESTWICK3_000851
BPBIO1_000949
BSPBIO_000861
SPECTRUM5_001665
paxpar
(-)-(3s,4r)-4-(p-fluorophenyl)-3-((3,4-methylenedioxy)phenoxy)methyl)piperidine
casbol
paroxetina [inn-spanish]
motivan
paroxetinum [inn-latin]
paroxetine [usan:inn:ban]
hsdb 7175
piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, (3s,4r)-
paxetil
piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, (3s-trans)-
frosinor
(-)-trans-4-(4-fluorophenyl)-3-(3,4-methylenedioxyphenoxymethyl)piperidine
brl 29060
(-)-trans-4-(p-fluorophenyl)-3-[[3,4-(methylenedioxy)phenoxy]methyl]-piperidine
paxil cr
piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-, (3s,4r)-
piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-, (3s-trans)-
(-)-paroxetine
fg 7051
(3s-trans)-3-[(1,3-benzodioxol-5-yl-oxy)methyl]-4-(4-fluorophenyl)piperidine
(-)-(3s,4r)-4-(p-fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine
AB00514724
paroxetine
61869-08-7
C07415
NCGC00025355-03
DB00715
paroxetine (tn)
D02362
paroxetine (usp/inn)
NCGC00025355-02
KBIO1_001828
KBIOSS_002232
KBIO2_007368
KBIO2_004800
KBIO2_002232
SPECPLUS_000788
NCGC00025355-07
NCGC00025355-06
NCGC00025355-05
NCGC00025355-04
HMS2090H05
NCGC00025355-08
(3s,4r)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine
NCGC00182968-01
NCGC00025355-09
bdbm50331515
paroxetine.hcl
tox21_113123
dtxsid3023425 ,
dtxcid703425
cas-61869-08-7
8pr ,
oxetine
unii-41vrh5220h
41vrh5220h ,
paroxetine [mart.]
paroxetine [vandf]
paroxetine [mi]
(3s,4r)-3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine
(-)-trans-4-(p-fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine
paroxetine [usan]
paroxetine [who-dd]
paroxetine [inn]
AKOS015888636
paroxetine hydrochloride (anhydrous or hemihydrate)
gtpl4790
SCHEMBL27799
NCGC00025355-12
tox21_113123_1
paroxetine hcl hemihydrate
AHOUBRCZNHFOSL-YOEHRIQHSA-N
AB00053704_23
AB00053704_22
AC-8185
3h-paroxetine
SBI-0051908.P002
Q408471
paroxetine hydrochloride anhydrous ep impurity e
BRD-K37991163-050-05-1
paroxetine, (+/-)-
paroxetine, trans-(+/-)-
piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, trans-
piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, (3r,4s)-rel-
unii-32q7tw8bx7
piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, trans-(+/-)-
(+/-)-paroxetine
130855-15-1
32q7tw8bx7 ,
rel-(3r,4s)-3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine
SDCCGSBI-0051908.P003
piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-,(3s,4r)-
NCGC00025355-22
CS-0083299
HY-122272
EN300-150199
(3s,4r)-3-[(1,3-dioxaindan-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine
paroxetinum (inn-latin)
n06ab05
paroxetine (mart.)
paroxetinum (latin)
paroxetina (inn-spanish)

Research Excerpts

Overview

Paroxetine (PX) is a widely used antidepressant with side effects such as weakness, dizziness, and trouble sleeping. It is an effective and well-tolerated alternative treatment for moderate-to-severe erythema of rosacea.

Excerpt	Reference	Relevance
"Paroxetine is a common pharmaceutical to treat depression and has been found to pose threats to aquatic organisms. "	( The Effects of Paroxetine on Benthic Microbial Food Web and Nitrogen Transformation in River Sediments. Chen, X; Li, Y; Niu, L; Shang, J; Wang, L; Wang, X; Zhang, H; Zhang, W, 2022)	2.52
"Paroxetine (PX) is a widely used antidepressant with side effects such as weakness, dizziness, and trouble sleeping. "	( Antidepressant and Neuroprotective Effects of 3-Hydroxy Paroxetine, an Analog of Paroxetine in Rats. Carrasco-Carballo, A; Chamorro-Arenas, D; Hernández-Arrambide, PE; Luna, F; Martínez, I; Mendieta, L; Parra, I; Sartillo-Piscil, F; Tizabi, Y, 2023)	2.6
"Paroxetine is an effective and well-tolerated alternative treatment for moderate-to-severe erythema of rosacea."	( Paroxetine is an effective treatment for refractory erythema of rosacea: Primary results from the Prospective Rosacea Refractory Erythema Randomized Clinical Trial. Gao, Q; Huang, Y; Jian, D; Li, J; Li, L; Liu, F; Shi, W; Tang, Y; Wang, B; Wang, P; Xie, H; Yang, J; Zhao, Z, 2023)	3.8
"Paroxetine is a selective serotonin reuptake inhibitor metabolized by cytochrome P450 (CYP)2D6. "	( Impact of CYP2D6 Genotype on Paroxetine Serum Concentration. Haslemo, T; Hole, K; Molden, E, 2023)	2.64
"Paroxetine (PRX) is a common antidepressant drug which widely existence in natural environment. "	( Paroxetine induced larva zebrafish cardiotoxicity through inflammation response. Gu, J; Ji, G; Song, F; Wu, L; Wu, W; Zhu, Y, 2023)	3.8
"Paroxetine (PAR) is a selective serotonin reuptake inhibitor (SSRI) antidepressant increasingly detected in surface waters worldwide. "	( Are early and young life stages of fish affected by paroxetine? A case study with Danio rerio. Ferreira, CSS; Kille, P; Oliveira, M; Venâncio, C, 2023)	2.6
"Paroxetine (PRXT) serves as a selective GRK2 inhibitor which is widely used to treat anxiety and depression for several decades."	( Paroxetine protects against bleomycin-induced pulmonary fibrosis by blocking GRK2/Smad3 pathway. Chen, G; Huang, J; Nie, H; Tang, Z; Zhao, K, 2023)	3.07
"Paroxetine is an effective drug for the treatment of depression and stress which has been commonly used in recent years. "	( Polyoxometalate/reduced graphene oxide modified pencil graphite sensor for the electrochemical trace determination of paroxetine in biological and pharmaceutical media. Oghli, AH; Soleymanpour, A, 2020)	2.21
"Paroxetine is a potent inhibitor of serotonin reuptake and is widely prescribed for the treatment of depression and other neurological disorders. "	( Recent Advances in the Synthesis of the Antidepressant Paroxetine. Domingues, HS; Patrício, P; Proença, MF; Rodrigues, AJ; Santos, J, 2021)	2.31
"Paroxetine is a valid choice in the comprehensive treatment of COPD."	( Comprehensive patterns of comorbidity: copd and depression. Aspects of treatment. Burya, LV; Kapustianskaya, AA; Kolenko, IA; Moisieieva, NV; Rumyantseva, MA; Shumeiko, OH, )	0.85
"Paroxetine is a selective serotonin reuptake inhibitor (SSRI) with several indications, one of which is for depression. "	( A Case Report of Serotonin Syndrome in a Patient on Selective Serotonin Reuptake Inhibitor (SSRI) Monotherapy. Blake, CS; Hudd, TR; Nguyen, TT; Rimola-Dejesus, Y; Zaiken, K, 2020)	2
"Paroxetine is a selective serotonin reuptake inhibitor used for the treatment of depression; this study investigated its other mechanisms by studying the expression and therefore involvement of norepinephrine transporter (NET) and serotonin transporter (5-HTT). "	( Antidepressive effect of paroxetine in a rat model: upregulating expression of serotonin and norepinephrine transporter. Li, N; Liu, D; Qin, LJ; Qiu, HM; Wang, LJ; Wu, XH; Yang, JX; Zhou, QX, 2013)	2.14
"Paroxetine is a potent selective serotonin reuptake inhibitor used for the treatment of depression and related mood disorders. "	( Determination of paroxetine in blood and urine using micellar liquid chromatography with electrochemical detection. Agrawal, N; Bose, D; Carda-Broch, S; Durgbanshi, A; Esteve-Romero, J; Marco-Peiró, S; Peris-Vicente, J, )	1.91
"Paroxetine is a selective serotonin reuptake inhibitor, and is thought to help decrease VMS by regulating body temperature via neurotransmitters."	( Paroxetine: a first for selective serotonin reuptake inhibitors - a new use: approved for vasomotor symptoms in postmenopausal women. Thacker, HL; Weber, L, 2014)	2.57
"Paroxetine is a second-generation antidepressant and a potent inhibitor of CYP2D6, the same isoenzyme involved in the metabolism of nebivolol."	( A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. Achim, M; Bocsan, C; Briciu, C; Buzoianu, A; Gheldiu, AM; Muntean, D; Neag, M; Popa, A; Vlase, L, 2014)	1.36
"Paroxetine is a selective serotonin reuptake inhibitor (SSRI) that is currently available on the market and is suspected of causing congenital malformations in babies born to mothers who take the drug during the first trimester of pregnancy. "	( Low-dose paroxetine exposure causes lifetime declines in male mouse body weight, reproduction and competitive ability as measured by the novel organismal performance assay. Galland, T; Gaukler, SM; Kandaris, KA; Liu, NM; Morrison, LC; Potts, WK; Ruff, JS; Underwood, TK; Yost, GS; Young, EL, )	1.99
"Paroxetine is a selective serotonin reuptake inhibitor (SSRI) that is clinically used for the treatment of depression in human patients. "	( Paroxetine differentially modulates LPS-induced TNFα and IL-6 production in mouse macrophages. Durairaj, H; Parameswaran, N; Steury, MD, 2015)	3.3
"Paroxetine is a selective serotonin reuptake inhibitor commonly prescribed for the treatment of depression, obsessive-compulsive disorder, panic disorder, social anxiety disorder and post-traumatic stress disorder. "	( Paroxetine in Postmortem Fluids and Tissues from Nine Aviation Accident Victims. Johnson, RD; Kemp, PM; Lewis, RJ, 2015)	3.3
"Paroxetine is a selective serotonin reuptake inhibitor (SSRI) and is used for the treatment of depression and anxiety problems, but suffers from the drawback of poor oral bioavailability (less than 50%) due to its extensive first pass metabolism. "	( Intranasal delivery of paroxetine nanoemulsion via the olfactory region for the management of depression: formulation, behavioural and biochemical estimation. Ali, J; Baboota, S; Gupta, BK; Kumar, S; Pandey, YR, 2016)	2.19
"Paroxetine is a selective serotonin re-uptake inhibitor (SSRI) available in immediate release and controlled release (CR) formulations. "	( Paroxetine: safety and tolerability issues. Ham, BJ; Han, C; Marks, DM; Masand, PS; Pae, CU; Park, MH; Patkar, AA, 2008)	3.23
"Paroxetine seems to be an effective, well-tolerated treatment for cholestatic pruritus due to gastrointestinal malignancy."	( [Paroxetine treatment of 3 cases of cholestatic pruritus due to gastrointestinal malignancy]. Nonaka, E; Suzuki, Y; Takita, N; Unotoro, J, 2010)	1.99
"Paroxetine is a dose-dependent dilator of the pupil and as expected a dose-dependent inhibitor of (+)-tramadol's O-demethylation."	( Two separate dose-dependent effects of paroxetine: mydriasis and inhibition of tramadol's O-demethylation via CYP2D6. Brosen, K; Damkier, P; Nielsen, AG; Noehr-Jensen, L; Pedersen, RS, 2010)	2.07
"Paroxetine is a drug of choice in the treatment of major depressive disorder (MDD). "	( CYP1A2 genetic polymorphisms are associated with treatment response to the antidepressant paroxetine. Chan, HW; Fang, CK; Hsiao, CF; Hsiao, MC; Hsu, YT; Kuo, HW; Lin, KM; Liu, CY; Liu, SC; Liu, YL; Lu, SC; Shen, WW; Tang, HS; Tian, JN; Tsai, IJ; Tsou, HH; Wu, CS, 2010)	2.02
"Paroxetine is a widely used antidepressant in clinic. "	( Paroxetine up-regulates neurogenesis in hippocampus-derived neural stem cell from fetal rats. Chen, YC; Fan, J; Peng, ZW; Tan, QR; Wang, HN; Wang, Y; Xue, F; Zhang, LY; Zhang, RG, 2013)	3.28
"Paroxetine CR is an effective and well-tolerated antidepressant exhibiting symptomatic improvement as early as week 1. "	( Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression. Dubé, EM; Golden, RN; McSorley, P; Nemeroff, CB; Pitts, CD, 2002)	1.99
"Paroxetine is a non-tricyclic serotonin reuptake inhibitor prescribed for the treatment of depression."	( [Increased perioperative blood loss during treatment with paroxetine]. Gouma, DJ; Koopman, MM; Levi, MM; Sewnath, ME; van Hillegersberg, R, 2002)	1.28
"Paroxetine is an effective long-term treatment for social anxiety disorder."	( Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study. Hair, T; Kumar, R; Stein, DJ; Versiani, M, 2002)	2.14
"Paroxetine is a potent selective serotonin reuptake inhibitor (SSRI) with indications for the treatment of depression, obsessive- compulsive disorder, panic disorder and social phobia. "	( Use of paroxetine for the treatment of depression and anxiety disorders in the elderly: a review. Bourin, M, 2003)	2.22
"Paroxetine is an extensively used SSRI that has been shown to impair erectile function in patients, to induce erectile dysfunction and to inhibit nitric oxide synthase (NOS) activity and NO production in animal models."	( Vardenafil reverses erectile dysfunction induced by paroxetine in rats. Angulo, J; Bischoff, E; Cuevas, P; Gabancho, S; Sáenz de Tejada, I, 2003)	1.29
"Paroxetine is a well-known antidepressant, used worldwide in therapeutics. "	( Synthesis of the major metabolites of paroxetine. de la Torre, R; Joglar, J; Roura, L; Segura, M, 2003)	2.03
"Paroxetine is a first-line antidepressant and has been reported to decrease plasma NO(x), theoretically suggesting a potential deleterious effect on the cardiovascular system."	( Paroxetine-induced increase in metabolic end products of nitric oxide. Archer, SL; Baker, GB; Lara, N; Le Mellédo, JM, 2003)	2.48
"Paroxetine is a selective serotonin re-uptake inhibitor that has been found effective in the treatment of major depression as well as a range of anxiety disorders."	( Paroxetine in the treatment of post-traumatic stress disorder: pooled analysis of placebo-controlled studies. Beebe, K; Davidson, J; Seedat, S; Stein, DJ, 2003)	2.48
"Paroxetine is a potent and selective serotonin reuptake inhibitor (SSRI) with some neuropharmacologic properties unique among this class of compounds. "	( Neuropharmacology of paroxetine. Nemeroff, CB; Owens, MJ, 2003)	2.08
"Paroxetine is a particularly well-studied psychopharmacologic agent in this regard."	( In vivo neuroimaging correlates of the efficacy of paroxetine in the treatment of mood and anxiety disorders. Kilts, C, 2003)	1.29
"Paroxetine is a widely studied selective serotonin reuptake inhibitor (SSRI) with evidence for efficacy and safety that is supported by a large body of published literature."	( Paroxetine treatment of major depressive disorder. Keller, MB, 2003)	2.48
"Paroxetine is a first-line antidepressant and has been reported to decrease plasma NOx, theoretically suggesting a potential deleterious effect on the cardiovascular system."	( Paroxetine-induced increase in metabolic end products of nitric oxide. Archer, SL; Baker, GB; Lara, N; Le Mellédo, JM, 2003)	2.48
"Paroxetine is a selective serotonin re-uptake inhibitor useful in the treatment of a wide range of psychiatric disorders. "	( Paroxetine in the treatment of generalised anxiety disorder. Bellew, K; Rickels, K; Rynn, MA; Snyderman, SH, 2004)	3.21
"Paroxetine is an effective and generally well-tolerated treatment for obsessive-compulsive disorder in children and adolescents."	( Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. Carpenter, DJ; Emslie, G; Gardiner, C; Geller, DA; Machin, A; Murphy, T; Perera, P; Wagner, KD; Wetherhold, E, 2004)	3.21
"Paroxetine is an effective, generally well-tolerated treatment for pediatric social anxiety disorder."	( A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Berard, R; Carpenter, DJ; Davy, K; Gee, M; Machin, A; Perera, P; Stein, MB; Wagner, KD; Wetherhold, E, 2004)	2
"Paroxetine CR is an effective and well-tolerated treatment for panic disorder. "	( Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder. Burnham, DB; Iyengar, MK; Perera, P; Sheehan, DV, 2005)	2.03
"Paroxetine is an example of an selective serotonin reuptake inhibitor agent, which has been well studied in the treatment of panic disorder and is efficacious and well-tolerated."	( Paroxetine in panic disorder: clinical management and long-term follow-up. Dannon, PN; Iancu, I; Kotler, M; Lowengrub, K, 2004)	2.49
"Paroxetine is a very potent inhibitor of CYP2D6."	( Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. Brøsen, K; Enggaard, TP; Laugesen, S; Pedersen, RS; Sindrup, SH, 2005)	2.49
"Paroxetine is an SSRI approved by the FDA and Health Canada for the treatment of a variety of psychiatric conditions."	( An evaluation of paroxetine in generalised social anxiety disorder. Bennett, M; Mancini, C; Patterson, B; Van Ameringen, M, 2005)	1.39
"Paroxetine is an effective treatment for hot flashes in women with or without a prior breast cancer."	( Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. Bunnell, C; Cullen, J; Gallagher, A; Gehan, E; Greep, N; Hayes, DF; Henry-Tilman, R; Isaacs, C; Osborne, M; Slack, R; Stearns, V; Ullmer, L, 2005)	3.21
"Paroxetine is a potent selective serotonin reuptake inhibitor with antidepressant and anxiolytic activity that is effective in the treatment of generalized anxiety disorder (GAD), improving the core symptoms of anxiety, worry, and tension. "	( Remission of generalized anxiety disorder: a review of the paroxetine clinical trials database. Duff, D; Iyengar, M; Rickels, K; Rynn, M, 2006)	2.02
"Paroxetine (Paxil) is a selective serotonin reuptake inhibitor (SSRI) and anxiolytic that is approved to treat numerous mood disorders. "	( Rare case of serotonin syndrome with therapeutic doses of paroxetine. Anandacoomarswamy, D; Godkar, D; Niranjan, S; Paruchuri, P; Sheth, K, )	1.82
"Paroxetine is believed to be a substrate of CYP2D6. "	( Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects. Inoue, Y; Kaneko, S; Niioka, T; Saito, M; Sato, Y; Tsuchimine, S; Yasui-Furukori, N, 2007)	2.04
"Paroxetine is a selective serotonin reuptake inhibitor (SSRI) with antidepressant and anxiolytic properties. "	( Paroxetine: current status in psychiatry. Pae, CU; Patkar, AA, 2007)	3.23
"Paroxetine (Paxil) is a widely prescribed antidepressant of the selective serotonin reuptake inhibitor (SSRI) class for which multiple cutaneous adverse effects have been reported, including urticaria, ecchymoses, vasculitis, and pruritus. "	( Urticarial vasculitis secondary to paroxetine. Cusack, CA; Ko, C; Welsh, JP, )	1.85
"Paroxetine is a selective serotonin reuptake inhibitor which stimulates antidiuretic hormone (ADH) release and may cause the syndrome of inappropriate ADH secretion with consecutive hyponatremia. "	( Fatal hyponatremia and other metabolic disturbances associated with psychotropic drug polypharmacy. Alfirevic, Z; Degoricija, V; Vucicevic, Z; Vukicevic-Badouin, D, 2007)	1.78
"Paroxetine is a widely used antidepressant that has received attention regarding suicide risk in younger patients."	( Paroxetine. Helmeste, D; Tang, SW, 2008)	3.23
"Paroxetine is a serotonin re-uptake inhibitor with good selectivity and no significant active metabolites. "	( Paroxetine. Helmeste, D; Tang, SW, 2008)	3.23
"Paroxetine is an effective antidepressant drug and potent serotonin (5-HT) uptake inhibitor. "	( Synthesis and characterization of an aryl-azidoparoxetine. A novel photo-affinity probe for serotonin-transporter. Bakish, D; Chudzik, J; Hrdina, PD; McCarthy, D; Ravindran, A, 1995)	1.99
"Paroxetine is a phenylpiperidine compound which is a selective serotonin reuptake inhibitor (SSRI). "	( Multicenter double blind study of paroxetine and amitriptyline in elderly depressed inpatients. Fartacek, R; Geretsegger, C; Heim, M; Mair, M; Platz, T; Stuppaeck, CH, 1995)	2.01
"[3H]Paroxetine is a more reliable ligand for studying the serotonin (5-HT) transporter complex than [3H]imipramine. "	( Binding of [3H]paroxetine to platelets of depressed patients: seasonal differences and effects of diagnostic classification. Cosyns, P; D'Hondt, P; Gommeren, W; Leysen, JE; Maes, M; Scharpé, S, 1994)	1.2
"Paroxetine is a trans-isomeric phenylpiperidine with antidepressant properties induced by selective inhibition of the neuronal high affinity uptake of serotonin. "	( [Paroxetine: pharmacokinetics and pharmacodynamics]. Hiemke, C, 1994)	2.64
"Paroxetine is a novel phenylpiperidine compound that is a potent and selective serotonin reuptake inhibitor. "	( Paroxetine: an overview of the efficacy and safety of a new selective serotonin reuptake inhibitor in the treatment of depression. Nemeroff, CB, 1993)	3.17
"Paroxetine is a novel phenylpiperidine antidepressant agent that acts as a potent and selective inhibitor of serotonin reuptake. "	( A double-blind, randomized, fluoxetine-controlled, multicenter study of paroxetine in the treatment of depression. Tignol, J, 1993)	1.96
"Paroxetine is a selective serotonin reuptake inhibitor (SSRI) recently approved for the treatment of major depression. "	( Paroxetine: a selective serotonin reuptake inhibiting antidepressant. Caley, CF; Weber, SS, 1993)	3.17
"Paroxetine is a selective serotonin reuptake inhibitor effective in a once-daily administration regimen in the treatment of depression. "	( Paroxetine. A review of its pharmacology, therapeutic use in depression and therapeutic potential in diabetic neuropathy. Holliday, SM; Plosker, GL, )	3.02
"Paroxetine is a selective and potent inhibitor of 5-hydroxytryptamine (5-HT) uptake into serotonergic neurones. "	( [3H]paroxetine binding in rat frontal cortex strongly correlates with [3H]5-HT uptake: effect of administration of various antidepressant treatments. Buckett, WR; Cheetham, SC; Heal, DJ; Slater, NA; Viggers, JA, 1993)	2.29
"Paroxetine is a new compound in the group of the selective serotonin-reuptake inhibitors. "	( Double-blind multicenter study of paroxetine and amitriptyline in depressed inpatients. Berzewski, H; Eckmann, F; Gonzalves, N; Kissling, W; Knorr, W; Magyar, I; Möller, HJ; Ressler, P; Rudolf, GA; Steinmeyer, EM, 1993)	2.01
"Paroxetine is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. "	( Adverse events after the abrupt discontinuation of paroxetine. Dominguez, RA; Goodnick, PJ, )	1.83
"Paroxetine is a potent inhibitor of serotonin re-uptake. "	( Paroxetine in the treatment of Chinese patients with depressive episode: a double-blind randomized comparison with imipramine. Chan, CH; Chiu, HJ; Hong, CJ, 1996)	3.18
"Paroxetine is a selective serotonergic reuptake inhibitor (SSRI)."	( Paroxetine and galactorrhea. Bizouard, P; Bonin, B; Sechter, D; Vandel, P, 1997)	2.46
"Paroxetine is a selective and potent serotonin reuptake inhibitor and its efficacy for the treatment of depression has been proven. "	( Analysis of sleep EEG microstructure in subchronic paroxetine treatment of healthy subjects. Benkert, O; Kögel, P; Mann, K; Röschke, J; Rossbach, W; Schlösser, R; Wagner, P, 1997)	1.99
"Paroxetine is a frequently used antidepressant and a potent inhibitor of the CYP2D6 isozyme in vitro (inhibition constant [Ki] = 0.15 micromol/L). "	( Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo. Herrmann, N; Kalow, W; Naranjo, CA; Ozdemir, V; Reed, K; Sellers, EM, 1997)	3.18
"Paroxetine is an effective and well-tolerated short-term treatment of panic disorder. "	( Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Ballenger, JC; Bushnell, W; Gergel, IP; Steiner, M; Wheadon, DE, 1998)	1.99
"Paroxetine is a potent and selective inhibitor of the neuronal reuptake of serotonin (5-hydroxytryptamine; 5-HT), which was previously reviewed as an antidepressant in Drugs in 1991. "	( Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders. Benfield, P; Gunasekara, NS; Noble, S, 1998)	3.19
"Paroxetine is an effective treatment for patients with generalized social phobia. "	( Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. Bushnell, W; Gergel, I; Liebowitz, MR; Lydiard, RB; Pitts, CD; Stein, MB, 1998)	3.19
"Paroxetine (Paxil) is a selective serotonin reuptake inhibitor, one of a new class of antidepressants used in the treatment of obsessive-compulsive disorder, panic disorder, and depression. "	( Distribution of paroxetine in three postmortem cases. Vermeulen, T, 1998)	2.09
"Paroxetine is a selective and potent serotonin reuptake inhibitor with reported antidepressant properties. "	( Conventional and spectral power analysis of all-night sleep EEG after subchronic treatment with paroxetine in healthy male volunteers. Benkert, O; Röschke, J; Rossbach, W; Schlösser, R, 1998)	1.96
"Paroxetine is a selective serotonin reuptake inhibitor with demonstrated efficacy in treating obsessive-compulsive disorder (OCD) in adults. "	( Paroxetine open-label treatment of pediatric outpatients with obsessive-compulsive disorder. Carroll, E; Fitzgerald, KD; Rosenberg, DR; Stewart, CM; Tawile, V, 1999)	3.19
"Paroxetine is an effective, well-tolerated treatment for patients with social phobia."	( Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group. Baldwin, D; Bobes, J; Faure, M; Scharwächter, I; Stein, DJ, 1999)	3.19
"Paroxetine hydrochloride is a promising new treatment for hot flashes in breast cancer survivors, and warrants further evaluation in a double-blind randomized placebo-controlled trial."	( A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Crawford, J; Ellis, MJ; Hanfelt, JJ; Hayes, DF; Isaacs, C; Kramer, R; Lawrence, W; Rowland, J; Stearns, V, 2000)	2.02
"Paroxetine is a potent selective inhibitor of serotonin reuptake."	( A depressed myocardium. MacIver, DH; Partridge, SJ; Solanki, T, 2000)	1.03
"Paroxetine is a selective serotonin reuptake inhibitor (SSRI) with proven efficacy in the treatment of depression, panic disorder and obsessive-compulsive disorder. "	( Clinical experience with paroxetine in social anxiety disorder. Baldwin, DS, 2000)	2.05
"Paroxetine is a safe and effective drug to treat depression in PD."	( Tolerability of paroxetine in Parkinson's disease: a prospective study. Antonini, A; Canesi, M; Mariani, CB; Pezzoli, G; Tesei, S; Zecchinelli, A, 2000)	1.37
"Paroxetine is a potent and selective serotonin reuptake inhibitor (SSRI) with currently approved indications for the treatment of depression, obsessive-compulsive disorder, panic disorder and social phobia. "	( Paroxetine: a review. Bourin, M; Chue, P; Guillon, Y, 2001)	3.2
"Paroxetine, 20 mg/day, is an effective and safe treatment for patients with generalized social anxiety disorder and significantly improves social anxiety, avoidance of social interactions, social disability, and overall clinical condition. "	( A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. Carpenter, D; Liebowitz, MR; Oakes, R; Pitts, CD; Stein, MB; Tancer, M, 2002)	2.01
"Paroxetine is a selective serotonin reuptake inhibitor (SSRI), with antidepressant and anxiolytic activity. "	( Paroxetine: an update of its use in psychiatric disorders in adults. Cheer, SM; Goa, KL; Matheson, AJ; Ormrod, D; Wagstaff, AJ, 2002)	3.2
"Paroxetine is a strong CYP2D6 inhibitor, and these results confirm previous studies showing an involvement of CYP2D6 in methadone metabolism with a stereoselectivity toward the (R)-enantiomer."	( Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers. Baumann, P; Begré, S; Cosendai-Savary, L; Eap, CB; Golay, KP; Jaquet-Rochat, S; Kosel, M; Ladewig, D; von Bardeleben, U, 2002)	2.48
"Paroxetine is a selective serotonin reuptake inhibitor (SSRI), with antidepressant and anxiolytic activity. "	( Spotlight on paroxetine in psychiatric disorders in adults. Cheer, SM; Goa, KL; Matheson, AJ; Ormrod, D; Wagstaff, AJ, 2002)	2.13
"Paroxetine is a selective serotonin reuptake inhibitor possessing anti-depressant activity. "	( The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes. Bloomer, JC; Haddock, RE; Lennard, MS; Tucker, GT; Woods, FR, 1992)	1.98
"Paroxetine was found to be an effective antidepressant drug when compared to placebo."	( A double-blind comparison of paroxetine and placebo in the treatment of depressed outpatients. Claghorn, J, 1992)	1.3
"Paroxetine is a new selective serotonin reuptake inhibitor which has been extensively evaluated as an antidepressant in clinical trials and a large computerized safety database has been accumulated. "	( Paroxetine: an overview of dosage, tolerability, and safety. Jenner, PN, 1992)	3.17
"Paroxetine is a selective serotonin reuptake inhibitor that is now licensed in various countries in Europe. "	( The advantages of paroxetine in different subgroups of depression. Montgomery, SA, 1992)	2.06
"Paroxetine is a potent and selective serotonin reuptake inhibitor (SSRI). "	( Paroxetine versus placebo: a double-blind comparison in depressed patients. Claghorn, JL; Dunbar, GC; Kiev, A; Rickels, K; Smith, WT, 1992)	3.17
"Paroxetine is an investigational antidepressant that acts through selective inhibition of serotonin reuptake at the synapse. "	( A double-blind, placebo-controlled study of paroxetine in depressed outpatients. Kiev, A, 1992)	1.99
"Paroxetine is a novel phenylpiperidine compound that acts as a selective serotonin reuptake inhibitor (SSRI). "	( An overview of paroxetine. Boyer, WF; Feighner, JP, 1992)	2.08
"Paroxetine is an investigational antidepressant that appears to act by selectively blocking neuronal serotonin uptake."	( The safety and efficacy of paroxetine compared with placebo in a double-blind trial of depressed outpatients. Claghorn, JL, 1992)	1.3
"Paroxetine is a phenylpiperidine compound that selectively inhibits neuronal serotonin uptake in man. "	( A placebo-controlled trial of paroxetine in the treatment of major depression. Glaudin, V; Smith, WT, 1992)	2.01
"Paroxetine is a novel antidepressant that selectively inhibits neuronal reuptake of serotonin. "	( A 6-week, double-blind trial of paroxetine, imipramine, and placebo in depressed outpatients. Fabre, LF, 1992)	2.01
"Paroxetine is a selective serotonin reuptake inhibitor with significant antidepressant properties. "	( Paroxetine in the treatment of depression: a comparison with imipramine and placebo. Boyer, WF; Feighner, JP, 1992)	3.17
"Paroxetine is a selective serotonin reuptake inhibitor which is being developed as an antidepressant. "	( Paroxetine in major depression: a double-blind trial with imipramine and placebo. Cohn, JB; Wilcox, CS, 1992)	3.17
"Paroxetine is an antidepressant that acts through selective inhibition of serotonin reuptake."	( Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression. Cohn, CK; Cohn, JB; Dunner, DL; Feighner, JP; Fieve, RR; Halikas, JP; Hartford, JT; Hearst, ED; Settle, EC; Walshe, T, 1992)	1.26
"Paroxetine is a highly potent and selective inhibitor of serotonin reuptake, being more potent in vitro than fluoxetine, fluvoxamine, and sertraline. "	( The pharmacologic profile of paroxetine, a new selective serotonin reuptake inhibitor. Johnson, AM; Tulloch, IF, 1992)	2.02
"Paroxetine is a potent inhibitor of sparteine oxidation by CYP2D6 in vivo."	( The relationship between paroxetine and the sparteine oxidation polymorphism. Allen, A; Allen, GD; Brøsen, K; Cooper, SM; Gram, LF; Hallas, J; Mellows, G; Sindrup, SH; Skjelbo, E; Tasker, TC, 1992)	1.31
"Paroxetine is a potent and selective inhibitor of the neuronal reuptake of serotonin, thereby facilitating serotoninergic transmission; this action appears to account for the antidepressant activity observed with this drug. "	( Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Clissold, SP; Dechant, KL, 1991)	3.17
"Paroxetine is a novel antidepressant drug with selective serotonin (5-HT) reuptake inhibitory properties. "	( Sleep laboratory studies on the single-dose effects of serotonin reuptake inhibitors paroxetine and fluoxetine on human sleep and awakening qualities. Anderer, P; Frey, R; Grünberger, J; Krupka, M; Saletu, B; See, WR, 1991)	1.95
"Paroxetine is a selective serotonin uptake inhibitor, which is being investigated as an antidepressant. "	( Paroxetine in the treatment of depression: a comparison with imipramine and placebo. Boyer, WF; Feighner, JP, 1989)	3.16
"Paroxetine is a selective and potent inhibitor of 5-hydroxytryptamine uptake into serotonergic neurons. "	( Characterization of [3H]paroxetine binding to rat cortical membranes. Claustre, Y; Graham, D; Habert, E; Langer, SZ; Tahraoui, L, 1985)	2.02
"[3H]Paroxetine is a highly selective ligand for the 5-hydroxytryptamine transporter complex and the specific binding of this ligand to membrane fractions from cerebral cortex or hippocampus was studied in rats treated with specific inhibitors of the uptake of 5-hydroxytryptamine and monoamine oxidase inhibitors. "	( Effect of chronic treatment with selective monoamine oxidase inhibitors and specific 5-hydroxytryptamine uptake inhibitors on [3H]paroxetine binding to cerebral cortical membranes of the rat. Graham, D; Langer, SZ; Tahraoui, L, 1987)	1.04
"Paroxetine was shown to be a potent (Ki = 1.1 nM) and specific inhibitor of [3H]-5-hydroxytryptamine (5-HT) uptake into rat cortical and hypothalamic synaptosomes in vitro. "	( Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Johnson, AM; Nelson, DR; Thomas, DR, 1987)	1.98
"Paroxetine is a new antidepressant drug. "	( Paroxetine in the treatment of depression. A double-blind multicenter study versus mianserin. Mertens, C; Pintens, H, 1988)	3.16
"Paroxetine is a novel and selective neuronal 5-hydroxy-tryptamine uptake inhibitor with anti-depressant activity. "	( Immunological studies on paroxetine, a novel anti-depressant drug. Dewdney, JM; Edwards, RG; Henderson, DC; Weston, BJ, 1988)	2.02
"Paroxetine is a potent and selective inhibitor of serotonin uptake into neurons. "	( Autoradiographic localization of 3H-paroxetine-labeled serotonin uptake sites in rat brain. De Souza, EB; Kuyatt, BL, 1987)	1.99
"Paroxetine (PAR) is a potent and selective inhibitor of serotonin uptake, and it has been demonstrated that 3H-PAR is a favorable candidate for labeling of the serotonin transport system. "	( [Characteristics of 3H-paroxetine-labeled serotonin uptake sites in rat brain]. Yoshida, Y, 1988)	2.03
"Paroxetine is a new antidepressant drug with potent serotonin (5HT) uptake inhibitory properties. "	( Paroxetine in the treatment of depression--a randomized comparison with amitriptyline. Laursen, AL; le Fèvre Honoré, P; Mikkelsen, PL; Rasmussen, S, 1985)	3.15

Effects

Paroxetine has a number of advantages as an antidepressant. Of particular interest is its ability to improve sleep early in treatment without daytime sedation or interference with psychomotor function.

Paroxetine has been approved for the treatment of major depressive disorder (MDD), obsessive-compulsive disorder, panic disorder (PD), generalised anxiety disorder, post traumatic stress disorder (PTSD) and social anxiety disorder (SAD) in adults. It is of high drug safety and has no significant effect on urine levels of neopterine in MDD patients.

Excerpt	Reference	Relevance
"Paroxetine probably has a NOS inhibitory activity either on nNOS or eNOS, in contrast to sertraline and fluoxetine."	( Paroxetine inhibited the relaxations induced by EFS in mice corpus cavernosum: is it a NOS inhibition? Kadioglu, M; Kalyoncu, NI; Kesim, M; Muci, E; Ozyavuz, R; Yaris, E, 2010)	2.52
"Paroxetine has a beneficial effect on measures of insulin sensitivity and may improve glycemic control. "	( Quality of life and metabolic status in mildly depressed women with type 2 diabetes treated with paroxetine: a single-blind randomised placebo controlled trial. Eriksson, JG; Paile-Hyvärinen, M; Wahlbeck, K, 2003)	1.98
"Paroxetine has a number of advantages as an antidepressant; of particular interest is its ability to improve sleep early in treatment without daytime sedation or interference with psychomotor function."	( The advantages of paroxetine in different subgroups of depression. Montgomery, SA, 1992)	1.34
"Paroxetine therapy has been used for treatment of patients with depression and Parkinson's disease (dPD) in many clinical studies, but, the effects of paroxetine in dPD patients are not completely understood. "	( The effects of paroxetine therapy on depressive symptom and motor function in the treatment of depression with Parkinson's disease: A meta-analysis. Chen, ML; Gou, L; Jiang, DQ; Jiang, LL; Mo, Y; Wang, Y; Wu, YL; Zang, QM, 2023)	2.71
"Paroxetine therapy has clinical benefits for improvement of depressive symptom and motor function in dPD patients, moreover, it is of high drug safety. "	( The effects of paroxetine therapy on depressive symptom and motor function in the treatment of depression with Parkinson's disease: A meta-analysis. Chen, ML; Gou, L; Jiang, DQ; Jiang, LL; Mo, Y; Wang, Y; Wu, YL; Zang, QM, 2023)	2.71
"Paroxetine has been demonstrated to undergo gestation-related reductions in plasma concentrations, to an extent which is dictated by the polymorphic state of CYP 2D6. "	( Precision dosing-based optimisation of paroxetine during pregnancy for poor and ultrarapid CYP2D6 metabolisers: a virtual clinical trial pharmacokinetics study. Almurjan, A; Badhan, RKS; Macfarlane, H, 2020)	2.27
"Paroxetine treatment has no significant effect on urine levels of neopterine in MDD patients."	( Urinary neopterine levels in patients with major depressive disorder: alterations after treatment with paroxetine and comparison with healthy controls. Atmaca, M; Güngör, BB; Özdel, K; Özen, NE; Taymur, I, 2015)	1.35
"Paroxetine has been approved for the treatment of major depressive disorder (MDD), obsessive-compulsive disorder, panic disorder (PD), generalised anxiety disorder, post traumatic stress disorder (PTSD), and social anxiety disorder (SAD) in adults, whereas paroxetine CR is approved for the treatment of MDD, SAD, PD and premenstrual dysphoric disorder in adults."	( Paroxetine: safety and tolerability issues. Ham, BJ; Han, C; Marks, DM; Masand, PS; Pae, CU; Park, MH; Patkar, AA, 2008)	2.51
"Paroxetine has been reported to be useful for management of stuttering symptoms, but only a few reports have examined its effects. "	( Investigating the efficacy of paroxetine in developmental stuttering. Battaglini, PP; Borelli, M; Busan, P; Evaristo, P; Monti, F; Pelamatti, G, )	1.86
"Paroxetine probably has a NOS inhibitory activity either on nNOS or eNOS, in contrast to sertraline and fluoxetine."	( Paroxetine inhibited the relaxations induced by EFS in mice corpus cavernosum: is it a NOS inhibition? Kadioglu, M; Kalyoncu, NI; Kesim, M; Muci, E; Ozyavuz, R; Yaris, E, 2010)	2.52
"Paroxetine has become an effectiveness treatment in anxiety disorders in adults. "	( [Paroxetine treatment for children and adolescents with anxiety disorders]. Blasco-Fontecilla, H; Calvo Ablanedo, R; Krauskopf Poblete, V; Madoz-Gúrpide, A; San Sebastián Cabasés, J, )	2.48
"Paroxetine has demonstrated efficacy in depression and anxiety disorders, including generalized anxiety disorder (GAD). "	( Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. Bryson, H; Hewett, K; Iyengar, MK; Jokinen, RH; Lepola, UM; Nordera, G; Stocchi, F, 2003)	2.05
"Paroxetine has a beneficial effect on measures of insulin sensitivity and may improve glycemic control. "	( Quality of life and metabolic status in mildly depressed women with type 2 diabetes treated with paroxetine: a single-blind randomised placebo controlled trial. Eriksson, JG; Paile-Hyvärinen, M; Wahlbeck, K, 2003)	1.98
"Paroxetine 20 mg/day has no psychomotor or behavioural toxicity and has no negative impact on BRT. "	( A placebo controlled investigation into the effects of paroxetine and mirtazapine on measures related to car driving performance. Hindmarch, I; Johnsen, S; Meadows, R; Ridout, F, 2003)	2.01
"Paroxetine has not been compared with cognitive therapy."	( Paroxetine: new indication. In social phobia: minimal assessment. , 2003)	2.48
"Paroxetine also has been shown to be a potent and selective inhibitor of the human serotonin transporter (SERT) and has recently been demonstrated to have moderate affinity for the norepinephrine transporter (NET)."	( Neuropharmacology of paroxetine. Nemeroff, CB; Owens, MJ, 2003)	1.36
"Paroxetine also has been shown to improve quality of life, and to improve sleep disturbances, which can be remarkably disabling, in patients with PTSD."	( Treatment of posttraumatic stress disorder: the impact of paroxetine. Davidson, JR, 2003)	1.28
"Paroxetine has not been reliably compared with benzodiazepines, psychotherapy or buspirone in patients with generalised anxiety."	( Paroxetine: new indication. In generalised anxiety: uncertain efficacy. , 2003)	2.48
"Paroxetine has been reported to weakly inhibit norepinephrine reuptake and nitric oxide production in addition to increasing serotonergic activity, potentially compounding the vasoconstrictive response."	( Transient ischemic attack reported with paroxetine use. Manos, GH; Wechsler, SM, 2004)	1.31
"Paroxetine has demonstrated efficacy in treating patients to remission across the range of anxiety disorders studied. "	( Remission rates in patients with anxiety disorders treated with paroxetine. Ballenger, JC, 2004)	2
"Paroxetine in particular has been speculated to increase the risk of breast cancer. "	( Breast cancer risk in a large cohort of female antidepressant medication users. Chen, W; Enger, SM; Haque, R; Petitti, DB, 2005)	1.77
"Paroxetine treatment has the potential to cause weight gain and sexual dysfunction, primarily anorgasmia and ejaculatory dysfunction for the long term."	( Paroxetine in panic disorder: clinical management and long-term follow-up. Dannon, PN; Iancu, I; Kotler, M; Lowengrub, K, 2004)	2.49
"Paroxetine has been the most studied agent in social anxiety disorder and has been shown to be effective in short-term, fixed- and flexible-dose placebo-controlled trials, as well as in long-term treatment."	( An evaluation of paroxetine in generalised social anxiety disorder. Bennett, M; Mancini, C; Patterson, B; Van Ameringen, M, 2005)	1.39
"Paroxetine has antihypertensive properties during periods of psychological stress in psychiatrically healthy subjects with a history of CAD, and so should be evaluated for potential cardio-protective qualities."	( Effects of paroxetine on cardiovascular response to mental stress in subjects with a history of coronary artery disease and no psychiatric diagnoses. Carson, SW; Davidson, C; Garbutt, JC; Golding, M; Guzzo, J; Hoyler, S; Kotlyar, M; Lazarus, C; Sontz, E, 2005)	2.16
"Paroxetine has been associated with increased rates of suicidality in adolescents treated in antidepressant clinical trials. "	( Brief report: paroxetine in younger and adult individuals at high risk for suicide. Bauer, MS; Kogan, JN; Marangell, LB; Sachs, G; Thase, ME; Wisniewski, SR, 2006)	2.14
"Paroxetine has been used widely for treatment of depressed patients with malignancies."	( [A case of hyponatremia associated with combination therapy of systemic chemotherapy and paroxetine]. Fujimoto, K; Koizumi, T; Komatsu, Y; Kubo, K; Saegusa, T; Urushihata, K; Yasuo, M, 2006)	1.28
"Paroxetine has been compared with the standard tricyclic antidepressants in a range of studies, and the efficacy and tolerability data from these studies have been collected together in the worldwide database on paroxetine."	( [Clinical effects of serotonin reuptake inhibitors--a review]. Feighner, JP, 1994)	1.01
"Paroxetine has also shown potential in the symptomatic treatment of diabetic neuropathy; however, further clinical experience is needed to confirm this preliminary result."	( Paroxetine. A review of its pharmacology, therapeutic use in depression and therapeutic potential in diabetic neuropathy. Holliday, SM; Plosker, GL, )	2.3
"Paroxetine has been shown to be effective in panic disorder in three 10- to 12-week studies. "	( Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators. Judge, R; Lecrubier, Y, 1997)	2.05
"Paroxetine has also been studied in several other disorders with a presumed serotonergic component, primarily obsessive compulsive disorder (OCD) and panic disorder."	( Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders. Benfield, P; Gunasekara, NS; Noble, S, 1998)	2.46
"Paroxetine has demonstrated efficacy in major depression in both young and elderly patients, with an improved tolerability profile over conventional antidepressants."	( Paroxetine: a review of clinical experience. Dunner, D; Kumar, R, 1998)	2.46
"Paroxetine has little affinity for catecholaminergic, dopaminergic or histaminergic systems and by comparison with tricyclic antidepressants (TCAs) has, therefore, a reduced propensity to cause central and autonomic side effects."	( Paroxetine: a review. Bourin, M; Chue, P; Guillon, Y, 2001)	2.47
"Paroxetine has repeatedly been shown to be effective in the treatment of panic disorder (PD) in adults, and, according to previous case observations, it may be useful in treating children and adolescents with PD as well. "	( Paroxetine in child and adolescent outpatients with panic disorder. Masi, G; Mata, B; Millepiedi, S; Mucci, M; Perugi, G; Toni, C, 2001)	3.2
"Paroxetine has been characterized as a highly potent and selective 5-hydroxytryptamine (serotonin) reuptake inhibitor. "	( Paroxetine: a pharmacological review. Johnson, AM, 1992)	3.17
"Paroxetine has been shown to be of similar efficacy to the tricyclic antidepressants but has lower cardiovascular toxicity in animal models and has no effects on heart rate, blood pressure or the electrocardiogram in healthy men receiving single 20-40 mg doses."	( Cardiovascular effects of antidepressants: studies of paroxetine in healthy men and depressed patients. Lewis, Y; Warrington, SJ, 1992)	1.25
"Paroxetine has a number of advantages as an antidepressant; of particular interest is its ability to improve sleep early in treatment without daytime sedation or interference with psychomotor function."	( The advantages of paroxetine in different subgroups of depression. Montgomery, SA, 1992)	1.34
"Paroxetine has been found to be superior to placebo and equivalent to amitriptyline, imipramine, clomipramine, and doxepin in treatment of depression."	( Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors. Grimsley, SR; Jann, MW, 1992)	2.45
"Paroxetine has shown some preliminary promise in the treatment of depressive illness resistant to tricyclic antidepressant therapy but further studies are required before any conclusions can be drawn."	( Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Clissold, SP; Dechant, KL, 1991)	2.45

Actions

Paroxetine failed to suppress the EEG arousal responses induced not only by auditory stimulation but also by electrical stimulation of the mesencephalic reticular formation, centromedian thalamus and posterior hypothalamus. The drug did produce significantly greater improvement than placebo for patients whose illness had lasted more than 1 year.

Excerpt	Reference	Relevance
"Paroxetine can inhibit pyroptosis and reduce osteoclast formation via inhibiting the NF-κB signaling pathway, suggesting that it may have therapeutic effects in patients with OA."	( Paroxetine Attenuates Chondrocyte Pyroptosis and Inhibits Osteoclast Formation by Inhibiting NF-κB Pathway Activation to Delay Osteoarthritis Progression. Gao, N; Gong, Y; Hong, H; Hong, Z; Jiang, T; Li, Z; Qiu, J; Zhang, W; Zheng, X, 2023)	3.8
"Paroxetine may cause adverse outcomes in the neonate when used during pregnancy and should be discontinued in women who are pregnant or trying to become pregnant. "	( Paroxetine use during pregnancy: is it safe? Thormahlen, GM, 2006)	3.22
"Paroxetine appears to produce an earlier improvement in agitation and psychic anxiety symptoms compared with fluoxetine."	( A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder. Bakish, D; Beauclair, L; Bélanger, MC; Chouinard, G; Manchanda, R; Morris, P; O'Neill, MC; Ravindran, A; Reesal, R; Remick, R; Saxena, B; Vasavan Nair, NP, 1999)	1.28
"The paroxetine-induced increase in noradrenaline (and 5-HT) was positively correlated with plasma concentrations of the drug, which were around the therapeutic range."	( Effect of a selective 5-hydroxytryptamine reuptake inhibitor on brain extracellular noradrenaline: microdialysis studies using paroxetine. Hajós-Korcsok, E; McTavish, SF; Sharp, T, 2000)	0.99
"Paroxetine did not suppress the locomotor activity of rats, showing that the described anti-exploratory effect was behaviourally specific to the plus-maze."	( 8-OH-DPAT, but not deramciclane, antagonizes the anxiogenic-like action of paroxetine in an elevated plus-maze. Abramov, U; Beljajev, S; Bourin, M; Kõks, S; Koovit, I; Vasar, E, 2001)	1.26
"The paroxetine-induced increase in extracellular dopamine concentration, but not 5-HT concentration, was inhibited by the 5-HT(3)-receptor antagonist granisetron."	( Effect of paroxetine on extracellular serotonin and dopamine levels in the prefrontal cortex. Nakayama, K, 2002)	1.2
"Paroxetine did produce significantly greater improvement than placebo for patients whose illness had lasted more than 1 year, and there was a significant reduction in suicidal ideation."	( A placebo-controlled trial of paroxetine in the treatment of major depression. Glaudin, V; Smith, WT, 1992)	1.29
"Paroxetine does not inhibit monoamine oxidase in vitro."	( An overview of the animal pharmacology of paroxetine. Johnson, AM, 1989)	1.26
"Paroxetine failed to suppress the EEG arousal responses induced not only by auditory stimulation but also by electrical stimulation of the mesencephalic reticular formation, centromedian thalamus and posterior hypothalamus, whereas imipramine and amitriptyline markedly inhibited these responses."	( Electroencephalographic effects of the new antidepressant paroxetine in the rabbit. Furuya, Y; Man'no, K; Ohno, M; Ohta, H; Sugihara, K; Tani, Y; Ueki, S; Watanabe, S, 1988)	1.24

Treatment

Paroxetine treatment led to > 80% serotonin transporter occupancy. Treatment with mirtazapine and venlafaxine during the second hospitalization caused clonus and disturbance of consciousness, and these adverse effects resulted in a prolonged period of hospitalization.

Excerpt	Reference	Relevance
"Paroxetine treatment was started (titrated from 5 to 40 mg/day) and doubled each week."	( When to Choose Paroxetine Treatment in Skin-Picking Disorder: A Case Report. Arıkan, MK; İlhan, R; Mat, MC; Oba, MÇ, 2023)	1.98
"Paroxetine treatment led to > 80% serotonin transporter occupancy. "	( Efficacy of Chronic Paroxetine Treatment in Mitigating Amyloid Pathology and Microgliosis in APPSWE/PS1ΔE9 Transgenic Mice. Finsen, B; Gramsbergen, JB; Hasselstrøm, J; Lambertsen, KL; Metaxas, A; Olesen, LØ; Severino, M; Sivasaravanaparan, M; von Linstow, CU; Wiborg, O, 2022)	2.49
"Paroxetine (37.5 mg/day) treatment during the first hospitalization did not cause any side effects, but treatment with mirtazapine (15 mg/day) and venlafaxine (150 mg/day) during the second hospitalization caused clonus and disturbance of consciousness, and these adverse effects resulted in a prolonged period of hospitalization."	( A case of mood disorder with severe side effects of antidepressants in association with resistance to thyroid hormone beta with a THRB mutation. Hasegawa, C; Komahashi-Sasaki, H; Maehara, R; Shimoda, K; Yasui-Furukori, N, 2022)	1.44
"Paroxetine treatment also blocks epinephrine-induced upregulation of hypertrophic and fibrotic genes as well as ADRB1 internalization in cardiomyocytes."	( Paroxetine Attenuates Cardiac Hypertrophy Via Blocking GRK2 and ADRB1 Interaction in Hypertension. Cai, J; Huang, Y; Jiang, W; Lu, Y; Peng, L; Sun, X; Wen, G; Wu, J; Yuan, H; Zhou, M, 2021)	2.79
"tDCS-paroxetine co-treatment had variable effects on 5-HT1A receptors and SERT mRNA."	( Antidepressant action of transcranial direct current stimulation in olfactory bulbectomised adolescent rats. Bambico, FR; Blundell, J; Conway, JD; Dinesh, OC; Hasan, SN; Nobrega, JN; Raymond, R; Waye, SC, 2021)	1.08
"Paroxetine treatment increased the levels of proinflammatory cytokines IFN-γ, TNF-α, and IL-6 and decreased Th2 cytokine levels."	( Differences in immunomodulatory properties between venlafaxine and paroxetine in patients with major depressive disorder. Chen, CY; Ho, PS; Huang, CC; Huang, SY; Kuo, SC; Liang, CS; Lu, RB; Shyu, JF; Yeh, YW; Yen, CH, 2018)	1.44
"Paroxetine treatment was suspended, and after 48 h IOP was 10 mm Hg in both eyes (BE)."	( Chronic angle-closure glaucoma related to paroxetine treatment. Garcia-Feijoo, J; Gonzelez-Romero, JC; Saenz-Frances, F; Santos-Bueso, E; Sierra-Rodriguez, MA, 2013)	1.38
"Paroxetine 7.5 mg treatment also significantly increased nighttime sleep duration (week 4, +31 vs +16 min for placebo; P = 0.0075), but no significant between-group differences in sleep-onset latency or sleep-related adverse events such as sedation were observed."	( Low-dose paroxetine (7.5 mg) improves sleep in women with vasomotor symptoms associated with menopause. Bhaskar, S; Joffe, H; Kazempour, K; Lippman, J; Mekonnen, H; Pinkerton, JV, 2015)	1.56
"Paroxetine treatment had minimal effect on bHR/bLR dams' pregnancy outcomes or maternal behavior."	( Early-life exposure to the SSRI paroxetine exacerbates depression-like behavior in anxiety/depression-prone rats. Akil, H; Clinton, SM; Cohen, JL; Fant, AD; Glover, ME; Jackson, NL; Pugh, PC, 2015)	1.42
"Paroxetine treatment of macrophages, however, significantly inhibited LPS-induced IL-6 production."	( Paroxetine differentially modulates LPS-induced TNFα and IL-6 production in mouse macrophages. Durairaj, H; Parameswaran, N; Steury, MD, 2015)	2.58
"Paroxetine treatment has no significant effect on urine levels of neopterine in MDD patients."	( Urinary neopterine levels in patients with major depressive disorder: alterations after treatment with paroxetine and comparison with healthy controls. Atmaca, M; Güngör, BB; Özdel, K; Özen, NE; Taymur, I, 2015)	1.35
"Paroxetine treatment did not affect acquisition or expression of fear-potentiated startle, suggesting that disturbed fear learning in SERT(-/-) results from developmental changes and not from reduced SERT functioning."	( Lifelong disturbance of serotonin transporter functioning results in fear learning deficits: Reversal by blockade of CRF1 receptors. Baas, JM; Bijlsma, EY; Groenink, L; Hendriksen, H; Millan, MJ, 2015)	1.14
"Paroxetine treatment also induced infralimbic neuronal activation."	( Paroxetine treatment, following behavioral suppression of PTSD-like symptoms in mice, prevents relapse by activating the infralimbic cortex. Ba-M'hamed, S; Bennis, M; Bentefour, Y; Garcia, R; Rakibi, Y, 2016)	2.6
"Paroxetine-treated long-time floating (PLF) and paroxetine-treated short-time floating (PSF) groups were stratified as proxies for drug non-responder and responder mice, respectively."	( Purine and pyrimidine metabolism: Convergent evidence on chronic antidepressant treatment response in mice and humans. Asara, JM; Dournes, C; Filiou, MD; Gassen, NC; Ising, M; Müller, MB; Park, DI; Rein, T; Sillaber, I; Turck, CW; Uhr, M; Webhofer, C, 2016)	1.16
"Paroxetine treatment, both in HCs and PD patients, induced a mean 9% increase per subject in LDL-C that normalized post-discontinuation, suggesting causality."	( Paroxetine-induced increase in LDL cholesterol levels. Abadia, MC; Baker, G; Gil, L; Lara, N; Le Melledo, JM; Mailo, K; Perez-Parada, J; Van Ameringen, M, 2009)	2.52
"Paroxetine CR treatment resulted in a significant increase in verbal declarative memory function in the group as a whole, as measured by the Wechsler Memory Scale-Revised, the Selective Reminding Test, and novel paragraph recall, and explicit recall of neutral words. "	( Neuropsychological functioning in patients with posttraumatic stress disorder following short-term paroxetine treatment. Afzal, N; Ashraf, A; Bremner, JD; Fani, N; Jawed, F; Kitayama, N; Reed, L, 2009)	2.01
"Paroxetine treatment could reverse the suppressive effect of corticosterone on ciliary body cell proliferation."	( Roles of paroxetine and corticosterone on adult mammalian ciliary body cell proliferation. Lau, BW; Lee, TM; Leung, N; Li, SY; So, KF; Tang, SW; Wang, H; Wang, NL; Yau, SY, 2010)	1.5
"Paroxetine-treated patients were significantly more improved than placebo-treated patients."	( A randomized, controlled trial of aerobic exercise in combination with paroxetine in the treatment of panic disorder. Bandelow, B; Broocks, A; Engel, K; Neubert, K; Wedekind, D; Weiss, N, 2010)	1.32
"Paroxetine pretreatment inhibits CYP2D6 without inducing relevant changes in oxycodone exposure, and partially blunts the pharmacodynamic effects of oxycodone due to intrinsic pharmacological activities."	( Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Drewe, J; Hammann, F; Krähenbühl, S; Kummer, O; Moser, C; Schaller, O, 2011)	1.09
"The paroxetine treatment group also experienced significant increases in depressive symptoms, clinical global severity scores and difficulty in social functioning; the fluoxetine treatment group did not."	( Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment. Jacobson, JG; Judge, R; Parry, MG; Quail, D, 2002)	1.02
"Paroxetine treatment induced significant decrease in platelet 5-HT concentrations in both responders and nonresponders, while no alterations in platelet 5-HT values were found in tianeptine-treated patients."	( The effects of paroxetine and tianeptine on peripheral biochemical markers in major depression. Jakovljević, M; Mihaljević-Peles, A; Mück-Seler, D; Pivac, N; Sagud, M, 2002)	1.39
"Paroxetine was used for treatment but was productive in only the first two cases."	( The effect of paroxetine on Taijinkyofusho: a report of three cases. Kobayashi, N; Kurauchi, S; Nomura, S; Sano, SY; Sawamura, T; Shigemura, J, 2003)	1.4
"Paroxetine treatment completely blocked 5-HT uptake into the thalamocortical fibers as indicated by the negative 5-HT-im in cortical barrel areas."	( Selective serotonin reuptake inhibitor disrupts organization of thalamocortical somatosensory barrels during development. Sari, Y; Xu, Y; Zhou, FC, 2004)	1.04
"Paroxetine treatment was significantly superior to placebo at weeks 3 through 12 on the Liebowitz Social Anxiety Scale, the Clinical Global Impression-Severity of Illness scale, and the Social Phobia Inventory, and at weeks 4 through 12 for response (P < .05 for all)."	( Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Gelenberg, AJ; Liebowitz, MR; Munjack, D, 2005)	1.31
"Paroxetine treatment has the potential to cause weight gain and sexual dysfunction, primarily anorgasmia and ejaculatory dysfunction for the long term."	( Paroxetine in panic disorder: clinical management and long-term follow-up. Dannon, PN; Iancu, I; Kotler, M; Lowengrub, K, 2004)	2.49
"Paroxetine treatment desensitized 5-HT(1A) receptor-mediated increases in oxytocin, ACTH and corticosterone to a comparable extent in all offspring and reduced the E(max) for ACTH only in prenatal cocaine-exposed offspring."	( Paroxetine is effective in desensitizing 5-HT1A receptor function in adult offspring exposed prenatally to cocaine. Battaglia, G; Carrasco, GA; Chen, Z; Muma, NA; Shankaran, M; Sripathirathan, K; Tetzlaff, J; Van De Kar, LD, 2005)	2.49
"With paroxetine pretreatment, the area under the plasma concentration-time curve (AUC) of (+)- and (-)-tramadol was increased (37% [P = .001] and 32% [P = .002], respectively), and the corresponding AUCs of(+)- and (-)-M1 were decreased (67% [P = .0004] and 40% [P = .0008], respectively). "	( Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. Brøsen, K; Enggaard, TP; Laugesen, S; Pedersen, RS; Sindrup, SH, 2005)	2.29
"Paroxetine-treated patients showed greater (P < .05) improvements than placebo-treated patients on the Clinical Global Impressions (CGI) scale."	( A randomized controlled trial of paroxetine for noncardiac chest pain. Beebe, KL; Beyer, JL; Clary, GL; Doraiswamy, PM; Hellegers, C; Krishnan, KR; Newby, LK; O'Connor, C; O'Connor, JF; Varia, I; Wagner, HR, 2006)	1.34
"Paroxetine treatment ameliorated the spatial navigation deficit in 3xTgAD male and female mice, without affecting swim speed or distance traveled, suggesting a preservation of cognitive function."	( Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice. Brown, M; Clark, RF; Gray, AJ; Guo, Z; Halagappa, VM; Iyun, T; Martin, B; Matsuoka, Y; Mattson, MP; Maudsley, S; Nelson, RL; Pearson, M, 2007)	1.35
"More paroxetine-treated patients withdrew due to adverse events than escitalopram- or placebo-treated patients."	( Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. Andersen, EW; Fineberg, N; Stein, DJ; Tonnoir, B, 2007)	1.02
"The paroxetine vehicle treated rats showed anhedonia even 14 days after acute dexamethasone administration."	( Repeated paroxetine treatment reverses anhedonia induced in rats by chronic mild stress or dexamethasone. Andreatini, R; Casarotto, PC, 2007)	1.24
"Paroxetine-treatment group, in contrast, shows a 34% increase in cell proliferation."	( Corticosteroid decreases subventricular zone cell proliferation, which could be reversed by paroxetine. Helmeste, DM; Lau, WM; Lee, TM; Qiu, G; So, KF; Tang, SW, 2007)	1.28
"In paroxetine-treated females these differences remained statistically significant."	( A monoamine oxidase B gene variant and short-term antidepressant treatment response. Dahmen, N; Kohnen, R; Müller, MJ; Rujescu, D; Stassen, HH; Szegedi, A; Tadić, A, 2007)	0.85
"The paroxetine pretreated rats did not show these cytokine changes following IFNalpha treatment."	( Role of paroxetine in interferon-alpha-induced immune and behavioural changes in male Wistar rats. Kaim-Basta, A; Kenny, C; Kim, YK; Kubera, M; Leonard, BE; Myint, AM; O'Mahony, S; Steinbusch, HW, 2007)	1.25
"Paroxetine treatment was discontinued on day 1 and atrioventricular block resolved on day 5, which was confirmed with a 24-hour Holter recording."	( Complete atrioventricular block associated with concomitant use of metoprolol and paroxetine. Bekar, L; Cumurcu, BE; Onalan, O, 2008)	1.29
"The paroxetine treatment did not alter the sensitivity of this alpha 2-adrenoceptor in the hypothalamus."	( Modulation of 5-HT release in the guinea-pig brain following long-term administration of antidepressant drugs. Blier, P; Bouchard, C, 1994)	0.77
"Paroxetine treatment caused a reduction in 5-HT immunoreactivity which was maximal 6 h after administration."	( Contributions of raphe-cortical and thalamocortical axons to the transient somatotopic pattern of serotonin immunoreactivity in rat cortex. Bennett-Clarke, CA; Chiaia, NL; Rhoades, RW, 1997)	1.02
"Paroxetine treatment resulted in a twofold to 21-fold decrease in CYP2D6 activity (p < 0.001). "	( Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo. Herrmann, N; Kalow, W; Naranjo, CA; Ozdemir, V; Reed, K; Sellers, EM, 1997)	3.18
"Paroxetine-treated subjects received a psychotherapy tailored for traumatic grief."	( A post hoc comparison of paroxetine and nortriptyline for symptoms of traumatic grief. Houck, PR; Jacobs, S; Miller, MD; Prigerson, HG; Reynolds, CF; Shear, MK; Zygmont, M, 1998)	1.32
"Paroxetine treatment costs also appear to be similar to those of amitriptyline and imipramine in terms of expected costs per patient."	( Paroxetine. A pharmacoeconomic evaluation of its use in depression. Whittington, R; Wilde, MI, 1995)	2.46
"One paroxetine-treated subject did not exhibit any CYP2D6 inhibition."	( CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline. Alfaro, CL; Ereshefsky, L; Lam, YW; Simpson, J, 1999)	1.01
"Paroxetine treatment reduced platelet 5-HT to 17% of baseline after 4 weeks of treatment. "	( Pretreatment platelet 5-HT concentration predicts the short-term response to paroxetine in major depression. Grupo de Trastornos Afectivos. Alvarez, E; Artigas, F; Figueras, G; Pérez, V; San Martino, O, 1999)	1.97
"Paroxetine treatment (19.7 +/- 4.7 mg/day for 105 +/- 37 days) resulted in a significant improvement in the frequency and intensity of panic attacks and also on the state anxiety inventory."	( Effects of paroxetine on heart period variability in patients with panic disorder: a study of holter ECG records. Igel, G; Jampala, VC; Kay, J; Sobelewski, E; Yeragani, VK, 1999)	1.41
"Paroxetine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC) of (R)- and (S)-metoprolol significantly (169 to 1,340 ng x h/mL [P < .001] and 279 to 1,418 ng x h/mL [P < .001], respectively), with an approximately twofold increase in both maximum plasma concentration and terminal elimination half-life. "	( Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Belpaire, FM; De Vriendt, C; Hemeryck, A; Lefebvre, RA, 2000)	3.19
"Paroxetine and drug-free treatment did not affect any of these parameters."	( Effects of antidepressants on weight and on the plasma levels of leptin, TNF-alpha and soluble TNF receptors: A longitudinal study in patients treated with amitriptyline or paroxetine. Haack, M; Hinze-Selch, D; Kraus, T; Kühn, M; Pollmächer, T; Schuld, A; Uhr, M, 2000)	1.22
"Paroxetine treatment improved symptoms of social anxiety, as measured by the LSAS, compared with placebo."	( Therapeutic advances: paroxetine for the treatment of social anxiety disorder. Bobes, J; Lydiard, RB, 2000)	1.34
"Paroxetine-treated patients experienced a significant weight increase, fluoxetine-treated patients had a modest but nonsignificant weight decrease, and patients treated with sertraline had a modest but nonsignificant weight increase."	( Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. Fava, M; Hoog, SL; Judge, R; Koke, SC; Nilsson, ME, 2000)	1.31
"Mean paroxetine treatment duration was 11.7 +/- 8.3 months, with a mean final dosage of 23.9 +/- 9.8 mg/day (range, 10-40 mg/day)."	( Paroxetine in child and adolescent outpatients with panic disorder. Masi, G; Mata, B; Millepiedi, S; Mucci, M; Perugi, G; Toni, C, 2001)	2.21
"Paroxetine treatment at the dose of 80 mg per day induced hypomania in a 37-year-old female with dysthymia and trichitillomania."	( Dose-response relationship of selective serotonin reuptake inhibitors treatment-emergent hypomania in depressive disorders. Ramasubbu, R, 2001)	1.03
"Paroxetine-treated patients in both dose groups demonstrated significantly greater improvement on primary outcome measures compared to placebo-treated patients in the intent-to-treat analysis. "	( Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. Beebe, KL; Marshall, RD; Oldham, M; Zaninelli, R, 2001)	2.06
"Paroxetine treatment did not affect neuroactive steroid concentrations, which were highly stable over 24 weeks."	( GABA(A) receptor-modulating neuroactive steroid composition in patients with panic disorder before and during paroxetine treatment. di Michele, F; Holsboer, F; Pasini, A; Romeo, E; Rupprecht, R; Ströhle, A; Yassouridis, A, 2002)	1.25
"Paroxetine pretreatment (10 mg kg-1, 30 min before-hand) reduced this uptake by 73%."	( Effects of monoamine uptake inhibitors on extracellular and platelet 5-hydroxytryptamine in rat blood: different effects of clomipramine and fluoxetine. Artigas, F; Ortiz, J, 1992)	1
"Treatment with paroxetine reduced cell viability, which was associated with marked increase in apoptosis, in both the cell lines."	( Anticancer activity of paroxetine in human colon cancer cells: Involvement of MET and ERBB3. Jang, WJ; Jeong, CH; Jung, SK; Vo, TTL, 2019)	1.16
"Treatment with paroxetine was performed per os with a dosage of 20 mg/g BW."	( Chronic social stress during adolescence: interplay of paroxetine treatment and ageing. Liebl, C; Müller, MB; Scharf, SH; Schmidt, MV; Sterlemann, V, 2013)	0.98
"Pretreatment with paroxetine increased the mean peak plasma concentrations (Cmax ) for unchanged nebivolol (1·78 ± 1·17 vs. "	( A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. Achim, M; Bocsan, C; Briciu, C; Buzoianu, A; Gheldiu, AM; Muntean, D; Neag, M; Popa, A; Vlase, L, 2014)	0.98
"Treatment of paroxetine-induced penile anesthesia in Post SSRI Sexual Dysfunction (PSSD) by Low-power Laser Irradiation (LPLI) is unknown in medical literature. "	( Penile anesthesia in Post SSRI Sexual Dysfunction (PSSD) responds to low-power laser irradiation: a case study and hypothesis about the role of transient receptor potential (TRP) ion channels. Georgiadis, J; Schweitzer, DH; van Coevorden, RS; Waldinger, MD, 2015)	0.79
"Treatment with paroxetine delays the decline in locomotion, in exploration and risk assessment behaviour, found in the APP/PS1 mice."	( Behavioural Phenotyping of APPswe/PS1δE9 Mice: Age-Rrelated Changes and Effect of Long-Term Paroxetine Treatment. Bouzinova, EV; Finsen, B; Hasselstrøm, JB; Olesen, LØ; Severino, M; Sivasaravanaparan, M; Wiborg, O, 2016)	0.99
"Treatment with paroxetine prevented degeneration of nigrostriatal DA neurons, increased striatal dopamine levels, and improved motor function."	( Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease. Chung, YC; Jin, BK; Kim, SR, 2010)	2.14
"Pre-treatment with paroxetine did not alter the thresholds for perception and discomfort during isobaric (4.7 +/- 2.3 vs. "	( Influence of the selective serotonin re-uptake inhibitor, paroxetine, on gastric sensorimotor function in humans. Broekaert, D; Coulie, B; Fischler, B; Janssens, J; Tack, J, 2003)	0.89
"Pre-treatment with paroxetine enhances gastric accommodation to a meal. "	( Influence of the selective serotonin re-uptake inhibitor, paroxetine, on gastric sensorimotor function in humans. Broekaert, D; Coulie, B; Fischler, B; Janssens, J; Tack, J, 2003)	0.89
"Treatment with paroxetine was associated with a significant improvement in standard social-phobia scores, although most patients remained symptomatic."	( Paroxetine: new indication. In social phobia: minimal assessment. , 2003)	2.1
"Pretreatment with paroxetine partially reduced MDMA effects on CD4 T and NK cells, whereas totally inhibiting the suppression of the immune response to mitogens and alterations in cytokines release."	( Paroxetine inhibits acute effects of 3,4-methylenedioxymethamphetamine on the immune system in humans. Bacosi, A; de la Torre, R; Di Carlo, S; Farré, M; Ortuño, J; Pacifici, R; Pichini, S; Roset, PN; Segura, J; Segura, M; Zuccaro, P, 2004)	2.09
"Pretreatment with paroxetine reduced the effects of 8-OH-DPAT on ejaculation in a dose-dependent manner and more strongly than fluvoxamine."	( Effects of chronic selective serotonin reuptake inhibitors on 8-OH-DPAT-induced facilitation of ejaculation in rats: comparison of fluvoxamine and paroxetine. Cools, AR; de Jong, TR; Olivier, B; Pattij, T; Veening, JG; Waldinger, MD, 2005)	0.85
"Treatment with paroxetine did not significantly increase QTcB or QTcF or any ECG parameters compared with placebo."	( Analysis of electrocardiographic data following use of paroxetine in pediatric depression and obsessive-compulsive disorder. Carpenter, DJ; Fong, R; Horrigan, JP; Krulewicz, S; Lipschitz, A; Perera, P; Wagner, KD, 2006)	0.92
"Pretreatment with paroxetine was associated with marked decreases of both physiological and subjective effects of MDMA, despite a 30% increase in MDMA plasma concentrations."	( Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics. Abanades, S; de la Torre, R; Farré, M; O'Mathúna, B; Peiró, AM; Roset, PN; Segura, M; Torrens, M, 2007)	0.89
"Treatment with paroxetine controlled-release may constitute an efficacious alternative for symptomatic perimenopausal and postmenopausal women after menopausal hormone discontinuation."	( Paroxetine versus placebo for women in midlife after hormone therapy discontinuation. Cohen, LS; Joffe, H; Petrillo, L; Rydzewski, M; Soares, CN; Somley, B; Viguera, AC; Yehezkel, R, 2008)	2.14
"Treatment with paroxetine began at a median of 17 months (range, 6-139 months) after the loss."	( A post hoc comparison of paroxetine and nortriptyline for symptoms of traumatic grief. Houck, PR; Jacobs, S; Miller, MD; Prigerson, HG; Reynolds, CF; Shear, MK; Zygmont, M, 1998)	0.94
"Treatment with paroxetine (0.1-2 mg/kg) reduced the number of open arm visits and time spent in open arms, and the ratio between open and total arm entries in the elevated plus-maze."	( 8-OH-DPAT, but not deramciclane, antagonizes the anxiogenic-like action of paroxetine in an elevated plus-maze. Abramov, U; Beljajev, S; Bourin, M; Kõks, S; Koovit, I; Vasar, E, 2001)	0.88
"Treatment with paroxetine was well tolerated, and the number and type of adverse events recorded in the paroxetine group correspond to the known safety profile of this medication."	( Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. Bellew, KM; Burnham, DB; Goddard, A; Iyengar, MK; McCafferty, JP; Pollack, MH; Zaninelli, R, 2001)	2.09
"Treatment with paroxetine significantly increased the baseline prolactin level independently of treatment response but positively correlated with paroxetine dose."	( Prolactin response to dl-fenfluramine challenge before and after treatment with paroxetine. Dulchin, MC; Ellis, SP; Li, S; Malone, KM; Mann, JJ; Oquendo, MA, 2001)	0.88
"Treatment with paroxetine was well tolerated, with the frequency and type of adverse events recorded for the paroxetine group corresponding to the known safety profile of this medication."	( Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. Dillingham, K; Pitts, CD; Ruggiero, L; Tucker, P; Yehuda, R; Zaninelli, R, 2001)	2.09
"Pretreatment with paroxetine dramatically altered the metabolism and kinetics of both tracers and appeared to displace both ligands primarily from regions with high SERT density."	( Comparison of (+)-(11)C-McN5652 and (11)C-DASB as serotonin transporter radioligands under various experimental conditions. Dannals, RF; Hilton, J; Mathews, WB; McCann, UD; Owonikoko, T; Ravert, HT; Ricaurte, GA; Scheffel, U; Szabo, Z; Wilson, AA, 2002)	0.64

Toxicity

Tianeptine appears to be as effective and as safe as paroxetine for the ambulatory treatment of major depression. Nausea and constipation occurred significantly more often with paroxetsine than with imipramine.

Excerpt	Reference	Relevance
" This is the first report of such a side effect associated with paroxetine use in man."	( Extra pyramidal side effects associated with paroxetine. Nicholson, SD, 1992)	0.78
" The adverse events reported with paroxetine were most likely to occur early in the course of treatment and there was no evidence of any increase in events in the elderly or with longer-term treatment."	( Paroxetine: an overview of dosage, tolerability, and safety. Jenner, PN, 1992)	2.01
" Nausea and constipation occurred significantly more often with paroxetine, but only 9% of paroxetine patients dropped out of the study due either in whole or in part to an adverse effect."	( The safety and efficacy of paroxetine compared with placebo in a double-blind trial of depressed outpatients. Claghorn, JL, 1992)	0.82
" Furthermore, paroxetine is relatively safe in overdose and has very little anticholinergic activity."	( The safety profile of paroxetine. Blumhardt, CL; Boyer, WF, 1992)	0.96
" However, a comparison of the relative toxic effects of MDMA and MBDB indicates that MBDB may be slightly less neurotoxic."	( Neurotoxic effects of the alpha-ethyl homologue of MDMA following subacute administration. Johnson, MP; Nichols, DE, 1989)	0.28
" The central monoamine stores of rats were significantly decreased with reserpine (5 mg/kg) prior to toxic injections of MDMA."	( Reserpine does not prevent 3,4-methylenedioxymethamphetamine-induced neurotoxicity in the rat. Hekmatpanah, CR; McKenna, DJ; Peroutka, SJ, 1989)	0.28
" As with other selective serotonin reuptake inhibitors, the most common side effect associated with paroxetine treatment is nausea, although this effect rarely leads to dose reduction or drug discontinuation."	( Paroxetine: an overview of the efficacy and safety of a new selective serotonin reuptake inhibitor in the treatment of depression. Nemeroff, CB, 1993)	1.94
" The fates of SSRI-associated sexual adverse effects and clinical managements of restoring these side effects were described."	( Female sexual side effects associated with selective serotonin reuptake inhibitors: a descriptive clinical study of 33 patients. Hsu, JH; Shen, WW, 1995)	0.29
"With some limitations in interpreting the data, the findings of this study suggest that SSRI-associated female sexual dysfunction occurs at a higher rate than we previously thought, equal potentials in implicating female sexual side effects among three SSRIs, and the absence or the low incidence of female sexual adverse effects from bupropion, and that these side effects can be managed by waiting for a spontaneous remission, dosage reduction of SSRIs, substitution with bupropion and other antidepressants, or the use of an antidote."	( Female sexual side effects associated with selective serotonin reuptake inhibitors: a descriptive clinical study of 33 patients. Hsu, JH; Shen, WW, 1995)	0.29
" There were 188 adverse events: insomnia, dizziness, headache, nausea, dry mouth and myoclonic jerks were the most common."	( Safety and tolerability of combined treatment with moclobemide and SSRIs: a systematic study of 50 patients. Hawley, CJ; McPhee, S; Pattinson, HA; Quick, SJ; Ratnam, S, 1996)	0.29
"To study the adverse drug reaction (ADR) profile of selective serotonin re-uptake inhibitors (SSRI) in Belgium and the Netherlands."	( [Reports of suspected side effects of selective serotonin reuptake inhibitors in Belgium and The Netherlands]. Kurz, X; Ottervanger, JP; Roisin, T; Stricker, BH; Van Ermen, AM, 1996)	0.29
"All adverse reactions of fluoxetine, fluvoxamine, paroxetine and sertraline, reported between the moment of registration of these drugs and January 1st 1995, were assessed for causality."	( [Reports of suspected side effects of selective serotonin reuptake inhibitors in Belgium and The Netherlands]. Kurz, X; Ottervanger, JP; Roisin, T; Stricker, BH; Van Ermen, AM, 1996)	0.55
"At the national monitoring centres of Belgium and of the Netherlands adverse reactions were reported 78 and 537 times, respectively."	( [Reports of suspected side effects of selective serotonin reuptake inhibitors in Belgium and The Netherlands]. Kurz, X; Ottervanger, JP; Roisin, T; Stricker, BH; Van Ermen, AM, 1996)	0.29
" More adverse reactions were reported in the Netherlands than in Belgium."	( [Reports of suspected side effects of selective serotonin reuptake inhibitors in Belgium and The Netherlands]. Kurz, X; Ottervanger, JP; Roisin, T; Stricker, BH; Van Ermen, AM, 1996)	0.29
"Selective serotonin reuptake inhibitors (SSRIs) are becoming widely used because of their favorable side-effect profile and their safety in overdose."	( Reversible hepatotoxicity of paroxetine in a patient with major depression. Boerner, RJ; Hegerl, U; Helmchen, C; Meyendorf, R, 1996)	0.59
" We have addressed the question of whether there is a 'serotonin withdrawal syndrome' by analysis of spontaneous reports of suspected adverse drug reactions (ADRs) associated with four SSRIs."	( A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. MacKay, AV; Price, JS; Waller, PC; Wood, SM, 1996)	0.29
" Hyponatraemia has previously been described as an adverse effect to fluoxetine and paroxetine, but not to citalopram."	( [Adverse effects of selective serotonin uptake inhibitors. Hyponatremia caused by Schwartz-Bartter syndrome]. Almdal, TP; Christensen, O; Sørensen, HA, 1996)	0.52
" Overall, 27% of the SSRI-treated patients had no adverse sexual side effects; in contrast, 86% of patients treated with bupropion had no adverse sexual effects, and 77% of bupropion-treated patients reported at least one aspect of heightened sexual functioning."	( Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline. DePalma, RL; Katholi, CR; Modell, JD; Modell, JG, 1997)	0.54
"SSRI-induced adverse sexual effects appear to be the rule rather than the exception and may be substantially underreported unless patients are specifically asked about the effects of these medications on various aspects of sexual function."	( Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline. DePalma, RL; Katholi, CR; Modell, JD; Modell, JG, 1997)	0.54
"English-language articles identified through MEDLINE (1985 through 1997), and case reports from the American Association of Poison Control Centers (AAPCC) (1987 through 1996) and United States Food and Drug Administration (FDA) adverse event database (through 1997) that describe findings of fatal and nonfatal overdoses involving SSRIs alone or in combination with other ingestants were reviewed."	( SSRI safety in overdose. Barbey, JT; Roose, SP, 1998)	0.3
" At very high doses (> 75 times the common daily dose), more serious adverse events, including seizures, electrocardiogram (ECG) changes, and decreased consciousness may occur."	( SSRI safety in overdose. Barbey, JT; Roose, SP, 1998)	0.3
"The article focuses on adverse drug reactions (ADR) to selective serotonin reuptake inhibitors (SSRI) concerning libido and sexual behaviour: cases of disinhibition of libido observed at the Psychiatric Hospital of Kilchberg near Zurich are described."	( Disinhibition of libido: an adverse effect of SSRI? Erazo, N; Greil, W; Grohmann, R; Horvath, A; Sassim, N, 2001)	0.31
"Selective serotonin reuptake inhibitors are widely used in the treatment of depressive and obsessive-compulsive disorders because of their low-frequency adverse effects."	( [Cutaneous adverse effects during selective serotonin reuptake inhibitors therapy: 2 cases]. Fiszenson, F; Grob, JJ; Jean Pastor, MJ; Jreissati, M; Richard, MA, )	0.13
"Adverse cutaneous effects of selective serotonin reuptake inhibitors are rare but the knowledge of these reactions is important because toxic epidermal necrolysis and Stevens-Johnson syndrome had been reported during fluoxetine (Prozac(R)) and fluvoxamine (Floxyfral(R)) treatment."	( [Cutaneous adverse effects during selective serotonin reuptake inhibitors therapy: 2 cases]. Fiszenson, F; Grob, JJ; Jean Pastor, MJ; Jreissati, M; Richard, MA, )	0.13
" Assessments included Clinical Global Impression Scales, Hamilton Rating Scales for Depression and Anxiety, Montgomery-Asberg Depression Rating Scale and the Patient Global Assessment Scale, in addition to a review of reported adverse events, vital sign measurements, electrocardiograms and clinical laboratory tests."	( A randomized, double-blind controlled comparison of nefazodone and paroxetine in the treatment of depression: safety, tolerability and efficacy in continuation phase treatment. Baldwin, DS; Hawley, CJ; Mellors, K, 2001)	0.55
"Tianeptine appears to be as effective and as safe as paroxetine for the ambulatory treatment of major depression."	( Efficacy and safety of tianeptine in major depression: evidence from a 3-month controlled clinical trial versus paroxetine. Azoulay, P; Septien, L; Waintraub, L, 2002)	0.78
" The tolerability evaluation was based on incidence of adverse events and routine laboratory tests."	( Efficacy and safety of amisulpride 50 mg versus paroxetine 20 mg in major depression: a randomized, double-blind, parallel group study. Cassano, GB; Jori, MC, 2002)	0.57
" This study evaluates a clinician-administered scale, the Toronto Side Effect Scale (TSES), in a natural practice clinic."	( Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. Bagby, RM; Kennedy, SH; Vanderkooy, JD, 2002)	0.52
" A measure of side-effect intensity distinguished paroxetine from the other antidepressants on a measure of sexual dysfunction."	( Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. Bagby, RM; Kennedy, SH; Vanderkooy, JD, 2002)	0.78
"These results confirm the clinical utility of the TSES as a simple, clinician-administered antidepressant side-effect scale."	( Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. Bagby, RM; Kennedy, SH; Vanderkooy, JD, 2002)	0.52
" As to the occurence of common adverse effects, no marked difference between subjects converted into the PM group and those who had no history of such conversion was found."	( Paroxetine-induced conversion of cytochrome P450 2D6 phenotype and occurence of adverse effects. Hadasová, E; Zourková, A, 2003)	1.76
"The Hamilton Depression Rating Scale-17 and Geriatric Depression Scale, severity of adverse events and dosing compliance indexes, and discontinuations due to adverse events."	( Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Hollander, SB; Kremer, C; Murphy, GM; Rodrigues, HE; Schatzberg, AF, 2004)	0.55
" However, the 5HTTLPR polymorphism had a dramatic effect on adverse events."	( Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Hollander, SB; Kremer, C; Murphy, GM; Rodrigues, HE; Schatzberg, AF, 2004)	0.55
"Although adverse events are a key factor in compliance, their evolution during treatment with antidepressants is poorly documented."	( What happens with adverse events during 6 months of treatment with selective serotonin reuptake inhibitors? Albert, A; De Bruyckere, K; Demyttenaere, K; Dewé, W; Mesters, P; Sangeleer, M, 2005)	0.33
" At each visit, the presence and severity of treatment-emergent adverse events were assessed systematically using the UKU Side Effect Rating Scale (UKU)."	( What happens with adverse events during 6 months of treatment with selective serotonin reuptake inhibitors? Albert, A; De Bruyckere, K; Demyttenaere, K; Dewé, W; Mesters, P; Sangeleer, M, 2005)	0.33
"Overall, the number of at least moderately severe adverse events decreased with time."	( What happens with adverse events during 6 months of treatment with selective serotonin reuptake inhibitors? Albert, A; De Bruyckere, K; Demyttenaere, K; Dewé, W; Mesters, P; Sangeleer, M, 2005)	0.33
"The time course of adverse events varies with the severity of depression, sex, completer or dropout status, and recurrent versus first-episode depression."	( What happens with adverse events during 6 months of treatment with selective serotonin reuptake inhibitors? Albert, A; De Bruyckere, K; Demyttenaere, K; Dewé, W; Mesters, P; Sangeleer, M, 2005)	0.33
" Irrespective of the mechanism, we recommend that all neonates exposed to antidepressants, particularly serotonin reuptake inhibitors (SSRIs), during the last trimester should be followed-up closely for adverse symptoms commencing in the first 10 days after birth."	( Neonatal symptoms following maternal paroxetine treatment: serotonin toxicity or paroxetine discontinuation syndrome? Clarke, P; Haddad, PM; Pal, BR; Sridhiran, S; Wieck, A, 2005)	0.6
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."	( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004)	0.32
" The drug was safe and well tolerable."	( [Clinical effectiveness and safety of paroxetine in post-stroke depression: results from a phase 4, open label, multicenter clinical trial with 26 weeks of follow-up]. Andor, G; Harcos, P; Horváth, S; Karányi, Z; Nagy, Z; Németh, G, 2006)	0.6
" Clinicians should select antidepressants considering their pharmacologic profiles and avoiding adverse effects."	( [Review of pharmacological efficacies and side effects of antidepressants]. Ikenouchi-Sugita, A; Nakamura, J; Yoshimura, R, 2007)	0.34
" Adverse events occurring in 10% of patients or more with adjunctive placebo or aripiprazole were akathisia (4."	( The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. Berman, RM; Carson, WH; Fava, M; Hennicken, D; Marcus, RN; McQuade, RD; Simon, JS; Thase, ME; Trivedi, MH, 2008)	0.35
"We wanted to determine to what extent adverse drug effects associated with a selective serotonin reuptake inhibitor (SSRI) were known but not assessed before application for registration of paroxetine."	( Common adverse events associated with an SSRI: meta-analysis of early paroxetine data. Aursnes, I; Gjertsen, MK, 2008)	0.77
"At the time of registration 19 of the adverse effects were statistically significant."	( Common adverse events associated with an SSRI: meta-analysis of early paroxetine data. Aursnes, I; Gjertsen, MK, 2008)	0.58
"Frequently occurring adverse reactions that are included in today's SPC for paroxetine were evident and documented already in the early studies accompanying the application for marketing authorization in 1989."	( Common adverse events associated with an SSRI: meta-analysis of early paroxetine data. Aursnes, I; Gjertsen, MK, 2008)	0.81
" The case indicates that emerging adverse effects via the pharmacokinetic interaction of these drugs when switching patients from fluvoxamine to paroxetine can occur."	( A case with occurring adverse effects when cross-over titration from fluvoxamine to paroxetine associated with increasing the plasma fluvoxamine level in major depressive disorder. Hori, H; Ikenouchi-Sugita, A; Nakamura, J; Ueda, N; Umene-Nakano, W; Yoshimura, R, 2009)	0.78
"The authors sought to identify predictors of self-harm adverse events in treatment-resistant, depressed adolescents during the first 12 weeks of treatment."	( Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. Asarnow, J; Birmaher, B; Brent, DA; Clarke, GN; Debar, LL; Emslie, GJ; Iyengar, S; Keller, MB; Kennard, B; Leonard, H; Mayes, TL; McCracken, JT; Onorato, M; Porta, G; Ritz, L; Ryan, ND; Spirito, A; Strober, M; Suddath, R; Vitiello, B; Zelazny, J, 2009)	0.35
", suicidal and non-suicidal self-injury adverse events were assessed by spontaneous report for the first 181 participants, and by systematic weekly assessment for the last 153 participants."	( Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. Asarnow, J; Birmaher, B; Brent, DA; Clarke, GN; Debar, LL; Emslie, GJ; Iyengar, S; Keller, MB; Kennard, B; Leonard, H; Mayes, TL; McCracken, JT; Onorato, M; Porta, G; Ritz, L; Ryan, ND; Spirito, A; Strober, M; Suddath, R; Vitiello, B; Zelazny, J, 2009)	0.35
"2%), but not serious adverse events (8."	( Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. Asarnow, J; Birmaher, B; Brent, DA; Clarke, GN; Debar, LL; Emslie, GJ; Iyengar, S; Keller, MB; Kennard, B; Leonard, H; Mayes, TL; McCracken, JT; Onorato, M; Porta, G; Ritz, L; Ryan, ND; Spirito, A; Strober, M; Suddath, R; Vitiello, B; Zelazny, J, 2009)	0.35
"Since predictors of suicidal adverse events also predict poor response to treatment, and many of these events occurred early in treatment, improving the speed of response to depression, by targeting of family conflict, suicidal ideation, and drug use may help to reduce their incidence."	( Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. Asarnow, J; Birmaher, B; Brent, DA; Clarke, GN; Debar, LL; Emslie, GJ; Iyengar, S; Keller, MB; Kennard, B; Leonard, H; Mayes, TL; McCracken, JT; Onorato, M; Porta, G; Ritz, L; Ryan, ND; Spirito, A; Strober, M; Suddath, R; Vitiello, B; Zelazny, J, 2009)	0.35
" Agomelatine is probably hepatotoxic; (8) In summary, agomelatine has unproven efficacy and poorly documented adverse effects."	( Agomelatine: new drug. Adverse effects and no proven efficacy. , 2009)	0.35
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."	( Developing structure-activity relationships for the prediction of hepatotoxicity. Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010)	0.36
" Although differences in risks for and prognoses of several diseases have been well documented, sex-based differences in responses to pharmaceutical treatments and accompanying risks of adverse events are less clear."	( Differences in efficacy and safety of pharmaceutical treatments between men and women: an umbrella review. Chapman, A; Gartlehner, G; Strobelberger, M; Thaler, K, 2010)	0.36
" There was no statistical significance among treatment arms in remission rates, secondary outcome measures, and adverse events."	( A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with treatment-resistant major depression. Calabrese, JR; Cao, L; Chen, J; Cui, X; Fang, Y; Gao, K; Hong, W; Jiang, K; Wang, Y; Wu, Z; Xu, Y; Yi, Z; Yuan, C, 2011)	0.63
" The most common adverse effects (AEs) with GSK372475 were dry mouth, headache, insomnia, and nausea."	( Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials. Alexander, R; Archer, G; Evoniuk, G; Graff, O; Krishnan, KR; Lavergne, A; Learned, S; Moate, R; Modell, JG; Ratti, E; Roychowdhury, S; Zamuner, S, 2012)	0.38
" Our system employs a sequential, propensity score-matched framework and signalling rules for prospective drug safety monitoring and identified signals for all three adverse drug reactions evaluated."	( Early steps in the development of a claims-based targeted healthcare safety monitoring system and application to three empirical examples. Avorn, J; Bohn, RL; Daniel, GW; Eisenberg, DF; Gagne, JJ; Patrick, AR; Rassen, JA; Rodgers, JK; Schneeweiss, S; Wahl, PM; Wasser, TE; Wilson, M, 2012)	0.38
"7 ng/ml, which can cause systemic adverse effects in patients at risk."	( Paroxetine markedly increases plasma concentrations of ophthalmic timolol; CYP2D6 inhibitors may increase the risk of cardiovascular adverse effects of 0.5% timolol eye drops. Backman, JT; Kautiainen, H; Mäenpää, J; Neuvonen, M; Neuvonen, PJ; Niemi, M; Volotinen-Maja, M, 2014)	1.85
"The use of a statistical approach to analyze cumulative adverse event (AE) reports has been encouraged by regulatory authorities."	( Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases. Anzai, T; Hashiguchi, M; Hinomura, Y; Kawaguchi, G; Marui, H; Matsushita, Y; Mochizuki, M; Nomura, K; Takahashi, K, 2015)	0.42
" All reported adverse events were considered to be mild."	( Pharmacokinetics and safety of paroxetine controlled-release tablet in healthy Chinese subjects: a single-dose three-period crossover study. Chen, R; Hu, P; Shen, K, 2016)	0.72
"It has been suggested that the efficacy of antidepressants has been overestimated in clinical trials owing to unblinding of drug treatments by adverse events."	( Efficacy of selective serotonin reuptake inhibitors and adverse events: meta-regression and mediation analysis of placebo-controlled trials. Barbui, C; Barth, M; Cipriani, A; Klostermann, S; Kriston, L; Linde, K, 2016)	0.43
"To investigate the association between adverse events and the efficacy of selective serotonin reuptake inhibitors (SSRIs)."	( Efficacy of selective serotonin reuptake inhibitors and adverse events: meta-regression and mediation analysis of placebo-controlled trials. Barbui, C; Barth, M; Cipriani, A; Klostermann, S; Kriston, L; Linde, K, 2016)	0.43
" Reporting of adverse events was used as an indicator of tolerability."	( Efficacy of selective serotonin reuptake inhibitors and adverse events: meta-regression and mediation analysis of placebo-controlled trials. Barbui, C; Barth, M; Cipriani, A; Klostermann, S; Kriston, L; Linde, K, 2016)	0.43
"Our results do not support, but also do not unequivocally disprove, the hypothesis that adverse events lead to an overestimation of the effect of SSRIs over placebo."	( Efficacy of selective serotonin reuptake inhibitors and adverse events: meta-regression and mediation analysis of placebo-controlled trials. Barbui, C; Barth, M; Cipriani, A; Klostermann, S; Kriston, L; Linde, K, 2016)	0.43
"Many adverse drug reactions are caused by the cytochrome P450 (CYP)-dependent activation of drugs into reactive metabolites."	( Development of a cell viability assay to assess drug metabolite structure-toxicity relationships. Jones, LH; Nadanaciva, S; Rana, P; Will, Y, 2016)	0.43
" The aim of this study was to examine the features and prevalence of adverse effects of paroxetine and sertraline in breastfed infants."	( Short-Term Safety of Paroxetine and Sertraline in Breastfed Infants: A Retrospective Cohort Study from a University Hospital. Arpaci, N; Uguz, F, 2016)	0.98
"The prevalence rate of adverse events in the infants was 12."	( Short-Term Safety of Paroxetine and Sertraline in Breastfed Infants: A Retrospective Cohort Study from a University Hospital. Arpaci, N; Uguz, F, 2016)	0.75
"The results suggest that the prevalence rate of adverse events in the infants exposed to sertraline or paroxetine is relatively low and mostly mild."	( Short-Term Safety of Paroxetine and Sertraline in Breastfed Infants: A Retrospective Cohort Study from a University Hospital. Arpaci, N; Uguz, F, 2016)	0.97
" In the continuation and taper phases combined there were 211 adverse events in the paroxetine group, 147 on imipramine and 100 on placebo."	( Study 329 continuation phase: Safety and efficacy of paroxetine and imipramine in extended treatment of adolescent major depression. Abi-Jaoude, E; Healy, D; Jureidini, J; Le Noury, J; Nardo, JM; Raven, M; Tufanaru, C, 2016)	0.91
" Relapse and adverse events on both active drugs open up the risks of a prescribing cascade."	( Study 329 continuation phase: Safety and efficacy of paroxetine and imipramine in extended treatment of adolescent major depression. Abi-Jaoude, E; Healy, D; Jureidini, J; Le Noury, J; Nardo, JM; Raven, M; Tufanaru, C, 2016)	0.68
"This is the first study to compare frequency of sexual side effect reporting between paroxetine and desipramine."	( A Comparison of Sexual Side Effects of Antidepressants With and Without Naltrexone. Petrakis, I; Ralevski, E; Thapa, M, )	0.36
" The combined dapoxetine with sildenafil therapy could significantly improve PE patients without ED as compared to paroxetine alone or dapoxetine alone or sildenafil alone with tolerated adverse effects."	( Comparison of the clinical efficacy and safety of the on-demand use of paroxetine, dapoxetine, sildenafil and combined dapoxetine with sildenafil in treatment of patients with premature ejaculation: A randomised placebo-controlled clinical trial. Abdelhamed, A; Abu El-Hamd, M, 2018)	0.92
" The laboratory test abnormity, and observed and self-reported adverse events were all assessed as the measurements of safety and tolerability."	( Efficacy and Safety of Agomelatine vs Paroxetine Hydrochloride in Chinese Han Patients with Major Depressive Disorder: A Multicentre, Double-Blind, Noninferiority, Randomized Controlled Trial. Gao, KR; Li, HF; Shen, YF; Yu, H; Yu, YM, 2018)	0.75
" The incidence of overall adverse events was similar in the 2 groups (agomelatine 49."	( Efficacy and Safety of Agomelatine vs Paroxetine Hydrochloride in Chinese Han Patients with Major Depressive Disorder: A Multicentre, Double-Blind, Noninferiority, Randomized Controlled Trial. Gao, KR; Li, HF; Shen, YF; Yu, H; Yu, YM, 2018)	0.75
" Due to many contradictory findings on the adverse effects and toxicities of SSRIs (especially genotoxicities), we reviewed the genotoxic effects of these drugs."	( A Systematic Review on the Genotoxic Effects of Selective Serotonin Reuptake Inhibitors. Abbaszadegan, MR; Ahmadimanesh, M; Hedayati, N; Jamialahmadi, T; Sahebkar, A; Yazdian-Robati, R, 2021)	0.62
" The data analytical platform Molecular Health Effect was utilized to map population ADR data from the US Food and Drug Administration (FDA) Adverse Event Reporting System to chemical and biological databases (such as UniProt and Reactome), for hypothesis generation regarding the underlying molecular mechanisms causing cardiotoxicity."	( A case study of a patient-centered reverse translational systems-based approach to understand adverse event profiles in drug development. Jackson, DB; Kim, S; Lahu, G; Lesko, LJ; Soldatos, TG; Trame, MN; Vakilynejad, M, 2022)	0.72
"5 mg/day) treatment during the first hospitalization did not cause any side effects, but treatment with mirtazapine (15 mg/day) and venlafaxine (150 mg/day) during the second hospitalization caused clonus and disturbance of consciousness, and these adverse effects resulted in a prolonged period of hospitalization."	( A case of mood disorder with severe side effects of antidepressants in association with resistance to thyroid hormone beta with a THRB mutation. Hasegawa, C; Komahashi-Sasaki, H; Maehara, R; Shimoda, K; Yasui-Furukori, N, 2022)	0.72
" Adverse events (AEs) were also recorded."	( Efficacy and Safety of Jianpi Jieyu Decoction for Patients with Mild-to-Moderate Depression of Xin (Heart)-Pi (Spleen) Deficiency Syndrome: A Multi-centre Randomized Controlled Study. Cao, J; Chen, D; Chen, JX; Chen, X; Guo, CL; Han, XY; Hong, X; Jiao, XZ; Jiao, YX; Li, MX; Liang, S; Liu, HM; Meng, S; Qi, JX; Wang, TT; Zhao, Y, 2023)	0.91
" Numerous studies in the past few decades have focused on the beneficial effects of PRX on depression, however, the toxic properties and the potential mechanisms remain unclear."	( Paroxetine induced larva zebrafish cardiotoxicity through inflammation response. Gu, J; Ji, G; Song, F; Wu, L; Wu, W; Zhu, Y, 2023)	2.35

Pharmacokinetics

The objective of this study was to evaluate genetic and pharmacokinetic factors to establish the pharmacotherapeutic effect of paroxetine (PAX) in patients with panic disorder (PD) The time (tmax ) to reach Cmax was 1·37 ± 0·88 (h) for the parent compound and its active metabolite after nebivolol administered alone. Paroxetne influenced nebivilol pharmacokinetics in healthy volunteers, but it did not have a significant effect on nebivlol pharmacodynamic parameters measured at rest.

Excerpt	Reference	Relevance
"The pharmacokinetic properties of the newer specific serotonin (5-HT) reuptake inhibitors are reviewed."	( Pharmacokinetics of the selective serotonin reuptake inhibitors. DeVane, CL, 1992)	0.28
" In nearly all extensive metabolizers the concentration-dose data were best described by a pharmacokinetic model assuming elimination by at least two kinetically distinct processes, one a high-affinity saturable process and one a low-affinity linear process."	( Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Brøsen, K; Gram, LF; Sindrup, SH, 1992)	0.52
" Also, steady-state pharmacokinetic parameters are not predictable from single-dose data."	( A review of the metabolism and pharmacokinetics of paroxetine in man. Greb, WH; Haddock, RE; Kaye, CM; Langley, PF; Mellows, G; Tasker, TC; Zussman, BD, 1989)	0.53
"To evaluate the pharmacokinetic properties, efficacy, and tolerability of paroxetine in elderly depressed patients, a clinical study was set up--initially at Aalborg Psychiatric Hospital in Denmark, and subsequently at the University Hospital in Linköping, Sweden."	( Paroxetine: pharmacokinetic and antidepressant effect in the elderly. Fjord-Larsen, T; Lundmark, J; Manniche, PM; Mengel, H; Møller-Nielsen, EM; Pauser, H; Scheel Thomsen, I; Wålinder, J, 1989)	1.95
" From a clinical point of view, it is of relevance that potency to inhibit the cytochrome P450 isozyme CYP2D6 gradually decreases from paroxetine, fluoxetine, norfluoxetine, desmethylcitalopram, fluvoxamine, and sertraline down to citalopram, explaining to a great extent differences in pharmacokinetic interactions between the SSRIs and tricyclic antidepressants, which are metabolized by this enzyme."	( Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror. Baumann, P; Rochat, B, 1995)	0.49
" The pharmacokinetic and pharmacodynamic properties of paroxetine taken together indicate that this selective serotonin uptake inhibitor seems advantageous to other antidepressant agents because of its high selectivity and poor toxicity."	( [Paroxetine: pharmacokinetics and pharmacodynamics]. Hiemke, C, 1994)	1.45
" An approximately 10-fold increase in the Cmax and AUC(24) of paroxetine and an approximately 2-fold increase in these parameters for sertraline occurred simultaneously with the desipramine concentration changes."	( Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. Alderman, J; Allison, J; Chung, M; Greenblatt, DJ; Harrison, W; Penenberg, D; Preskorn, SH, 1997)	0.79
" In light of recent reports that the selective serotonin reuptake inhibitor antidepressants may be weak CYP3A4 inhibitors, this study was designed to investigate the effects of paroxetine on the pharmacodynamic and pharmacokinetic profile of terfenadine."	( Paroxetine does not affect the cardiac safety and pharmacokinetics of terfenadine in healthy adult men. Benincosa, LJ; Etheredge, RC; Everitt, DE; Jorkasky, DK; Martin, DE; Zussman, BD, 1997)	1.93
"None of the pharmacokinetic parameters of thiothixene were significantly altered by a 3-day treatment with paroxetine."	( The effect of paroxetine on thiothixene pharmacokinetics. Bader, G; Guthrie, SK; Hariharan, M; Kumar, AA; Tandon, R, 1997)	0.87
" Estimation of the mean elimination half-life of clozapine 2 weeks after start of fluvoxamine comedication revealed an increase from 17 hours to about 50 hours whereas there was no change under paroxetine coadministration."	( Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. Anghelescu, I; Härter, S; Hiemke, C; Szegedi, A; Weigmann, H; Wetzel, H; Wiesner, J, 1998)	0.7
" A single 10-mg dose of paroxetine was then administered followed by 5 days of blood and urine collection for pharmacokinetic analyses."	( Paroxetine pharmacokinetics in depressed children and adolescents. Blumer, JL; Branicky, L; Fiala, S; Findling, RL; Myers, C; O'Riordan, MA; Reed, MD; Waldorf, B, 1999)	2.05
" The mean half-life of paroxetine was 11."	( Paroxetine pharmacokinetics in depressed children and adolescents. Blumer, JL; Branicky, L; Fiala, S; Findling, RL; Myers, C; O'Riordan, MA; Reed, MD; Waldorf, B, 1999)	2.06
" They differ, however, in their pharmacokinetic properties."	( Pharmacokinetics of selective serotonin reuptake inhibitors. Härtter, S; Hiemke, C, 2000)	0.31
" At the end of each study week, the steady-state pharmacokinetic parameters of nortriptyline or paroxetine were determined within the dose interval."	( Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Andersson, K; Bertilsson, L; Härtter, S; Laine, K; Svensson, JO; Tybring, G; Widén, J, 2001)	0.79
" The published literature contains a substantial amount of supportive data documenting the safety, tolerability, and pharmacokinetic and pharmacodynamic properties of paroxetine."	( Pharmacokinetics, drug interactions, and tolerability of paroxetine and paroxetine CR. DeVane, CL, 2003)	0.76
" Potential pharmacokinetic advantages of these formulations include lower peak plasma drug concentrations and smaller fluctuations between peak and trough plasma drug concentrations, which might influence the tolerability of these medications."	( Immediate-release versus controlled-release formulations: pharmacokinetics of newer antidepressants in relation to nausea. DeVane, CL, 2003)	0.32
" A comparison is also presented between several methods based on animal pharmacokinetic data, using the same set of proprietary compounds, and it lends further support for the use of this method, as opposed to methods that require the gathering of pharmacokinetic data in laboratory animals."	( Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics. Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY, 2004)	0.32
" The present study reports the pharmacokinetic results of up to eight serum samples per patient."	( Serum disposition of sertraline, N-desmethylsertraline and paroxetine: a pharmacokinetic evaluation of repeated drug concentration measurements during 6 months of treatment for major depression. Aberg-Wistedt, A; Agren, H; Akerblad, AC; Bengtsson, F; Höglund, P; Reis, M, 2004)	0.57
" Pharmacokinetic sampling and safety assessments occurred at baseline and subsequently on the final treatment day of each dosing level."	( Multiple dose pharmacokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive-compulsive disorder. Bartolic, EI; Carpenter, DJ; Danoff, TM; Findling, RL; Fong, R; Gaedigk, A; Gomeni, R; Leeder, JS; Nucci, G; Piergies, AA, 2006)	0.61
"To develop a population pharmacokinetic (PK) model using sparse sampling of long-term treatment with paroxetine in elderly depressed subjects, incorporating CYP2D6 genotype as well as other covariates."	( Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling. Bies, RR; Feng, Y; Ferrell, RE; Kimak, MA; Pollock, BG; Reynolds, CF, 2006)	1.99
" This study investigated the pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole on the basis of 155 drug monitoring samples from psychiatric patients treated with therapeutic doses of aripiprazole (10-30 mg/day)."	( Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients. Lunde, H; Lunder, N; Molden, E; Refsum, H, 2006)	0.33
" Although elimination half-life differed significantly (16."	( Effect of itraconazole on pharmacokinetics of paroxetine: the role of gut transporters. Inoue, Y; Kaneko, S; Niioka, T; Saito, M; Sato, Y; Yasui-Furukori, N, 2007)	0.6
"A rapid and validated liquid chromatography coupled to tandem mass spectrometric method (LC-MS-MS) has been developed and applied to pharmacokinetic and bioequivalence studies in 24 healthy male Korean volunteers."	( Determination of paroxetine in plasma by liquid chromatography coupled to tandem mass spectrometry for pharmacokinetic and bioequivalence studies. Hur, Y; Jeon, YC; Jhee, OH; Kang, JS; Kim, KH; Lee, HS; Lee, MH; Lee, SE; Lee, SH; Seo, HK; Shaw, LM, 2007)	0.68
" The aim of the study was to evaluate the pharmacodynamic and pharmacokinetic interaction between paroxetine and MDMA in humans."	( Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics. Abanades, S; de la Torre, R; Farré, M; O'Mathúna, B; Peiró, AM; Roset, PN; Segura, M; Torrens, M, 2007)	0.78
"The plasma concentration curve of paroxetine following a single oral dose administration conformed to the two-compartment open model."	( [Pharmacokinetics of paroxetine tablet in healthy Chinese volunteers]. Lin, YH; Liu, WX; Liu, WZ; Liu, Y; Wang, HC; Yang, H; Zhu, J, 2008)	0.94
"It can be concluded that the single-dose pharmacokinetic profile of ramosetron 10 microg is not affected to a clinically relevant degree by paroxetine 20 mg once daily administered for 10 days."	( The effect of paroxetine on the pharmacokinetics, safety, and tolerability of ramosetron in healthy subjects. den Adel, M; Kadokura, T; Krauwinkel, WJ; Nishida, A; Takeshige, T, 2008)	0.91
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
"The objective of this study was to evaluate genetic and pharmacokinetic factors affecting the initial pharmacotherapeutic effect of paroxetine (PAX) in Japanese patients with panic disorder (PD)."	( Genetic and pharmacokinetic factors affecting the initial pharmacotherapeutic effect of paroxetine in Japanese patients with panic disorder. Akiyama, K; Hirokane, G; Inoue, Y; Morita, S; Saeki, Y; Saito, A; Shimoda, K; Ueda, M; Watanabe, T; Yamada, N, 2009)	0.78
"To describe a case of flecainide-induced delirium associated with a pharmacokinetic drug interaction with paroxetine."	( Delirium in a patient with toxic flecainide plasma concentrations: the role of a pharmacokinetic drug interaction with paroxetine. Gugger, JJ; Tsao, YY, 2009)	0.78
" A MEDLINE search (1966-January 2009) revealed one in vivo pharmacokinetic study on the interaction between flecainide, a CYP2D6 substrate, and paroxetine, a CYP2D6 inhibitor, as well as 3 case reports of flecainide-induced delirium."	( Delirium in a patient with toxic flecainide plasma concentrations: the role of a pharmacokinetic drug interaction with paroxetine. Gugger, JJ; Tsao, YY, 2009)	0.76
"This randomized, crossover study examined the effects of paroxetine (a potent CYP2D6 inhibitor) on the pharmacokinetic parameters of a single dose of the novel antipsychotic agent, paliperidone extended-release tablets (paliperidone ER), in healthy subjects."	( The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tablets. Berwaerts, J; Chang, I; Cleton, A; Eerdekens, M; Herben, V; van de Vliet, I; van Hoek, P, 2009)	0.95
"Results suggest that no clinically relevant pharmacokinetic interaction occurs when paroxetine and paliperidone ER are co-administered and, therefore, initiation or discontinuation of concomitant treatment with CYP2D6-inhibiting drugs does not appear to warrant an adjustment in paliperidone ER dosage."	( The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tablets. Berwaerts, J; Chang, I; Cleton, A; Eerdekens, M; Herben, V; van de Vliet, I; van Hoek, P, 2009)	0.93
" These results demonstrate a pharmacokinetic interaction between paroxetine and both formulations of metoprolol."	( Influence of metoprolol dosage release formulation on the pharmacokinetic drug interaction with paroxetine. Bleske, BE; Brook, R; Kerber, K; Nielsen, J; Shea, M; Stout, SM; Welage, LS, 2011)	0.83
"to assess the impact of paroxetine coadministration on the stereoselective pharmacokinetic (PK) properties of carvedilol."	( The impact of paroxetine coadministration on stereospecific carvedilol pharmacokinetics. Bleske, BE; Brook, R; Kerber, K; Nielsen, J; Shea, M; Stout, SM; Welage, LS, 2010)	1.03
" We performed a three-way, placebo-controlled, double-blind cross-over study to assess the pharmacokinetic and pharmacodynamic consequences of drug interactions with oxycodone."	( Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Drewe, J; Hammann, F; Krähenbühl, S; Kummer, O; Moser, C; Schaller, O, 2011)	0.37
"Inhibition of CYP3A4 by ketoconazole increases the exposure and some pharmacodynamic effects of oxycodone."	( Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Drewe, J; Hammann, F; Krähenbühl, S; Kummer, O; Moser, C; Schaller, O, 2011)	0.37
" Plasma concentrations of oxycodone and its oxidative metabolites were measured over 48 hours, and pharmacokinetic and pharmacodynamic parameters subsequently evaluated."	( Effect of inhibition of cytochrome P450 enzymes 2D6 and 3A4 on the pharmacokinetics of intravenous oxycodone: a randomized, three-phase, crossover, placebo-controlled study. Grönlund, J; Hagelberg, NM; Laine, K; Neuvonen, PJ; Olkkola, KT; Saari, TI, 2011)	0.37
" However, data on potential drug-drug interactions between tamsulosin and inhibitors of CYP2D6 and 3A4 are limited and information on potential pharmacodynamic consequences of such pharmacokinetic interactions is missing."	( Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin. Mattheus, M; Mehlburger, L; Michel, MC; Tatami, S; Troost, J; Tsuda, Y; Wein, M, 2011)	0.63
"85), respectively, and increased the terminal half-life (t(1/2) ) of tamsulosin HCl from 11."	( Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin. Mattheus, M; Mehlburger, L; Michel, MC; Tatami, S; Troost, J; Tsuda, Y; Wein, M, 2011)	0.63
"The objective of this study was to evaluate genetic and pharmacokinetic factors to establish the pharmacotherapeutic effect of paroxetine (PAX) in patients with panic disorder (PD)."	( Determinants of pharmacodynamic trajectory of the therapeutic response to paroxetine in Japanese patients with panic disorder. Akiyama, K; Hayashi, Y; Inoue, Y; Ishiguro, S; Kato, K; Saeki, Y; Saito, A; Shimoda, K; Ueda, M; Watanabe, T, 2011)	0.81
"After receiving metoprolol on days 1 (before paroxetine) and 8 (after paroxetine), S- and R-metoprolol pharmacokinetic parameters and exercise heart rate and blood pressure responses were measured."	( Effects of paroxetine on the pharmacokinetics and pharmacodynamics of immediate-release and extended-release metoprolol. Parker, RB; Soberman, JE, 2011)	1.02
" The lack of pharmacokinetic data and clinical trials currently limits the use of this drug in clinical avian practice."	( Pharmacokinetics of paroxetine, a selective serotonin reuptake inhibitor, in Grey parrots (Psittacus erithacus erithacus): influence of pharmaceutical formulation and length of dosing. Fink-Gremmels, J; Haritova, A; Lumeij, JT; Schoemaker, NJ; Smit, JW; van Maarseveen, EM; van Zeeland, YR, 2013)	0.71
"Conducting pharmacokinetic (PK) studies in pregnant women is challenging."	( A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women. Isoherranen, N; Ke, AB; Nallani, SC; Rostami-Hodjegan, A; Unadkat, JD; Zhao, P, 2013)	0.39
"To develop a pharmacokinetic model able to describe the nonlinear pharmacokinetics of paroxetine (PRX) and to predict the drug-drug interaction between PRX and metoprolol under various dosage regimens."	( Pharmacokinetic model incorporating mechanism-based inactivation of CYP2D6 can explain both non-linear kinetics and drug interactions of paroxetine. Hori, S; Mikami, A; Ohtani, H; Sawada, Y, 2013)	0.82
"A pharmacokinetic model of PRX incorporating mechanism-based inhibition was developed."	( Pharmacokinetic model incorporating mechanism-based inactivation of CYP2D6 can explain both non-linear kinetics and drug interactions of paroxetine. Hori, S; Mikami, A; Ohtani, H; Sawada, Y, 2013)	0.59
"This Phase I, open-label, single- and multiple-dose study evaluated the pharmacokinetic properties, safety and tolerability of LDMP in postmenopausal, nonsmoking women aged ≥40 years."	( Pharmacokinetic properties of once-daily oral low-dose mesylate salt of paroxetine (LDMP 7.5 mg) following single and multiple doses in healthy postmenopausal women. Bhaskar, S; Cristina Castelli, M; Lippman, J, 2013)	0.62
" Blood samples were collected predose and up to 120 hours postdose on day 1 (single-dose pharmacokinetic profile), at predose (after 12 doses) on day 18, and at predose and up to 24 hours postdose on day 19 (multiple-dose pharmacokinetic profile)."	( Pharmacokinetic properties of once-daily oral low-dose mesylate salt of paroxetine (LDMP 7.5 mg) following single and multiple doses in healthy postmenopausal women. Bhaskar, S; Cristina Castelli, M; Lippman, J, 2013)	0.62
" On day 1, median Tmax was ~6 hours, and mean t1/2 was 17."	( Pharmacokinetic properties of once-daily oral low-dose mesylate salt of paroxetine (LDMP 7.5 mg) following single and multiple doses in healthy postmenopausal women. Bhaskar, S; Cristina Castelli, M; Lippman, J, 2013)	0.62
" We characterized the transplacental transfer of paroxetine in perfused human placenta, fitting a pharmacokinetic model to the results and applying the model and parameters to evaluate a tapered dosage regimen."	( Characterization of transplacental transfer of paroxetine in perfused human placenta: development of a pharmacokinetic model to evaluate tapered dosing. Fujii, T; Hori, S; Matsuoka, S; Nagai, M; Ohtani, H; Satoh, H; Sawada, Y; Taketani, Y, 2013)	0.9
" The pharmacokinetic parameters of nebivolol and its active metabolite were analysed by non-compartmental modelling."	( A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. Achim, M; Bocsan, C; Briciu, C; Buzoianu, A; Gheldiu, AM; Muntean, D; Neag, M; Popa, A; Vlase, L, 2014)	0.64
" The time (tmax ) to reach Cmax was 1·37 ± 0·88 (h) and 3·11 ± 1·76 (h) for the parent compound and its active metabolite after nebivolol administered alone and 3·96 ± 1·76 (h), respectively, 7·33 ± 7·84 (h) after pretreatment with paroxetine."	( A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. Achim, M; Bocsan, C; Briciu, C; Buzoianu, A; Gheldiu, AM; Muntean, D; Neag, M; Popa, A; Vlase, L, 2014)	0.83
" Paroxetine influenced nebivolol pharmacokinetics in healthy volunteers, but it did not have a significant effect on nebivolol pharmacodynamic parameters measured at rest, although the clinical relevance of this drug interaction needs further investigation."	( A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. Achim, M; Bocsan, C; Briciu, C; Buzoianu, A; Gheldiu, AM; Muntean, D; Neag, M; Popa, A; Vlase, L, 2014)	1.55
"Complete absence of paroxetine-induced ejaculation delay is presumably related to pharmacodynamic factors and perhaps to 5-HT1A receptor gene polymorphism."	( Nonresponders to daily paroxetine and another SSRI in men with lifelong premature ejaculation: a pharmacokinetic dose-escalation study for a rare phenomenon. Janssen, PK; Schweitzer, DH; Touw, D; Waldinger, MD, 2014)	1.04
"To evaluate the ability of two biomarkers in reflecting venlafaxine pharmacokinetic variations, and to further examine their relationship with venlafaxine treatment outcomes."	( The influences of CYP2D6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: exploring predictive biomarkers for treatment outcomes. Choi, JY; Chung, MW; Ha, JH; Jiang, F; Kim, HD; Kim, YH; Lee, SY; Na, HS; Seo, DW; Shin, HJ, 2015)	0.42
"Two well-defined influencing factors: CYP2D6 genotypes and drug interactions were enriched into a three-period crossover study to produce venlafaxine pharmacokinetic variations: In each period, healthy CYP2D6 extensive metabolizers (EM group; n = 12) and CYP2D610/10 intermediate metabolizers (IM group; n = 12) were pretreated with clarithromycin (CYP3A4 inhibitor), or nothing (control), or clarithromycin + paroxetine (CYP3A4 + CYP2D6 inhibitors), before administration of a single-dose of 75 mg venlafaxine."	( The influences of CYP2D6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: exploring predictive biomarkers for treatment outcomes. Choi, JY; Chung, MW; Ha, JH; Jiang, F; Kim, HD; Kim, YH; Lee, SY; Na, HS; Seo, DW; Shin, HJ, 2015)	0.58
" Blood samples were collected for pharmacokinetic analysis."	( Study of pharmacokinetic interaction of paroxetine and roxithromycin on bencycloquidium bromide in healthy subjects. Agbokponto, JE; Ding, L; Liang, M; Liu, R; Liu, Z; Luo, Z, 2015)	0.68
" Geometric mean Cmax were 187."	( Study of pharmacokinetic interaction of paroxetine and roxithromycin on bencycloquidium bromide in healthy subjects. Agbokponto, JE; Ding, L; Liang, M; Liu, R; Liu, Z; Luo, Z, 2015)	0.68
" We compared 168 hours pharmacokinetic profiles of both analytes after a single oral 20 mg dose of ibogaine in 21 healthy subjects who had been pretreated for 6 days with placebo or the CYP2D6 inhibitor paroxetine."	( Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers. Garbe, K; Glue, P; Hung, CT; Jakobi, H; Lenagh-Glue, Z; Lyudin, A; Winter, H, 2015)	0.6
" Polysomnography and blood sampling for pharmacokinetic analysis were performed on the pre-dose night and nights 1 and 3 of dosing in each period."	( Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 1, a pharmacokinetic/pharmacodynamic comparison with paroxetine in healthy men. Areberg, J; Buchberg, J; Højer, AM; Nutt, DJ; Wilson, S, 2015)	0.62
" This study examined the influence of the coadministration of paroxetine, a strong selective CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone (and hydromorphone) in healthy adults."	( Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. Cipriano, A; Friedman, K; Harris, SC; Kapil, RP; Michels, G; Mondal, SA; Shet, M, 2015)	1.05
"Hydrocodone mean Cmax and t½ and median Tmax values were similar with paroxetine or placebo coadministration (16."	( Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. Cipriano, A; Friedman, K; Harris, SC; Kapil, RP; Michels, G; Mondal, SA; Shet, M, 2015)	1.04
"This study investigated population pharmacokinetics of paroxetine, and then performed an integrated analysis of exposure and clinical outcome using population pharmacokinetic parameter estimates in depressed patients treated with paroxetine."	( Exposure-outcome analysis in depressed patients treated with paroxetine using population pharmacokinetics. Chun, MR; Chung, MW; Kim, DK; Kim, HD; Kim, JR; Lee, SY; Lim, SW; Myung, W; Na, HS; Woo, HI, 2015)	0.91
" Pharmacokinetic parameters of paroxetine were calculated using non-compartmental analysis with Win-Nonlin software."	( Pharmacokinetics and safety of paroxetine controlled-release tablet in healthy Chinese subjects: a single-dose three-period crossover study. Chen, R; Hu, P; Shen, K, 2016)	1.01
"The absorption of controlled-release paroxetine was delayed with a median tmax of 8 - 10 hours and the mean t1/2 was 12 - 14 hours across all doses."	( Pharmacokinetics and safety of paroxetine controlled-release tablet in healthy Chinese subjects: a single-dose three-period crossover study. Chen, R; Hu, P; Shen, K, 2016)	0.99
" In this study, we attempted to evaluate the degree of the impact of different CYP2D6 genotypes on the pharmacokinetic (PK) variability of paroxetine in a Japanese population using a population PK approach."	( Influence of the cytochrome P450 2D6 10/10 genotype on the pharmacokinetics of paroxetine in Japanese patients with major depressive disorder: a population pharmacokinetic analysis. Aoki, A; Iwashita, K; Matsuda, K; Nakashima, H; Nishimura, M; Ogusu, N; Oniki, K; Ono, T; Saruwatari, J; Shimoda, K; Tsuchimine, S; Ueda, M; Yasui-Furukori, N, 2016)	0.86
" In this article, we report the evidence that contributed to the implementation of pharmacokinetic pharmacogenetic guidelines for antidepressants primarily metabolized by CYP2D6 and CYP2C19."	( Pharmacokinetic Pharmacogenetic Prescribing Guidelines for Antidepressants: A Template for Psychiatric Precision Medicine. Black, JL; Elliott, MA; Frye, MA; Nassan, M; Nicholson, WT; Rohrer Vitek, CR, 2016)	0.43
"In recent years, physiologically based PharmacoKinetic (PBPK) modeling has received growing interest as a useful tool for the assessment of drug pharmacokinetics."	( Prediction of drug-drug interactions using physiologically-based pharmacokinetic models of CYP450 modulators included in Simcyp software. Daali, Y; Desmeules, JA; Marsousi, N; Rudaz, S, 2018)	0.48
"The aim of this work was to predict the extent of Cytochrome P450 2D6 (CYP2D6)-mediated drug-drug interactions (DDIs) in different CYP2D6 genotypes using physiologically-based pharmacokinetic (PBPK) modeling."	( Physiologically-Based Pharmacokinetic Modeling for the Prediction of CYP2D6-Mediated Gene-Drug-Drug Interactions. Daali, Y; Desmeules, J; Storelli, F, 2019)	0.51
"A pharmacokinetic modelling approach was applied to examine gestational changes in trough plasma concentrations for CYP 2D6 phenotypes, followed by necessary dose adjustment strategies to maintain paroxetine levels within a therapeutic range of 20-60 ng/ml."	( Precision dosing-based optimisation of paroxetine during pregnancy for poor and ultrarapid CYP2D6 metabolisers: a virtual clinical trial pharmacokinetics study. Almurjan, A; Badhan, RKS; Macfarlane, H, 2020)	1.02

Compound-Compound Interactions

The role of paroxetine in clinically significant drug-drug interactions has long been suspected, but only isolated cases provide any evidence. The present study tested the effect of different selective 5-HT(1A) receptor antagonists (WAY 100635, NAD-299, p-MPPI and LY 426965) in combination with a SSRI.

Excerpt	Reference	Relevance
" The observation that the binding of some, but not all, ligands requires reduced sulfhydryl groups, suggests that differential mechanisms and/or different binding domains do exist for agents which interact at the neuronal 5-HT transporter."	( Role of essential sulfhydryl groups in drug interactions at the neuronal 5-HT transporter. Differences between amphetamines and 5-HT uptake inhibitors. Kuhn, DM; Wolf, WA, 1992)	0.28
" The case report questions the long term use of pain killers combined with psycho-active drugs in chronic non malignant pain, especially if pain is under control."	( Nightmares and hallucinations after long-term intake of tramadol combined with antidepressants. De Laat, M; Devulder, J; Dumoulin, K; Renson, A; Rolly, G, 1996)	0.29
") was administered in combination with WAY100635 (0."	( Effect of a selective 5-HT reuptake inhibitor in combination with 5-HT1A and 5-HT1B receptor antagonists on extracellular 5-HT in rat frontal cortex in vivo. Gartside, SE; Sharp, T; Umbers, V, 1997)	0.3
" To minimize the potential for an adverse event, the practitioner must remember the drug-drug interactions, and possible consequences when one of these antidepressants is being prescribed."	( Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. Richelson, E, 1997)	0.3
" Here we determined whether the beta-adrenoceptor/5-HT1A receptor ligands (+/-)-pindolol, (-)-tertatolol and (-)-penbutolol, interact with paroxetine in a similar manner."	( Effects of (-)-tertatolol, (-)-penbutolol and (+/-)-pindolol in combination with paroxetine on presynaptic 5-HT function: an in vivo microdialysis and electrophysiological study. Clifford, EM; Cowen, PJ; Gartside, SE; Sharp, T, 1999)	0.73
" Paroxetine, in combination with WAY 100635, attenuated the hypothermic effects of 8-OH-DPAT as early as 3 days, with a full reversal evident following 7 days, whereas paroxetine, although attenuating the hypothermic effects in OB group by day 7, only reversed it fully after 14 days."	( Onset of the effects of the 5-HT1A antagonist, WAY-100635, alone, and in combination with paroxetine, on olfactory bulbectomy and 8-OH-DPAT-induced changes in the rat. Cryan, JF; Leonard, BE; McGrath, C; Norman, TR, 1999)	1.43
" The present study tested the effect of different selective 5-HT(1A) receptor antagonists (WAY 100635, NAD-299, p-MPPI and LY 426965) in combination with a SSRI (paroxetine), on postsynaptic 5-HT function measured by increased expression of the immediate early gene, Arc."	( Effect of different 5-HT1A receptor antagonists in combination with paroxetine on expression of the immediate-early gene Arc in rat brain. Gray, K; Newson, M; Pei, Q; Sharp, T; Sprakes, M; Tordera, R, 2003)	0.75
" The role of paroxetine in clinically significant drug-drug interactions, especially involving metabolic inhibitory effects on the substrates of cytochrome p450 2D6, has long been suspected, but only isolated cases provide any evidence."	( Pharmacokinetics, drug interactions, and tolerability of paroxetine and paroxetine CR. DeVane, CL, 2003)	0.93
" The present findings suggest that NK1 receptor antagonists, when combined with a SSRI, augment 5-HT release by modulating substance P/5-HT interactions in the dorsal raphe nucleus."	( Blockade of substance P (neurokinin 1) receptors enhances extracellular serotonin when combined with a selective serotonin reuptake inhibitor: an in vivo microdialysis study in mice. De Felipe, C; Froger, N; Gardier, AM; Guiard, BP; Guilloux, JP; Hunt, SP; Lanfumey, L; Przybylski, C; Seif, I, 2004)	0.32
"Attempts at predicting drug-drug interactions perpetrated by paroxetine from in vitro data have utilized reversible enzyme inhibition models and have been unsuccessful to date, grossly underpredicting interaction magnitude."	( In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude. Obach, RS; Venkatakrishnan, K, 2005)	0.82
"Patients taking antidepressants are more likely to also be taking multiple medications, increasing the risk of adverse drug-drug interactions (DDIs)."	( The potential for clinically significant drug-drug interactions involving the CYP 2D6 system: effects with fluoxetine and paroxetine versus sertraline. Choi, J; Golbeck, AL; Neff, M; Preskorn, SH; Shah, R, 2007)	0.55
"To observe the clinical efficacy and adverse reactions of Paroxetine combined with electro-acupuncture (EA) in treating depression."	( Clinical observation on treatment of depression by electro-acupuncture combined with Paroxetine. Gong, SH; Liu, JQ; Liu, JS; Liu, S; Shi, ZY; Zhang, GJ, 2007)	0.81
"Forty-two patients with depression were randomly assigned to the observation group (22 patients) treated with EA combined with Paroxetine, and the control group (20 patients) treated with Paroxetine alone, and the therapeutic course for both groups was 6 weeks."	( Clinical observation on treatment of depression by electro-acupuncture combined with Paroxetine. Gong, SH; Liu, JQ; Liu, JS; Liu, S; Shi, ZY; Zhang, GJ, 2007)	0.77
"EA combined with Paroxetine has better clinical efficacy than that of Paroxetine alone, with milder adverse reaction and quicker initiation of effect."	( Clinical observation on treatment of depression by electro-acupuncture combined with Paroxetine. Gong, SH; Liu, JQ; Liu, JS; Liu, S; Shi, ZY; Zhang, GJ, 2007)	0.9
"Flecainide and pharmacologically similar agents that interact with sodium channels may cause delirium in susceptible patients."	( Delirium in a patient with toxic flecainide plasma concentrations: the role of a pharmacokinetic drug interaction with paroxetine. Gugger, JJ; Tsao, YY, 2009)	0.56
" The CYP2D6 inhibitor paroxetine has previously been shown to interact with metoprolol tartrate."	( Influence of metoprolol dosage release formulation on the pharmacokinetic drug interaction with paroxetine. Bleske, BE; Brook, R; Kerber, K; Nielsen, J; Shea, M; Stout, SM; Welage, LS, 2011)	0.9
" They were treated by paroxetine combined with CXM or placebo for 8 weeks."	( [Clinical observation on treatment of major depressive disorder by paroxetine combined with chaihu xiaoyao mixture]. Long, B; Yi, ZH; Zhu, LP, 2010)	0.91
"25] for all analytes, indicating a drug-drug interaction."	( Randomized open-label drug-drug interaction trial of dextromethorphan/quinidine and paroxetine in healthy volunteers. Pope, LE; Schoedel, KA; Sellers, EM, 2012)	0.6
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."	( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012)	0.38
"To observe the clinical efficacy of Yiqiyangxin Chinese medicine compound combined with cognitive therapy on generalized anxiety disorders."	( Efficacy of Yiqiyangxin Chinese medicine compound combined with cognitive therapy in the treatment of generalized anxiety disorders. Ding, JY; Wang, T; Xiao, SR; Xu, GX; Zeng, Y, 2012)	0.38
"A total of 202 generalized anxiety disorders patients were randomly allocated to a control condition (Paroxetine combined with cognitive therapy) or a treatment condition (Yiqiyangxin Chinese medicine compound combined with cognitive therapy)."	( Efficacy of Yiqiyangxin Chinese medicine compound combined with cognitive therapy in the treatment of generalized anxiety disorders. Ding, JY; Wang, T; Xiao, SR; Xu, GX; Zeng, Y, 2012)	0.59
"Yiqiyangxin Chinese medicine compound combined with cognitive therapy can significantly reduce the recurrence after medicine withdrawal and is effective on generalized anxiety disorders."	( Efficacy of Yiqiyangxin Chinese medicine compound combined with cognitive therapy in the treatment of generalized anxiety disorders. Ding, JY; Wang, T; Xiao, SR; Xu, GX; Zeng, Y, 2012)	0.38
"To develop a pharmacokinetic model able to describe the nonlinear pharmacokinetics of paroxetine (PRX) and to predict the drug-drug interaction between PRX and metoprolol under various dosage regimens."	( Pharmacokinetic model incorporating mechanism-based inactivation of CYP2D6 can explain both non-linear kinetics and drug interactions of paroxetine. Hori, S; Mikami, A; Ohtani, H; Sawada, Y, 2013)	0.82
"The developed model enabled us to quantitatively estimate drug-drug interactions of PRX and CYP2D6 substrate drugs, and to predict optimal dosage regimens."	( Pharmacokinetic model incorporating mechanism-based inactivation of CYP2D6 can explain both non-linear kinetics and drug interactions of paroxetine. Hori, S; Mikami, A; Ohtani, H; Sawada, Y, 2013)	0.59
" In this 6-week randomized controlled trial with 4-week follow-up, 160 patients with major depressive disorder (MDD) were randomly assigned to paroxetine (PRX) alone (n = 48) or combined with 18 sessions of manual acupuncture (MA, n = 54) or electrical acupuncture (EA, n = 58)."	( A 6-week randomized controlled trial with 4-week follow-up of acupuncture combined with paroxetine in patients with major depressive disorder. Chen, JQ; Guo, SC; Huang, Y; Li, GL; Lin, RY; Pan, JY; Qu, SS; Wang, CQ; Wong, HK; Zhang, YC; Zhang, ZJ; Zhao, CH, 2013)	0.81
"Given increased knowledge from molecular biology and pharmacology, it is apparent that multiple factors can interact to produce clinically meaningful differences in a drug's effect in specific individuals (i."	( Complexities of personalized medicine: how genes, drug-drug interactions, dosing schedules, and other factors can combine to produce clinically meaningful differences in a drug's effect. Preskorn, SH, 2013)	0.39
" Subjects received a single 45-mg dacomitinib dose alone and in combination with paroxetine (30 mg/day for 10 consecutive days, with dacomitinib administered on day 4) at steady-state levels."	( A phase I open-label study to investigate the potential drug-drug interaction between single-dose dacomitinib and steady-state paroxetine in healthy volunteers. Bello, CL; Boutros, T; Checchio, TM; Giri, N; Kocinsky, HS; LaBadie, RR; Ni, G; Richie, N; Ruiz-Garcia, A, 2014)	0.83
" All the pharmacokinetic parameters presented statistically significant differences when paroxetine was administered with nebivolol."	( A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. Achim, M; Bocsan, C; Briciu, C; Buzoianu, A; Gheldiu, AM; Muntean, D; Neag, M; Popa, A; Vlase, L, 2014)	0.86
"Pharmacogenetics may allow for a personalized treatment, but a combination with clinical variables may further enhance prediction."	( Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: the result of two pooled RCTs. Azuma, J; Kato, M; Kinoshita, T; Nonen, S; Serretti, A; Takekita, Y; Wakeno, M, 2015)	0.42
"To investigate the clinical value of Paroxetine combined with mid-frequency electrical pulse acupoint stimulation (EPAS) in the treatment of premature ejaculation (PE)."	( [Clinical efficacy of Paroxetine combined with mid-frequency electrical pulse acupoint stimulation for premature ejaculation]. Kang, ZP; Li, T; Ouyang, H; Tan, Y; Wang, SH; Wang, WR; Xie, S; Xie, ZP, 2015)	1
"Totally 69 PE patients were equally assigned to receive oral Paroxetine 20 mg/d, mid-frequency EPAS, or oral Paroxetine 10 mg/d combined with mid-frequency EPAS (P + EPAS) , all for 8 weeks."	( [Clinical efficacy of Paroxetine combined with mid-frequency electrical pulse acupoint stimulation for premature ejaculation]. Kang, ZP; Li, T; Ouyang, H; Tan, Y; Wang, SH; Wang, WR; Xie, S; Xie, ZP, 2015)	0.97
"Oral Paroxetine combined with mid-frequency EPAS has a higher safety and efficacy than either Paroxetine or EPAS alone in the treatment of PE."	( [Clinical efficacy of Paroxetine combined with mid-frequency electrical pulse acupoint stimulation for premature ejaculation]. Kang, ZP; Li, T; Ouyang, H; Tan, Y; Wang, SH; Wang, WR; Xie, S; Xie, ZP, 2015)	1.25
" The aim of this study was to determine whether the zolpidem combined with paroxetine would be effective in the treatment of patients with primary insomnia."	( Effect and safety of paroxetine combined with zolpidem in treatment of primary insomnia. Liu, Y; Mao, HJ; Song, MF; Tang, GZ; Wang, SD; Xu, XH; Yin, Y; Yu, ZH, 2017)	1
"Ninety patients meeting DSM-IV criteria for primary insomnia were randomly assigned to 8 weeks of treatment with zolpidem combined with paroxetine (the combined treatment group, n = 45) or zolpidem combined with placebo (the control group, n = 45)."	( Effect and safety of paroxetine combined with zolpidem in treatment of primary insomnia. Liu, Y; Mao, HJ; Song, MF; Tang, GZ; Wang, SD; Xu, XH; Yin, Y; Yu, ZH, 2017)	0.98
"Eight weeks of the zolpidem combined with paroxetine treatment to patients with primary insomnia is more effective than zolpidem treatment only in sleep maintenance and early morning awakenings."	( Effect and safety of paroxetine combined with zolpidem in treatment of primary insomnia. Liu, Y; Mao, HJ; Song, MF; Tang, GZ; Wang, SD; Xu, XH; Yin, Y; Yu, ZH, 2017)	1.04
" This leads to CYP2D6-mediated drug-drug interactions (DDI)."	( The burden and management of cytochrome P450 2D6 (CYP2D6)-mediated drug-drug interaction (DDI): co-medication of metoprolol and paroxetine or fluoxetine in the elderly. Bahar, MA; Borgsteede, SD; Bos, JHJ; Hak, E; Wilffert, B, 2017)	0.66
" This paper examined the effectiveness of rTMS on first episode depressed patients when combined with antidepressant drugs."	( Randomized controlled trial of repetitive transcranial magnetic stimulation combined with paroxetine for the treatment of patients with first-episode major depressive disorder. Chen, WH; Li, N; Li, SX; Lu, L; Shi, L; Song, M; Wang, XY; Wang, YM; Yang, LL, 2017)	0.68
" The magnitude of drug-drug interaction between dextromethorphan and paroxetine was higher in homozygous than in heterozygous subjects (14."	( Impact of CYP2D6 Functional Allelic Variations on Phenoconversion and Drug-Drug Interactions. Daali, Y; Desmeules, J; Lenglet, S; Matthey, A; Storelli, F; Thomas, A, 2018)	0.72
" It has been demonstrated to be informative and helpful to quantify the modification in drug exposure due to specific physio-pathological conditions, age, genetic polymorphisms, ethnicity and particularly drug-drug interactions (DDIs)."	( Prediction of drug-drug interactions using physiologically-based pharmacokinetic models of CYP450 modulators included in Simcyp software. Daali, Y; Desmeules, JA; Marsousi, N; Rudaz, S, 2018)	0.48
"Metoprolol (a CYP2D6 substrate) is often co-prescribed with paroxetine/fluoxetine (a CYP2D6 inhibitor) because the clinical relevance of this drug-drug interaction (DDI) is still unclear."	( The impact of CYP2D6 mediated drug-drug interaction: a systematic review on a combination of metoprolol and paroxetine/fluoxetine. Bahar, MA; Borgsteede, SD; Hak, E; Kamp, J; Wilffert, B, 2018)	0.94
"The aim of this work was to predict the extent of Cytochrome P450 2D6 (CYP2D6)-mediated drug-drug interactions (DDIs) in different CYP2D6 genotypes using physiologically-based pharmacokinetic (PBPK) modeling."	( Physiologically-Based Pharmacokinetic Modeling for the Prediction of CYP2D6-Mediated Gene-Drug-Drug Interactions. Daali, Y; Desmeules, J; Storelli, F, 2019)	0.51
" Preliminary studies have shown that traditional chinese medicine prescriptions combined with paroxetine is effective in treating postpartum depression."	( Paroxetine combined with traditional chinese medicine prescriptions in the treatment of postpartum depression: A systematic review of randomized controlled trials. Gong, A; Wu, Z; Zeng, M, 2022)	2.38
"The meta analysis results show that paroxetine combined with traditional chinese medicine prescriptions can reduce the Hamilton Depression Scale (HAMD) score [WMD = -7."	( Paroxetine combined with traditional chinese medicine prescriptions in the treatment of postpartum depression: A systematic review of randomized controlled trials. Gong, A; Wu, Z; Zeng, M, 2022)	2.44
"In this preliminary study involving healthy participants, paroxetine combined with oxycodone, compared with oxycodone alone, significantly decreased the ventilatory response to hypercapnia on days 1 and 5, whereas quetiapine combined with oxycodone did not cause such an effect."	( Effect of Paroxetine or Quetiapine Combined With Oxycodone vs Oxycodone Alone on Ventilation During Hypercapnia: A Randomized Clinical Trial. Boughner, R; Burkhart, K; Dahan, A; Davis, MC; Florian, J; Ford, K; Gershuny, V; Han, X; Ismaiel, OA; Matta, M; Patel, V; Prentice, K; Racz, R; Rouse, R; Sanabria, C; Shah, A; Stone, M; Strauss, DG; van der Schrier, R; Wang, C; Weaver, J, 2022)	1.37

Bioavailability

Paroxetine is a selective serotonin reuptake inhibitor (SSRI) and is used for the treatment of depression and anxiety problems. It suffers from the drawback of poor oral bioavailability (less than 50%) due to its extensive first pass metabolism.

Excerpt	Reference	Relevance
" They are well absorbed orally but exhibit an extensive first-pass extraction in the liver."	( Pharmacokinetics of the selective serotonin reuptake inhibitors. DeVane, CL, 1992)	0.28
" Paroxetine is well absorbed from the gastrointestinal tract and undergoes first-pass metabolism that is partially saturable."	( The pharmacologic profile of paroxetine, a new selective serotonin reuptake inhibitor. Johnson, AM; Tulloch, IF, 1992)	1.49
"Paroxetine is well absorbed from the gastrointestinal tract, and appears to undergo first-pass metabolism which is partially saturable."	( A review of the metabolism and pharmacokinetics of paroxetine in man. Greb, WH; Haddock, RE; Kaye, CM; Langley, PF; Mellows, G; Tasker, TC; Zussman, BD, 1989)	1.97
" Paroxetine is applied orally at single daily doses of 20 to 50 mg and well absorbed from the gastrointestinal tract."	( [Paroxetine: pharmacokinetics and pharmacodynamics]. Hiemke, C, 1994)	2.11
" Its bioavailability is not affected by food or antacids; its mean half-life of about 24 hours is consistent with once-a-day dosing; also, it has no pharmacologically active metabolites."	( Paroxetine: an overview of the efficacy and safety of a new selective serotonin reuptake inhibitor in the treatment of depression. Nemeroff, CB, 1993)	1.73
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."	( QSAR model for drug human oral bioavailability. Topliss, JG; Yoshida, F, 2000)	0.31
" Paroxetine is well absorbed orally and undergoes extensive first pass metabolism that is partially saturable."	( Paroxetine: a review. Bourin, M; Chue, P; Guillon, Y, 2001)	2.66
" After a sudden recurrence of seizures when generic valproic acid was substituted for the brand-name product, an investigation by the US Food and Drug Administration found a difference in bioavailability between the 2 formulations."	( The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Borgheini, G, 2003)	0.32
" Paroxetine CR delays the onset and controls the rate of absorption of medication."	( Efficacy and tolerability of controlled-release paroxetine. Golden, RN, 2003)	1.48
" The present study demonstrated that the bioavailability of paroxetine was increased by itraconazole, suggesting a possible involvement of P-glycoprotein in the pharmacokinetics of paroxetine."	( Effect of itraconazole on pharmacokinetics of paroxetine: the role of gut transporters. Inoue, Y; Kaneko, S; Niioka, T; Saito, M; Sato, Y; Yasui-Furukori, N, 2007)	0.84
" Moreover, because endogenous gonadal hormones modulate both BDNF expression and serotonin biosynthesis and bioavailability and regulate brain functions like affective and cognitive functions, we proposed to evaluate the effects of a treatment with paroxetine, an SSRI, in a group of postmenopausal women and to clarify the possible relationship between paroxetine, plasma BDNF levels, and climacteric symptoms."	( Paroxetine increases brain-derived neurotrophic factor in postmenopausal women. Bucci, F; Casarosa, E; Cubeddu, A; Genazzani, AR; Giannini, A; Luisi, M; Luisi, S; Merlini, S; Pluchino, N, 2010)	1.98
"The oral bioavailability of some drugs is markedly lower in cynomolgus monkeys than in humans."	( Species differences in intestinal metabolic activities of cytochrome P450 isoforms between cynomolgus monkeys and humans. Komuro, S; Mizuki, Y; Nishimuta, H; Sato, K; Yabuki, M, 2011)	0.37
"6 h) and a low bioavailability (31±15%)."	( Pharmacokinetics of paroxetine, a selective serotonin reuptake inhibitor, in Grey parrots (Psittacus erithacus erithacus): influence of pharmaceutical formulation and length of dosing. Fink-Gremmels, J; Haritova, A; Lumeij, JT; Schoemaker, NJ; Smit, JW; van Maarseveen, EM; van Zeeland, YR, 2013)	0.71
" After that the selected formula of PAX liposomal gel transdermal patch was applied to rabbits for in vivo bioavailability study in comparison with oral administration of the marketed PAX tablet."	( Transdermal drug delivery of paroxetine through lipid-vesicular formulation to augment its bioavailability. Abary, MY; Bendas, ER; El Rehem, RT; El-Nabarawi, MA, 2013)	0.68
"The relative contribution of hepatic compared with intestinal oxidative metabolism is a crucial factor in drug oral bioavailability and therapeutic efficacy."	( Application of a novel regulatable Cre recombinase system to define the role of liver and gut metabolism in drug oral bioavailability. Gilbert, I; Henderson, CJ; McLaren, AW; McLaughlin, LA; Osuna-Cabello, M; Taylor, M; Wolf, CR, 2015)	0.42
" In contrast MAOi antidepressants, that also increase extracellular serotonin bioavailability have little or no effects on this condition."	( Differential modulation of Nav1.7 and Nav1.8 channels by antidepressant drugs. Beaulieu, JM; Chahine, M; Poulin, H; Thériault, O, 2015)	0.42
"Paroxetine is a selective serotonin reuptake inhibitor (SSRI) and is used for the treatment of depression and anxiety problems, but suffers from the drawback of poor oral bioavailability (less than 50%) due to its extensive first pass metabolism."	( Intranasal delivery of paroxetine nanoemulsion via the olfactory region for the management of depression: formulation, behavioural and biochemical estimation. Ali, J; Baboota, S; Gupta, BK; Kumar, S; Pandey, YR, 2016)	2.19
" Also, many of the P2R ligands still lack bioavailability due to charged groups or hydrolytic (either enzymatic or chemical) instability."	( Medicinal chemistry of adenosine, P2Y and P2X receptors. Jacobson, KA; Müller, CE, 2016)	0.43
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" An orally bioavailable GRK2 inhibitor could offer unique therapeutic outcomes that cannot be attained by current heart failure treatments that directly target GPCRs or angiotensin-converting enzyme."	( Hit-to-lead optimization and discovery of a potent, and orally bioavailable G protein coupled receptor kinase 2 (GRK2) inhibitor. DesJarlais, RL; Gaul, MD; Hermans, A; Huang, DZ; Krosky, D; Liu, Z; Lu, HR; Milligan, CM; Petrounia, I; Qi, J; Spurlino, JC; Wang, W; Xu, G; Xu, JZ, 2020)	0.56

Dosage Studied

This paper evaluates the pharmacokinetic properties and potential side effects of single and repeated dosing of paroxetine in Grey parrots. Women exposed to >25 mg/day of parxetine during the first trimester of pregnancy were at increased risk of having an infant with major congenital malformations.

Excerpt	Relevance	Reference
" Following reduction of neuroleptic dosage and addition of paroxetine he developed severe extra-pyramidal side effects."	( Extra pyramidal side effects associated with paroxetine. Nicholson, SD, 1992)	0.79
" A comprehensive review of data on dosage supports the recommendation that 20 mg paroxetine daily is the optimal therapeutic dose for most patients."	( Paroxetine: an overview of dosage, tolerability, and safety. Jenner, PN, 1992)	1.95
"The pharmacology and pharmacokinetics, adverse effects, drug interactions, efficacy, and dosage and administration of the new selective serotonin reuptake inhibitors paroxetine, sertraline, and fluvoxamine are reviewed."	( Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors. Grimsley, SR; Jann, MW, 1992)	1.92
" In dose-response studies (0-200 mg/kg), 50 mg/kg was the threshold dose for Bmax effects and 200 mg/kg was lethal."	( Plasticity and ontogeny of the central 5-HT transporter: effect of neonatal 5,7-dihydroxytryptamine lesions in the rat. Martens, JM; Pranzatelli, MR, 1992)	0.28
" Paroxetine was significantly superior to placebo in the treatment of melancholia and a clear dose-response relationship was established."	( Paroxetine in the treatment of melancholia and severe depression. Dunbar, GC; Stoker, MJ; Tignol, J, 1992)	2.64
"The dose regimen for paroxetine in the treatment of depression has been well established through a number of individual dosing studies and analyses from the worldwide clinical data base."	( Optimal dose regimen for paroxetine. Dunbar, GC; Dunner, DL, 1992)	0.91
" The nausea rarely leads to drug discontinuation or even dosage reduction."	( An overview of paroxetine. Boyer, WF; Feighner, JP, 1992)	0.64
" Plasma concentrations of paroxetine at steady state (8-147 ng/ml) were in the normal range for a 30-mg daily dosing regimen."	( No influence of the antidepressant paroxetine on carbamazepine, valproate and phenytoin. Andersen, BB; Dam, M; Kristensen, HB; Lund, J; Mengel, H; Mikkelsen, M; Pedersen, B; Vesterager, A, )	0.71
" The primary adverse events associated with serotonin reuptake inhibitors involve the gastrointestinal system, although side effects may be less frequent at lower dosage levels."	( Clinical overview of serotonin reuptake inhibitors. Rickels, K; Schweizer, E, 1990)	0.28
"The possible neurotoxic effects of the alpha-ethyl homologue of MDMA, N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine (MBDB), were examined following a regimen of twice daily dosing for four days."	( Neurotoxic effects of the alpha-ethyl homologue of MDMA following subacute administration. Johnson, MP; Nichols, DE, 1989)	0.28
" Elimination half-lives also showed variability between these elderly patients, but tended to be longer after cessation of multiple dosing than after a single dose."	( Paroxetine: pharmacokinetic and antidepressant effect in the elderly. Fjord-Larsen, T; Lundmark, J; Manniche, PM; Mengel, H; Møller-Nielsen, EM; Pauser, H; Scheel Thomsen, I; Wålinder, J, 1989)	1.72
" This selectivity for 5-HT uptake was maintained after oral dosing for 14 days."	( Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Johnson, AM; Nelson, DR; Thomas, DR, 1987)	0.54
" Each drug was administered for 6 weeks after a 1 week run-in period at a daily dosage of 30 mg for paroxetine or 60 mg for mianserin."	( Paroxetine in the treatment of depression. A double-blind multicenter study versus mianserin. Mertens, C; Pintens, H, 1988)	1.93
"The effect of single and repeated dosing of paroxetine on the in vivo noradrenaline uptake process, as determined by tyramine pressor response tests, was evaluated in normal healthy subjects."	( A comparison of the effect of paroxetine and amitriptyline on the tyramine pressor response test. Hassan, SM; Turner, P; Wainscott, G, 1985)	0.82
") both reversed the inhibitory effect of paroxetine and, when used as a pretreatment, caused a pronounced shift to the right of the paroxetine dose-response curve."	( Interaction between a selective 5-HT1A receptor antagonist and an SSRI in vivo: effects on 5-HT cell firing and extracellular 5-HT. Gartside, SE; Hajós, M; Sharp, T; Umbers, V, 1995)	0.56
" At t1/2 of 24 h makes once-daily dosing feasible and allows for new steady-state concentrations and wash-out within a reasonable time after dose adjustment."	( Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline. Preskorn, S, 1994)	0.51
" Two weeks following this dosage regimen, shown to markedly reduce 5-hydroxytryptamine terminals, both glucocorticoid receptor and mineralocorticoid receptor messenger RNA expression were significantly decreased (30-47% fall) in the granule cells of the dentate gyrus and pyramidal cells of CA1-CA4 fields of Ammon's horn, but not in parietal cortex neurons."	( Chronic 3,4-methylenedioxymethamphetamine administration decreases glucocorticoid and mineralocorticoid receptor, but increases 5-hydroxytryptamine1C receptor gene expression in the rat hippocampus. Kelly, PA; Seckl, JR; Sharkey, J; Yau, JL, 1994)	0.29
" In keeping with previous data obtained with other sigma receptor ligands, low doses of sertraline and of clorgyline potentiated selectively with a bell-shaped dose-response curve the effect of N-methyl-D-aspartate (NMDA) on pyramidal neurons in the CA3 region of the rat dorsal hippocampus."	( Modification of the N-methyl-D-aspartate response by antidepressant sigma receptor ligands. Bergeron, R; De Montigny, C; Debonnel, G, 1993)	0.29
"To review the pharmacology, pharmacokinetics, clinical investigations, adverse effects, and dosing strategies of paroxetine as a treatment of major depression."	( Paroxetine: a selective serotonin reuptake inhibiting antidepressant. Caley, CF; Weber, SS, 1993)	1.94
" Our results suggest that brofaromine at the clinically used dosage of 150 mg/day does indeed inhibit 5-HT uptake, as evidenced by measurements of 3H-paroxetine binding to platelets."	( Serotonin uptake inhibition by the monoamine oxidase inhibitor brofaromine. Feldtrauer, JJ; Germer, M; Graf, T; Howald, H; Waldmeier, PC, 1993)	0.49
"With some limitations in interpreting the data, the findings of this study suggest that SSRI-associated female sexual dysfunction occurs at a higher rate than we previously thought, equal potentials in implicating female sexual side effects among three SSRIs, and the absence or the low incidence of female sexual adverse effects from bupropion, and that these side effects can be managed by waiting for a spontaneous remission, dosage reduction of SSRIs, substitution with bupropion and other antidepressants, or the use of an antidote."	( Female sexual side effects associated with selective serotonin reuptake inhibitors: a descriptive clinical study of 33 patients. Hsu, JH; Shen, WW, 1995)	0.29
" They were prescribed the drug for a minimum of 10 weeks, and the maximum dosage was 40 mg/day."	( Adverse events after the abrupt discontinuation of paroxetine. Dominguez, RA; Goodnick, PJ, )	0.38
" At the mean dosage of 47."	( Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation. Chale, RA; Chartier, MJ; Coté, D; Hazen, AL; Kroft, CD; Stein, MB; Walker, JR, 1996)	1.74
" The dosage was designed as a fixed-adjustable regimen for an active treatment period of six weeks."	( Paroxetine in the treatment of Chinese patients with depressive episode: a double-blind randomized comparison with imipramine. Chan, CH; Chiu, HJ; Hong, CJ, 1996)	1.74
" Indeed, planned pharmacokinetic drug interactions at the level of P450s have been proposed to reduce cyclosporine dosage requirements, to reduce variability of TCA levels, and to manipulate the contribution of alternative metabolic pathways to minimize toxic effects."	( Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part II. Harvey, AT; Preskorn, SH, 1996)	0.29
" Neither d-fenfluramine, paroxetine, or ipsapirone following acute dosage had a statistically significant effect on nocturnal melatonin synthesis."	( Nocturnal plasma melatonin concentrations in healthy volunteers: effect of single doses of d-fenfluramine, paroxetine, and ipsapirone. Burrows, GD; Nathan, PJ; Norman, TR, 1996)	0.81
" After 5 days of therapy the patient reported no adverse effects, and the paroxetine dosage was increased to 20 mg every morning."	( Possible paroxetine-induced bruxism. Adler, DA; Bungay, KM; Romanelli, F, 1996)	0.94
"Eighty patients aged between 20-65 years and suffering from bipolar disease according to DSM IV criteria, were treated with paroxetine for os at the single dosage of 20-40 mg/die."	( [Efficacy and tolerability of paroxetine in the treatment of the depressive phase of bipolar disorders]. Ambrosio, LA; Barrese, E; Buccomino, D; Filippo, A; Marchese, G; Morelli, A; Musacchio, R; Pupo, F; Romano, FE, 1996)	0.79
" We discuss a possible relation between serotonin syndrome and a highly dosed combination therapy with moclobemide."	( [Depressive stupor--malignant neuroleptic syndrome--serotonin syndrome. A case contribution to a difficult differential diagnosis]. König, F; Löble, M; Wolfersdorf, M, 1996)	0.29
" The dose-response curve was biphasic for citalopram with a maximum of 64% inhibition."	( Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike? Meier, E; Sánchez, C, 1997)	0.3
" 15 HIV-infected subjects (10 patients with a major depressive episode and 5 patients with an adjustment disorder with depressed mood, according to the DSM IV diagnostic criteria) were administered paroxetine at a daily dosage of 20 mg."	( Efficacy of paroxetine for the treatment of depression in the context of HIV infection. Gambini, O; Garghentini, G; Grassi, B; Lazzarin, A; Scarone, S, 1997)	0.86
"Sixty patients were randomly assigned to receive dosage titrated upward to between 50-150 mg/day of fluvoxamine (N = 30) or 20-50 mg/day of paroxetine (N = 30)."	( A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients. Feiger, A; Kiev, A, 1997)	0.76
"63 mmol/l, and 693 ng/ml, respectively; the latter was six times higher than the upper concentrations seen in patients on this dosage of the drug."	( Serotonin syndrome after lithium add-on medication to paroxetine. Bagli, M; Laux, G; Rao, ML; Sobanski, T, 1997)	0.55
" Dosage was flexible (5-30 mg/day); also, the patients were free to chose between continuous medication and medication in the luteal phase only."	( A naturalistic study of paroxetine in premenstrual syndrome: efficacy and side-effects during ten cycles of treatment. Andersch, B; Eriksson, E; Sundblad, C; Wikander, I, 1997)	0.6
" On the final day of coadministration, the rate-corrected QT interval (QTc) was unaltered compared with terfenadine dosed alone; maximum QTc values (mean [SEM]) were 404 (4) and 405 (5) msec, respectively."	( Paroxetine does not affect the cardiac safety and pharmacokinetics of terfenadine in healthy adult men. Benincosa, LJ; Etheredge, RC; Everitt, DE; Jorkasky, DK; Martin, DE; Zussman, BD, 1997)	1.74
" On re-exposition with a lower clozapine dosage the increase was significantly lower."	( Dose-dependent pharmacokinetic interaction of clozapine and paroxetine in an extensive metabolizer. Ewald, R; Frank, UG; Joos, AA; Kaschka, WP; König, F; Mörike, KE, 1997)	0.54
" Thus, in all patients, fluvoxamine induced relevant increases in serum concentrations of clozapine and its metabolites, probably by the inhibition of enzymes catalyzing the degradation of clozapine and N-desmethylclozapine, whereas paroxetine, at a usual clinically effective dosage of 20 mg/day, did not cause significant pharmacokinetic interactions."	( Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. Anghelescu, I; Härter, S; Hiemke, C; Szegedi, A; Weigmann, H; Wetzel, H; Wiesner, J, 1998)	0.69
") After initiating morphine or making any change of dose or route of administration, the dosage should be evaluated after approximately 24 hours."	( The management of chronic pain in patients with breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Canadian Society of Palliative Care Physicians. Canadian Association of Radiation Oncologist , 1998)	0.3
"), shifted the dose-response relationships to the right for each of the antidepressant agents (dothiepin, amitriptyline, sibutramine, (+)-oxaprotiline and paroxetine)."	( The involvement of the opioidergic system in the antinociceptive mechanism of action of antidepressant compounds. Gray, AM; Sewell, RD; Spencer, PS, 1998)	0.5
" The initial daily dosage of paroxetine (or placebo) was 20 mg with increases of 10 mg/d weekly (flexible dosing to a maximum of 50 mg/d) permitted after the second week of treatment."	( Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. Bushnell, W; Gergel, I; Liebowitz, MR; Lydiard, RB; Pitts, CD; Stein, MB, 1998)	2.03
" The purpose of this study was to assess whether there was a difference in expenditures during the first 90 days of SSRI therapy with paroxetine or sertraline versus fluoxetine in patients who were also receiving a stable dosage of a nonpsychiatric drug also metabolized by the CYP-450 2D6 or 3A4 isoenzyme systems."	( Economic consequences of selective serotonin reuptake inhibitor use with drugs also metabolized by the cytochrome P-450 system. Croghan, TW; Crown, WH; Hylan, TR; Melfi, CA; Meneades, LM; Ozminkowski, RJ; Robinson, RL, )	0.33
" Cost, number of prescriptions, and dosage strength data is also presented."	( Trends in the use of selective serotonin reuptake inhibitors in nine Department of Veterans Affairs outpatient facilities. Voris, JC, 1999)	0.3
" An antidepressant drug utilization review study performed in two different HMO models revealed important variations among available SSRI therapies in terms of dosage escalation and discontinuation, as well as concomitant medication costs associated with treating side effects."	( Antidepressant utilization in managed care: an evaluation of SSRI use in two HMO settings. Navarro, R; Spangler, M; Valler, WE, 1995)	0.29
" While one group of investigators suggested that the overall cost of administering paroxetine may also be less than that for fluoxetine and sertraline when drug costs and labour costs associated with dosage adjustment are taken into account, more data are required before conclusions on the relative pharmacoeconomic merits of SSRIs can be made."	( Paroxetine. A pharmacoeconomic evaluation of its use in depression. Whittington, R; Wilde, MI, 1995)	1.96
" Efficacy was assessed weekly with the 21-item Hamilton Rating Scale for Depression (HAM-D) and the Clinical Global Impression Scale (CGI), and safety was assessed with the Dosage Record and Treatment Emergent Symptom Scale."	( Paroxetine and amitriptyline augmentation of lithium in the treatment of major depression: a double-blind study. Bauer, M; Meister, W; Müller-Oerlinghausen, B; Zaninelli, R, 1999)	1.75
" From week 7-12, dosing could be adjusted biweekly, as required (paroxetine 20-50 mg/day, and fluoxetine 20-80 mg/day)."	( A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder. Bakish, D; Beauclair, L; Bélanger, MC; Chouinard, G; Manchanda, R; Morris, P; O'Neill, MC; Ravindran, A; Reesal, R; Remick, R; Saxena, B; Vasavan Nair, NP, 1999)	0.8
" When the dosage was diminished very gradually the symptoms were mild."	( [Severe withdrawal symptoms with fever during paroxetine tapering off]. Peeters, FP; Zandbergen, J, 1999)	0.56
" Paroxetine did not have to be discontinued in any of the patients because of side effects; the most serious side effects included hyperactivity/behavioral activation in 3 younger patients (< 10 years) necessitating dosage reduction but not discontinuation."	( Paroxetine open-label treatment of pediatric outpatients with obsessive-compulsive disorder. Carroll, E; Fitzgerald, KD; Rosenberg, DR; Stewart, CM; Tawile, V, 1999)	2.66
" In each session, dose-response curves to both locally infused noradrenaline acid tartrate (0."	( Comparison of the effects of venlafaxine, desipramine, and paroxetine on noradrenaline- and methoxamine-evoked constriction of the dorsal hand vein. Abdelmawla, AH; Bradshaw, CM; Langley, RW; Szabadi, E, 1999)	0.55
" Five-day repeat dosing of a typical SSRI, paroxetine, increased climbing, a distinctive antidepressive behavior, 1 h after but not 1 h before treatment."	( Effects of repeated selective serotonin reuptake inhibitor paroxetine treatments on mouse forced swimming. Akagawa, Y; Hishikawa, Y; Maruyama, A; Masuda, Y; Shimizu, T, 1999)	0.81
" However, there is no data on the dosage of selective serotonin uptake inhibitors (SSRIs) required to maintain symptom resolution in women treated for major depression during pregnancy."	( Dose of selective serotonin uptake inhibitors across pregnancy: clinical implications. Hostetter, A; Llewellyn, A; McLaughlin, E; Stowe, ZN; Strader, JR, 2000)	0.31
" Thirty-three subjects with DSM-IV panic disorder, with or without agoraphobia, were randomized to receive either paroxetine or a placebo with flexible dosing (10-50 mg/day)."	( Do selective serotonin re-uptake inhibitors enhance the efficacy of very brief cognitive behavioral therapy for panic disorder? A pilot study. Chartier, MJ; Graham, R; Ron Norton, G; Stein, MB; Walker, JR, 2000)	0.52
") using the same dosing regimen as described above."	( Sibutramine does not decrease the number of 5-HT re-uptake sites in rat brain and, like fluoxetine, protects against the deficits produced by dexfenfluramine. Cheetham, SC; Heal, DJ; Slater, NA; Viggers, JA, 2000)	0.31
"Fifty-seven highly recurrent unipolar patients, excluded from previous long-term studies with selective serotonin reuptake inhibitors (SSRIs) after they experienced a new recurrence, were acutely treated with the full dosage of the SSRIs they were on."	( Will a second prophylactic treatment with a higher dosage of the same antidepressant either prevent or delay new depressive episodes? Bongiorno, F; Franchini, L; Rossini, D; Smeraldi, E; Spagnolo, C; Zanardi, R, 2000)	0.31
" In vivo platelet activation, secretion, and dose-response aggregation of the controls and patients was measured after overnight bedrest under basal conditions, and after a mild exercise challenge."	( Platelet reactivity in depressed patients treated with paroxetine: preliminary findings. Baron, A; Hanson, SR; Knight, BT; Manatunga, A; Marzec, UM; Musselman, DL; Nemeroff, CB; Penna, S; Reemsnyder, A, 2000)	0.55
" It is also suggested that positron emission tomography may be used to define therapeutic dosing early on in the process of clinical evaluation of new treatment strategies."	( Pindolol augmentation of antidepressant treatment: recent contributions from brain imaging studies. Broft, A; Laruelle, M; Martinez, D, 2000)	0.31
" The maternal fixed dosage of paroxetine was 10, 20, or 40 mg/day for a minimum of 30 days before the samples were drawn."	( Paroxetine levels in postpartum depressed women, breast milk, and infant serum. Kim, J; Kostaras, X; Misri, S; Riggs, KW, 2000)	2.04
" Tremor activity was assessed weekly, quantitatively by accelerometry and qualitatively with the Dosage Record and Treatment Emergent Symptom Scale."	( Changes in quantitatively assessed tremor during treatment of major depression with lithium augmented by paroxetine or amitriptyline. Bauer, M; Jobert, M; Müller-Oerlinghausen, B; Zaninelli, R, 2001)	0.52
" The risk appears to be greater with higher dosage therapy."	( Retinopathy associated with high-dose interferon alfa-2b therapy. Aaberg, TM; Greiner, K; Hejny, C; Lawson, DH; Sternberg, P, 2001)	0.31
" To determine whether selective serotonin reuptake inhibitors (SSRI) induced hypomania is secondary to medication effects, we examined the dose-response relationship of SSRI-induced hypomania in two patients with depressive disorder."	( Dose-response relationship of selective serotonin reuptake inhibitors treatment-emergent hypomania in depressive disorders. Ramasubbu, R, 2001)	0.31
"Paroxetine, with a daily dosage from 20 to 40 mg, is an effective tool in normalizing the metabolic status of CYP2D6 ultrarapid metabolizers."	( Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Andersson, K; Bertilsson, L; Härtter, S; Laine, K; Svensson, JO; Tybring, G; Widén, J, 2001)	2.01
"Selective serotonin reuptake inhibitors are commonly used to treat major depression; however, the percentage of serotonin (5-HT) transporter (5-HTT) sites occupied during clinical dosing is unknown."	( Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study. Ginovart, N; Goulding, V; Hood, K; Houle, S; Hussey, D; Meyer, JH; Wilson, AA, 2001)	0.58
" Paroxetine (n = 6) or placebo (n = 9) was given in a double-blind format for 8 weeks using a flexible dosing schedule."	( Paroxetine for social anxiety and alcohol use in dual-diagnosed patients. Brady, KT; Davidson, JR; Johnson, MR; Randall, CL; Sonne, SC; Thevos, AK; Thomas, SE; Willard, SL, 2001)	2.66
" Thirty men with an intravaginal ejaculation latency time (IELT) less than 1 minute were randomly assigned to receive paroxetine (20 mg/day) and citalopram (20 mg/day) for 5 weeks, after taking half the dosage in the first week."	( SSRIs and ejaculation: a double-blind, randomized, fixed-dose study with paroxetine and citalopram. Olivier, B; Waldinger, MD; Zwinderman, AH, 2001)	0.75
" Secondary criteria confirmed the antidepressant efficacy of both medications, with no difference between tianeptine and paroxetine (Hamilton Depression Rating Scale global score at endpoint, Clinical Global Impression final scores, number of responders, delay-to-response, rate of dosage doubling at day 21)."	( Efficacy and safety of tianeptine in major depression: evidence from a 3-month controlled clinical trial versus paroxetine. Azoulay, P; Septien, L; Waintraub, L, 2002)	0.73
" Further data analyses are needed to determine whether more specific guidelines for paroxetine dosage escalation in social anxiety disorder can be drawn."	( A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. Carpenter, D; Liebowitz, MR; Oakes, R; Pitts, CD; Stein, MB; Tancer, M, 2002)	0.79
" However, the time course for maximum inhibition to occur or for inhibition to dissipate when dosing is discontinued, requires clarification."	( Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline, and paroxetine in healthy volunteers. Boulton, DW; DeVane, CL; Goldman, J; Liston, HL; Markowitz, JS; Risch, SC, 2002)	0.53
" This raises the important question of whether once-weekly enteric-coated fluoxetine, 90 mg, is effective for maintenance of response in patients whose depressive symptoms have responded to daily dosing with selective serotonin reuptake inhibitors (SSRIs) such as citalopram, paroxetine, or sertraline."	( Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression. Brown, EB; Gonzales, JS; Miner, CM; Munir, R, 2002)	0.76
" In addition, the different dose-response to fluvoxamine suggests that 5-HT(1B) knockout mice have possible adaptations of 5-HT transporters in order to compensate for the loss of the terminal 5-HT(1B) autoreceptor."	( The effects of selective serotonin reuptake inhibitors on extracellular 5-HT levels in the hippocampus of 5-HT(1B) receptor knockout mice. De Groote, L; Olivier, B; Westenberg, HG, 2002)	0.31
"For paroxetine and fluoxetine, plasma concentrations and dosage strongly influence the magnitude of enzyme inhibition."	( CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6. Alfaro, CL; Ereshefsky, L; Gaedigk, A; Lam, YW; Simpson, J, 2002)	0.87
" To ameliorate or avoid the associated symptoms, client education is recommended, and dosage tapering is encouraged whenever possible."	( Selective serotonin reuptake inhibitor. Discontinuation syndrome. Finfgeld, DL, 2002)	0.31
"To investigate a dose-response relationship for paroxetine administration, and to determine whether a lower dose of paroxetine is sufficient to increase plasma ACTH and cortisol."	( Paroxetine as a 5-HT neuroendocrine probe. Inoue, N; Iwakawa, M; Kojima, H; Nakamura, J; Shiraishi, Y; Soeda, S; Son, Y; Soya, A; Terao, T; Ueda, N; Yoshimura, R, 2003)	2.02
"A self-control and follow-up study on subclinical dosage of antidepressants therapy (fluoxetine 10 mg/d, paroxetine 10 mg/d or doxepin 45 mg/d) for 9-12 wks in 46 patients with refractory IBS symptoms according to Rome II criteria was performed, the clinical outcomes were evaluated by scales changes of symptom-related-anxiety, severity index of symptom, and quality of life specific of IBS, as well as general psychiatric health by SCL-90 during treatment and follow-up periods."	( [Treatment of refractory irritable bowel syndrome with subclinical dosage of antidepressants]. Pan, GZ; Qian, JM; Wang, WA, 2003)	0.53
"Treatment of refractory IBS with subclinical dosage antidepressant is rational and effective, However a further study on its mechanisms is suggested."	( [Treatment of refractory irritable bowel syndrome with subclinical dosage of antidepressants]. Pan, GZ; Qian, JM; Wang, WA, 2003)	0.32
" Twenty-four men with an intravaginal ejaculation latency time (IELT) less than 1 minute were randomly assigned to paroxetine (20 mg/d) or mirtazapine (30 mg/d) for a period of 6 weeks; half the dosage was given in the first week."	( Antidepressants and ejaculation: a double-blind, randomized, fixed-dose study with mirtazapine and paroxetine. Olivier, B; Waldinger, MD; Zwinderman, AH, 2003)	0.75
" Considerations of the pharmacokinetic properties of paroxetine support a rationale for the development of new dosage forms that maintain the efficacy yet improve the tolerability profile of the selective serotonin reuptake inhibitors."	( Pharmacokinetics, drug interactions, and tolerability of paroxetine and paroxetine CR. DeVane, CL, 2003)	0.81
" The described methods were successfully employed with high degrees of precision and accuracy for the estimation of total drug content in human plasma and pharmaceutical dosage forms of POT."	( Voltammetric and HPLC techniques for the determination of paroxetine hydrochloride. Biryol, I; Erk, N, 2003)	0.56
"Limited information is available regarding optimal dosing or long-term pharmacotherapy with serotonin reuptake inhibitors in obsessive-compulsive disorder."	( Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. Allen, A; Burnham, DB; Hollander, E; Oakes, R; Steiner, M; Wheadon, DE, 2003)	0.54
" In phase 2, 263 phase 1 completers were enrolled in 6 months of flexibly dosed open-label paroxetine treatment."	( Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. Allen, A; Burnham, DB; Hollander, E; Oakes, R; Steiner, M; Wheadon, DE, 2003)	0.76
" During weeks 7 through 10, patients received the dosage determined during the titration period."	( Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control. Rosenthal, M, 2003)	0.53
" The reduction in left amygdala volume in patients correlated significantly with higher paroxetine dosage at the time of the follow-up scan and total cumulative paroxetine exposure between the scans."	( Amygdala volume reductions in pediatric patients with obsessive-compulsive disorder treated with paroxetine: preliminary findings. Banerjee, SP; Ivey, J; Lorch, E; MacMillan, S; Madden, R; McMeniman, M; Moore, GJ; Rosenberg, DR; Szeszko, PR, 2004)	0.76
" The mean levodopa equivalent dosage (LED) was 1010+/-318 mg before surgery and 116+/-93 mg 3 months after surgery."	( Effects of deep brain stimulation of the subthalamic nucleus on sleep architecture in parkinsonian patients. Bergamasco, B; Cicolin, A; Fattori, E; Guastamacchia, G; Lanotte, MM; Lopiano, L; Makrydakis, G; Mutani, R; Tavella, A; Terreni, A; Torre, E; Zibetti, M, 2004)	0.32
"5 mg/d, are reasonable initial dosages, and if symptoms do not improve within a week or two, the dosage can be doubled."	( Management of hot flashes in breast cancer survivors and men with prostate cancer. Stearns, V, 2004)	0.32
" Multiple SSRI dosing ranges were evaluated in autistic patients of different ages with various functional impairments."	( Treating functional impairment of autism with selective serotonin-reuptake inhibitors. Eichner, SF; Jones, JR; Moore, ML, 2004)	0.32
" After a baseline week of documentation of the frequency of hot flashes, patients were assigned to receive paroxetine; the initial dosage was 12."	( Pilot evaluation of paroxetine for treating hot flashes in men. Barton, DL; Carpenter, LA; Christensen, BJ; Gettman, MT; Loprinzi, CL; Novotny, PJ; Sloan, JA, 2004)	0.86
"Paroxetine controlled release (CR) is approved for the treatment of major depressive disorder (MDD) in the dosage range of 25 to 62."	( Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder. Carfagno, ML; Dillingham, KE; Perera, P; Pigotti, TA; Pitts, CD; Trivedi, MH, 2004)	2.05
"The Hamilton Depression Rating Scale-17 and Geriatric Depression Scale, severity of adverse events and dosing compliance indexes, and discontinuations due to adverse events."	( Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Hollander, SB; Kremer, C; Murphy, GM; Rodrigues, HE; Schatzberg, AF, 2004)	0.55
" Paxil was prescribed in an initial dosage of 20 mg daily during 12 weeks."	( [Clinical effects of paxil in poststroke rehabilitation]. Poverennova, IE; Zolotovskaia, IA, 2005)	0.33
"Three simple and sensitive spectrophotometric methods were developed and validated for determination of the hydrochloride salts of fluoxetine, sertraline, and paroxetine in their pharmaceutical dosage forms."	( Development and validation of spectrophotometric methods for determination of fluoxetine, sertraline, and paroxetine in pharmaceutical dosage forms. Darwish, IA, )	0.54
"Patients withdrawn from CT were allowed no more than 3 booster sessions during continuation; patients assigned to continuation medication were kept at full dosage levels."	( Prevention of relapse following cognitive therapy vs medications in moderate to severe depression. Amsterdam, JD; DeRubeis, RJ; Freeman, BB; Gallop, R; Haman, KL; Hollon, SD; Lovett, ML; O'Reardon, JP; Salomon, RM; Shelton, RC; Young, PR, 2005)	0.33
"We analyzed paroxetine concentrations in serum of 46 depressed patients during treatment with a fixed dosage of 40 mg paroxetine."	( Paroxetine serum concentrations in depressed patients and response to treatment. Deuschle, M; Gilles, M; Härtter, S; Heuser, I; Hiemke, C; Kellner, S; Krumm, B; Shams, M, 2005)	2.15
"It is concluded that paroxetine at a dosage of 20 mg once daily for 3 consecutive days significantly inhibits the metabolism of tramadol to its active metabolite M1 and reduces but does not abolish the hypoalgesic effect of tramadol in human experimental pain models, particularly in opioid-sensitive tests."	( Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. Brøsen, K; Enggaard, TP; Laugesen, S; Pedersen, RS; Sindrup, SH, 2005)	2.09
"This clinical trial evaluated luteal phase dosing with paroxetine controlled release (CR) (12."	( Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder. Bergeron, R; Gee, MD; Hirschberg, AL; Holland, F; Steiner, M; Van Erp, E, 2005)	0.88
"A multicenter, randomized, double-blind, placebo-controlled, 3-arm, fixed-dose study of luteal phase dosing with paroxetine CR in the treatment of PMDD."	( Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder. Bergeron, R; Gee, MD; Hirschberg, AL; Holland, F; Steiner, M; Van Erp, E, 2005)	0.84
"For the treatment of PMDD, luteal phase dosing with 12."	( Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder. Bergeron, R; Gee, MD; Hirschberg, AL; Holland, F; Steiner, M; Van Erp, E, 2005)	0.63
" However, the optimal dosing schedule of pindolol remains controversial."	( A mathematical model for paroxetine antidepressant effect time course and its interaction with pindolol. Dauphin, A; Gruwez, B; Tod, M, 2005)	0.63
"The current study examined the pharmacokinetics (PK), safety, and tolerability of paroxetine after repeated multiple oral dosing in children and adolescents with major depressive or obsessive-compulsive disorder."	( Multiple dose pharmacokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive-compulsive disorder. Bartolic, EI; Carpenter, DJ; Danoff, TM; Findling, RL; Fong, R; Gaedigk, A; Gomeni, R; Leeder, JS; Nucci, G; Piergies, AA, 2006)	0.84
"Rexetin was used in the dosage of 20-60 mg daily during 6 weeks in the treatment of 25 patients with depression."	( [Rexetin in the therapy of depressive states]. Bobrov, AS; Kovaleva, AV; Pavlova, ON; Petrun'ko, OV, 2005)	0.33
" Antidepressant medication costs, however, are significantly higher when fluoxetine is the initial SSRI rather than sertraline or paroxetine, reflecting the larger proportion of fluoxetine patients prescribed a daily dosage of two or more capsules."	( Comparing SSRI treatment costs for depression using retrospective claims data: the role of nonrandom selection and skewed data. Berndt, ER; Colucci, SV; Grudzinski, AN; Miceli, R; Russell, JM; Xu, Y, )	0.34
" Dosing strategies for the SSRIs sertraline and paroxetine are provided, and an algorithm for PTSD pharmacotherapy is discussed."	( Pharmacologic treatment of acute and chronic stress following trauma: 2006. Davidson, JR, 2006)	0.59
" The data indicate that female and male subjects with different CYP2D6 polymorphisms have different elimination rates and therefore may need to be dosed differently based on metabolizer genotype."	( Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling. Bies, RR; Feng, Y; Ferrell, RE; Kimak, MA; Pollock, BG; Reynolds, CF, 2006)	1.78
" After three weeks on paroxetine, he was given another trial of clozapine at a starting dosage of 25 mg/daily."	( Fatal neuroleptic malignant syndrome in a previously long-term user of clozapine following its reintroduction in combination with paroxetine. Bernabei, R; Capurso, S; Gambassi, G; Liperoti, R; Tarsitani, P, 2006)	0.85
" No dosage adjustment should be required when lasofoxifene is coadministered with ketoconazole, fluconazole, paroxetine or other agents that inhibit these CYP enzymes."	( Effects of three cytochrome P450 inhibitors, ketoconazole, fluconazole, and paroxetine, on the pharmacokinetics of lasofoxifene. Bramson, C; Gardner, M; Milton, A; Ouellet, D; Randinitis, E; Remmers, AE; Roman, D, 2007)	0.78
" The two groups were compared for sex, age, maintenance dosage of paroxetine, duration of treatment with paroxetine, presence of adverse reactions in the early phase of treatment with paroxetine, and method of paroxetine withdrawal (abrupt or tapered)."	( Discontinuation syndrome associated with paroxetine in depressed patients: a retrospective analysis of factors involved in the occurrence of the syndrome. Himei, A; Okamura, T, 2006)	0.84
" The occurrence of the discontinuation syndrome did not correlate with sex, maintenance dosage of paroxetine or duration of treatment with the drug."	( Discontinuation syndrome associated with paroxetine in depressed patients: a retrospective analysis of factors involved in the occurrence of the syndrome. Himei, A; Okamura, T, 2006)	0.82
" It appears that the discontinuation syndrome can be prevented by carefully tapering the dosage of paroxetine when treatment is withdrawn."	( Discontinuation syndrome associated with paroxetine in depressed patients: a retrospective analysis of factors involved in the occurrence of the syndrome. Himei, A; Okamura, T, 2006)	0.82
" Those not rated as significantly improved were then randomly assigned to placebo (N = 27) or paroxetine (N = 25) for 10 weeks, with a flexible dosage design (maximum 60 mg by week 7)."	( A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults. Blanco, C; Garcia, W; Lewis-Fernandez, R; Liebowitz, MR; Lin, SH; Marshall, RD; Neria, Y; Sanchez-Lacay, A; Schneier, F; Simpson, HB; Vermes, D, 2007)	0.87
"To determine if voluntary prescription change forms for antidepressant drugs could induce dosing changes and reduce the cost of antidepressant therapy in a Medicaid population."	( Initial results of the use of prescription order change forms to achieve dose form optimization (consolidation and tablet splitting) of SSRI antidepressants in a state Medicaid program. Hamer, AM; Hartung, DM; Haxby, DG; Ketchum, KL; Pollack, DA, )	0.13
" A more intensive dosing regimen (10 or 20 mg/kg twice daily for 4 days) was used to examine PMA/MDMA effects on cortical 5-HT content."	( Repeated administration of the substituted amphetamine p-methoxyamphetamine produces reductions in cortical 5-HT transporter binding but not 5-HT content, unlike 3,4-methylenedioxyamethamphetamine. Callaghan, PD; Daws, LC; Farrand, K; Hughes, P; Irvine, RJ; Salem, A, 2006)	0.33
" The hypomanic symptoms subsided gradually as the dosage was reduced and the patient thereafter remained in a euthymic state while on venlafaxine at a dose of 18."	( [Unipolar depression suddenly switches to hypomania in a patient who has just started taking venlafaxine]. Krol, DG; Nolen, WA, 2006)	0.33
" The varying sensitivity of scales that measure the severity of depression is one of the many factors affecting the evaluation of the dose-response relationship with antidepressants."	( Dose-response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder. Bech, P; Kajdasz, DK; Porsdal, V, 2006)	0.33
" The relevant dosage was already fixed during the acute treatment."	( Comparison of Hypericum extract WS 5570 and paroxetine in ongoing treatment after recovery from an episode of moderate to severe depression: results from a randomized multicenter study. Anghelescu, IG; Kieser, M; Klement, S; Kohnen, R; Szegedi, A, 2006)	0.59
" This study attempts to quantify the association between first trimester exposure to paroxetine and congenital cardiac malformations, adjusting for possible confounders, and to quantify the dose-response relationship between paroxetine use and cardiac defects."	( First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Bérard, A; Blais, L; Oraichi, D; Ramos, E; Rey, E; St-André, M, 2007)	0.86
" Depression occurs in approximately one-third of patients during antiviral therapy and can lead to reduction in treatment dosage or discontinuation of treatment, thus reducing the likelihood of clearing HCV infection."	( A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. Hauser, P; Indest, DW; Loftis, JM; Moles, JK; Morasco, BJ; Rifai, MA, 2007)	0.65
" Following baseline evaluations, the patients were assigned to receive venlafaxine 75-225 mg/day with the mean dosage 141."	( Venlafaxine vs. paroxetine in the acute phase of treatment for major depressive disorder among Han Chinese population in Taiwan. Chen, YC; Lu, RB; Wu, YS, 2007)	0.69
"0), their satisfaction reasons were elicited by three multiple-choice responses: efficacy, fewer side effects, and lower dosing frequency."	( Patient satisfaction with antidepressants: an Internet-based study. Nomura, S; Sato, Y; Shigemura, J; Yoshino, A, 2008)	0.35
" A secondary analysis of dose-response relationships indicated that this advantage was not attributable to the studies using higher doses of duloxetine."	( Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. Detke, MJ; Ossanna, MJ; Pritchett, YL; Swindle, RW; Thase, ME; Xu, J, 2007)	0.34
"5 yr of age) were randomly assigned to receive a dosage of 50 mg/day of fluvoxamine (n=53) or 20 mg/day of paroxetine (n=52)."	( Evaluation of double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients in menopause transition. Ikeda, A; Ueki, M; Ushiroyama, T, 2004)	0.78
" Phase 1 consisted of 10 weeks of open-label paroxetine CR flexibly dosed to a maximum of 62."	( Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. Connor, KM; Davidson, JR; Hoge, EA; LeBeau, RT; Pollack, MH; Simon, NM; Worthington, JJ; Zhang, W, 2008)	0.9
" His depression had not lessened after 12 days, and the dosage was increased to 20mg daily."	( [Paroxetine-induced hyponatremia in an elderly man due to the syndrome of inappropriate secretion of antidiuretic hormone]. Akishita, M; Eto, M; Ota, H; Ouchi, Y; Yamaguchi, K; Yamaguchi, Y, 2008)	1.26
"Selective serotonin reuptake inhibitors were found to be effective in treating premenstrual symptoms, with continuous dosing regimens favored for effectiveness."	( Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: a meta-analysis. Aperi, J; Borenstein, J; Jones, JB; Karne, A; Shah, NR; Shemtov, R, 2008)	0.35
"To prospectively quantify the dose-response effects of paroxetine and the influence of the serotonin transporter gene (SLC6A4) promoter polymorphism (5-HTTLPR) on platelet function."	( Effect of the selective serotonin reuptake inhibitor paroxetine on platelet function is modified by a SLC6A4 serotonin transporter polymorphism. Abdelmalik, N; Barwari, K; Büller, HR; Kamphuisen, PW; Meijers, JC; Middeldorp, S; Ruhé, HG; Schene, AH; van den Dool, EJ, 2008)	0.84
"In a 12-week open-label, noncomparative, prospective study, 71 subjects with primary BMS were assigned to receive an initial dosage of paroxetine (10 or 20 mg/day)."	( An open-label, noncomparative, dose escalation pilot study of the effect of paroxetine in treatment of burning mouth syndrome. Hata, H; Kitagawa, Y; Kitamori, S; Onodera, M; Yamazaki, Y, 2009)	0.79
" The incidence of adverse reactions for the initial daily dosage of 10 mg (41%) was significantly lower than that for 20 mg (76%) (chi(2) test)."	( An open-label, noncomparative, dose escalation pilot study of the effect of paroxetine in treatment of burning mouth syndrome. Hata, H; Kitagawa, Y; Kitamori, S; Onodera, M; Yamazaki, Y, 2009)	0.58
" The CYP2D6 substrate desipramine (50 mg) was administered alone on day 1 and coadministered on day 6 of dosing with either desvenlafaxine or paroxetine."	( The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults. Ahmed, S; Fatato, P; Isler, JA; Jiang, Q; Nichols, AI; Patroneva, A; Paul, J; Pedersen, RD; Shenouda, M, 2009)	0.83
"7 year; 4 females) received 12 weeks of open-label paroxetine treatment, flexibly dosed up to 60 mg/day."	( A pilot study of the effects of chronic paroxetine administration on hippocampal N-acetylaspartate in generalized anxiety disorder. Amiel, JM; Coplan, JD; Mao, X; Mathew, SJ; Price, RB; Shungu, DC; Smith, EL, 2010)	0.88
" Non-responders on combination therapy had the dosage of both drugs increased by 50%."	( Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. Blier, P; Boucher, N; de Montigny, C; Debonnel, G; Gobbi, G; Hébert, C; Turcotte, JE, 2009)	0.7
" Nevertheless, few studies have covered dosing aspects in order to minimize fetal antidepressant exposure while limiting the risk of treatment failure."	( Effect of cytochrome P450 2D6 genotype on maternal paroxetine plasma concentrations during pregnancy. Belitser, SV; Egberts, TC; Schobben, AF; Ververs, FF; Visser, GH; Voorbij, HA; Zwarts, P, 2009)	0.6
" Pharmacokinetic (PK)/RO modeling based on the PET results predicted that once daily dosing of >30mg LY686017 led to sustained trough RO of over 80%."	( Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder. Gehlert, DR; Iyengar, S; Kielbasa, W; Marek, G; Mozley, D; Peng, X; Tauscher, J; Vandenhende, F, 2010)	0.36
" Patients who stopped taking paroxetine abruptly experienced paroxetine discontinuation syndrome significantly more often than patients who had a tapering off of the dosage of medication."	( Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome. Haraguchi, K; Ieiri, I; Imuta, N; Kobayashi, D; Koyama, S; Mine, K; Murata, Y; Nishimura, R, 2010)	0.86
"Studies have demonstrated an influence of dosage release formulations on drug interactions and enantiomeric plasma concentrations."	( Influence of metoprolol dosage release formulation on the pharmacokinetic drug interaction with paroxetine. Bleske, BE; Brook, R; Kerber, K; Nielsen, J; Shea, M; Stout, SM; Welage, LS, 2011)	0.59
"A sensitive and simple spectrofluorimetric method has been developed and validated for the determination of the antidepressant paroxetine HCl (PXT) in its dosage forms."	( Spectrofluorimetric determination of paroxetine HCl in pharmaceuticals via derivatization with 4-chloro-7- nitrobenzo-2-oxa-1,3-diazole (NBD-Cl). Belal, F; El-Enany, N; Elmansi, H; Walsh, M, 2011)	0.85
" Apomorphine and ± 8-OH-DPAT had an inhibiting effect on sexual behavior, but only females dosed with apomorphine showed a different response in avoiders and approachers, more inhibiting effect in avoiders than approachers."	( A new female rat animal model for hypoactive sexual desire disorder; behavioral and pharmacological evidence. Chan, JS; de Jong, TR; Olivier, B; Oosting, RS; Snoeren, EM; Waldinger, MD, 2011)	0.37
" Repeated-measures anova on sub-items scores of the Panic Attack Anticipatory Anxiety Scale (PAAS) and Dosage Record and Treatment Emergent Symptom Scale (DOTES), respectively, used as outcome measures of effectiveness and tolerability, were performed."	( Slow vs standard up-titration of paroxetine in the treatment of panic disorder: a prospective randomized trial. Altamura, C; Bosi, MF; Buoli, M; Dell'osso, B, 2010)	0.64
" In all groups, (±)8-OH-DPAT showed a clear dose-dependent inhibition of sexual behaviors in vehicle-treated females and a right-shifted dose-response effect in the paroxetine-treated rats."	( Chronic paroxetine treatment does not affect sexual behavior in hormonally sub-primed female rats despite 5-HT₁(A) receptor desensitization. Olivier, B; Oosting, RS; Refsgaard, LK; Snoeren, EM; Waldinger, MD, 2011)	1
"A total of 60 MDD patients with a score above 18 on the Hamilton Anxiety Rating Scale (HARS) were randomly assigned to 8 weeks of fixed dosing treatment with mirtazapine (15-30 mg/day) and paroxetine (10-20 mg/day)."	( Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial. Cho, HB; Jeong, HS; Jung, JY; Kim, J; Kim, JE; Kim, TS; Lyoo, IK; Shin, E; Yoon, SJ, 2011)	0.76
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."	( FDA-approved drug labeling for the study of drug-induced liver injury. Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011)	0.37
" The approved dosage of DMQ is DM 20 mg and Q 10 mg twice daily."	( Randomized open-label drug-drug interaction trial of dextromethorphan/quinidine and paroxetine in healthy volunteers. Pope, LE; Schoedel, KA; Sellers, EM, 2012)	0.6
" Thus, patients should be monitored for AEs and dosage adjustment considered when combining these two agents."	( Randomized open-label drug-drug interaction trial of dextromethorphan/quinidine and paroxetine in healthy volunteers. Pope, LE; Schoedel, KA; Sellers, EM, 2012)	0.6
" This paper evaluates the pharmacokinetic properties and potential side effects of single and repeated dosing of paroxetine in Grey parrots (Psittacus erithacus erithacus)."	( Pharmacokinetics of paroxetine, a selective serotonin reuptake inhibitor, in Grey parrots (Psittacus erithacus erithacus): influence of pharmaceutical formulation and length of dosing. Fink-Gremmels, J; Haritova, A; Lumeij, JT; Schoemaker, NJ; Smit, JW; van Maarseveen, EM; van Zeeland, YR, 2013)	0.92
" Subjects were followed for 12 weeks (6-week dosage adjustment, 6-week maintenance)."	( A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Black, KJ; Brodsky, M; Christine, CW; Como, PG; Elmer, L; Factor, SA; Fernandez, HH; Horn, S; Hyson, HC; Jiang, W; Juncos, J; Kurlan, R; Lyness, JM; Manning, C; Marsh, L; McDermott, MP; McDonald, W; Panisset, M; Pearson, N; Pfeiffer, R; Press, D; Richard, IH; Rottenberg, D; Serrano Ramos, C; Shulman, L; Singer, C; Slevin, J, 2012)	0.38
" In the present work we studied the in vivo effect of a classic chronic dosing schedule of MDMA in rats, alone or combined with a chronic schedule of NIC, on the density of nAChR and on serotonin reuptake transporters."	( 3,4-Methylenedioxy-methamphetamine induces in vivo regional up-regulation of central nicotinic receptors in rats and potentiates the regulatory effects of nicotine on these receptors. Camarasa, J; Escubedo, E; Garcia-Ratés, S; Pubill, D, 2013)	0.39
" Therefore, we asked if a physiologically based pharmacokinetic (PBPK) model could be used to evaluate different dosing regimens for pregnant women."	( A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women. Isoherranen, N; Ke, AB; Nallani, SC; Rostami-Hodjegan, A; Unadkat, JD; Zhao, P, 2013)	0.39
"To develop a pharmacokinetic model able to describe the nonlinear pharmacokinetics of paroxetine (PRX) and to predict the drug-drug interaction between PRX and metoprolol under various dosage regimens."	( Pharmacokinetic model incorporating mechanism-based inactivation of CYP2D6 can explain both non-linear kinetics and drug interactions of paroxetine. Hori, S; Mikami, A; Ohtani, H; Sawada, Y, 2013)	0.82
" Using the developed model and estimated parameters, an optimal dosage regimen for metoprolol during withdrawal of PRX was simulated."	( Pharmacokinetic model incorporating mechanism-based inactivation of CYP2D6 can explain both non-linear kinetics and drug interactions of paroxetine. Hori, S; Mikami, A; Ohtani, H; Sawada, Y, 2013)	0.59
" Upon tapering PRX from 20 mg/ day to 10 mg/day for 14 days then 5 mg/day for 14 days until cessation, the optimal dosage regimen to resume 120 mg/day of metoprolol based on the developed model was as follows: 30 mg/day during concomitant administration, 40 mg/day for the next 14 days, 60 mg/day for the next 14 days, and finally 120 mg/day."	( Pharmacokinetic model incorporating mechanism-based inactivation of CYP2D6 can explain both non-linear kinetics and drug interactions of paroxetine. Hori, S; Mikami, A; Ohtani, H; Sawada, Y, 2013)	0.59
"The developed model enabled us to quantitatively estimate drug-drug interactions of PRX and CYP2D6 substrate drugs, and to predict optimal dosage regimens."	( Pharmacokinetic model incorporating mechanism-based inactivation of CYP2D6 can explain both non-linear kinetics and drug interactions of paroxetine. Hori, S; Mikami, A; Ohtani, H; Sawada, Y, 2013)	0.59
" Data were derived from an earlier study, designed to compare efficacy and tolerability of fixed dosage of extended-release venlafaxine, mitazapine, paroxetine, and risperidone, sodium valproate, buspirone, trazodone or thyroid hormone augmenting to paroxetine in those patients."	( Difference in remission in a Chinese population with anxious versus nonanxious treatment-resistant depression: a report of OPERATION study. Cao, L; Chen, J; Fang, Y; Hong, W; Peng, D; Wu, Z; Yuan, C; Zhang, C, 2013)	0.59
" Treatment with paroxetine was performed per os with a dosage of 20 mg/g BW."	( Chronic social stress during adolescence: interplay of paroxetine treatment and ageing. Liebl, C; Müller, MB; Scharf, SH; Schmidt, MV; Sterlemann, V, 2013)	0.98
"8 mg/kg once daily) was administered to rats (PM and PC groups) by an intragastric gavage, and the same dosage of vehicle was administered to rats in the VM and VC groups."	( Antidepressive effect of paroxetine in a rat model: upregulating expression of serotonin and norepinephrine transporter. Li, N; Liu, D; Qin, LJ; Qiu, HM; Wang, LJ; Wu, XH; Yang, JX; Zhou, QX, 2013)	0.69
" The study sample was divided into two groups: controls (n=33) maintained their own therapy with paroxetine tablets; 38 patients maintained the same dosage of paroxetine, but shifted to liquid formulation 10 mg/ml."	( Paroxetine drops versus paroxetine tablets: evaluation of compliance in a six-month study. Cigala Fulgosi, M; Colombo, C; Colombo, L; Delmonte, D; Gavinelli, C; Marcheggiani, E; Rossini, D; Zanardi, R, )	1.79
" Then dosage could be maintained at 10 mg or increased according to clinical response."	( Potential benefits of slow titration of paroxetine treatment in an elderly population: eight-week results from a naturalistic setting. De Ronchi, D; Gibiino, S; Mori, E; Serretti, A, 2013)	0.66
" At the eighth week, significant higher dropouts in patients administered with abrupt dosage was observed (12."	( Potential benefits of slow titration of paroxetine treatment in an elderly population: eight-week results from a naturalistic setting. De Ronchi, D; Gibiino, S; Mori, E; Serretti, A, 2013)	0.66
" Mean plasma concentrations attained predose on days 18 and 19 (days 13 and 14 of multiple dosing) and at 24 hours postdose (day 20) were similar, suggesting that steady state was achieved by day 13 of multiple dosing after 12 daily doses."	( Pharmacokinetic properties of once-daily oral low-dose mesylate salt of paroxetine (LDMP 7.5 mg) following single and multiple doses in healthy postmenopausal women. Bhaskar, S; Cristina Castelli, M; Lippman, J, 2013)	0.62
" The variables discussed include dose, dosing schedule, genes, drug-drug interactions, and other medical factors."	( Complexities of personalized medicine: how genes, drug-drug interactions, dosing schedules, and other factors can combine to produce clinically meaningful differences in a drug's effect. Preskorn, SH, 2013)	0.39
"The aim of this study was to determine whether a tapered dosage regimen of paroxetine in pregnant women might be useful to avoid withdrawal syndromes in neonates after delivery."	( Characterization of transplacental transfer of paroxetine in perfused human placenta: development of a pharmacokinetic model to evaluate tapered dosing. Fujii, T; Hori, S; Matsuoka, S; Nagai, M; Ohtani, H; Satoh, H; Sawada, Y; Taketani, Y, 2013)	0.88
" The serum paroxetine concentration increased with increasing dosage and was not significantly different between responders and nonresponders."	( Nonresponders to daily paroxetine and another SSRI in men with lifelong premature ejaculation: a pharmacokinetic dose-escalation study for a rare phenomenon. Janssen, PK; Schweitzer, DH; Touw, D; Waldinger, MD, 2014)	1.1
" We calculated the ratio of the mean doses for each study and weighted it by the total sample size to find the weighted mean ratio for each drug, which was then used to define the drug׳s dosage equivalent to fluoxetine 40mg/d."	( Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials. Barbui, C; Cipriani, A; Furukawa, TA; Hayasaka, Y; Leucht, S; Magni, LR; Ogawa, Y; Purgato, M; Takeshima, N, 2015)	0.42
" In the primary analysis, fluoxetine 40mg/day was equivalent to paroxetine dosage of 34."	( Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials. Barbui, C; Cipriani, A; Furukawa, TA; Hayasaka, Y; Leucht, S; Magni, LR; Ogawa, Y; Purgato, M; Takeshima, N, 2015)	0.66
" The allocation to either high- and low-dose antidepressants was not randomized and the dose was guided by a case-by-case decision, which hampers to draw a firm conclusion on dose-response issues and renders the findings as preliminary."	( Antidepressant dose and treatment response in bipolar depression: Reanalysis of the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) data. Mimura, M; Mizushima, J; Nio, S; Suzuki, T; Tada, M; Uchida, H, 2015)	0.42
"We compared the effect of vortioxetine, paroxetine and placebo after three days of dosing on sleep architecture."	( Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 1, a pharmacokinetic/pharmacodynamic comparison with paroxetine in healthy men. Areberg, J; Buchberg, J; Højer, AM; Nutt, DJ; Wilson, S, 2015)	0.88
"In this study, the coadministration of single-dose HYD with paroxetine at steady state did not alter systemic exposure to hydrocodone, suggesting that HYD can be coadministered with CYP2D6 inhibitors at therapeutic doses, without dosage modification."	( Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. Cipriano, A; Friedman, K; Harris, SC; Kapil, RP; Michels, G; Mondal, SA; Shet, M, 2015)	1.05
" The present study was designed to clarify the relationship between dosage and treatment response in major depressive disorder."	( Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder. Bloch, MH; Freemantle, N; Jakubovski, E; Taylor, MJ; Varigonda, AL, 2016)	0.43
" Endpoint and tolerability analyses were analyzed using meta-regression and stratified subgroup analysis by predefined SSRI dose categories in order to assess the effect of SSRI dosing on the efficacy and tolerability of SSRIs for major depressive disorder."	( Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder. Bloch, MH; Freemantle, N; Jakubovski, E; Taylor, MJ; Varigonda, AL, 2016)	0.43
" Food and Drug Administration (FDA) on the risk of suicidality among children associated with use of antidepressants, but the warning's effect on dosing of antidepressants has not been evaluated."	( Dosing of Selective Serotonin Reuptake Inhibitors Among Children and Adults Before and After the FDA Black-Box Warning. Azrael, D; Bushnell, GA; Miller, M; Pate, V; Stürmer, T; Swanson, SA; White, A, 2016)	0.43
"The proportion of commercially insured children initiating an SSRI with a low dose was higher after the 2004 FDA warning on the risk of suicidality among children, suggesting improved prescribing practices surrounding SSRI dosing among children."	( Dosing of Selective Serotonin Reuptake Inhibitors Among Children and Adults Before and After the FDA Black-Box Warning. Azrael, D; Bushnell, GA; Miller, M; Pate, V; Stürmer, T; Swanson, SA; White, A, 2016)	0.43
" All drugs showed maximum occupancy at 4h after dosing and then decreasing occupancies with time."	( Time-course of serotonin transporter occupancy by single dose of three SSRIs in human brain: A positron emission tomography study with [(11)C]DASB. Arakawa, R; Kim, W; Ogawa, K; Okubo, Y; Sakayori, T; Tateno, A, 2016)	0.43
" In contrast, among doses above these, there was no indication of a dose-response relationship."	( A mega-analysis of fixed-dose trials reveals dose-dependency and a rapid onset of action for the antidepressant effect of three selective serotonin reuptake inhibitors. Eriksson, E; Hieronymus, F; Nilsson, S, 2016)	0.43
" Therefore, in women with a uterus, it is recommended that physicians prescribe combination therapy only to treat menopausal symptoms such as vasomotor symptoms (hot flashes) and vaginal atrophy, using the smallest effective dosage for the shortest possible duration."	( Hormone Therapy and Other Treatments for Symptoms of Menopause. Crider, M; Hill, DA; Hill, SR, 2016)	0.43
"AD treatment is an important factor for preventing suicide, since the use of AD at adequate dosage and for a proper duration was associated with a lower suicide risk."	( Antidepressant use in suicides: a case-control study from the Friuli Venezia Giulia Region, Italy, 2005-2014. Balestrieri, M; Castelpietra, G; De Vido, C; Gobbato, M; Isacsson, G; Valent, F, 2017)	0.46
" The dosage of paroxetine was the average dose per day in each week."	( Randomized controlled trial of repetitive transcranial magnetic stimulation combined with paroxetine for the treatment of patients with first-episode major depressive disorder. Chen, WH; Li, N; Li, SX; Lu, L; Shi, L; Song, M; Wang, XY; Wang, YM; Yang, LL, 2017)	1.03
" Thirteen gene positive and symptomatic patients (9M/4W, HD-stage II, age> 40y) together 11 gender/age matched controls without a concurrent diagnosis of psychiatric disorders, underwent a blood test to determine BDNF storage and membrane-bound SERT in platelets by an ELISA immune-enzyme dosage and [3H]-paroxetine ([3H]-PAR) binding, respectively."	( Brain-Derived Neurotrophic Factor (BDNF) and Serotonin Transporter (SERT) in Platelets of Patients with Mild Huntington's Disease: Relationships with Social Cognition Symptoms. Betti, L; Bonuccelli, U; Ceravolo, R; Giannaccini, G; Kiferle, L; Mazzucchi, S; Palego, L; Palermo, G; Unti, E, 2018)	0.66
" The approach can be valuable for providing a reliable estimate of TE, for conducting risk/benefit analysis, and for determining dosage recommendations."	( Model-Informed Approach to Assess the Treatment Effect Conditional to the Level of Placebo Response. Bressolle-Gomeni, FMM; Fava, M; Gomeni, R; Goyal, N; Rabinowitz, J, 2019)	0.51
"Recent meta-analyses on dose-response relationships of SSRIs are largely based on indirect evidence."	( In search of a dose-response relationship in SSRIs-a systematic review, meta-analysis, and network meta-analysis. Adams, A; Baethge, C; Braun, C; Bschor, T; Kuhr, K; Rink, L, 2020)	0.56
" Comparisons of dosage groups (low, medium, and high) resulted in only small and clinically non-significant differences for SSRIs as a group, the strongest relating to medium vs low doses (SMD: -0."	( In search of a dose-response relationship in SSRIs-a systematic review, meta-analysis, and network meta-analysis. Adams, A; Baethge, C; Braun, C; Bschor, T; Kuhr, K; Rink, L, 2020)	0.56
"There is no conclusive level I or level II evidence of a clinically meaningful dose-response relationship of SSRIs as a group or of single substances."	( In search of a dose-response relationship in SSRIs-a systematic review, meta-analysis, and network meta-analysis. Adams, A; Baethge, C; Braun, C; Bschor, T; Kuhr, K; Rink, L, 2020)	0.56
"Since several recent meta-analyses report a dose-response relationship for the antidepressant effect of the selective serotonin reuptake inhibitors (SSRIs), we investigated how these drugs are dosed in clinical practice."	( Low SSRI dosing in clinical practice-a register-based longitudinal study. Eriksson, E; Hieronymus, F; Lisinski, A; Wallerstedt, SM, 2021)	0.62
" The lack of consensus regarding effective dosing of SSRIs may have contributed to this state of affairs."	( Low SSRI dosing in clinical practice-a register-based longitudinal study. Eriksson, E; Hieronymus, F; Lisinski, A; Wallerstedt, SM, 2021)	0.62
" Physicochemical, thermal, spectroscopic, diffractometric analysis and in-vitro dissolution tests of the intermediate products and the finished dosage forms were performed."	( Performance and paroxetine stability in tablets manufactured by fused deposition modelling-based 3D printing. Carvalho, FG; Fernandes, AI; Figueiredo, S; Pinto, JF, 2022)	1.07
"PRX tablets, meeting compendial limits, were manufactured by 3DP, envisaging their clinical use as individually designed dosage forms."	( Performance and paroxetine stability in tablets manufactured by fused deposition modelling-based 3D printing. Carvalho, FG; Fernandes, AI; Figueiredo, S; Pinto, JF, 2022)	1.07
" Small and mostly insignificant differences in average daily metoprolol dosage were found between patients treated with the various antidepressants."	( Co-prescription of metoprolol and CYP2D6-inhibiting antidepressants before and after implementation of an optimized drug interaction database in Norway. Gedde-Dahl, A; Molden, E; Spigset, O, 2022)	0.72
" This case report is novel is several aspects: the tics emergence was immediate whereas previous cases were delayed; the tics symptoms were measured and quantified by a validated scale; a dose-response relationship was observed; to our knowledge, our case was the first adolescent female reported; and finally, paroxetine was well-tolerated as a substitute, although it is unclear whether the observed tics-sparing effect is co-incidental, ideocratic or can be replicated."	( Sertraline-Induced Tics: A Case Report and Narrative Review. Arasu, R; Badeshae, S; Chen, W; Furlong, Y, 2023)	1.08
" No known medication dosage increases had been made, nor had any new serotonergic agents been added to the patient's drug regimen."	( A 70-Year-Old Woman Presenting with Confusion and Muscle Spasms Due to Serotonin Syndrome Associated with Paroxetine and Quetiapine Treatment. Mostel, E; Patel, S; Wiener, BG, 2022)	0.93
" This well-powered study shows that the guidelines should consider the importance of CYP2D6 genotype for personalized dosing of paroxetine."	( Impact of CYP2D6 Genotype on Paroxetine Serum Concentration. Haslemo, T; Hole, K; Molden, E, 2023)	1.41

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Role	Description
antidepressant	Antidepressants are mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions.
anxiolytic drug	Anxiolytic drugs are agents that alleviate anxiety, tension, and anxiety disorders, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions.
serotonin uptake inhibitor	A compound that specifically inhibits the reuptake of serotonin in the brain. This increases the serotonin concentration in the synaptic cleft which then activates serotonin receptors to a greater extent.
hepatotoxic agent	A role played by a chemical compound exihibiting itself through the ability to induce damage to the liver in animals.
P450 inhibitor	An enzyme inhibitor that interferes with the activity of cytochrome P450 involved in catalysis of organic substances.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
piperidines
benzodioxoles
organofluorine compound	An organofluorine compound is a compound containing at least one carbon-fluorine bond.
aromatic ether	Any ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASE	Homo sapiens (human)	Potency	44.6684	0.0040	23.8416	100.0000	AID485290
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	5.3080	0.0060	38.0041	19,952.5996	AID1159523
ATAD5 protein, partial	Homo sapiens (human)	Potency	29.0810	0.0041	10.8903	31.5287	AID493107
GLS protein	Homo sapiens (human)	Potency	5.6234	0.3548	7.9355	39.8107	AID624146
TDP1 protein	Homo sapiens (human)	Potency	13.1150	0.0008	11.3822	44.6684	AID686978; AID686979
GLI family zinc finger 3	Homo sapiens (human)	Potency	6.3086	0.0007	14.5928	83.7951	AID1259392
AR protein	Homo sapiens (human)	Potency	19.3227	0.0002	21.2231	8,912.5098	AID1259247; AID743035; AID743042; AID743054; AID743063
estrogen receptor 2 (ER beta)	Homo sapiens (human)	Potency	26.6032	0.0006	57.9133	22,387.1992	AID1259378
nuclear receptor subfamily 1, group I, member 3	Homo sapiens (human)	Potency	19.9496	0.0010	22.6508	76.6163	AID1224893
progesterone receptor	Homo sapiens (human)	Potency	29.8493	0.0004	17.9460	75.1148	AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	5.0091	0.0123	7.9835	43.2770	AID1645841
glucocorticoid receptor [Homo sapiens]	Homo sapiens (human)	Potency	30.1065	0.0002	14.3764	60.0339	AID720691
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	26.6032	0.0030	41.6115	22,387.1992	AID1159552
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	28.4973	0.0002	29.3054	16,493.5996	AID743069; AID743075; AID743078; AID743079
G	Vesicular stomatitis virus	Potency	1.3338	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2D6	Homo sapiens (human)	Potency	0.4437	0.0010	8.3798	61.1304	AID1645840
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	23.7781	0.0355	20.9770	89.1251	AID504332
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a	Homo sapiens (human)	Potency	33.4915	0.0017	23.8393	78.1014	AID743083
thyroid stimulating hormone receptor	Homo sapiens (human)	Potency	21.1317	0.0016	28.0151	77.1139	AID1224895
activating transcription factor 6	Homo sapiens (human)	Potency	11.9856	0.1434	27.6121	59.8106	AID1159516
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a	Homo sapiens (human)	Potency	18.9959	19.7391	45.9784	64.9432	AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)	Homo sapiens (human)	Potency	23.9145	0.0578	21.1097	61.2679	AID1159526; AID1159528
NPC intracellular cholesterol transporter 1 precursor	Homo sapiens (human)	Potency	58.0479	0.0126	2.4518	25.0177	AID485313
D(1A) dopamine receptor	Homo sapiens (human)	Potency	11.2202	0.0224	5.9449	22.3872	AID488981
chromobox protein homolog 1	Homo sapiens (human)	Potency	44.6684	0.0060	26.1688	89.1251	AID488953
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	9.8374	0.0003	23.4451	159.6830	AID743065; AID743067
atrial natriuretic peptide receptor 2 precursor	Homo sapiens (human)	Potency	14.6892	0.0066	9.8094	18.4927	AID1347050
ras-related protein Rab-9A	Homo sapiens (human)	Potency	58.0479	0.0002	2.6215	31.4954	AID485297
serine/threonine-protein kinase mTOR isoform 1	Homo sapiens (human)	Potency	20.3239	0.0037	8.6189	23.2809	AID2660; AID2666; AID2667; AID2668
nuclear factor erythroid 2-related factor 2 isoform 1	Homo sapiens (human)	Potency	11.8823	0.0006	27.2152	1,122.0200	AID743202
M-phase phosphoprotein 8	Homo sapiens (human)	Potency	33.5875	0.1778	24.7352	79.4328	AID488949
Interferon beta	Homo sapiens (human)	Potency	1.3338	0.0033	9.1582	39.8107	AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	1.3338	0.0123	8.9648	39.8107	AID1645842
Cellular tumor antigen p53	Homo sapiens (human)	Potency	29.8493	0.0023	19.5956	74.0614	AID651631; AID720552
D(1A) dopamine receptor	Sus scrofa (pig)	Potency	26.1216	0.0037	8.1081	23.2809	AID2667
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Potency	39.8107	0.0096	10.5250	35.4813	AID1479145
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	1.3338	0.0123	8.9648	39.8107	AID1645842
ATPase family AAA domain-containing protein 5	Homo sapiens (human)	Potency	26.6032	0.0119	17.9420	71.5630	AID651632
Ataxin-2	Homo sapiens (human)	Potency	31.0423	0.0119	12.2221	68.7989	AID588378; AID651632
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	1.3338	0.0123	8.9648	39.8107	AID1645842
ATP-dependent phosphofructokinase	Trypanosoma brucei brucei TREU927	Potency	0.8492	0.0601	10.7453	37.9330	AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Sodium-dependent noradrenaline transporter	Mus musculus (house mouse)	Ki	0.0200	0.0120	0.0905	0.2900	AID134216
Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)	IC50 (µMol)	3.9000	0.0003	2.6311	9.0000	AID1207758
Myeloperoxidase	Homo sapiens (human)	IC50 (µMol)	0.0200	0.0200	1.8811	7.6800	AID1446226
Aldo-keto reductase family 1 member B1	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0860	0.0004	1.8773	10.0000	AID625207
Aldo-keto reductase family 1 member B1	Rattus norvegicus (Norway rat)	Ki	0.0860	0.0032	2.2887	9.3160	AID625207
Muscarinic acetylcholine receptor M2	Homo sapiens (human)	IC50 (µMol)	0.5320	0.0000	1.2326	7.7930	AID625152
Muscarinic acetylcholine receptor M2	Homo sapiens (human)	Ki	0.1890	0.0000	0.6902	10.0000	AID625152
Muscarinic acetylcholine receptor M4	Homo sapiens (human)	IC50 (µMol)	0.2440	0.0000	1.1546	7.5858	AID625154
Muscarinic acetylcholine receptor M4	Homo sapiens (human)	Ki	0.0340	0.0000	0.7951	9.1201	AID625154
ATP-dependent translocase ABCB1	Homo sapiens (human)	IC50 (µMol)	29.8000	0.0002	2.3185	10.0000	AID681144
Muscarinic acetylcholine receptor M5	Homo sapiens (human)	IC50 (µMol)	0.1230	0.0001	0.9917	8.0000	AID625155
Muscarinic acetylcholine receptor M5	Homo sapiens (human)	Ki	0.0890	0.0000	0.7292	6.9183	AID625155
Quinolone resistance protein NorA	Staphylococcus aureus	IC50 (µMol)	7.0000	7.0000	8.5000	9.7000	AID612622
Cytochrome P450 2D6	Homo sapiens (human)	IC50 (µMol)	0.5003	0.0000	2.0151	10.0000	AID1332024; AID625249
Cytochrome P450 2D6	Homo sapiens (human)	Ki	4.8500	0.0001	1.1986	8.0000	AID589095
Muscarinic acetylcholine receptor M1	Homo sapiens (human)	IC50 (µMol)	0.1450	0.0000	1.4039	10.0000	AID625151
Muscarinic acetylcholine receptor M1	Homo sapiens (human)	Ki	0.0350	0.0000	0.5972	9.1201	AID625151
Angiotensin-converting enzyme	Oryctolagus cuniculus (rabbit)	IC50 (µMol)	10.4293	0.0000	1.6129	10.0000	AID625171
Angiotensin-converting enzyme	Oryctolagus cuniculus (rabbit)	Ki	8.5445	0.0004	2.0337	8.6606	AID625171
Aldo-keto reductase family 1 member B1	Bos taurus (cattle)	Ki	0.0004	0.0004	0.0018	0.0044	AID408801
Alpha-2B adrenergic receptor	Rattus norvegicus (Norway rat)	Ki	6.3100	0.0000	0.9296	10.0000	AID36948
Muscarinic acetylcholine receptor M3	Homo sapiens (human)	IC50 (µMol)	0.1790	0.0001	1.0104	9.9280	AID625153
Muscarinic acetylcholine receptor M3	Homo sapiens (human)	Ki	0.0380	0.0000	0.5405	7.7600	AID625153
Beta-adrenergic receptor kinase 1	Bos taurus (cattle)	IC50 (µMol)	1.0800	0.0350	0.8737	1.3800	AID1460843; AID1744430
Potassium voltage-gated channel subfamily A member 3	Homo sapiens (human)	IC50 (µMol)	31.9000	0.0020	3.1969	8.0000	AID1866612
Alpha-2C adrenergic receptor	Rattus norvegicus (Norway rat)	Ki	6.3100	0.0000	0.9708	10.0000	AID36948
Alpha-2A adrenergic receptor	Rattus norvegicus (Norway rat)	Ki	6.3100	0.0000	0.9375	10.0000	AID36948
Sodium-dependent noradrenaline transporter	Homo sapiens (human)	IC50 (µMol)	0.0930	0.0008	1.5416	20.0000	AID387487; AID625207
Sodium-dependent noradrenaline transporter	Homo sapiens (human)	Ki	0.0880	0.0003	1.4656	10.0000	AID254338; AID625207
Sodium-dependent dopamine transporter	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.8492	0.0007	0.9774	9.7000	AID64685; AID64686
Sodium-dependent dopamine transporter	Rattus norvegicus (Norway rat)	Ki	0.4000	0.0003	0.3708	8.1600	AID65494
Beta-adrenergic receptor kinase 1	Homo sapiens (human)	IC50 (µMol)	1.2400	0.0420	1.2276	2.5000	AID1302237; AID1302251; AID1460842; AID1894055
Substance-P receptor	Homo sapiens (human)	IC50 (µMol)	0.9000	0.0000	0.0952	6.8130	AID739023
Rhodopsin kinase GRK1	Bos taurus (cattle)	IC50 (µMol)	100.0000	4.1000	4.1000	4.1000	AID1460844
Sodium-dependent serotonin transporter	Homo sapiens (human)	IC50 (µMol)	0.0007	0.0001	0.8645	8.7096	AID1332024; AID387488; AID625222; AID739022
Sodium-dependent serotonin transporter	Homo sapiens (human)	Ki	0.0002	0.0000	0.7048	8.1930	AID1332036; AID1783171; AID254322; AID302140; AID361595; AID361596; AID408801; AID408802; AID625222
Sodium-dependent serotonin transporter	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0003	0.0003	0.8197	8.4900	AID205038
Sodium-dependent serotonin transporter	Rattus norvegicus (Norway rat)	Ki	0.0006	0.0000	0.7056	10.0000	AID204534; AID204695
G protein-coupled receptor kinase 5	Homo sapiens (human)	IC50 (µMol)	100.0000	0.0246	0.2720	0.8300	AID1302239
G protein-coupled receptor kinase 5	Bos taurus (cattle)	IC50 (µMol)	100.0000	0.4400	0.4400	0.4400	AID1460845
P2X purinoceptor 4	Rattus norvegicus (Norway rat)	IC50 (µMol)	2.4500	2.4500	2.5000	2.6000	AID1528205; AID709133
Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)	IC50 (µMol)	3.9000	0.0003	2.5955	9.0000	AID1207758
Sodium-dependent dopamine transporter	Homo sapiens (human)	IC50 (µMol)	0.6720	0.0007	1.8419	46.0000	AID625256
Sodium-dependent dopamine transporter	Homo sapiens (human)	Ki	0.4670	0.0002	1.1115	8.0280	AID254319; AID625256
Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)	IC50 (µMol)	10.4293	0.0009	1.9014	10.0000	AID625171
Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)	Ki	8.5445	0.0021	1.8407	10.0000	AID625171
Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)	IC50 (µMol)	3.9000	0.0003	2.6311	9.0000	AID1207758
Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)	IC50 (µMol)	3.9000	0.0003	2.2545	9.6000	AID1207758
Rhodopsin kinase GRK1	Homo sapiens (human)	IC50 (µMol)	100.0000	0.0578	0.1586	0.3400	AID1302238
Sodium-dependent serotonin transporter	Mus musculus (house mouse)	Ki	0.0004	0.0004	0.5957	4.1000	AID134217
Sodium-dependent dopamine transporter	Mus musculus (house mouse)	Ki	0.4600	0.4040	0.6873	1.0350	AID134215
Nuclear receptor subfamily 3 group C member 3	Bos taurus (cattle)	IC50 (µMol)	10.4293	0.1048	2.8398	8.3173	AID625171
Nuclear receptor subfamily 3 group C member 3	Bos taurus (cattle)	Ki	8.5445	0.0858	2.9542	8.6606	AID625171
P2X purinoceptor 4	Homo sapiens (human)	IC50 (µMol)	2.8067	0.1560	2.9352	6.1000	AID1064727; AID1528204; AID709142
Sigma non-opioid intracellular receptor 1	Homo sapiens (human)	IC50 (µMol)	5.3660	0.0003	0.7028	5.3660	AID625223
Sigma non-opioid intracellular receptor 1	Homo sapiens (human)	Ki	2.2550	0.0000	0.4901	10.0000	AID625223
Transporter	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.5350	0.0008	1.9562	8.8000	AID147593
Transporter	Rattus norvegicus (Norway rat)	Ki	0.6596	0.0001	0.8667	10.0000	AID147740
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
5-hydroxytryptamine receptor 1A	Homo sapiens (human)	Kd	30.8114	0.0001	0.9528	5.0119	AID438555
Sodium-dependent noradrenaline transporter	Homo sapiens (human)	Kd	0.0400	0.0008	0.2533	1.0600	AID145563
Beta-adrenergic receptor kinase 1	Homo sapiens (human)	Kd	2.9800	0.1700	5.5791	22.4940	AID1698791
Sodium-dependent serotonin transporter	Homo sapiens (human)	Kd	0.0001	0.0001	0.0317	0.2000	AID204080
Sodium-dependent serotonin transporter	Rattus norvegicus (Norway rat)	Kd	0.0002	0.0002	0.0002	0.0002	AID204516
Sodium-dependent dopamine transporter	Homo sapiens (human)	Kd	0.4900	0.0250	2.1443	9.3000	AID64372
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Beta-adrenergic receptor kinase 1	Mus musculus (house mouse)	MEC	10.0000	10.0000	10.0000	10.0000	AID1460863
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
visual perception	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
detection of light stimulus involved in visual perception	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
calcium ion import across plasma membrane	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle G2/M phase transition	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
ER overload response	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
in utero embryonic development	Cellular tumor antigen p53	Homo sapiens (human)
somitogenesis	Cellular tumor antigen p53	Homo sapiens (human)
release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic progenitor cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
T cell proliferation involved in immune response	Cellular tumor antigen p53	Homo sapiens (human)
B cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
T cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
response to ischemia	Cellular tumor antigen p53	Homo sapiens (human)
nucleotide-excision repair	Cellular tumor antigen p53	Homo sapiens (human)
double-strand break repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
protein import into nucleus	Cellular tumor antigen p53	Homo sapiens (human)
autophagy	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
Ras protein signal transduction	Cellular tumor antigen p53	Homo sapiens (human)
gastrulation	Cellular tumor antigen p53	Homo sapiens (human)
neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
protein localization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA replication	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
determination of adult lifespan	Cellular tumor antigen p53	Homo sapiens (human)
mRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
rRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
response to salt stress	Cellular tumor antigen p53	Homo sapiens (human)
response to inorganic substance	Cellular tumor antigen p53	Homo sapiens (human)
response to X-ray	Cellular tumor antigen p53	Homo sapiens (human)
response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of gene expression	Cellular tumor antigen p53	Homo sapiens (human)
cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
viral process	Cellular tumor antigen p53	Homo sapiens (human)
glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
cerebellum development	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell growth	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of telomere maintenance via telomerase	Cellular tumor antigen p53	Homo sapiens (human)
T cell differentiation in thymus	Cellular tumor antigen p53	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
regulation of tissue remodeling	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV	Cellular tumor antigen p53	Homo sapiens (human)
multicellular organism growth	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of mitochondrial membrane permeability	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
entrainment of circadian clock by photoperiod	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial DNA repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
transcription initiation-coupled chromatin remodeling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of proteolysis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
response to antibiotic	Cellular tumor antigen p53	Homo sapiens (human)
fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
circadian behavior	Cellular tumor antigen p53	Homo sapiens (human)
bone marrow development	Cellular tumor antigen p53	Homo sapiens (human)
embryonic organ development	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Cellular tumor antigen p53	Homo sapiens (human)
protein stabilization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of helicase activity	Cellular tumor antigen p53	Homo sapiens (human)
protein tetramerization	Cellular tumor antigen p53	Homo sapiens (human)
chromosome organization	Cellular tumor antigen p53	Homo sapiens (human)
neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic stem cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
type II interferon-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
cardiac septum morphogenesis	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of programmed necrotic cell death	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Cellular tumor antigen p53	Homo sapiens (human)
thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
necroptotic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to xenobiotic stimulus	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to ionizing radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV-C	Cellular tumor antigen p53	Homo sapiens (human)
stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to actinomycin D	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
replicative senescence	Cellular tumor antigen p53	Homo sapiens (human)
oxidative stress-induced premature senescence	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
oligodendrocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of execution phase of apoptosis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of G1 to G0 transition	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of miRNA processing	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of pentose-phosphate shunt	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
regulation of fibroblast apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
hydrogen peroxide catabolic process	Myeloperoxidase	Homo sapiens (human)
response to yeast	Myeloperoxidase	Homo sapiens (human)
hypochlorous acid biosynthetic process	Myeloperoxidase	Homo sapiens (human)
respiratory burst involved in defense response	Myeloperoxidase	Homo sapiens (human)
defense response	Myeloperoxidase	Homo sapiens (human)
response to oxidative stress	Myeloperoxidase	Homo sapiens (human)
response to mechanical stimulus	Myeloperoxidase	Homo sapiens (human)
removal of superoxide radicals	Myeloperoxidase	Homo sapiens (human)
response to food	Myeloperoxidase	Homo sapiens (human)
response to lipopolysaccharide	Myeloperoxidase	Homo sapiens (human)
low-density lipoprotein particle remodeling	Myeloperoxidase	Homo sapiens (human)
hydrogen peroxide catabolic process	Myeloperoxidase	Homo sapiens (human)
negative regulation of apoptotic process	Myeloperoxidase	Homo sapiens (human)
defense response to fungus	Myeloperoxidase	Homo sapiens (human)
response to gold nanoparticle	Myeloperoxidase	Homo sapiens (human)
defense response to bacterium	Myeloperoxidase	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
nervous system development	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
regulation of heart contraction	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
response to virus	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
presynaptic modulation of chemical synaptic transmission	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
regulation of smooth muscle contraction	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
chemical synaptic transmission	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
signal transduction	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
cell surface receptor signaling pathway	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
regulation of locomotion	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
chemical synaptic transmission	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
G2/M transition of mitotic cell cycle	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic metabolic process	ATP-dependent translocase ABCB1	Homo sapiens (human)
response to xenobiotic stimulus	ATP-dependent translocase ABCB1	Homo sapiens (human)
phospholipid translocation	ATP-dependent translocase ABCB1	Homo sapiens (human)
terpenoid transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
regulation of response to osmotic stress	ATP-dependent translocase ABCB1	Homo sapiens (human)
transmembrane transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
transepithelial transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
stem cell proliferation	ATP-dependent translocase ABCB1	Homo sapiens (human)
ceramide translocation	ATP-dependent translocase ABCB1	Homo sapiens (human)
export across plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
transport across blood-brain barrier	ATP-dependent translocase ABCB1	Homo sapiens (human)
positive regulation of anion channel activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
carboxylic acid transmembrane transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	ATP-dependent translocase ABCB1	Homo sapiens (human)
regulation of chloride transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
behavioral fear response	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
G protein-coupled receptor signaling pathway	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
serotonin receptor signaling pathway	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
gamma-aminobutyric acid signaling pathway	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
positive regulation of cell population proliferation	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of serotonin secretion	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of vasoconstriction	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
exploration behavior	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of dopamine metabolic process	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
serotonin metabolic process	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of hormone secretion	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of behavior	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
gastric acid secretion	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
dopamine transport	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
transmission of nerve impulse	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
regulation of phosphatidylinositol dephosphorylation	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
chemical synaptic transmission	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
coumarin metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
alkaloid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 2D6	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
isoquinoline alkaloid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2D6	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2D6	Homo sapiens (human)
negative regulation of binding	Cytochrome P450 2D6	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2D6	Homo sapiens (human)
negative regulation of cellular organofluorine metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
arachidonic acid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
positive regulation of monoatomic ion transport	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
signal transduction	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
neuromuscular synaptic transmission	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
nervous system development	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
regulation of locomotion	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
saliva secretion	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
cognition	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
regulation of postsynaptic membrane potential	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
regulation of glial cell proliferation	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
positive regulation of intracellular protein transport	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
postsynaptic modulation of chemical synaptic transmission	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
chemical synaptic transmission	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
retinoid metabolic process	Aldo-keto reductase family 1 member B1	Bos taurus (cattle)
prostaglandin metabolic process	Aldo-keto reductase family 1 member B1	Bos taurus (cattle)
retinol metabolic process	Aldo-keto reductase family 1 member B1	Bos taurus (cattle)
calcium-mediated signaling	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
regulation of monoatomic ion transmembrane transporter activity	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
smooth muscle contraction	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
signal transduction	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
synaptic transmission, cholinergic	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
nervous system development	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
positive regulation of insulin secretion	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
protein modification process	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
positive regulation of smooth muscle contraction	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
saliva secretion	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
ion channel modulating, G protein-coupled receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
ligand-gated ion channel signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
regulation of smooth muscle contraction	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
chemical synaptic transmission	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
desensitization of G protein-coupled receptor signaling pathway	Beta-adrenergic receptor kinase 1	Bos taurus (cattle)
G protein-coupled receptor internalization	Beta-adrenergic receptor kinase 1	Bos taurus (cattle)
negative regulation of the force of heart contraction by chemical signal	Beta-adrenergic receptor kinase 1	Bos taurus (cattle)
protein phosphorylation	Beta-adrenergic receptor kinase 1	Bos taurus (cattle)
intracellular protein transport	Beta-adrenergic receptor kinase 1	Bos taurus (cattle)
G protein-coupled receptor signaling pathway	Beta-adrenergic receptor kinase 1	Bos taurus (cattle)
G protein-coupled acetylcholine receptor signaling pathway	Beta-adrenergic receptor kinase 1	Bos taurus (cattle)
regulation of signal transduction	Beta-adrenergic receptor kinase 1	Bos taurus (cattle)
peptidyl-serine phosphorylation	Beta-adrenergic receptor kinase 1	Bos taurus (cattle)
positive regulation of smoothened signaling pathway	Beta-adrenergic receptor kinase 1	Bos taurus (cattle)
negative regulation of striated muscle contraction	Beta-adrenergic receptor kinase 1	Bos taurus (cattle)
cardiac muscle contraction	Beta-adrenergic receptor kinase 1	Bos taurus (cattle)
negative regulation of relaxation of smooth muscle	Beta-adrenergic receptor kinase 1	Bos taurus (cattle)
positive regulation of protein localization to cilium	Beta-adrenergic receptor kinase 1	Bos taurus (cattle)
potassium ion transport	Potassium voltage-gated channel subfamily A member 3	Homo sapiens (human)
optic nerve development	Potassium voltage-gated channel subfamily A member 3	Homo sapiens (human)
corpus callosum development	Potassium voltage-gated channel subfamily A member 3	Homo sapiens (human)
protein homooligomerization	Potassium voltage-gated channel subfamily A member 3	Homo sapiens (human)
action potential	Potassium voltage-gated channel subfamily A member 3	Homo sapiens (human)
potassium ion transmembrane transport	Potassium voltage-gated channel subfamily A member 3	Homo sapiens (human)
monoamine transport	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neurotransmitter transport	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
chemical synaptic transmission	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
response to xenobiotic stimulus	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
response to pain	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
norepinephrine uptake	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neuron cellular homeostasis	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
amino acid transport	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
norepinephrine transport	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
dopamine uptake involved in synaptic transmission	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
sodium ion transmembrane transport	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
desensitization of G protein-coupled receptor signaling pathway	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
negative regulation of the force of heart contraction by chemical signal	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathway	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
tachykinin receptor signaling pathway	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
heart development	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
peptidyl-serine phosphorylation	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
viral genome replication	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
receptor internalization	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
positive regulation of catecholamine secretion	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
negative regulation of striated muscle contraction	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
symbiont entry into host cell	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
cardiac muscle contraction	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
negative regulation of relaxation of smooth muscle	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
regulation of the force of heart contraction	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
protein phosphorylation	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
aggressive behavior	Substance-P receptor	Homo sapiens (human)
positive regulation of leukocyte migration	Substance-P receptor	Homo sapiens (human)
angiotensin-mediated drinking behavior	Substance-P receptor	Homo sapiens (human)
inflammatory response	Substance-P receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Substance-P receptor	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Substance-P receptor	Homo sapiens (human)
tachykinin receptor signaling pathway	Substance-P receptor	Homo sapiens (human)
long-term memory	Substance-P receptor	Homo sapiens (human)
associative learning	Substance-P receptor	Homo sapiens (human)
detection of abiotic stimulus	Substance-P receptor	Homo sapiens (human)
response to ozone	Substance-P receptor	Homo sapiens (human)
positive regulation of epithelial cell migration	Substance-P receptor	Homo sapiens (human)
response to auditory stimulus	Substance-P receptor	Homo sapiens (human)
regulation of smooth muscle cell migration	Substance-P receptor	Homo sapiens (human)
positive regulation of synaptic transmission, cholinergic	Substance-P receptor	Homo sapiens (human)
positive regulation of synaptic transmission, GABAergic	Substance-P receptor	Homo sapiens (human)
response to estradiol	Substance-P receptor	Homo sapiens (human)
response to progesterone	Substance-P receptor	Homo sapiens (human)
response to nicotine	Substance-P receptor	Homo sapiens (human)
operant conditioning	Substance-P receptor	Homo sapiens (human)
sperm ejaculation	Substance-P receptor	Homo sapiens (human)
eating behavior	Substance-P receptor	Homo sapiens (human)
positive regulation of vascular permeability	Substance-P receptor	Homo sapiens (human)
response to ethanol	Substance-P receptor	Homo sapiens (human)
positive regulation of action potential	Substance-P receptor	Homo sapiens (human)
positive regulation of blood pressure	Substance-P receptor	Homo sapiens (human)
positive regulation of ossification	Substance-P receptor	Homo sapiens (human)
positive regulation of vasoconstriction	Substance-P receptor	Homo sapiens (human)
positive regulation of hormone secretion	Substance-P receptor	Homo sapiens (human)
behavioral response to pain	Substance-P receptor	Homo sapiens (human)
regulation of smooth muscle cell proliferation	Substance-P receptor	Homo sapiens (human)
positive regulation of lymphocyte proliferation	Substance-P receptor	Homo sapiens (human)
positive regulation of epithelial cell proliferation	Substance-P receptor	Homo sapiens (human)
positive regulation of stress fiber assembly	Substance-P receptor	Homo sapiens (human)
response to electrical stimulus	Substance-P receptor	Homo sapiens (human)
smooth muscle contraction involved in micturition	Substance-P receptor	Homo sapiens (human)
positive regulation of uterine smooth muscle contraction	Substance-P receptor	Homo sapiens (human)
positive regulation of flagellated sperm motility	Substance-P receptor	Homo sapiens (human)
signal transduction	Rhodopsin kinase GRK1	Bos taurus (cattle)
visual perception	Rhodopsin kinase GRK1	Bos taurus (cattle)
regulation of opsin-mediated signaling pathway	Rhodopsin kinase GRK1	Bos taurus (cattle)
protein autophosphorylation	Rhodopsin kinase GRK1	Bos taurus (cattle)
monoamine transport	Sodium-dependent serotonin transporter	Homo sapiens (human)
response to hypoxia	Sodium-dependent serotonin transporter	Homo sapiens (human)
neurotransmitter transport	Sodium-dependent serotonin transporter	Homo sapiens (human)
response to nutrient	Sodium-dependent serotonin transporter	Homo sapiens (human)
memory	Sodium-dependent serotonin transporter	Homo sapiens (human)
circadian rhythm	Sodium-dependent serotonin transporter	Homo sapiens (human)
response to xenobiotic stimulus	Sodium-dependent serotonin transporter	Homo sapiens (human)
response to toxic substance	Sodium-dependent serotonin transporter	Homo sapiens (human)
positive regulation of gene expression	Sodium-dependent serotonin transporter	Homo sapiens (human)
positive regulation of serotonin secretion	Sodium-dependent serotonin transporter	Homo sapiens (human)
negative regulation of cerebellar granule cell precursor proliferation	Sodium-dependent serotonin transporter	Homo sapiens (human)
negative regulation of synaptic transmission, dopaminergic	Sodium-dependent serotonin transporter	Homo sapiens (human)
response to estradiol	Sodium-dependent serotonin transporter	Homo sapiens (human)
social behavior	Sodium-dependent serotonin transporter	Homo sapiens (human)
vasoconstriction	Sodium-dependent serotonin transporter	Homo sapiens (human)
sperm ejaculation	Sodium-dependent serotonin transporter	Homo sapiens (human)
negative regulation of neuron differentiation	Sodium-dependent serotonin transporter	Homo sapiens (human)
positive regulation of cell cycle	Sodium-dependent serotonin transporter	Homo sapiens (human)
negative regulation of organ growth	Sodium-dependent serotonin transporter	Homo sapiens (human)
behavioral response to cocaine	Sodium-dependent serotonin transporter	Homo sapiens (human)
enteric nervous system development	Sodium-dependent serotonin transporter	Homo sapiens (human)
brain morphogenesis	Sodium-dependent serotonin transporter	Homo sapiens (human)
serotonin uptake	Sodium-dependent serotonin transporter	Homo sapiens (human)
membrane depolarization	Sodium-dependent serotonin transporter	Homo sapiens (human)
platelet aggregation	Sodium-dependent serotonin transporter	Homo sapiens (human)
cellular response to retinoic acid	Sodium-dependent serotonin transporter	Homo sapiens (human)
cellular response to cGMP	Sodium-dependent serotonin transporter	Homo sapiens (human)
regulation of thalamus size	Sodium-dependent serotonin transporter	Homo sapiens (human)
conditioned place preference	Sodium-dependent serotonin transporter	Homo sapiens (human)
sodium ion transmembrane transport	Sodium-dependent serotonin transporter	Homo sapiens (human)
amino acid transport	Sodium-dependent serotonin transporter	Homo sapiens (human)
apoptotic process	G protein-coupled receptor kinase 5	Homo sapiens (human)
G protein-coupled receptor signaling pathway	G protein-coupled receptor kinase 5	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	G protein-coupled receptor kinase 5	Homo sapiens (human)
tachykinin receptor signaling pathway	G protein-coupled receptor kinase 5	Homo sapiens (human)
regulation of G protein-coupled receptor signaling pathway	G protein-coupled receptor kinase 5	Homo sapiens (human)
positive regulation of cell population proliferation	G protein-coupled receptor kinase 5	Homo sapiens (human)
Wnt signaling pathway	G protein-coupled receptor kinase 5	Homo sapiens (human)
negative regulation of apoptotic process	G protein-coupled receptor kinase 5	Homo sapiens (human)
fat cell differentiation	G protein-coupled receptor kinase 5	Homo sapiens (human)
protein autophosphorylation	G protein-coupled receptor kinase 5	Homo sapiens (human)
regulation of cell cycle	G protein-coupled receptor kinase 5	Homo sapiens (human)
protein phosphorylation	G protein-coupled receptor kinase 5	Homo sapiens (human)
regulation of signal transduction	G protein-coupled receptor kinase 5	Homo sapiens (human)
apoptotic process	G protein-coupled receptor kinase 5	Bos taurus (cattle)
Wnt signaling pathway	G protein-coupled receptor kinase 5	Bos taurus (cattle)
negative regulation of apoptotic process	G protein-coupled receptor kinase 5	Bos taurus (cattle)
protein autophosphorylation	G protein-coupled receptor kinase 5	Bos taurus (cattle)
calcium ion transport	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
sensory perception of sound	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
positive regulation of adenylate cyclase activity	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
positive regulation of calcium ion transport	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
regulation of atrial cardiac muscle cell membrane repolarization	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
calcium ion import	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
calcium ion transmembrane transport	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
cardiac muscle cell action potential involved in contraction	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
membrane depolarization during cardiac muscle cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
membrane depolarization during SA node cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
regulation of potassium ion transmembrane transporter activity	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
regulation of potassium ion transmembrane transport	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
calcium ion import across plasma membrane	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
monoamine transport	Sodium-dependent dopamine transporter	Homo sapiens (human)
neurotransmitter transport	Sodium-dependent dopamine transporter	Homo sapiens (human)
lactation	Sodium-dependent dopamine transporter	Homo sapiens (human)
sensory perception of smell	Sodium-dependent dopamine transporter	Homo sapiens (human)
locomotory behavior	Sodium-dependent dopamine transporter	Homo sapiens (human)
response to xenobiotic stimulus	Sodium-dependent dopamine transporter	Homo sapiens (human)
response to iron ion	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopamine transport	Sodium-dependent dopamine transporter	Homo sapiens (human)
adenohypophysis development	Sodium-dependent dopamine transporter	Homo sapiens (human)
response to nicotine	Sodium-dependent dopamine transporter	Homo sapiens (human)
positive regulation of multicellular organism growth	Sodium-dependent dopamine transporter	Homo sapiens (human)
regulation of dopamine metabolic process	Sodium-dependent dopamine transporter	Homo sapiens (human)
response to cocaine	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopamine biosynthetic process	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopamine catabolic process	Sodium-dependent dopamine transporter	Homo sapiens (human)
response to ethanol	Sodium-dependent dopamine transporter	Homo sapiens (human)
cognition	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopamine uptake involved in synaptic transmission	Sodium-dependent dopamine transporter	Homo sapiens (human)
response to cAMP	Sodium-dependent dopamine transporter	Homo sapiens (human)
norepinephrine uptake	Sodium-dependent dopamine transporter	Homo sapiens (human)
prepulse inhibition	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopamine uptake	Sodium-dependent dopamine transporter	Homo sapiens (human)
hyaloid vascular plexus regression	Sodium-dependent dopamine transporter	Homo sapiens (human)
amino acid transport	Sodium-dependent dopamine transporter	Homo sapiens (human)
norepinephrine transport	Sodium-dependent dopamine transporter	Homo sapiens (human)
sodium ion transmembrane transport	Sodium-dependent dopamine transporter	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of heart rate by hormone	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of membrane potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
positive regulation of DNA-templated transcription	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion homeostasis	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cardiac muscle contraction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)

Process	via Protein(s)	Taxonomy
voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
metal ion binding	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
high voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
transcription cis-regulatory region binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
core promoter sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
TFIID-class transcription factor complex binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
protease binding	Cellular tumor antigen p53	Homo sapiens (human)
p53 binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity	Cellular tumor antigen p53	Homo sapiens (human)
mRNA 3'-UTR binding	Cellular tumor antigen p53	Homo sapiens (human)
copper ion binding	Cellular tumor antigen p53	Homo sapiens (human)
protein binding	Cellular tumor antigen p53	Homo sapiens (human)
zinc ion binding	Cellular tumor antigen p53	Homo sapiens (human)
enzyme binding	Cellular tumor antigen p53	Homo sapiens (human)
receptor tyrosine kinase binding	Cellular tumor antigen p53	Homo sapiens (human)
ubiquitin protein ligase binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase regulator activity	Cellular tumor antigen p53	Homo sapiens (human)
ATP-dependent DNA/DNA annealing activity	Cellular tumor antigen p53	Homo sapiens (human)
identical protein binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase binding	Cellular tumor antigen p53	Homo sapiens (human)
protein heterodimerization activity	Cellular tumor antigen p53	Homo sapiens (human)
protein-folding chaperone binding	Cellular tumor antigen p53	Homo sapiens (human)
protein phosphatase 2A binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Cellular tumor antigen p53	Homo sapiens (human)
14-3-3 protein binding	Cellular tumor antigen p53	Homo sapiens (human)
MDM2/MDM4 family protein binding	Cellular tumor antigen p53	Homo sapiens (human)
disordered domain specific binding	Cellular tumor antigen p53	Homo sapiens (human)
general transcription initiation factor binding	Cellular tumor antigen p53	Homo sapiens (human)
molecular function activator activity	Cellular tumor antigen p53	Homo sapiens (human)
promoter-specific chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
chromatin binding	Myeloperoxidase	Homo sapiens (human)
peroxidase activity	Myeloperoxidase	Homo sapiens (human)
protein binding	Myeloperoxidase	Homo sapiens (human)
heparin binding	Myeloperoxidase	Homo sapiens (human)
heme binding	Myeloperoxidase	Homo sapiens (human)
metal ion binding	Myeloperoxidase	Homo sapiens (human)
G protein-coupled acetylcholine receptor activity	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
arrestin family protein binding	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
G protein-coupled acetylcholine receptor activity	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
protein binding	ATP-dependent translocase ABCB1	Homo sapiens (human)
ATP binding	ATP-dependent translocase ABCB1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
efflux transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
ATP hydrolysis activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
ubiquitin protein ligase binding	ATP-dependent translocase ABCB1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
carboxylic acid transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
phosphatidylcholine floppase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
phosphatidylethanolamine flippase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
ceramide floppase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
floppase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
receptor-receptor interaction	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
serotonin binding	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
phosphatidylinositol phospholipase C activity	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
protein binding	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
G protein-coupled acetylcholine receptor activity	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2D6	Homo sapiens (human)
iron ion binding	Cytochrome P450 2D6	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2D6	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2D6	Homo sapiens (human)
heme binding	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
phosphatidylinositol phospholipase C activity	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
protein binding	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled acetylcholine receptor activity	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
retinal dehydrogenase activity	Aldo-keto reductase family 1 member B1	Bos taurus (cattle)
prostaglandin H2 endoperoxidase reductase activity	Aldo-keto reductase family 1 member B1	Bos taurus (cattle)
allyl-alcohol dehydrogenase activity	Aldo-keto reductase family 1 member B1	Bos taurus (cattle)
glycerol dehydrogenase [NADP+] activity	Aldo-keto reductase family 1 member B1	Bos taurus (cattle)
all-trans-retinol dehydrogenase (NADP+) activity	Aldo-keto reductase family 1 member B1	Bos taurus (cattle)
phosphatidylinositol phospholipase C activity	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
protein binding	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
G protein-coupled acetylcholine receptor activity	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
signaling receptor activity	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
acetylcholine binding	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
protein kinase activity	Beta-adrenergic receptor kinase 1	Bos taurus (cattle)
G protein-coupled receptor kinase activity	Beta-adrenergic receptor kinase 1	Bos taurus (cattle)
protein binding	Beta-adrenergic receptor kinase 1	Bos taurus (cattle)
ATP binding	Beta-adrenergic receptor kinase 1	Bos taurus (cattle)
alpha-2A adrenergic receptor binding	Beta-adrenergic receptor kinase 1	Bos taurus (cattle)
Edg-2 lysophosphatidic acid receptor binding	Beta-adrenergic receptor kinase 1	Bos taurus (cattle)
beta-adrenergic receptor kinase activity	Beta-adrenergic receptor kinase 1	Bos taurus (cattle)
voltage-gated monoatomic ion channel activity	Potassium voltage-gated channel subfamily A member 3	Homo sapiens (human)
protein binding	Potassium voltage-gated channel subfamily A member 3	Homo sapiens (human)
outward rectifier potassium channel activity	Potassium voltage-gated channel subfamily A member 3	Homo sapiens (human)
delayed rectifier potassium channel activity	Potassium voltage-gated channel subfamily A member 3	Homo sapiens (human)
actin binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neurotransmitter:sodium symporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
dopamine:sodium symporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
norepinephrine:sodium symporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
protein binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
monoamine transmembrane transporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
alpha-tubulin binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
metal ion binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
beta-tubulin binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
protein kinase activity	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
G protein-coupled receptor kinase activity	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
protein binding	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
ATP binding	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
alpha-2A adrenergic receptor binding	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
Edg-2 lysophosphatidic acid receptor binding	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
beta-adrenergic receptor kinase activity	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
G protein-coupled receptor binding	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
tachykinin receptor activity	Substance-P receptor	Homo sapiens (human)
protein binding	Substance-P receptor	Homo sapiens (human)
substance P receptor activity	Substance-P receptor	Homo sapiens (human)
protein binding	Rhodopsin kinase GRK1	Bos taurus (cattle)
ATP binding	Rhodopsin kinase GRK1	Bos taurus (cattle)
rhodopsin kinase activity	Rhodopsin kinase GRK1	Bos taurus (cattle)
integrin binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
monoatomic cation channel activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
serotonin:sodium:chloride symporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
protein binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
monoamine transmembrane transporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
antiporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
syntaxin-1 binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
cocaine binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
sodium ion binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
identical protein binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
nitric-oxide synthase binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
actin filament binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
serotonin binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
protein serine/threonine kinase activity	G protein-coupled receptor kinase 5	Homo sapiens (human)
G protein-coupled receptor kinase activity	G protein-coupled receptor kinase 5	Homo sapiens (human)
protein kinase C binding	G protein-coupled receptor kinase 5	Homo sapiens (human)
protein binding	G protein-coupled receptor kinase 5	Homo sapiens (human)
ATP binding	G protein-coupled receptor kinase 5	Homo sapiens (human)
phospholipid binding	G protein-coupled receptor kinase 5	Homo sapiens (human)
beta-adrenergic receptor kinase activity	G protein-coupled receptor kinase 5	Homo sapiens (human)
protein kinase activity	G protein-coupled receptor kinase 5	Homo sapiens (human)
protein serine/threonine kinase activity	G protein-coupled receptor kinase 5	Bos taurus (cattle)
G protein-coupled receptor kinase activity	G protein-coupled receptor kinase 5	Bos taurus (cattle)
ATP binding	G protein-coupled receptor kinase 5	Bos taurus (cattle)
lipid binding	G protein-coupled receptor kinase 5	Bos taurus (cattle)
high voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
protein binding	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
ankyrin binding	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
metal ion binding	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
alpha-actinin binding	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
voltage-gated calcium channel activity involved SA node cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
protease binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
signaling receptor binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopamine:sodium symporter activity	Sodium-dependent dopamine transporter	Homo sapiens (human)
protein binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
monoamine transmembrane transporter activity	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopamine binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
amine binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
protein-containing complex binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
metal ion binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
protein phosphatase 2A binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
heterocyclic compound binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
norepinephrine:sodium symporter activity	Sodium-dependent dopamine transporter	Homo sapiens (human)
transcription cis-regulatory region binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inward rectifier potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
delayed rectifier potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
ubiquitin protein ligase binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
identical protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein homodimerization activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
C3HC4-type RING finger domain binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
scaffold protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
protein binding	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
calmodulin binding	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
high voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
small molecule binding	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
metal ion binding	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
molecular function activator activity	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
high voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
protein binding	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
calmodulin binding	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
high voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
metal ion binding	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
alpha-actinin binding	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
voltage-gated calcium channel activity involved in AV node cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
protein kinase activity	Rhodopsin kinase GRK1	Homo sapiens (human)
ATP binding	Rhodopsin kinase GRK1	Homo sapiens (human)
rhodopsin kinase activity	Rhodopsin kinase GRK1	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
ATP binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
ATP hydrolysis activity	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA clamp unloader activity	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
purinergic nucleotide receptor activity	P2X purinoceptor 4	Homo sapiens (human)
extracellularly ATP-gated monoatomic cation channel activity	P2X purinoceptor 4	Homo sapiens (human)
signaling receptor binding	P2X purinoceptor 4	Homo sapiens (human)
copper ion binding	P2X purinoceptor 4	Homo sapiens (human)
protein binding	P2X purinoceptor 4	Homo sapiens (human)
ATP binding	P2X purinoceptor 4	Homo sapiens (human)
zinc ion binding	P2X purinoceptor 4	Homo sapiens (human)
identical protein binding	P2X purinoceptor 4	Homo sapiens (human)
cadherin binding	P2X purinoceptor 4	Homo sapiens (human)
ligand-gated calcium channel activity	P2X purinoceptor 4	Homo sapiens (human)
RNA binding	Ataxin-2	Homo sapiens (human)
epidermal growth factor receptor binding	Ataxin-2	Homo sapiens (human)
protein binding	Ataxin-2	Homo sapiens (human)
mRNA binding	Ataxin-2	Homo sapiens (human)
G protein-coupled opioid receptor activity	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
protein binding	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
photoreceptor outer segment	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
membrane	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
perikaryon	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
voltage-gated calcium channel complex	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
nuclear body	Cellular tumor antigen p53	Homo sapiens (human)
nucleus	Cellular tumor antigen p53	Homo sapiens (human)
nucleoplasm	Cellular tumor antigen p53	Homo sapiens (human)
replication fork	Cellular tumor antigen p53	Homo sapiens (human)
nucleolus	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrion	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial matrix	Cellular tumor antigen p53	Homo sapiens (human)
endoplasmic reticulum	Cellular tumor antigen p53	Homo sapiens (human)
centrosome	Cellular tumor antigen p53	Homo sapiens (human)
cytosol	Cellular tumor antigen p53	Homo sapiens (human)
nuclear matrix	Cellular tumor antigen p53	Homo sapiens (human)
PML body	Cellular tumor antigen p53	Homo sapiens (human)
transcription repressor complex	Cellular tumor antigen p53	Homo sapiens (human)
site of double-strand break	Cellular tumor antigen p53	Homo sapiens (human)
germ cell nucleus	Cellular tumor antigen p53	Homo sapiens (human)
chromatin	Cellular tumor antigen p53	Homo sapiens (human)
transcription regulator complex	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex	Cellular tumor antigen p53	Homo sapiens (human)
extracellular region	Myeloperoxidase	Homo sapiens (human)
extracellular space	Myeloperoxidase	Homo sapiens (human)
nucleus	Myeloperoxidase	Homo sapiens (human)
nucleoplasm	Myeloperoxidase	Homo sapiens (human)
lysosome	Myeloperoxidase	Homo sapiens (human)
secretory granule	Myeloperoxidase	Homo sapiens (human)
azurophil granule lumen	Myeloperoxidase	Homo sapiens (human)
azurophil granule	Myeloperoxidase	Homo sapiens (human)
intracellular membrane-bounded organelle	Myeloperoxidase	Homo sapiens (human)
extracellular exosome	Myeloperoxidase	Homo sapiens (human)
phagocytic vesicle lumen	Myeloperoxidase	Homo sapiens (human)
extracellular space	Myeloperoxidase	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
clathrin-coated endocytic vesicle membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
asymmetric synapse	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
symmetric synapse	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
presynaptic membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
neuronal cell body	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
axon terminus	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
postsynaptic membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
glutamatergic synapse	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
cholinergic synapse	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
synapse	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
dendrite	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
postsynaptic membrane	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
dendrite	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
synapse	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
cytoplasm	ATP-dependent translocase ABCB1	Homo sapiens (human)
plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
cell surface	ATP-dependent translocase ABCB1	Homo sapiens (human)
membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
apical plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
extracellular exosome	ATP-dependent translocase ABCB1	Homo sapiens (human)
external side of apical plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
postsynaptic membrane	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
dendrite	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
synapse	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
mitochondrion	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2D6	Homo sapiens (human)
cytoplasm	Cytochrome P450 2D6	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2D6	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
membrane	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
presynaptic membrane	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
axon terminus	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
Schaffer collateral - CA1 synapse	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
postsynaptic density membrane	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
glutamatergic synapse	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
cholinergic synapse	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
synapse	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
dendrite	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
endoplasmic reticulum membrane	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
basal plasma membrane	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
basolateral plasma membrane	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
postsynaptic membrane	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
synapse	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
dendrite	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
cytoplasm	Beta-adrenergic receptor kinase 1	Bos taurus (cattle)
cytosol	Beta-adrenergic receptor kinase 1	Bos taurus (cattle)
plasma membrane	Beta-adrenergic receptor kinase 1	Bos taurus (cattle)
membrane	Beta-adrenergic receptor kinase 1	Bos taurus (cattle)
cell projection	Beta-adrenergic receptor kinase 1	Bos taurus (cattle)
presynapse	Beta-adrenergic receptor kinase 1	Bos taurus (cattle)
postsynapse	Beta-adrenergic receptor kinase 1	Bos taurus (cattle)
plasma membrane	Potassium voltage-gated channel subfamily A member 3	Homo sapiens (human)
presynaptic membrane	Potassium voltage-gated channel subfamily A member 3	Homo sapiens (human)
calyx of Held	Potassium voltage-gated channel subfamily A member 3	Homo sapiens (human)
membrane raft	Potassium voltage-gated channel subfamily A member 3	Homo sapiens (human)
postsynaptic membrane	Potassium voltage-gated channel subfamily A member 3	Homo sapiens (human)
glutamatergic synapse	Potassium voltage-gated channel subfamily A member 3	Homo sapiens (human)
voltage-gated potassium channel complex	Potassium voltage-gated channel subfamily A member 3	Homo sapiens (human)
axon	Potassium voltage-gated channel subfamily A member 3	Homo sapiens (human)
membrane	Potassium voltage-gated channel subfamily A member 3	Homo sapiens (human)
plasma membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
cell surface	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neuronal cell body membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
presynaptic membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
plasma membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
axon	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
cytoplasm	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
cytosol	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
plasma membrane	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
cilium	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
membrane	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
presynapse	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
postsynapse	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
plasma membrane	Substance-P receptor	Homo sapiens (human)
cell surface	Substance-P receptor	Homo sapiens (human)
dendrite	Substance-P receptor	Homo sapiens (human)
sperm flagellum	Substance-P receptor	Homo sapiens (human)
cell body	Substance-P receptor	Homo sapiens (human)
sperm head	Substance-P receptor	Homo sapiens (human)
sperm midpiece	Substance-P receptor	Homo sapiens (human)
plasma membrane	Substance-P receptor	Homo sapiens (human)
sperm midpiece	Substance-P receptor	Homo sapiens (human)
photoreceptor disc membrane	Rhodopsin kinase GRK1	Bos taurus (cattle)
plasma membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
focal adhesion	Sodium-dependent serotonin transporter	Homo sapiens (human)
endosome membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
endomembrane system	Sodium-dependent serotonin transporter	Homo sapiens (human)
presynaptic membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
membrane raft	Sodium-dependent serotonin transporter	Homo sapiens (human)
synapse	Sodium-dependent serotonin transporter	Homo sapiens (human)
postsynaptic membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
serotonergic synapse	Sodium-dependent serotonin transporter	Homo sapiens (human)
synapse	Sodium-dependent serotonin transporter	Homo sapiens (human)
plasma membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
neuron projection	Sodium-dependent serotonin transporter	Homo sapiens (human)
cytosol	G protein-coupled receptor kinase 5	Homo sapiens (human)
plasma membrane	G protein-coupled receptor kinase 5	Homo sapiens (human)
nuclear speck	G protein-coupled receptor kinase 5	Homo sapiens (human)
nuclear membrane	G protein-coupled receptor kinase 5	Homo sapiens (human)
cytoplasm	G protein-coupled receptor kinase 5	Homo sapiens (human)
nucleus	G protein-coupled receptor kinase 5	Bos taurus (cattle)
plasma membrane	G protein-coupled receptor kinase 5	Bos taurus (cattle)
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
plasma membrane	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
Z disc	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
voltage-gated calcium channel complex	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
L-type voltage-gated calcium channel complex	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
cytoplasm	Sodium-dependent dopamine transporter	Homo sapiens (human)
plasma membrane	Sodium-dependent dopamine transporter	Homo sapiens (human)
cell surface	Sodium-dependent dopamine transporter	Homo sapiens (human)
membrane	Sodium-dependent dopamine transporter	Homo sapiens (human)
axon	Sodium-dependent dopamine transporter	Homo sapiens (human)
neuron projection	Sodium-dependent dopamine transporter	Homo sapiens (human)
neuronal cell body	Sodium-dependent dopamine transporter	Homo sapiens (human)
axon terminus	Sodium-dependent dopamine transporter	Homo sapiens (human)
membrane raft	Sodium-dependent dopamine transporter	Homo sapiens (human)
postsynaptic membrane	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopaminergic synapse	Sodium-dependent dopamine transporter	Homo sapiens (human)
flotillin complex	Sodium-dependent dopamine transporter	Homo sapiens (human)
axon	Sodium-dependent dopamine transporter	Homo sapiens (human)
presynaptic membrane	Sodium-dependent dopamine transporter	Homo sapiens (human)
plasma membrane	Sodium-dependent dopamine transporter	Homo sapiens (human)
neuronal cell body membrane	Sodium-dependent dopamine transporter	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cell surface	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
perinuclear region of cytoplasm	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel complex	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inward rectifier potassium channel complex	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cytoplasm	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
plasma membrane	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
sarcoplasmic reticulum	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
T-tubule	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
I band	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
L-type voltage-gated calcium channel complex	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
voltage-gated calcium channel complex	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
cytoplasm	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
plasma membrane	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
postsynaptic density	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
membrane	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
Z disc	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
dendrite	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
perikaryon	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
postsynaptic density membrane	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
L-type voltage-gated calcium channel complex	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
voltage-gated calcium channel complex	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
photoreceptor disc membrane	Rhodopsin kinase GRK1	Homo sapiens (human)
cytoplasm	Rhodopsin kinase GRK1	Homo sapiens (human)
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
Elg1 RFC-like complex	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
nucleus	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
lysosomal membrane	P2X purinoceptor 4	Homo sapiens (human)
plasma membrane	P2X purinoceptor 4	Homo sapiens (human)
membrane	P2X purinoceptor 4	Homo sapiens (human)
cell junction	P2X purinoceptor 4	Homo sapiens (human)
neuronal cell body	P2X purinoceptor 4	Homo sapiens (human)
terminal bouton	P2X purinoceptor 4	Homo sapiens (human)
dendritic spine	P2X purinoceptor 4	Homo sapiens (human)
cell body	P2X purinoceptor 4	Homo sapiens (human)
perinuclear region of cytoplasm	P2X purinoceptor 4	Homo sapiens (human)
extracellular exosome	P2X purinoceptor 4	Homo sapiens (human)
plasma membrane	P2X purinoceptor 4	Homo sapiens (human)
cytoplasm	Ataxin-2	Homo sapiens (human)
Golgi apparatus	Ataxin-2	Homo sapiens (human)
trans-Golgi network	Ataxin-2	Homo sapiens (human)
cytosol	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
membrane	Ataxin-2	Homo sapiens (human)
perinuclear region of cytoplasm	Ataxin-2	Homo sapiens (human)
ribonucleoprotein complex	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
nuclear envelope	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
nuclear inner membrane	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
nuclear outer membrane	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
endoplasmic reticulum	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
endoplasmic reticulum membrane	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
lipid droplet	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
cytosol	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
postsynaptic density	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
membrane	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
growth cone	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
cytoplasmic vesicle	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
anchoring junction	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
postsynaptic density membrane	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
endoplasmic reticulum	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
cilium	Beta-adrenergic receptor kinase 1	Mus musculus (house mouse)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1347412	qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID64372	Equilibrium dissociation constant (KD) for Competitive binding between [3H]WIN-35428 and the compound at human transporter-hDAT	1998	Bioorganic & medicinal chemistry letters, Mar-03, Volume: 8, Issue:5	Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group.
AID1636485	Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 9.1 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1744429	Inhibition of human GRK5 using porcine brain tubulin as substrate incubated for 3 to 5 mins by [gamma32P]ATP based radiometric assay	2021	Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1	Generation of Highly Selective, Potent, and Covalent G Protein-Coupled Receptor Kinase 5 Inhibitors.
AID1220554	Fraction unbound in Wistar Han rat brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Species independence in brain tissue binding using brain homogenates.
AID496830	Antimicrobial activity against Leishmania major	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID588218	FDA HLAED, lactate dehydrogenase (LDH) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID612622	Inhibition of NorA in Staphylococcus aureus 1199B assessed as inhibition of ethidium bromide efflux dose response curve based fluorometric assay	2011	Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16	Evolution from a natural flavones nucleus to obtain 2-(4-Propoxyphenyl)quinoline derivatives as potent inhibitors of the S. aureus NorA efflux pump.
AID302140	Displacement of [3H]paroxetine from SERT receptor in human platelet membrane	2007	Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24	1-Aminocyclopentane-1,2,4-tricarboxylic acids screening on glutamatergic and serotonergic systems.
AID496831	Antimicrobial activity against Cryptosporidium parvum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1528204	Antagonist activity at human P2X4 receptor tranfected in human 1321N1 cells assessed as inhibition of ATP-induced calcium influx incubated for 10 mins by Fluo2-AM staining based inverted fluorescence microscopic method	2019	Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24	Discovery and Characterization of the Potent and Selective P2X4 Inhibitor
AID1332024	Inhibition of human SERT expressed in CHO cell membranes assessed as reduction in [3H]serotonin uptake preincubated for 10 mins followed by [3H]serotonin addition measured after 20 mins by liquid scintillation counting method	2017	Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1	Discovery of SMP-304, a novel benzylpiperidine derivative with serotonin transporter inhibitory activity and 5-HT
AID1302248	Inhibition of GRK2 in C57BL/6 mouse cardiomyocytes assessed as increase in contractility at 10 uM preincubated for 10 mins followed by beta adrenergic receptor agonist isoproterenol addition for 2 mins	2016	Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8	Structure-Based Design, Synthesis, and Biological Evaluation of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors.
AID311934	Dissociation constant, pKa of the compound	2008	Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2	Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID496819	Antimicrobial activity against Plasmodium falciparum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588215	FDA HLAED, alkaline phosphatase increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID539464	Solubility of the compound in 0.1 M phosphate buffer at 600 uM at pH 7.4 after 24 hrs by LC/MS/MS analysis	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID496823	Antimicrobial activity against Trichomonas vaginalis	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID616837	Anti-depressant activity in mouse assessed as immobility effect at 10 mg/kg, po after 60 mins by forced swimming test	2011	Journal of medicinal chemistry, Sep-22, Volume: 54, Issue:18	Design and synthesis of novel arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.
AID26362	Ionization constant (pKa)	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID1460843	Inhibition of bovine GRK2 S670A mutant after 5 mins in presence of ATP by phosphorimaging assay	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Structure-Based Design of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors Based on Paroxetine.
AID29359	Ionization constant (pKa)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID588214	FDA HLAED, liver enzyme composite activity	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID503311	Antiproliferative activity against human PC3 cells at 10 uM after 120 hrs by MTT assay relative to DMSO	2006	Nature chemical biology, Jun, Volume: 2, Issue:6	Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID1302237	Inhibition of full length C-terminal hexahistidine tagged GRK2 (unknown origin) S670A mutant expressed in High Five cells using Bac to Bac insect cell expression system using tubulin as substrate by SDS-PAGE method	2016	Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8	Structure-Based Design, Synthesis, and Biological Evaluation of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors.
AID373224	Cmin in human at 20 mg, po qd for 10 days	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects.
AID1222793	Dissociation constant, pKa of the compound	2013	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5	Which metabolites circulate?
AID1446226	Inhibition of recombinant MPO (unknown origin) assessed as reduction in taurine chloramine production preincubated with enzyme and taurine followed by H2O2 addition measured after 5 mins	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.
AID204516	The potency of the [3H]paroxetine for 5-HT transporters	1994	Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9	Synthesis of 2 beta-acyl-3 beta-aryl-8-azabicyclo[3.2.1]octanes and their binding affinities at dopamine and serotonin transport sites in rat striatum and frontal cortex.
AID699540	Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID678713	Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID373226	Apparent oral clearance in human at 20 mg, po qd for 10 days	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID587251	Displacement of [3H]-WIN 35,428 from DAT in rabbit striatal membrane	2011	European journal of medicinal chemistry, Mar, Volume: 46, Issue:3	Synthesis, molecular docking and binding studies of selective serotonin transporter inhibitors.
AID612589	Antibacterial activity against Staphylococcus aureus 1199B norA++ and A116E GrlA mutation by M7-A7 CLSI microdilution method	2011	Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16	Evolution from a natural flavones nucleus to obtain 2-(4-Propoxyphenyl)quinoline derivatives as potent inhibitors of the S. aureus NorA efflux pump.
AID588217	FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID681144	TP_TRANSPORTER: cell accumulation of calcein in L-MDR1 cells	2003	The Journal of pharmacology and experimental therapeutics, Apr, Volume: 305, Issue:1	Inhibition of P-glycoprotein by newer antidepressants.
AID1449985	Inhibition of RND efflux pump in Enterobacter cloacae isolate 117029 assessed as potentiation of minocycline-induced antibacterial activity at 8 ug/ml after 18 to 24 hrs by microbroth dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	A Tobramycin Vector Enhances Synergy and Efficacy of Efflux Pump Inhibitors against Multidrug-Resistant Gram-Negative Bacteria.
AID588219	FDA HLAED, gamma-glutamyl transferase (GGT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1866614	Inhibition of human Kv1.3 expressed in HEK293 cells assessed as inhibition of tetracyclin induced current at 30 uM at holding potential of -80 mV by patch clamp method relative to control	2022	Journal of natural products, 04-22, Volume: 85, Issue:4	Jatrophane Diterpenoids with Kv1.3 Ion Channel Inhibitory Effects from
AID254338	Binding inhibition towards human norepinephrine transporter	2005	Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19	Conformationally restricted homotryptamines. 2. Indole cyclopropylmethylamines as selective serotonin reuptake inhibitors.
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID781328	pKa (acid-base dissociation constant) as determined by Luan ref: Pharm. Res. 2005	2014	Pharmaceutical research, Apr, Volume: 31, Issue:4	Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID1302252	Selectivity ratio of IC50 for C-terminal hexahistidine tagged bovine GRK1 to IC50 for human GRK2 S670A mutant	2016	Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8	Structure-Based Design, Synthesis, and Biological Evaluation of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors.
AID1220556	Fraction unbound in CD-1 mouse brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Species independence in brain tissue binding using brain homogenates.
AID739022	Displacement of [125I]RTI-55 from human recombinant SERT expressed in HEK293 cells after 1 hr by scintillation counting analysis	2013	Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8	Discovery of disubstituted piperidines and homopiperidines as potent dual NK1 receptor antagonists-serotonin reuptake transporter inhibitors for the treatment of depression.
AID1866613	Cytotoxicity against HEK293 cells assessed as reduction in cell proliferation at 30 uM	2022	Journal of natural products, 04-22, Volume: 85, Issue:4	Jatrophane Diterpenoids with Kv1.3 Ion Channel Inhibitory Effects from
AID1866612	Inhibition of human Kv1.3 expressed in HEK293 cells assessed as inhibition of tetracyclin induced current at holding potential of -80 mV by patch clamp method	2022	Journal of natural products, 04-22, Volume: 85, Issue:4	Jatrophane Diterpenoids with Kv1.3 Ion Channel Inhibitory Effects from
AID1220560	Fraction unbound in human occipital cortex at 1 uM after 6 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Species independence in brain tissue binding using brain homogenates.
AID27167	Delta logD (logD6.5 - logD7.4)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID361596	Displacement of [3H]paroxetine from human SERT expressed in HEK293 cells	2008	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16	3-(4-(6-Fluoroalkoxy-3,4-dihydroisoquinoline-2(1H)-yl)cyclohexyl)-1H-indole-5-carbonitriles for SERT imaging: chemical synthesis, evaluation in vitro and radiofluorination.
AID496821	Antimicrobial activity against Leishmania	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID8002	Observed volume of distribution	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID612586	Antibacterial activity against Staphylococcus aureus K1902 bearing norA-deficient mutation by M7-A7 CLSI microdilution method	2011	Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16	Evolution from a natural flavones nucleus to obtain 2-(4-Propoxyphenyl)quinoline derivatives as potent inhibitors of the S. aureus NorA efflux pump.
AID373239	Decrease in serotonin concentration in human platelets at 20 mg, po qd for 10 days followed by 16 days washout period and treated with 20 mg, po qd for 10 days coadministered with fosamprenavir at 700 mg, po bid and ritonavir at 100 mg, po bid relative to	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects.
AID1215122	Percentage unbound in solid supported porcine brain membrane vesicles at 5 uM by TRANSIL assay	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
AID1460847	Inhibition of ROCK1 (unknown origin) at 10 uM by ADP-Glo kinase assay	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Structure-Based Design of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors Based on Paroxetine.
AID1129361	Unbound fraction in HEK293 cell homogenate at 0.1 uM by equilibrium dialysis based UPLC-MS/MS analysis	2014	Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7	A high-throughput cell-based method to predict the unbound drug fraction in the brain.
AID395324	Lipophilicity, log D at pH 7.4 by liquid chromatography	2009	Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6	Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID1460846	Inhibition of mouse PKA using CREBtide as substrate after 30 mins in presence of ATP by ADP-Glo kinase assay	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Structure-Based Design of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors Based on Paroxetine.
AID669748	Inhibition of norA in wild type Staphylococcus aureus SA1199 expressing assessed as potentiation of ciprofloxacin MIC by checkerboard assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Pyrazolo[4,3-c][1,2]benzothiazines 5,5-dioxide: a promising new class of Staphylococcus aureus NorA efflux pump inhibitors.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID669749	Inhibition of norA overexpressed in Staphylococcus aureus SA1199B coexpressing A116E GrlA mutation assessed as potentiation of ciprofloxacin MIC by checkerboard assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Pyrazolo[4,3-c][1,2]benzothiazines 5,5-dioxide: a promising new class of Staphylococcus aureus NorA efflux pump inhibitors.
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID65494	Inhibitory constant towards reuptake of [125I]-12 from dopamine transporter in rat striatal membranes	1994	Journal of medicinal chemistry, May-13, Volume: 37, Issue:10	Synthesis and characterization of radioiodinated N-(3-iodopropen-1-yl)-2 beta-carbomethoxy-3 beta-(4-chlorophenyl)tropanes: potential dopamine reuptake site imaging agents.
AID612583	Inhibition of NorA in Staphylococcus aureus 1199B assessed as inhibition of ethidium bromide efflux at 50 uM by fluorimetry	2011	Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16	Evolution from a natural flavones nucleus to obtain 2-(4-Propoxyphenyl)quinoline derivatives as potent inhibitors of the S. aureus NorA efflux pump.
AID28681	Partition coefficient (logD6.5)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID373242	Apparent volume of distribution in human	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects.
AID625277	FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI	2011	Drug discovery today, Aug, Volume: 16, Issue:15-16	FDA-approved drug labeling for the study of drug-induced liver injury.
AID1449983	Inhibition of RND efflux pump in Enterobacter cloacae isolate 117029 assessed as potentiation of minocycline-induced antibacterial activity by measuring minocycline MIC at 8 ug/ml after 18 to 24 hrs by microbroth dilution assay (Rvb = 128 to 256 ug/ml)	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	A Tobramycin Vector Enhances Synergy and Efficacy of Efflux Pump Inhibitors against Multidrug-Resistant Gram-Negative Bacteria.
AID330659	Effect on life span of Caenorhabditis elegans at 50 uM	2007	Nature, Nov-22, Volume: 450, Issue:7169	An antidepressant that extends lifespan in adult Caenorhabditis elegans.
AID709133	Antagonist activity at rat P2X4 receptor by cell-based calcium influx assay	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	N-substituted phenoxazine and acridone derivatives: structure-activity relationships of potent P2X4 receptor antagonists.
AID1460852	Half life in CD-1 mouse liver microsomes at 1 uM measured up to 60 mins in presence of NADPH by LC-MS/MS analysis	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Structure-Based Design of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors Based on Paroxetine.
AID709142	Antagonist activity at human P2X4 receptor expressed in 1321N1 cells assessed as inhibition of ATP-induced cytosolic calcium influx compound preincubated for 30 mins before ATP treatment by Fluo-4 AM fluorescence method	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	N-substituted phenoxazine and acridone derivatives: structure-activity relationships of potent P2X4 receptor antagonists.
AID496828	Antimicrobial activity against Leishmania donovani	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1449968	Inhibition of RND efflux pump in XDR Pseudomonas aeruginosa isolate P262-101856 infected in Galleria mellonella assessed as potentiation of minocycline-induced antibacterial activity by measuring larval death rate at 75 mg/kg co-treated with 75 mg/kg mino	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	A Tobramycin Vector Enhances Synergy and Efficacy of Efflux Pump Inhibitors against Multidrug-Resistant Gram-Negative Bacteria.
AID1220558	Fraction unbound in Beagle dog brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Species independence in brain tissue binding using brain homogenates.
AID179990	Tested in vivo for serotonin syndrome antagonizing activity in rat	1990	Journal of medicinal chemistry, Oct, Volume: 33, Issue:10	Pyrroloisoquinoline antidepressants. 3. A focus on serotonin.
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID496829	Antimicrobial activity against Leishmania infantum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1636371	Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 21.7 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of N	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID395327	Dissociation constant, pKa by capillary electrophoresis	2009	Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6	Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID1460845	Inhibition of bovine GRK5 after 5 mins after 5 mins in presence of ATP by phosphorimaging assay	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Structure-Based Design of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors Based on Paroxetine.
AID1847246	Antiviral activity against Ebola virus infected in African green monkey assessed as reduction in viral infection incubated for 48 hrs by CellTiter-Glo Luminescent Cell Viability Assay	2021	European journal of medicinal chemistry, Nov-05, Volume: 223	Potential pharmacological strategies targeting the Niemann-Pick C1 receptor and Ebola virus glycoprotein interaction.
AID1220555	Fraction unbound in Sprague-Dawley rat brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Species independence in brain tissue binding using brain homogenates.
AID1894055	Inhibition of GRK2 (unknown origin)	2021	Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3	Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases.
AID373229	Half life in human at 20 mg, po qd for 10 days followed by 16 days washout period and treated with 20 mg, po qd for 10 days coadministered with fosamprenavir at 700 mg, po bid and ritonavir at 100 mg, po bid	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects.
AID669742	Inhibition of norA-mediated EtBr efflux in Staphylococcus aureus SA1199B overexpressing norA and expressing A116E GrlA mutation at 50 uM by fluorometry	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Pyrazolo[4,3-c][1,2]benzothiazines 5,5-dioxide: a promising new class of Staphylococcus aureus NorA efflux pump inhibitors.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID612588	Antibacterial activity against wild-type norA expressing Staphylococcus aureus 1199 by M7-A7 CLSI microdilution method	2011	Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16	Evolution from a natural flavones nucleus to obtain 2-(4-Propoxyphenyl)quinoline derivatives as potent inhibitors of the S. aureus NorA efflux pump.
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID678717	Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1211295	Unbound fraction in plasma (unknown origin) at pH 7.63 after 6 hrs by equilibrium dialysis method in presence of 5% CO2	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
AID678715	Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID134216	Tested in vitro for norepinephrine (NE) neuronal uptake inhibition	1990	Journal of medicinal chemistry, Oct, Volume: 33, Issue:10	Pyrroloisoquinoline antidepressants. 3. A focus on serotonin.
AID588216	FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID587249	Displacement of [3H]-paroxetine from SERT in rabbit cortical membrane	2011	European journal of medicinal chemistry, Mar, Volume: 46, Issue:3	Synthesis, molecular docking and binding studies of selective serotonin transporter inhibitors.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID612590	Potentiation of ciprofloxacin-antibacterial activity against wild-type Staphylococcus aureus ATCC 25923 assessed as reduction in ciprofloxacin MIC by M7-A7 CLSI microdilution method	2011	Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16	Evolution from a natural flavones nucleus to obtain 2-(4-Propoxyphenyl)quinoline derivatives as potent inhibitors of the S. aureus NorA efflux pump.
AID408802	Displacement of [3H]paroxetine from human SERT expressed in HEK293 cells	2008	Bioorganic & medicinal chemistry, Jun-15, Volume: 16, Issue:12	Carbon-11 labeled indolylpropylamine analog as a new potential PET agent for imaging of the serotonin transporter.
AID612612	Inhibition of NorA in Staphylococcus aureus 1199B norA++ and A116E GrlA mutation assessed as reduction in ciprofloxacin MIC at 25 ug/mL	2011	Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16	Evolution from a natural flavones nucleus to obtain 2-(4-Propoxyphenyl)quinoline derivatives as potent inhibitors of the S. aureus NorA efflux pump.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1211294	Unbound fraction in plasma (unknown origin) at pH 7.4 after 6 hrs by equilibrium dialysis method in presence of 5% CO2	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
AID1211297	Drug recovery in plasma (unknown origin)	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
AID425652	Total body clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID1215121	Fraction unbound in Wistar rat brain homogenate at 5 uM after 5 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
AID205038	Inhibition of [3H]paroxetine (0.2 nM) binding to 5-HT transporter	1998	Journal of medicinal chemistry, Jan-15, Volume: 41, Issue:2	Synthesis and ligand binding of tropane ring analogues of paroxetine.
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1302253	Selectivity ratio of IC50 for C-terminal hexahistidine tagged bovine GRK5 to IC50 for human GRK2 S670A mutant	2016	Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8	Structure-Based Design, Synthesis, and Biological Evaluation of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors.
AID1450006	Inhibition of RND efflux pump in Pseudomonas aeruginosa PAO1 assessed as increase in tetracycline uptake up to 8.2 ug/ml measured at 1 min interval for 30 mins by fluorescence assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	A Tobramycin Vector Enhances Synergy and Efficacy of Efflux Pump Inhibitors against Multidrug-Resistant Gram-Negative Bacteria.
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1636427	Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 13 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NAD	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID230244	Ratio of NET to that of SERT	2003	Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25	Syntheses and binding studies of new [(aryl)(aryloxy)methyl]piperidine derivatives and related compounds as potential antidepressant drugs with high affinity for serotonin (5-HT) and norepinephrine (NE) transporters.
AID1064727	Antagonist activity at human P2X4 receptor expressed in human 1321N1 cells assessed as inhibition of ATP-induced cytosolic calcium influx preincubated for 30 mins followed by ATP addition by Fluo-4 AM dye-based fluorescence assay	2014	Bioorganic & medicinal chemistry, Feb-01, Volume: 22, Issue:3	Carbamazepine derivatives with P2X4 receptor-blocking activity.
AID554098	Inhibition of NorA in Staphylococcus aureus 1199B assessed as reduction in ethidium bromide efflux at 50 uM by fluorimetry after 5 mins	2011	Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1	Discovery of novel inhibitors of the NorA multidrug transporter of Staphylococcus aureus.
AID612585	Antibacterial activity against wild-type Staphylococcus aureus ATCC 25923 by M7-A7 CLSI microdilution method	2011	Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16	Evolution from a natural flavones nucleus to obtain 2-(4-Propoxyphenyl)quinoline derivatives as potent inhibitors of the S. aureus NorA efflux pump.
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID64685	Binding affinity against dopamine transporter (DAT) by displacement of [3H]WIN-35428 in male wistar rats	2003	Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25	Syntheses and binding studies of new [(aryl)(aryloxy)methyl]piperidine derivatives and related compounds as potential antidepressant drugs with high affinity for serotonin (5-HT) and norepinephrine (NE) transporters.
AID186981	Inhibition of [3H]5-HT reuptake into rat frontal cortex synaptosomes	1998	Bioorganic & medicinal chemistry letters, Mar-03, Volume: 8, Issue:5	Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group.
AID1332036	Displacement of [3H]citalopram from human SERT expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting method	2017	Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1	Discovery of SMP-304, a novel benzylpiperidine derivative with serotonin transporter inhibitory activity and 5-HT
AID1460855	Inhibition of GRK2 in isoproterenol-stimulated C57/BL6 mouse cardiomyocytes assessed as increase in contractility by measuring cell shortening at 10 uM pretreated for 10 mins followed by beta-AR agonist isoproterenol addition for 2 mins	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Structure-Based Design of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors Based on Paroxetine.
AID1449929	Inhibition of RND efflux pump in Pseudomonas aeruginosa PAO1 assessed as potentiation of minocycline-induced antibacterial activity by measuring minocycline MIC at 8 ug/ml after 18 to 24 hrs by microbroth dilution assay (Rvb = 8 ug/ml)	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	A Tobramycin Vector Enhances Synergy and Efficacy of Efflux Pump Inhibitors against Multidrug-Resistant Gram-Negative Bacteria.
AID1220559	Fraction unbound in cynomolgus monkey brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Species independence in brain tissue binding using brain homogenates.
AID186980	Inhibition of [3H]- NE reuptake into rat hippocampal synaptosomes	1998	Bioorganic & medicinal chemistry letters, Mar-03, Volume: 8, Issue:5	Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group.
AID204695	Displacement of [3H]citalopram from rat cortical serotonin transporter (SERT)	2002	Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5	Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 2: 4-substituted 6-nitroquipazines.
AID1332031	Antidepressant-like activity in Wistar rat assessed as decrease in immobility time at 3 and 10 mg/kg, po administered 30 mins post start of training session for 2 days measured 2 hrs post last dose by forced swimming test	2017	Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1	Discovery of SMP-304, a novel benzylpiperidine derivative with serotonin transporter inhibitory activity and 5-HT
AID589095	Mechanism based inhibition of human cytochrome P450 2D6 measured by dextromethorphan O-demethylation	2005	Current drug metabolism, Oct, Volume: 6, Issue:5	Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID1212341	Cytotoxicity against human Fa2N-4 cells by lactate dehydrogenase assay	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
AID1302238	Inhibition of GRK1 (unknown origin) using tubulin as substrate by SDS-PAGE method	2016	Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8	Structure-Based Design, Synthesis, and Biological Evaluation of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1863562	Antiviral activity against pseudotyped Ebola virus assessed as inhibition of viral entry	2022	European journal of medicinal chemistry, Oct-05, Volume: 240	Discovery of potent ebola entry inhibitors with (3S,4aS,8aS)-2-(3-amino-2-hydroxypropyl) decahydroisoquinoline-3-carboxamide scaffold.
AID227282	Effect on helpless behavior in rats and the number of escape failures was determined in shuttle-box session-1 (SB-1) at 1 mg/kg dose	2001	Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3	New 1-aryl-3-(4-arylpiperazin-1-yl)propane derivatives, with dual action at 5-HT1A serotonin receptors and serotonin transporter, as a new class of antidepressants.
AID1472913	Binding affinity to Ebola virus Zaire Mayinga-76 recombinant GP protein assessed as change in melting temperature at 500 uM by SYPRO orange dye-based fluorescence assay	2018	Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3	Target Identification and Mode of Action of Four Chemically Divergent Drugs against Ebolavirus Infection.
AID496824	Antimicrobial activity against Toxoplasma gondii	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID373240	Toxicity in human assessed as serious adverse events at 20 mg, po qd for 10 days	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects.
AID3719	Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes	2003	Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25	Syntheses and binding studies of new [(aryl)(aryloxy)methyl]piperidine derivatives and related compounds as potential antidepressant drugs with high affinity for serotonin (5-HT) and norepinephrine (NE) transporters.
AID678712	Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID5476	Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes	2003	Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25	Syntheses and binding studies of new [(aryl)(aryloxy)methyl]piperidine derivatives and related compounds as potential antidepressant drugs with high affinity for serotonin (5-HT) and norepinephrine (NE) transporters.
AID587252	Ratio of Ki for NET in rabbit cortical membrane to Ki for SERT in rabbit cortical membrane	2011	European journal of medicinal chemistry, Mar, Volume: 46, Issue:3	Synthesis, molecular docking and binding studies of selective serotonin transporter inhibitors.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1783171	Displacement of [125I]RTI55 binding from human wild type SERT	2021	European journal of medicinal chemistry, Aug-05, Volume: 220	Tuning the activity of known drugs via the introduction of halogen atoms, a case study of SERT ligands - Fluoxetine and fluvoxamine.
AID1460842	Inhibition of GRK2 (unknown origin)	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Structure-Based Design of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors Based on Paroxetine.
AID373227	AUC (0 to 24 hrs) in human at 20 mg, po qd for 10 days followed by 16 days washout period and treated with 20 mg, po qd for 10 days coadministered with fosamprenavir at 700 mg, po bid and ritonavir at 100 mg, po bid	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects.
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID438555	Binding affinity to 5HT1A receptor	2009	Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19	Physical binding pocket induction for affinity prediction.
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID373241	Toxicity in human assessed as serious adverse events at 20 mg, po qd for 10 days followed by 16 days washout period and treated with 20 mg, po qd for 10 days coadministered with fosamprenavir at 700 mg, po bid and ritonavir at 100 mg, po bid	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects.
AID1211296	Unbound fraction in plasma (unknown origin) under normal atmospheric condition at pH 7.72 after 6 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
AID699539	Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1460844	Inhibition of bovine GRK1 (1 to 535 residues) after 5 mins after 5 mins in presence of ATP by phosphorimaging assay	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Structure-Based Design of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors Based on Paroxetine.
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1215126	Ratio of fraction unbound in Wistar rat brain homogenate at 5 uM after 5 hrs by equilibrium dialysis method to fraction unbound in solid supported porcine brain membrane vesicles at 5 uM by TRANSIL assay	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
AID699541	Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID387488	Inhibition of serotonin uptake at human SERT expressed in JAR cells	2008	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18	Synthesis and activity of 1-(3-amino-1-phenylpropyl)indolin-2-ones: a new class of selective norepinephrine reuptake inhibitors.
AID496825	Antimicrobial activity against Leishmania mexicana	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID373238	Decrease in serotonin concentration in human platelets at 20 mg, po qd for 10 days relative to control	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects.
AID36948	Ability to displace [3H]rauwolscine from Alpha-2 adrenergic receptor in rat cortical membranes	1997	Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7	Structure-activity studies for a novel series of N-(arylethyl)-N-(1,2,3,4-tetrahydronaphthalen-1-ylmethyl)-N-methylamine s possessing dual 5-HT uptake inhibiting and alpha2-antagonistic activities.
AID144700	Noncompetitive inhibition of N-methyl-D-aspartate (NMDA) Receptor, by the displacement of [3H]MK-801 in rat brain membranes; nd means not determined	1998	Bioorganic & medicinal chemistry letters, Mar-03, Volume: 8, Issue:5	Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group.
AID496832	Antimicrobial activity against Trypanosoma brucei rhodesiense	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID408801	Displacement of [3H]citalopram from human SERT expressed in HEK293 cells	2008	Bioorganic & medicinal chemistry, Jun-15, Volume: 16, Issue:12	Carbon-11 labeled indolylpropylamine analog as a new potential PET agent for imaging of the serotonin transporter.
AID330665	Effect on life span of Caenorhabditis elegans at 250 uM	2007	Nature, Nov-22, Volume: 450, Issue:7169	An antidepressant that extends lifespan in adult Caenorhabditis elegans.
AID678722	Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID669745	Antibacterial activity against wild type Staphylococcus aureus SA1199 expressing norA by microdilution method	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Pyrazolo[4,3-c][1,2]benzothiazines 5,5-dioxide: a promising new class of Staphylococcus aureus NorA efflux pump inhibitors.
AID588210	Human drug-induced liver injury (DILI) modelling dataset from Ekins et al	2010	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12	A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1449982	Inhibition of RND efflux pump in Klebsiella pneumoniae isolate 116381 assessed as potentiation of minocycline-induced antibacterial activity by measuring minocycline MIC at 8 ug/ml after 18 to 24 hrs by microbroth dilution assay (Rvb = 128 ug/ml)	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	A Tobramycin Vector Enhances Synergy and Efficacy of Efflux Pump Inhibitors against Multidrug-Resistant Gram-Negative Bacteria.
AID186979	Inhibition of [3H]- DA reuptake into rat striatal synaptosomes	1998	Bioorganic & medicinal chemistry letters, Mar-03, Volume: 8, Issue:5	Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group.
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1212314	Drug uptake in lysosomes of human Fa2N-4 cells assessed as inhibition of LysoTracker Red fluorescence after 30 mins	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
AID587253	Ratio of Ki for DAT in rabbit striatal membrane to Ki for SERT in rabbit cortical membrane	2011	European journal of medicinal chemistry, Mar, Volume: 46, Issue:3	Synthesis, molecular docking and binding studies of selective serotonin transporter inhibitors.
AID678716	Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID612584	Antibacterial activity against NorA-expressing Staphylococcus aureus 1199B by M7-A7 CLSI microdilution method	2011	Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16	Evolution from a natural flavones nucleus to obtain 2-(4-Propoxyphenyl)quinoline derivatives as potent inhibitors of the S. aureus NorA efflux pump.
AID1472911	Antiviral activity against Ebolavirus infected in african green monkey Vero E6 cells assessed as reduction in virus entry after 48 hrs by by Celltiter-Glo luminescent assay	2018	Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3	Target Identification and Mode of Action of Four Chemically Divergent Drugs against Ebolavirus Infection.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID204534	Binding affinity to the serotonin transporter (SERT) measured by displacement of [3H]paroxetine in male wistar rats	2003	Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25	Syntheses and binding studies of new [(aryl)(aryloxy)methyl]piperidine derivatives and related compounds as potential antidepressant drugs with high affinity for serotonin (5-HT) and norepinephrine (NE) transporters.
AID395325	Lipophilicity, log P by microemulsion electrokinetic chromatography	2009	Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6	Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID64686	Displacement of [3H]WIN-35428(0.5 nM) from Dopamine transporter	1998	Journal of medicinal chemistry, Jan-15, Volume: 41, Issue:2	Synthesis and ligand binding of tropane ring analogues of paroxetine.
AID1211293	Unbound fraction in plasma (unknown origin) under normal atmospheric condition at pH 7.22 after 6 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
AID425653	Renal clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID1220557	Fraction unbound in Hartley guinea pig brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Species independence in brain tissue binding using brain homogenates.
AID387487	Inhibition of norepinephrine uptake at human NET expressed in MDCK cells	2008	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18	Synthesis and activity of 1-(3-amino-1-phenylpropyl)indolin-2-ones: a new class of selective norepinephrine reuptake inhibitors.
AID227285	Effect on helpless behavior in rats and the number of escape failures was determined in shuttle-box session-2 (SB-2) at 1 mg/kg dose	2001	Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3	New 1-aryl-3-(4-arylpiperazin-1-yl)propane derivatives, with dual action at 5-HT1A serotonin receptors and serotonin transporter, as a new class of antidepressants.
AID669744	Antibacterial activity against Staphylococcus aureus SA1199B overexpressing norA and expressing A116E GrlA mutation by microdilution method	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Pyrazolo[4,3-c][1,2]benzothiazines 5,5-dioxide: a promising new class of Staphylococcus aureus NorA efflux pump inhibitors.
AID1449987	Antibacterial activity against Enterobacter cloacae isolate 117029 after 18 to 24 hrs by microbroth dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	A Tobramycin Vector Enhances Synergy and Efficacy of Efflux Pump Inhibitors against Multidrug-Resistant Gram-Negative Bacteria.
AID587250	Displacement of [3H]-Nisoxetine from NET in rabbit cortical membrane	2011	European journal of medicinal chemistry, Mar, Volume: 46, Issue:3	Synthesis, molecular docking and binding studies of selective serotonin transporter inhibitors.
AID496820	Antimicrobial activity against Trypanosoma brucei	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID227289	Effect on helpless behavior in rats and the number of escape failures was determined in shuttle-box session-3 (SB-3) at 1 mg/kg dose	2001	Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3	New 1-aryl-3-(4-arylpiperazin-1-yl)propane derivatives, with dual action at 5-HT1A serotonin receptors and serotonin transporter, as a new class of antidepressants.
AID314312	Inhibition of NorA-mediated efflux in Staphylococcus aureus K2361	2008	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4	Synthesis and evaluation of PSSRI-based inhibitors of Staphylococcus aureus multidrug efflux pumps.
AID1698791	Binding affinity to full length human GRK2 by Thermofluor thermal shift assay	2020	Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23	Hit-to-lead optimization and discovery of a potent, and orally bioavailable G protein coupled receptor kinase 2 (GRK2) inhibitor.
AID204703	Inhibition of [3H]citalopram binding to Serotonin transporter of rat cerebral cortex	2000	Bioorganic & medicinal chemistry letters, Jul-17, Volume: 10, Issue:14	Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 1.
AID1302251	Inhibition of human GRK2 S670A mutant preincubated for 30 mins using tubulin as substrate followed by ATP addition	2016	Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8	Structure-Based Design, Synthesis, and Biological Evaluation of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors.
AID229545	Relative binding to noradrenaline and serotonin transporters (ratio of Ki)	1998	Journal of medicinal chemistry, Jan-15, Volume: 41, Issue:2	Synthesis and ligand binding of tropane ring analogues of paroxetine.
AID612587	Antibacterial activity against Staphylococcus aureus K2378 bearing norA++ efficient mutation by M7-A7 CLSI microdilution method	2011	Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16	Evolution from a natural flavones nucleus to obtain 2-(4-Propoxyphenyl)quinoline derivatives as potent inhibitors of the S. aureus NorA efflux pump.
AID669746	Antibacterial activity against norA-deficient Staphylococcus aureus SAK1902 by microdilution method	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Pyrazolo[4,3-c][1,2]benzothiazines 5,5-dioxide: a promising new class of Staphylococcus aureus NorA efflux pump inhibitors.
AID678714	Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID7783	Unbound fraction (plasma)	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID1302240	Inhibition of PKA (unknown origin) using CREBtide as substrate by ADP-Glo kinase assay	2016	Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8	Structure-Based Design, Synthesis, and Biological Evaluation of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors.
AID314313	Inhibition of MepA-mediated efflux in Staphylococcus aureus K2886	2008	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4	Synthesis and evaluation of PSSRI-based inhibitors of Staphylococcus aureus multidrug efflux pumps.
AID387489	Selectivity for human NET over human SERT	2008	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18	Synthesis and activity of 1-(3-amino-1-phenylpropyl)indolin-2-ones: a new class of selective norepinephrine reuptake inhibitors.
AID147740	Binding affinity against norepinephrine transporter (NET) by displacement of [3H]nisoxetine in male wistar rats	2003	Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25	Syntheses and binding studies of new [(aryl)(aryloxy)methyl]piperidine derivatives and related compounds as potential antidepressant drugs with high affinity for serotonin (5-HT) and norepinephrine (NE) transporters.
AID204080	Equilibrium dissociation constant (KD) for Competitive binding between [3H]- imipramine and the compound at human transporter-hSERT	1998	Bioorganic & medicinal chemistry letters, Mar-03, Volume: 8, Issue:5	Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group.
AID29813	Oral bioavailability in human	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID373222	AUC (0 to 24 hrs) in human at 20 mg, po qd for 10 days	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects.
AID298031	Lipophilicity, log D at pH7.4	2007	Journal of medicinal chemistry, Sep-20, Volume: 50, Issue:19	High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.
AID1211298	Dissociation constant, pKa of the compound	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
AID298032	Acid dissociation constant, pKa of the compound	2007	Journal of medicinal chemistry, Sep-20, Volume: 50, Issue:19	High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.
AID1449986	Antibacterial activity against Klebsiella pneumoniae isolate 116381 after 18 to 24 hrs by microbroth dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	A Tobramycin Vector Enhances Synergy and Efficacy of Efflux Pump Inhibitors against Multidrug-Resistant Gram-Negative Bacteria.
AID373228	Cmax in human at 20 mg, po qd for 10 days followed by 16 days washout period and treated with 20 mg, po qd for 10 days coadministered with fosamprenavir at 700 mg, po bid and ritonavir at 100 mg, po bid	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects.
AID132117	Tested in vivo for head twitches antagonizing activity in mice	1990	Journal of medicinal chemistry, Oct, Volume: 33, Issue:10	Pyrroloisoquinoline antidepressants. 3. A focus on serotonin.
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1472910	Binding affinity to Ebola virus Zaire Mayinga-76 recombinant GP protein by SYPRO orange dye-based fluorescence assay	2018	Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3	Target Identification and Mode of Action of Four Chemically Divergent Drugs against Ebolavirus Infection.
AID145563	Equilibrium dissociation constant (KD) for Competitive binding between [3H]- nisoxatine and the compound at human Norepinephrine transporter	1998	Bioorganic & medicinal chemistry letters, Mar-03, Volume: 8, Issue:5	Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group.
AID254319	Binding inhibition towards human dopamine transporter	2005	Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19	Conformationally restricted homotryptamines. 2. Indole cyclopropylmethylamines as selective serotonin reuptake inhibitors.
AID1449931	Inhibition of RND efflux pump in Pseudomonas aeruginosa PAO1 assessed as potentiation of minocycline-induced antibacterial activity at 8 ug/ml after 18 to 24 hrs by checker board assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	A Tobramycin Vector Enhances Synergy and Efficacy of Efflux Pump Inhibitors against Multidrug-Resistant Gram-Negative Bacteria.
AID1207758	Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits	2013	Scientific reports, , Volume: 3	MICE models: superior to the HERG model in predicting Torsade de Pointes.
AID1744445	Inhibition of PKA (unknown origin) incubated for 30 mins using REBtide substrate by ADP-Glo assay	2021	Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1	Generation of Highly Selective, Potent, and Covalent G Protein-Coupled Receptor Kinase 5 Inhibitors.
AID1302241	Inhibition of ROCK1 (unknown origin) at 10 uM by ADP-Glo kinase assay	2016	Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8	Structure-Based Design, Synthesis, and Biological Evaluation of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID497005	Antimicrobial activity against Pneumocystis carinii	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1472912	Antiviral activity against Ebolavirus infected in human HepG2 cells assessed as reduction in virus entry after 48 hrs by Celltiter-Glo luminescent assay	2018	Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3	Target Identification and Mode of Action of Four Chemically Divergent Drugs against Ebolavirus Infection.
AID373223	Cmax in human at 20 mg, po qd for 10 days	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects.
AID739023	Displacement of [125I]substance P from human recombinant NK1 receptor expressed in human U373 cells after 1 hr by scintillation counting analysis	2013	Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8	Discovery of disubstituted piperidines and homopiperidines as potent dual NK1 receptor antagonists-serotonin reuptake transporter inhibitors for the treatment of depression.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID254322	Binding inhibition towards human serotonin transporter	2005	Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19	Conformationally restricted homotryptamines. 2. Indole cyclopropylmethylamines as selective serotonin reuptake inhibitors.
AID147593	Inhibition of [3H]nisoxetine (0.5 nM) binding to Noradrenaline transporter	1998	Journal of medicinal chemistry, Jan-15, Volume: 41, Issue:2	Synthesis and ligand binding of tropane ring analogues of paroxetine.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID373225	Half life in human at 20 mg, po qd for 10 days	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects.
AID496817	Antimicrobial activity against Trypanosoma cruzi	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1528205	Antagonist activity at rat P2X4 receptor tranfected in human 1321N1 cells assessed as inhibition of ATP-induced calcium influx incubated for 10 mins by Fluo2-AM staining based inverted fluorescence microscopic method	2019	Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24	Discovery and Characterization of the Potent and Selective P2X4 Inhibitor
AID496818	Antimicrobial activity against Trypanosoma brucei brucei	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1332032	Toxicity in Wistar rat assessed as increase in spontaneous locomotor activity at 3 and 10 mg/kg, po administered 26 and 2 hrs prior to testing measured for 30 mins	2017	Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1	Discovery of SMP-304, a novel benzylpiperidine derivative with serotonin transporter inhibitory activity and 5-HT
AID134215	Tested in vitro for dopamine(DA) neuronal uptake inhibition	1990	Journal of medicinal chemistry, Oct, Volume: 33, Issue:10	Pyrroloisoquinoline antidepressants. 3. A focus on serotonin.
AID361595	Displacement of [3H]citalopram from human SERT expressed in HEK293 cells	2008	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16	3-(4-(6-Fluoroalkoxy-3,4-dihydroisoquinoline-2(1H)-yl)cyclohexyl)-1H-indole-5-carbonitriles for SERT imaging: chemical synthesis, evaluation in vitro and radiofluorination.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID206400	Concentration required to reduce Minimum inhibitory concentration (MIC) of Norfloxacin against Staphylococcus aureus 1199B by 8 folds	2004	Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12	Structural differences between paroxetine and femoxetine responsible for differential inhibition of Staphylococcus aureus efflux pumps.
AID1744430	Inhibition of bovine GRK2 using porcine brain tubulin as substrate incubated for 3 to 5 mins by [gamma32P]ATP based radiometric assay	2021	Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1	Generation of Highly Selective, Potent, and Covalent G Protein-Coupled Receptor Kinase 5 Inhibitors.
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1460863	Inhibition of GRK2 in isoproterenol-stimulated C57/BL6 mouse cardiomyocytes assessed as increase in contractility by measuring cell shortening pretreated for 10 mins followed by beta-AR agonist isoproterenol addition for 2 mins	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Structure-Based Design of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors Based on Paroxetine.
AID196387	Inhibition of uptake of [3H]5-HT in synaptosomes from rat cortex	1997	Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7	Structure-activity studies for a novel series of N-(arylethyl)-N-(1,2,3,4-tetrahydronaphthalen-1-ylmethyl)-N-methylamine s possessing dual 5-HT uptake inhibiting and alpha2-antagonistic activities.
AID229542	Relative binding to dopamine and serotonin transporters (ratio of Ki)	1998	Journal of medicinal chemistry, Jan-15, Volume: 41, Issue:2	Synthesis and ligand binding of tropane ring analogues of paroxetine.
AID496827	Antimicrobial activity against Leishmania amazonensis	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID311933	Inhibition of ASM in rat PC12 cells assessed as residual activity at 10 uM	2008	Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2	Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID588209	Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset	2010	Chemical research in toxicology, Jul-19, Volume: 23, Issue:7	Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1302239	Inhibition of GRK5 (unknown origin) using tubulin as substrate by SDS-PAGE method	2016	Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8	Structure-Based Design, Synthesis, and Biological Evaluation of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors.
AID1449984	Inhibition of RND efflux pump in Klebsiella pneumoniae isolate 116381 assessed as potentiation of minocycline-induced antibacterial activity at 8 ug/ml after 18 to 24 hrs by microbroth dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	A Tobramycin Vector Enhances Synergy and Efficacy of Efflux Pump Inhibitors against Multidrug-Resistant Gram-Negative Bacteria.
AID750897	Inhibition of NorA in Staphylococcus aureus 1199B harboring grlA A116E mutant assessed as inhibition of ethidium bromide efflux at 50 uM measured for 5 mins by fluorometric analysis relative to control	2013	Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12	Re-evolution of the 2-phenylquinolines: ligand-based design, synthesis, and biological evaluation of a potent new class of Staphylococcus aureus NorA efflux pump inhibitors to combat antimicrobial resistance.
AID669747	Antibacterial activity against Staphylococcus aureus SAK2378 overexpressing norA by microdilution method	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Pyrazolo[4,3-c][1,2]benzothiazines 5,5-dioxide: a promising new class of Staphylococcus aureus NorA efflux pump inhibitors.
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID134217	Tested in vitro for serotonin(5-HT) neuronal uptake inhibition	1990	Journal of medicinal chemistry, Oct, Volume: 33, Issue:10	Pyrroloisoquinoline antidepressants. 3. A focus on serotonin.
AID496826	Antimicrobial activity against Entamoeba histolytica	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID612619	Inhibition of wild-type norA expressing Staphylococcus aureus 1199 assessed as reduction in ciprofloxacin MIC	2011	Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16	Evolution from a natural flavones nucleus to obtain 2-(4-Propoxyphenyl)quinoline derivatives as potent inhibitors of the S. aureus NorA efflux pump.
AID1449930	Antibacterial activity against Pseudomonas aeruginosa PAO1 after 18 to 24 hrs by microbroth dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	A Tobramycin Vector Enhances Synergy and Efficacy of Efflux Pump Inhibitors against Multidrug-Resistant Gram-Negative Bacteria.
AID1332035	Ratio of IC50 for human SERT expressed in CHO cell membranes assessed as reduction in [3H]serotonin uptake to Ki for [3H]citalopram from human SERT expressed in HEK293 cell membranes	2017	Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1	Discovery of SMP-304, a novel benzylpiperidine derivative with serotonin transporter inhibitory activity and 5-HT
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347049	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378	qHTS for Inhibitors of ATXN expression: Validation
AID1347045	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347050	Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836	Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation	2002	The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16	Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID588349	qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1346637	Human P2X4 (P2X receptors)	2016	Neuropharmacology, 05, Volume: 104	Medicinal chemistry of adenosine, P2Y and P2X receptors.
AID1346943	Human SERT (Monoamine transporter subfamily)	1997	European journal of pharmacology, Dec-11, Volume: 340, Issue:2-3	Pharmacological profile of antidepressants and related compounds at human monoamine transporters.
AID1346943	Human SERT (Monoamine transporter subfamily)	2016	Nature, Apr-21, Volume: 532, Issue:7599	X-ray structures and mechanism of the human serotonin transporter.
AID1346637	Human P2X4 (P2X receptors)	2013	Molecular pharmacology, Apr, Volume: 83, Issue:4	P2X receptors as drug targets.
AID1159550	Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening	2015	Nature cell biology, Nov, Volume: 17, Issue:11	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	127 (3.18)	18.7374
1990's	989 (24.75)	18.2507
2000's	1700 (42.54)	29.6817
2010's	954 (23.87)	24.3611
2020's	226 (5.66)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1,031 (24.22%)	5.53%
Reviews	402 (9.44%)	6.00%
Case Studies	611 (14.35%)	4.05%
Observational	10 (0.23%)	0.25%
Other	2,203 (51.75%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (215)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Randomized, 2-Way Crossover, Bioequivalence Study of Paroxetine Hydrochloride 40 mg Film-Coated Tablets and Paxil® 40 mg Film-Coated Tablets Administered as 1 x 40 mg Film-Coated Tablet in Healthy Subjects Under Fed Conditions [NCT00841659]	Phase 1	24 participants (Actual)	Interventional	2002-08-31	Completed
Endobiotics for Phenotyping of Human Cytochrome P450 Enzymes: Use of Metabolomics for the Identification of New CYP2D6 Endogenous Biomarkers in Healthy Volunteers [NCT04188028]		40 participants (Actual)	Interventional	2019-01-01	Completed
Study of Antidepressants in Parkinson's Disease [NCT00086190]	Phase 3	115 participants (Actual)	Interventional	2005-06-30	Completed
Effect of Tamsulosin on Premature Ejaculation Compared With Paroxetine Hydrochloride [NCT03879746]	Phase 3	160 participants (Anticipated)	Interventional	2019-04-30	Not yet recruiting
Influence of Pharmacogenetic Factors, Paroxetine and Clarithromycin on Pharmacokinetics of Clomiphene [NCT01289756]	Phase 1	20 participants (Actual)	Interventional	2009-12-31	Completed
Effects of Antidepressant on Postsynaptic Signal Transduction in Serotonergic System of Depressed Patients [NCT01352572]		300 participants (Anticipated)	Interventional	2002-01-31	Active, not recruiting
Special Drug Use Investigation for PAXIL Tablet (Long-term) [NCT01371448]		339 participants (Actual)	Observational	2001-05-31	Completed
Special Drug Use Investigation for PAXIL Tablet (Pediatric Panic Disorder) [NCT01376128]		96 participants (Actual)	Observational	2008-03-31	Completed
Open-Label, Two-Period Phase 1 Study in Healthy Subjects to Evaluate the Potential Effect of Multiple Doses of Paroxetine on the Pharmacokinetics and Safety of HBI-3000 [NCT04650542]	Phase 1	39 participants (Actual)	Interventional	2021-02-21	Completed
Development of A Technique to Predict Antidepressant Responsiveness in Depressive Patients [NCT01237275]		300 participants (Anticipated)	Interventional	1999-10-31	Active, not recruiting
An Open-Label Study to Assess the Effect of CYP2D6 Inhibitor Paroxetine on the Single-Dose Pharmacokinetics of JNJ-31001074 in Healthy Subjects [NCT01159821]	Phase 1	14 participants (Actual)	Interventional	2010-08-31	Completed
Prediction of Antidepressant Response Using Pharmacogenetics of Bioamine Transporter and Peripheral Lymphocytic Phenotype [NCT01352559]		1,000 participants (Anticipated)	Interventional	2001-11-30	Active, not recruiting
Special Drug Use Investigation for PAXIL Tablet (Investigation in Case of Administered From 20mg/Day) [NCT01371474]		1,483 participants (Actual)	Observational	2006-04-30	Completed
Electrophysiological Results of the Efficacy of Deep Transcranial Magnetic Stimulation on Mood State and Quality of Life in Obsessive Compulsive Disorder Patients [NCT05188833]		30 participants (Anticipated)	Interventional	2020-05-17	Active, not recruiting
A Phase I, Randomized, Open-Label, Active- and Placebo-Controlled Parallel Group Study of the Effect of Subcutaneous and Intravenous Methylnaltrexone on CYP450 2D6 Activity in Healthy Extensive Metabolizers of Dextromethorphan [NCT01367535]	Phase 1	54 participants (Actual)	Interventional	2006-03-31	Completed
Drug Use Investigation for PAXIL Tablet [NCT01371435]		3,708 participants (Actual)	Observational	2001-04-30	Completed
Special Drug Use Investigation for PAXIL (Paroxetine) Social Anxiety Disorder (Long-term) [NCT01376271]		600 participants (Actual)	Observational	2010-01-31	Completed
Randomized, Open Label, 2-way Crossover, Single Dose Bioequivalence Study of Paroxetine IR Tablets Manufactured in GSKT and Mississauga Sites in Healthy Chinese Participants Under Fasting and Fed Conditions [NCT03329573]	Phase 1	85 participants (Actual)	Interventional	2018-05-30	Completed
A Randomized, Double-Blind, Parallel Group, Placebo- and Active-Controlled, Phase 4 Study Evaluating the Effect of Vortioxetine 10 and 20 mg/Day vs Paroxetine 20 mg/Day on Sexual Functioning in Healthy Subjects [NCT02932904]	Phase 4	361 participants (Actual)	Interventional	2016-11-21	Completed
Special Drug Use Investigation for PAXIL Tablet (20mg-Clinical Symptom Progression) [NCT01371461]		390 participants (Actual)	Observational	2004-01-31	Completed
Pilot Study of Paroxetine and Fluconazole for the Treatment of HIV Associated Neurocognitive Disorder (HAND) [NCT01354314]	Phase 1/Phase 2	45 participants (Actual)	Interventional	2010-11-30	Completed
A Ten-week, Multicenter, Randomized, Double-Blind, Placebo-and Active-Controlled, Paralleled-Group, Flexible-Dose Study Evaluating the Efficacy, Safety and Tolerability of GSK372475 or Paroxetine Compared to Placebo in Adult Subjects Diagnosed With Major [NCT00420641]	Phase 2	492 participants (Actual)	Interventional	2006-12-19	Completed
Initial Severity and Antidepressant Efficacy for Anxiety Disorders: an Individual Patient Data Meta-analysis [NCT02476136]		8,800 participants (Anticipated)	Observational	2015-05-31	Active, not recruiting
Measurement-based Care vs. Standard Care for Major Depressive Disorder: a Randomized Controlled Trial With Masked Raters [NCT02191124]	Phase 4	164 participants (Actual)	Interventional	2011-06-30	Completed
An Oral Single-dose, Randomized, Balanced, Open-label, Two-sequence, Two-treatment, Two-period, Crossover Bioequivalence Study of Paroxetine Tablets 20 mg of GlaxoSmithKline Pharmaceuticals S.A, With That of PAXIL (Paroxetine) Tablets 20 mg of GlaxoSmithK [NCT04311463]	Phase 1	38 participants (Actual)	Interventional	2020-12-09	Completed
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause [NCT01361308]	Phase 3	614 participants (Actual)	Interventional	2011-05-31	Completed
Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene [NCT02237937]	Phase 4	80 participants (Anticipated)	Interventional	2011-09-30	Recruiting
Risk of Phenoconversion in Genetic Extensive Metabolizers Healthy Volunteers Carriers of One Fully-Functional and One Non-Functional Allele Versus Carriers of Two Fully-Functional Alleles [NCT03054220]		34 participants (Actual)	Interventional	2016-07-31	Completed
An Open Label Randomized Two-way Crossover Study to Investigate the Effect of Paroxetine Mediated CYP2D6 Inhibition on the Single Oral Dose Pharmacokinetics of Tamsulosin in Healthy Male Volunteers (CYP2D6 Extensive Metabolizers) [NCT02264184]	Phase 1	24 participants (Actual)	Interventional	2008-09-30	Completed
Randomized, 2-Way Crossover, Bioequivalence Study of Paroxetine Hydrochloride 40 mg Film-Coated Tablets and Paxil® 40 mg Film-Coated Tablets Administered as 1 x 40 mg Film-Coated Tablet in Healthy Subjects Under Fasting Conditions [NCT00841698]	Phase 1	50 participants (Actual)	Interventional	2002-10-31	Completed
An 8-week, Multicenter, Randomized, Double-blind, Placebo- and Paroxetine-controlled Study of the Efficacy, Safety and Tolerability of Agomelatine 25 or 50 mg Given Once Daily in the Treatment of Major Depressive Disorder (MDD) Followed by a 52-week Open- [NCT00463242]	Phase 3	501 participants (Actual)	Interventional	2007-03-31	Completed
A Phase 3, Randomized, Double-Blind, Parallel Group, 10-Week Placebo Controlled Fixed Dose Study Of PD 0332334 And Paroxetine Evaluating The Efficacy And Safety Of PD 0332334 For The Treatment Of Generalized Anxiety Disorder [NCT00658008]	Phase 3	501 participants (Actual)	Interventional	2008-04-30	Terminated(stopped due to Please see Detailed Description for termination reason.)
An Eight-week, Multicenter, Double-blind, Placebo- and Paroxetine-controlled Study Evaluating the Efficacy and Tolerability of Two Fixed Doses of SSR149415 (250 mg Bid and 100 mg Bid) in Outpatients With Generalized Anxiety Disorder [NCT00374166]	Phase 2	325 participants (Actual)	Interventional	2006-08-31	Completed
A Multi-Center, Randomized, Double-Blind, Parallel-Group Study Evaluating The Sexual Functioning of Healthy Adults After Receiving Multiple-Dose Regimens of Vilazodone, Paroxetine, or Placebo [NCT02097147]	Phase 1	202 participants (Actual)	Interventional	2014-03-31	Completed
Combination of Paroxetine CR and Quetiapine for the Treatment of Refractory Generalized Anxiety Disorder [NCT00113295]	Phase 4	50 participants (Actual)	Interventional	2004-02-29	Completed
Early Intervention for PTSD in Iraqi Veterans [NCT00641173]		0 participants (Actual)	Interventional	2008-09-30	Withdrawn(stopped due to Withdrawn by funding source)
A Phase 3, Randomized, Double-Blind, Parallel Group, 10-Week Placebo Controlled Fixed Dose Study of PD 0332334 and Paroxetine Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder [NCT00658762]	Phase 3	286 participants (Actual)	Interventional	2008-05-31	Terminated(stopped due to Please see Detailed Description for termination reason.)
A Phase 3, Randomized, Double-Blind, Parallel Group, 10-Week Placebo Controlled Fixed Dose Study Of PD 0332334 And Paroxetine Evaluating The Efficacy And Safety Of PD 0332334 For The Treatment Of Generalized Anxiety Disorder [NCT00658372]	Phase 3	360 participants (Actual)	Interventional	2008-05-31	Terminated(stopped due to Please see Detailed Description for termination reason.)
Predict Antidepressant Responsiveness Using Pharmacogenomics [NCT01228357]		1,000 participants (Anticipated)	Interventional	2003-02-28	Recruiting
Serotonin-norepinephrine Reuptake Inhibitors and Acute Kidney Injury [NCT02320240]		3,255,526 participants (Actual)	Observational	2013-06-30	Completed
Definitive Selection of Neuroimaging Biomarkers in Anxiety Disorder and Obsessive-compulsive Disorder: A Longitudinal Functional Magnetic Resonance Imaging （ fMRI ）Study With Paroxetine Treatment [NCT03894085]		150 participants (Anticipated)	Interventional	2019-05-30	Recruiting
A Randomized, Open-label, Trial of Lithium Versus Paroxetine in Subjects With Major Depression Who Have a Family History of Bipolar Disorder or Completed Suicide [NCT01416220]	Phase 4	2 participants (Actual)	Interventional	2011-09-30	Completed
Continuation Electroconvulsive Therapy Associated With Pharmacotherapy Versus Pharmacotherapy Alone for Relapse Prevention in Major Depression. A Clinical, Controlled, Prospective and Randomized Trial [NCT01305707]	Phase 4	104 participants (Actual)	Interventional	2009-07-31	Terminated(stopped due to Difficulties in recruiting)
Discontinuation of Antipsychotics and Antidepressants Among Patients With Dementia and BPSD Living in Nursing Homes - a 24 Weeks Double Blind RCT. [NCT00594269]	Phase 4	149 participants (Actual)	Interventional	2008-08-31	Completed
A 4-Week, Double-Blind, Randomized, Multicenter, Fixed Dose, Placebo-Controlled, Parallel Group Study of Lorazepam and Paroxetine in Patients With Generalized Anxiety Disorder: Assessment of a New Instrument Intended to Capture Rapid Onset [NCT00715039]		169 participants (Actual)	Interventional	2003-10-31	Completed
Single-Dose Fed Bioequivalence Study of Paroxetine Hydrochloride Tablets (40 mg; Mylan) and Paxil® Tablets (40 mg; GSK) in Healthy Adult Volunteers [NCT00650403]	Phase 1	66 participants (Actual)	Interventional	2006-12-31	Completed
An Open-label, Randomized, Single Dose, Two-period Crossover Study to Demonstrate Bioequivalence Between the Controlled Release Paroxetine Tablet (37.5 mg) Manufactured at Cidra and Mississauga [NCT00749359]	Phase 1	166 participants (Actual)	Interventional	2008-07-07	Completed
TRY FIRST: A 12-Week, Randomized, Open-Label Trial of Duloxetine Versus Generic SSRIs in the Treatment of a Severe Depressive Episode [NCT00666757]	Phase 4	750 participants (Actual)	Interventional	2008-05-31	Completed
Paroxetine-CR (Paxil-CR) in the Treatment of Patients With Fibromyalgia Syndrome: A Randomized, Double Blind, Parallel Group, Flexible Dose, Placebo Controlled Trial. [NCT00610610]	Phase 4	120 participants (Actual)	Interventional	2002-01-31	Completed
Pharmacogenomic Study to Predict Antidepressant Responsiveness in Depressed Patients [NCT00817375]		1,000 participants (Anticipated)	Interventional	2003-02-28	Recruiting
A Double-Blind, Multicenter Study Evaluating the Efficacy and Safety of One Fixed Dose of SR58611A (700 mg/Day) Versus Placebo and Paroxetine (20 mg/Day) in Patients With a Recurrent Major Depressive Episode. [NCT00825019]	Phase 3	306 participants (Actual)	Interventional	2003-09-30	Completed
An Eight-week, Double-blind Study to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses of Saredutant (100 mg and 30 mg) Once Daily in Combination With Paroxetine 20 mg Once Daily Compared to Saredutant Placebo in Combination With Paroxeti [NCT00629551]	Phase 3	825 participants (Actual)	Interventional	2008-02-29	Completed
A Comparison of Prolonged Exposure Therapy, Pharmacotherapy, and Their Combination for PTSD: What Works Best, and for Whom [NCT04961190]	Phase 4	300 participants (Anticipated)	Interventional	2022-05-25	Recruiting
Psycho-biological Substrates of Therapeutic Benefit of Thermal Cure on Generalized Anxiety Disorders (Insula-TOP) [NCT03277339]	Phase 4	52 participants (Actual)	Interventional	2017-01-19	Completed
An Open-label, 2-Part, Phase 1 Clinical Trial to Evaluate Drug Interactions When DA-8010 is Co-administered With Paroxetine or Mirabegron in Healthy Adults [NCT05992428]	Phase 1	36 participants (Anticipated)	Interventional	2023-08-22	Recruiting
Assessment of PACAP-BDNF Signaling System Involvement in Etiology and Treatment of Major Depression [NCT00944996]		100 participants (Actual)	Interventional	2009-06-30	Completed
Paroxetines Effect on Tramadols Metabolism and Pharmakodynamics: a Dose Response Study [NCT00785603]	Phase 4	12 participants (Actual)	Interventional	2008-08-31	Active, not recruiting
Effect of Selective Serotonin Reuptake Inhibitor Antidepressants on Semen Parameters [NCT00385762]		35 participants (Actual)	Observational	2007-01-31	Completed
A Parallel Randomized Double Blind Placebo Controlled Clinical Trial to Study the Efficacy and Safety of Paroxetine Daily Doses of 15 mg and 20 mg in the Treatment of Premature Ejaculation [NCT01024491]	Phase 3	174 participants (Actual)	Interventional	2008-08-31	Completed
Lofexidine Pharmacokinetics in the Presence of Paroxetine, a Strong CYP2D6 Inhibitor, in Healthy Volunteers [NCT02681198]	Phase 1	24 participants (Actual)	Interventional	2016-01-31	Completed
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms [NCT06049797]		1,000 participants (Anticipated)	Observational	2023-11-15	Recruiting
A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder, the Orion Trial [NCT01360866]	Phase 3	2,944 participants (Actual)	Interventional	2011-10-31	Completed
Naltrexone & SSRI in Alcoholics With Depression/PTSD [NCT00338962]	Phase 3	88 participants (Actual)	Interventional	2001-10-31	Completed
Monoamine Transporters Genotypes: Risk of PTSD and Related Comorbidities [NCT00403455]	Phase 3	38 participants (Actual)	Interventional	2006-10-31	Completed
A Double-Blind, Multicenter Study Evaluating the Efficacy and Safety of One Fixed Dose of SR58611A (700 mg/Day) Versus Placebo and Paroxetine (20 mg/Day) in Patients With a Recurrent Major Depressive Episode. [NCT00825058]	Phase 3	317 participants (Actual)	Interventional	2003-11-30	Completed
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Clinical Effects of Controlled Release Paroxetine in the Treatment of Major Depressive Disorder [NCT00866294]	Phase 3	416 participants (Actual)	Interventional	2009-04-30	Completed
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder [NCT00797966]	Phase 2	850 participants (Actual)	Interventional	2009-05-31	Completed
A Phase 2, Exploratory, Eight-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause [NCT00786188]	Phase 2	102 participants (Actual)	Interventional	2008-11-30	Completed
Luteal Phase Administration of Paroxetine for the Treatment of PMDD: A Randomized, Double-Blind, Placebo-Controlled Trial in Canadian Women [NCT00620581]	Phase 3	0 participants	Interventional		Completed
Single-Dose Food In Vivo Bioequivalence Study of Paroxetine Hydrochloride Controlled-Release Tablets (25 mg; Mylan) to Paxil CR™ Tablets (25 mg; GlaxoSmithKline) in Healthy Volunteers [NCT00647881]	Phase 1	75 participants (Actual)	Interventional	2005-04-30	Completed
Single-Dose Fasting In Vivo Bioequivalence Study of Paroxetine Hydrochloride Controlled-Release Tablets (25 mg; Mylan) to Paxil CR™ Tablets (25 mg; GlaxoSmithKline) in Healthy Volunteers [NCT00648427]	Phase 1	75 participants (Actual)	Interventional	2005-04-30	Completed
Efficacy of Three Treatment Modalities for Panic Disorder Among Individuals Consulting Emergency Departments for Non Cardiac Chest Pain [NCT00736346]		204 participants (Anticipated)	Interventional	2005-10-31	Recruiting
Long-term, Open, Naturalistic, Randomized Clinical Trial With Clonazepam and Paroxetine in Panic Disorder With or Without Agoraphobia [NCT02852577]	Phase 4	120 participants (Actual)	Interventional	2000-01-31	Completed
Phase 4 Study of Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness [NCT00817011]		1,000 participants (Anticipated)	Interventional	2006-04-30	Recruiting
Hypothalamus-pituitary-adrenal System: Role of the Mineralocorticoid Receptor and Longitudinal Study in Depressed Patients [NCT01049347]	Phase 3	127 participants (Actual)	Interventional	1997-10-31	Completed
Clinical Study to Investigate the Effect of the Combination of Psychotropic Drugs and an Opioid on Ventilation [NCT04310579]	Phase 1	55 participants (Actual)	Interventional	2020-06-15	Completed
A Randomized, Double-Blind, Multicenter Study Of Sertraline Compared With Paroxetine In The Treatment Of Panic Disorder [NCT00677352]	Phase 4	321 participants (Actual)	Interventional	2008-05-31	Completed
The Effect of Paroxetine on the Plasma Levels of Timolol Using Ophthalmic 0.5% Timolol Eye Drops and 0.1% Timolol Eye Gel in Healthy Volunteers [NCT00879099]	Phase 1	12 participants (Anticipated)	Interventional	2009-04-30	Completed
Phase 4 Study of Panic Disorder That Expresses to Change of Cerebral Glucose Metabolism After 12 Week of Paroxetine Treatment [NCT00767754]	Phase 4	37 participants (Actual)	Interventional	2007-01-31	Completed
Lamotrigine as an Antidepressant Augmentation Agent in Treatment Refractory Unipolar Depression [NCT00901407]		138 participants (Actual)	Interventional	2003-12-31	Completed
A Steady-state, Two-period Crossover Study to Compare the Pharmacokinetic Profile of Paroxetine After Repeated Daily Dosing of the Controlled-release Paroxetine Tablet (25 mg) With That of the Standard Immediate-release Paroxetine Tablet (20 mg) in Health [NCT01000857]	Phase 1	26 participants (Actual)	Interventional	2009-11-05	Completed
A Study to Investigate the Effect of Antidepressants on the Treatment for Korean Major Depressive Disorder (MDD) Patients [NCT00926835]	Phase 4	692 participants (Actual)	Interventional	2009-05-31	Terminated(stopped due to due to patient recruitment difficulties)
Definitive Selection of Neuroimaging Biomarkers for the Diagnosis and Treatment to Common Mental Disorders [NCT04218981]		200 participants (Anticipated)	Interventional	2020-01-15	Recruiting
A Randomised, Double-blind, Placebo Controlled, Parallel Group , Flexible Dose Study to Evaluate the Efficacy and Safety of Paxil® Tablets in Children and Adolescents With Major Depressive Disorder [NCT00812812]	Phase 4	56 participants (Actual)	Interventional	2009-03-31	Terminated
Efficacy and Safety of Paroxetine Controlled Release for Major Depressive Disorder in Irritable Bowel Syndrome Patients: An Open-label, Randomized, add-on Study [NCT01916200]	Phase 4	0 participants (Actual)	Interventional	2014-01-31	Withdrawn(stopped due to This study was Cancelled Before Active)
A Randomized, Double-blind, Double-dummy, Controlled Trial of Lithium Versus Paroxetine in Subjects With Major Depression Who Have a Family History of Bipolar Disorder or Completed Suicide - a Pilot Study [NCT00400088]	Phase 3	2 participants (Actual)	Interventional	2007-06-30	Terminated(stopped due to Recruitment difficulties)
The Use of Quantitative EEG (QEEG) as a Predictor of Treatment Outcome in Major Depressive Disorder [NCT00157547]	Phase 4	95 participants (Actual)	Interventional	2003-04-30	Completed
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Forced Dose Titration Study Evaluating the Efficacy and Safety of GW679769 and Paroxetine in Subjects With Social Anxiety Disorder [NCT00273039]	Phase 2	242 participants (Actual)	Interventional	2005-08-31	Completed
A Randomized, Double-Blind Comparison of LY686017, Paroxetine, and Placebo in the Treatment of Social Anxiety Disorder [NCT00191022]	Phase 2	185 participants	Interventional	2004-12-31	Completed
A Single-blind Trial of Risperidone vs. Paroxetine for Treatment of Panic Attacks [NCT00206765]	Phase 2	90 participants (Anticipated)	Interventional	2003-01-31	Terminated
A Placebo-controlled Trial of Adjunctive Quetiapine for Refractory PTSD [NCT00292370]	Phase 4	124 participants (Actual)	Interventional	2006-01-31	Completed
A Multicenter, Randomized, Double-blind, Paroxetine-referenced, Parallel-group Study to Evaluate the Safety, Efficacy, and Tolerability of 3 Fixed Doses (50mg, 100mg, AND 200mg) of Desvenlafaxine Succinate Sustained-release Tablets in Adult Outpatients Wi [NCT00445679]	Phase 3	807 participants (Actual)	Interventional	2007-07-31	Completed
Assessment of the Efficacy of Paroxetine in the Prevention of Depressive Syndrome in Patients With Chronic Hepatitis C Treated by PEG-Interferon Alfa Plus Ribavirin. Multicentric, Double-Blinded, Randomized Study. ANRS HC18 Paropeg [NCT00196664]	Phase 3	144 participants (Anticipated)	Interventional	2005-10-31	Completed
Clinical Evaluation of BRL29060 A in Generalized Anxiety Disorder [NCT00135525]	Phase 2	0 participants	Interventional	2003-05-31	Completed
Paroxetine Controlled Release in the Treatment of Symptomatic Menopausal Women Following Discontinuation of Hormone Therapy [NCT00225914]	Phase 4	64 participants (Actual)	Interventional	2004-09-30	Completed
Single-Dose Fasting Bioequivalence Study of Paroxetine Hydrochloride Tablets (40 mg; Mylan) and Paxil® Tablets (40 mg; GSK) in Healthy Adult Volunteers [NCT00648193]	Early Phase 1	36 participants (Actual)	Interventional	2006-12-31	Completed
An Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Active-referenced (Paroxetine), Fixed-dose Study on the Efficacy of Vortioxetine on Cognitive Dysfunction in Working Patients With Major Depressive Disorder [NCT02279966]	Phase 3	152 participants (Actual)	Interventional	2014-10-31	Completed
[NCT02273154]	Phase 4	240 participants (Anticipated)	Interventional	2014-08-31	Recruiting
Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies [NCT02893371]		1,037,352 participants (Actual)	Observational	2016-09-30	Completed
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause [NCT01101841]	Phase 3	570 participants (Actual)	Interventional	2010-03-31	Completed
Paroxetine Versus Bupropion for Suicide Ideators or Attempters With Major Depressive Disorder [NCT00429169]	Phase 4	101 participants (Actual)	Interventional	2004-06-30	Terminated(stopped due to Interim analysis showed differential treatment effects.)
BRL29060A in Posttraumatic Stress Disorder [NCT00839397]	Phase 3	52 participants (Actual)	Interventional	2002-05-31	Completed
An Open Label, Randomized, Three-period Crossover Study to Compare the Pharmacokinetic Profile of Paroxetine After Single Doses of the Controlled-release Paroxetine Tablets at the Dose Levels of 12.5, 25 and 50mg in Healthy Japanese Male Subjects [NCT00938184]	Phase 1	18 participants (Actual)	Interventional	2009-07-14	Completed
Neural Correlates of Early Intervention for PTSD [NCT00665678]	Phase 4	160 participants (Anticipated)	Interventional	2008-04-30	Terminated
Effects of Paxil CR on Neural Circuits in PTSD [NCT00672776]	Phase 4	40 participants (Actual)	Interventional	2003-05-31	Completed
Group Cognitive Behavioral Therapy Versus Fluoxetine for Obsessive-Compulsive Disorder: a Randomized Open Trial for Any Patient. [NCT00680602]	Phase 4	158 participants (Actual)	Interventional	2006-01-31	Completed
A Randomized, Controlled Trial on the Effects of Paroxetine Versus Placebo in Combination With Aerobic Exercise or Relaxation Training in the Treatment of Panic Disorder [NCT00540098]	Phase 4	75 participants (Actual)	Interventional	2001-09-30	Completed
"Single-center, Randomized, Open-label, Two-way Crossover Study to Characterize Phenotyping Metrics of the Basel Cocktail After CYP Induction or Inhibition in Healthy Male Subjects" [NCT01386593]	Phase 1	16 participants (Actual)	Interventional	2011-05-31	Completed
Paroxetine Treatment in Outpatients With Comorbid PTSD and Substance Dependence [NCT00330239]	Phase 4	25 participants	Interventional	2003-01-31	Completed
Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study [NCT00177567]	Phase 4	60 participants	Interventional	2001-07-31	Completed
A 6- Week, Randomized, Double-Blind, Parallel-Group, Active-and Placebo-Controlled Trial to Assess the Efficacy of R228060 in Adult Subjects With Major Depressive Disorder (MDD) [NCT00073203]	Phase 2	488 participants	Interventional		Completed
Maintenance Therapies in Late-Life Depression 2 (MTLD-2) [NCT00178100]	Phase 4	225 participants	Interventional	1999-03-31	Completed
Paroxetine for the Prevention of IFN-Alpha Associated Depression in Patients With Chronic Hepatitis C [NCT00209118]		60 participants	Interventional		Completed
Randomized Trial of Paroxetine-CR for the Treatment of Patients With Post-Traumatic Stress Disorder (PTSD) Remaining Symptomatic After Initial Exposure Therapy [NCT00215163]	Phase 2/Phase 3	17 participants (Actual)	Interventional	2002-12-31	Completed
Comparison of Aripiprazole Augmentation vs Switching to Different Class of Antidepressants for Patients With MDD Who Are Partially/Minimally Responsive to Current Antidepressants:Randomized, Rater-blinded, Prospective Study [NCT01488266]		90 participants (Anticipated)	Interventional	2011-11-30	Active, not recruiting
A Phase I, Randomized, Two-Period, Single-Center Study to Assess the Effect of CYP2D6 and CYP2C19 Inhibitors on a Single Oral Dose of AV650 (300 mg) in Healthy Subjects [NCT00456560]	Phase 1	30 participants (Anticipated)	Interventional	2007-04-30	Completed
[NCT00492414]	Phase 4	0 participants	Interventional		Recruiting
A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, fMRI and PET Study Comparing Emotional Challenge-induced Regional Cerebral Blood Flow Changes Before and After 8 Weeks of Treatment With Placebo and Paroxetine in Subjects With Social Anxiety [NCT00470483]	Phase 1	56 participants (Actual)	Interventional	2007-01-22	Completed
Prospective 24-week Study, Comparing Clinical Outcomes Between Switching Antidepressants and Maintaining the Same Antidepressant in Patients With Major Depressive Disorder Who do Not Show a 20% Reduction in Symptoms at Week 2 [NCT00519012]	Phase 4	200 participants (Anticipated)	Interventional	2007-08-31	Recruiting
A Placebo-Controlled Study to Investigate the Onset of Action of Paroxetine When Used for the Treatment of Premenstrual Dysphoria [NCT00516113]	Phase 4	24 participants (Actual)	Interventional	2000-10-31	Completed
Paroxetine in the Treatment of Chronic Primary Insomnia: A Double-Blind, Randomized, Placebo-Controlled Study of Efficacy Over Six Weeks [NCT00178048]	Phase 4	66 participants	Interventional	1998-09-30	Completed
Comparative Evaluation of Vortioxetine Versus Other Antidepressants With Pregabalin Augmentation in Treatment-resistant Burning Mouth Syndrome: a Prospective Longitudinal Clinical Trial With Treatment Response Prediction [NCT06025474]	Phase 3	203 participants (Anticipated)	Interventional	2023-01-01	Recruiting
[NCT02934035]		10,000 participants (Anticipated)	Observational	2016-09-30	Active, not recruiting
A Three-Part, Open-Label, Fixed-Sequence Study to Evaluate the Effect of Multiple Doses of Itraconazole, Phenytoin, and Paroxetine on the Single-Dose Pharmacokinetics of Poziotinib in Healthy Adult Subjects [NCT04981704]	Phase 1	74 participants (Actual)	Interventional	2021-04-08	Completed
Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder (PTSD) - A Placebo-controlled, Single-Blind Comparative Study - [NCT00557622]	Phase 2	5 participants (Actual)	Interventional	2008-01-25	Terminated(stopped due to difficulty in achieving target enrollment numbers)
Dose Ranging Study of the Effect of Paroxetine on COAT-Platelet Production in Normal Volunteers and Patients With Cardiovascular Disease [NCT00229528]	Phase 4	25 participants	Interventional	2004-03-31	Completed
A Feasibility Study of Positron Emission Tomography (PET) of the Serotonin Transporter (SERT) Before and After Treatment With Conjugated Equine Estrogen or Paroxetine for Hot Flashes [NCT00249847]		5 participants (Actual)	Interventional	2005-10-31	Terminated(stopped due to Unable to complete accrual; elected to close the study in April 2008.)
Serotonin and the Upper Airway in Obstructive Sleep Apnea [NCT00100464]	Phase 4	0 participants	Interventional	2000-11-30	Completed
A Comparative Single Center, Randomized Neuropathic Pain Assessment Study Involving Patients With Clinically Definite Multiple Sclerosis (MS) Receiving Treatment With Either Pregabalin or Paroxetine [NCT00291148]	Phase 3	75 participants (Anticipated)	Interventional	2006-03-31	Completed
Multicentre, Double-blind, Randomised, Parallel Group, Placebo Controlled, Phase 3 Study of the Efficacy & Safety of Quetiapine Fumarate & Paroxetine as Monotherapy in Adult Patients With Bipolar Depression for 8 Weeks & Quetiapine in Continuation (Abbrev [NCT00119652]	Phase 3	676 participants (Actual)	Interventional	2005-05-31	Completed
Comparative Responses to 15 Different Antidepressants in Major Depressive Disorder - Results From a Long-term Nation-wide Population-based Study Emulating a Randomized Trial [NCT05952713]		73,336 participants (Actual)	Observational	2022-10-01	Completed
A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Fixed Dose Study Comparing the Efficacy and Safety of GW597599/Paroxetine Combination or Paroxetine Monotherapy to Placebo in Patients With Social Anxiety Disorder (SAD) [NCT00403962]	Phase 2	204 participants	Interventional	2004-11-30	Completed
A Study of the Effects of Paroxetine vs. Duloxetine on Heart Rate Variability and Autonomic Cardiovascular Control [NCT00136383]	Phase 2/Phase 3	40 participants (Anticipated)	Interventional	2005-03-31	Completed
A Pilot Study of Double-blind Comparison of Vilazodone to Paroxetine in Geriatric Depression [NCT01608295]	Phase 4	65 participants (Actual)	Interventional	2012-07-31	Completed
A Randomized, Open-Label, 3-Period Crossover Study to Evaluate the Effect of Multiple Doses of DVS SR and Paroxetine on the CYP2D6 Biotransformation of Codeine to Morphine in Healthy Subjects. [NCT00456898]	Phase 1	40 participants	Interventional	2007-01-31	Completed
A Multi-Centre, Double-Blind, Randomised, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SRTM) in Combination With an Antidepressant in the Treatment of Patients With Major [NCT00351910]	Phase 3	494 participants (Actual)	Interventional	2006-05-31	Completed
Duloxetine Versus Paroxetine in the Acute Treatment of Major Depression [NCT00489775]	Phase 3	480 participants	Interventional	2004-01-31	Completed
SSRI Versus Bupropion in High-Risk Major Depressive Disorder [NCT01748955]	Phase 4	15 participants (Actual)	Interventional	2010-06-30	Completed
Geriatric Depression: Neurobiology of Treatment [NCT00178035]	Phase 4	158 participants	Interventional	1999-12-31	Completed
A Randomised, Triple Blind, Placebo-controlled Trial Comparing the Effects of Cognitive Therapy, Paroxetine and Both Cognitive Therapy and Paroxetine in the Treatment of Patients With Primary Social Phobia [NCT00184106]	Phase 4	86 participants (Actual)	Interventional	2004-10-31	Completed
Single-Site, Double-Blind, Flexible-Dose, Placebo-Controlled Study of the Efficacy, Tolerability, & Safety of Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS) [NCT00610909]	Phase 4	60 participants (Actual)	Interventional	2002-01-31	Completed
Combination Treatment for PTSD After the WTC Attack [NCT01130103]	Phase 4	37 participants (Actual)	Interventional	2004-03-31	Completed
A Double-blind, Randomized, Placebo- and Active-Controlled Study of F2695 SR in Adult Patients With Fatigue Associated With Major Depressive Disorder [NCT01254305]	Phase 2	262 participants (Actual)	Interventional	2011-04-30	Completed
A Randomized, Open-Label, Cross-Over Drug Interaction Study to Evaluate the Effects of Desvenlafaxine (DVS SR) and Paroxetine on the Pharmacokinetics of Desipramine in Healthy Subjects [NCT00329147]	Phase 3	20 participants (Anticipated)	Interventional	2006-05-31	Completed
A Single-Blind Trial of Risperidone vs. Paroxetine for Treatment of Panic Attacks [NCT00457106]		90 participants (Anticipated)	Interventional	2002-06-30	Completed
Randomized Trial of Paroxetine-CR for the Treatment of Patients With Post Traumatic Stress Disorder Remaining Symptomatic After Initial Exposure Therapy [NCT00121888]	Phase 1/Phase 2	60 participants	Interventional	2002-12-31	Completed
Biological Aspects of Depression and Antidepressant Drugs [NCT00018733]		0 participants	Interventional	1996-09-30	Completed
Treatment of Panic Disorder: Long Term Strategies [NCT00000368]	Phase 3	379 participants (Actual)	Interventional	1999-02-28	Completed
Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) [NCT00012558]		5,000 participants	Interventional	1998-09-30	Completed
A Double-Blind, Multicenter, Placebo and Active-Controlled, Acute Extension Study of 2 Doses of MK-0869 in the Treatment of Patients With Major Depressive Disorder [NCT00048607]	Phase 3	600 participants (Actual)	Interventional	2002-07-30	Completed
An Open Label Study Assessing Paxil CR (Paroxetine CR) in Patients With Major Depressive Disorder Who Discontinued Treatment With Selective Serotonin Reuptake Inhibitors or a Selective Serotonin/Norepinephrine Reuptake Inhibitor Due to Intolerability [NCT00049972]	Phase 4	646 participants	Interventional	2002-09-30	Completed
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Fixed Dose Study Evaluating the Efficacy and Safety of Paroxetine CR in Elderly Outpatients Diagnosed With Major Depressive Disorder [NCT00067444]	Phase 3	560 participants (Actual)	Interventional	2003-06-30	Completed
Randomised, Double-blind, Placebo Controlled, Cross-over Study Comparing the Effects of Both Single Dose and Repeated Dosing Treatment for 14 Days of Vestipitant or Vestipitant / Paroxetine Combination in an Enriched Population of Subjects With Tinnitus & [NCT00394056]	Phase 2	26 participants (Actual)	Interventional	2006-12-31	Completed
Treatment Effects on Platelet Calcium in Hypertensive and Depressed Patients [NCT00018759]	Phase 4	0 participants	Interventional	2001-03-31	Completed
Combined Treatment With a Benzodiazepine (Clonazepam) and a Selective Serotonin Reuptake Inhibitor (Paroxetine) for Rapid Treatment of Posttraumatic Stress Disorder (PTSD) [NCT00025740]	Phase 4	78 participants	Interventional	2001-10-31	Completed
Combined Treatment With A Benzodiazepine (Clonazepam) And A Selective Serotonin Reuptake Inhibitor (Paroxetine) For Rapid Treatment Of Panic Disorder With Depression [NCT00031317]	Phase 4	60 participants	Interventional	2002-02-28	Completed
A Worldwide, Multicenter, Double-Blind, Parallel, Active-Controlled, Long-Term Safety Study of MK0869 in Outpatients With Major Depressive Disorder [NCT00034983]	Phase 3	900 participants (Actual)	Interventional	2001-10-29	Completed
A Double-Blind, Multicenter, Placebo- and Active-Controlled Acute and Extension Study of MK0869 in the Treatment of Patients With Major Depressive Disorder With Melancholic Features [NCT00035009]	Phase 3	468 participants (Actual)	Interventional	2001-09-20	Completed
A Randomized, Open, Three-period Crossover Study to Compare the Pharmacokinetic Profile of Paroxetine After Single Dosing of Each Enteric-coated Geomatrix Control Release Tablet Strength (12.5, 25, 37.5mg) in Healthy Chinese Subjects [NCT00406003]	Phase 1	6 participants (Actual)	Interventional	2006-03-24	Completed
A Steady-state Study to Assess the Pharmacokinetic Profile of Paroxetine After 14 Day Repeated Daily Dosing of the Controlled Release Paroxetine Tablet (25 mg) in Healthy Chinese Subjects [NCT00406432]	Phase 1	12 participants (Actual)	Interventional	2006-05-09	Completed
Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD) [NCT00397722]	Phase 2	299 participants (Actual)	Interventional	2006-11-09	Completed
Pilot Study of Venlafaxine Extended Release (XR) in the Treatment of Panic Disorder (PD) in Comparison to Paroxetine. [NCT00195598]	Phase 3	70 participants (Anticipated)	Interventional	2005-01-31	Completed
An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Fixed-Dose Study Comparing the Efficacy and Safety of GW597599B or Paroxetine to Placebo in Moderately to Severely Depressed Patients With Major Depressive Disorder [NCT00048204]	Phase 2	372 participants (Actual)	Interventional	2002-11-04	Completed
CBT Augmentation of Paroxetine for Social Anxiety [NCT00074802]	Phase 3	150 participants (Actual)	Interventional	2003-12-31	Completed
Antidepressant Prophylaxis for Interferon-Induced Depression: Efficacy of Paroxetine; THE HEPDEP II STUDY [NCT00357045]	Phase 4	0 participants	Interventional		Completed
Effects of Serotonin Transporter Inhibition on the Subjective Response to LSD in Healthy Subjects [NCT05175430]	Phase 1	24 participants (Anticipated)	Interventional	2022-10-24	Active, not recruiting
[NCT02655354]		635 participants (Actual)	Interventional	2015-10-31	Completed
Prazosin vs. Paroxetine in Combat Stress Symptoms in OIF/OEF Returnees [NCT00261729]		210 participants (Anticipated)	Interventional	2004-07-31	Completed
Phase 4 Study of Clinical Pharmacogenomics of Antidepressant Response [NCT00269334]	Phase 4	400 participants	Interventional	2005-12-31	Not yet recruiting
Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Social Phobia/Social Anxiety Disorder (SAD) -A Open-Label, Uncontrolled, Long-term Study- [NCT00264654]	Phase 3	50 participants (Actual)	Interventional	2005-10-31	Completed
Incident Type II Diabetes Mellitus Among Patients Exposed to the Combination of Pravastatin and Paroxetine [NCT01602913]		1 participants (Actual)	Observational	2011-12-31	Completed
Post-marketing Clinical Study on PAXIL Tablet in Patients With Depression or Depressive Mood - A Study on Combination of PAXIL Tablet and Benzodiazepines [NCT00259883]	Phase 4	150 participants (Actual)	Interventional	2005-06-30	Completed
Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Social Phobia/Social Anxiety Disorder (SAD) -A Double-blind, Placebo-controlled Study- [NCT00318669]	Phase 3	390 participants (Actual)	Interventional	2005-12-31	Completed
A Double-blind, Triple Dummy, Placebo-controlled, Randomised, Parallel Group Positron Emission Tomography Study to Investigate the Effects of a 8 Week Administration of GW597599 and Paroxetine Either Alone or in Combination on Regional Cerebral Blood Flow [NCT00343707]	Phase 2	72 participants (Actual)	Interventional	2004-11-30	Completed
Algorithm Guided Treatment Strategies for Major Depressive Disorder [NCT01764867]	Phase 4	1,080 participants (Anticipated)	Interventional	2012-06-30	Recruiting
Antidepressant Treatments During Pregnancy and Lactation: Prediction of Drug Exposure Through Breastfeeding and Evaluation of Drug Effect on the Neonatal Adaptation and the Development of the Young Child [NCT01796132]	Phase 4	500 participants (Anticipated)	Interventional	2012-08-31	Recruiting
The ROLE of ParoXetine in Patients Taking Telaprevir-based Hepatitis C Therapy: Lack of a Drug-drug Interaction? (ROLEX) [NCT01841502]	Phase 2	3 participants (Actual)	Interventional	2013-05-31	Terminated(stopped due to Telaprevir will not be used in NL, no more inclusions are expected.)
Efficacy and Safety of Oxybutynin Versus Paroxetine in Breast Cancer Patients With Aromatase Inhibitor-induced Vasomotor Symptoms. [NCT05637671]	Phase 3	146 participants (Anticipated)	Interventional	2022-02-10	Recruiting
Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder [NCT01460212]	Phase 4	80 participants (Anticipated)	Interventional	2011-12-31	Recruiting
A Double-blind, Active-controlled, Randomized Study Comparing Mirtazapine Combined With Paroxetine or Paroxetine Monotherapy in Patients With Major Depressive Patients Without Early Improvement in the First 2 Weeks [NCT01458626]	Phase 4	525 participants (Actual)	Interventional	2012-11-14	Completed
A Phase 3, Randomized, Double-Blind, Parallel Group, 10-Week Placebo Controlled Fixed Dose Study of PD 0332334 and Paroxetine Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder [NCT00836069]	Phase 3	5 participants (Actual)	Interventional	2008-10-31	Terminated(stopped due to Pfizer has terminated the execution of this protocol)
Treatment of Depression in Patients With Parkinson's Disease [NCT00062738]	Phase 2	52 participants (Actual)	Interventional	2003-06-30	Completed
Effectiveness and Safety of Transcutaneous Posterior Tibial Nerve Stimulation for Premature Ejaculation Treatment [NCT04207723]		120 participants (Anticipated)	Interventional	2020-07-15	Recruiting
"An Open Label, 2-part, One-sequence, 3-period Study to Evaluate Drug-drug Interactions Between DWN12088 and Nebivolol or Paroxetine in Healthy Male Volunteers" [NCT04888728]	Phase 1	24 participants (Actual)	Interventional	2021-06-30	Completed
Neurofunctional Markers of SSRI Treatment Response in PTSD [NCT00700999]	Phase 4	65 participants (Actual)	Interventional	2008-10-31	Completed
Efficacy of Exposure and Response Prevention（ERP） and SSRIs, and Its Predictors in Obsessive-Compulsive Disorder [NCT02022709]	Phase 4	78 participants (Actual)	Interventional	2014-01-31	Completed
Efficacy of Interpersonal Psychotherapy in Treatment Resistant Depression [NCT01896349]		74 participants (Anticipated)	Interventional	2013-04-30	Recruiting
Treatment of Pediatric OCD for SRI Partial Responders [NCT00074815]	Phase 3	124 participants (Actual)	Interventional	2003-09-30	Completed
Smoking, Antidepressants, and Response to Mental Stress [NCT00218439]		105 participants (Actual)	Interventional	2005-10-31	Completed
Evaluation of Pharmacokinetics of Paroxetine Following Single and Repeat Oral Administration of Mesafem (7.5 mg Paroxetine Mesylate) Capsules in Healthy Postmenopausal Women [NCT01829919]	Phase 1	24 participants (Actual)	Interventional	2011-07-31	Completed
Assessing Tolerability and Efficacy of Vortioxetine Versus SSRIs in Elderly Patients With Depression: a Pragmatic, Multicenter, Open-label, Parallel-group, Superiority, Randomized Trial [NCT03779789]	Phase 4	362 participants (Actual)	Interventional	2019-02-01	Completed
Paroxetine-mediated GRK2 Inhibition to Reduce Cardiac Remodeling After Acute Myocardial Infarction (CARE-AMI): a Randomized Controlled Pilot Study [NCT03274752]	Phase 2	50 participants (Actual)	Interventional	2017-10-26	Completed
An International, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Controlled Study of the Efficacy and Safety of Sustained-Release Quetiapine Fumarate (Seroquel SR™ ) in the Treatment of Generalized Anxiety Disorder (SILV [NCT00322595]	Phase 3	800 participants (Anticipated)	Interventional	2006-05-31	Completed
Comparison of Antidepressants in the Real-World: Retrospective Cohort Study Using Big Data [NCT04446039]		405,349 participants (Actual)	Observational	2022-07-04	Completed
A Multicentre, Double-blind, Active Controlled Trial to Evaluate the Clinical Effects of Immediate Release Paroxetine and Controlled Release Paroxetine in the Treatment of Major Depression [NCT00368303]	Phase 3	362 participants	Interventional	2006-12-31	Completed
Research on Standardized Electronic Cognitive Training Technique in Early Stage of Senile Depression With Cognitive Impairment [NCT05588102]		128 participants (Anticipated)	Interventional	2021-05-18	Recruiting
Clinical Study to Investigate the Effect of Administration of Selective Serotonin Reuptake Inhibitors (SSRIs) and an Opioid on Ventilation [NCT05470465]	Phase 1	27 participants (Actual)	Interventional	2022-09-01	Completed
Paroxetine for Comorbid Social Anxiety Disorder and Alcoholism [NCT00246441]	Phase 4	42 participants (Actual)	Interventional	2002-03-31	Completed
Comparative Effectiveness of Newer Antidepressants in Combination With Pregabalin for Fibromyalgia Syndrome: A Controlled Randomized Study [NCT02451475]	Phase 1/Phase 2	75 participants (Actual)	Interventional	2013-02-28	Completed
Phase 4 Clinical Pharmacogenomics of Antidepressant Response [NCT00384020]		402 participants (Actual)	Observational	2006-01-31	Completed
Efficacy of Hydroxyzine Versus Treatment as Usual for Panic Disorder: An Eight-Week, Open Label, Pilot, Randomized Controlled Trial. [NCT05737511]	Phase 4	80 participants (Anticipated)	Interventional	2023-12-30	Not yet recruiting
Treatment of Tinnitus With Migraine Medications: A Randomized Clinical Trial [NCT04404439]	Phase 4	150 participants (Anticipated)	Interventional	2019-09-26	Recruiting
Pharmacovigilance in Gerontopsychiatric Patients [NCT02374567]	Phase 3	407 participants (Actual)	Interventional	2015-01-31	Terminated
Endothelial, Autonomic and Pressure Effects of Paroxetine in Recent Postmenopause Women With Hot Flashes: a Randomized Placebo Controlled Clinical Trial [NCT03149419]	Phase 4	140 participants (Actual)	Interventional	2016-03-01	Completed
Effects of Paroxetine on Cardiovascular Function in Septic Patients: a Randomized Placebo Controlled Trial [NCT05725837]	Phase 2	92 participants (Anticipated)	Interventional	2023-06-10	Recruiting
Neural Circuits in Women With Abuse and Posttraumatic Stress Disorder [NCT01681849]	Phase 4	91 participants (Actual)	Interventional	2009-07-31	Completed
The GRK2 Inhibitor Paroxetine as a Novel Adjunct to Conventional Therapy in Rheumatoid Arthritis Patients. A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial. [NCT04757571]	Phase 1/Phase 2	120 participants (Anticipated)	Interventional	2021-02-01	Recruiting
Effects of Treatment on Decision-making in Major Depression [NCT01916824]	Phase 4	53 participants (Actual)	Interventional	2013-08-31	Completed
Secondary Prevention With Paroxetine vs. Placebo in Subthreshold Posttraumatic Stress Disorder (PTSD) [NCT00560612]	Phase 4	12 participants (Actual)	Interventional	2006-01-31	Completed
A Phase 1, Single-center, Open-label, Sequential Drug Interaction Study Between AVP-786 (Deuterated [d6] Dextromethorphan Hydrobromide [DM]/Quinidine Sulfate [Q]) and Paroxetine and Between AVP-786 and Duloxetine in Healthy Subjects [NCT02174822]	Phase 1	56 participants (Actual)	Interventional	2014-01-31	Completed
Relative Bioavailability Study Between the Formulations: Paroxetine 25 mg Tablets With Controlled Release Manufactured by GSK Mississauga and Paroxetine 25 mg Tablets With Controlled Release Manufactured by SmithKline Beecham (Cidra), Fed Administration i [NCT01339247]	Phase 1	60 participants (Actual)	Interventional	2009-10-20	Completed
An Open-Label Randomized, Single-Dose, 2-way Crossover Bioequivalence Study of Paroxetine Hydrochloride 20 mg Tablets and Paxil® Under Fasting Conditions and Under Fed Conditions in Chinese Healthy Volunteers [NCT03504475]	Phase 1	53 participants (Actual)	Interventional	2018-03-29	Completed
A Pilot Study Examining the Gut Microbiota in Patients With Obsessive-Compulsive Disorder vs. Healthy Controls and Following 12-weeks of Open-label Selective Serotonin Reuptake Inhibitors Treatment [NCT02285699]		43 participants (Anticipated)	Interventional	2014-11-01	Completed
An Open-Label, Single Arm, Dose Escalating Concentration-QT Study to Investigate the Cardiac Effects and Safety of Paroxetine in Healthy Adult Participants [NCT06065735]	Phase 1	36 participants (Anticipated)	Interventional	2023-09-29	Not yet recruiting
A Placebo-Controlled Trial of Prazosin vs. Paroxetine in Combat Stress-Related PTSD Nightmares and Sleep Disturbance [NCT00202449]		59 participants (Actual)	Interventional	2004-07-31	Terminated(stopped due to recruitment difficulties)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00062738 (2) [back to overview]	Percent Responders
NCT00062738 (2) [back to overview]	Hamilton Depression Scale
NCT00074802 (7) [back to overview]	Liebowitz Self-Report Disability Scale (LSRDS)
NCT00074802 (7) [back to overview]	Liebowitz Social Anxiety Scale (LSAS)
NCT00074802 (7) [back to overview]	Quality of Life Inventory (QOLI)
NCT00074802 (7) [back to overview]	Social Phobia Scale (SPS)
NCT00074802 (7) [back to overview]	Social Interaction Anxiety Scale (SIAS)
NCT00074802 (7) [back to overview]	Clinical Global Impression Improvement Scale (CGI-I)
NCT00074802 (7) [back to overview]	Brief Fear of Negative Evaluation Scale (BFNE)
NCT00074815 (1) [back to overview]	Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS)
NCT00086190 (17) [back to overview]	Change in Parkinson's Disease Questionnaire (PDQ) - 39 - Overall
NCT00086190 (17) [back to overview]	Change in Pittsburgh Sleep Quality Index (PSQI)
NCT00086190 (17) [back to overview]	Change in Short Form 36 Health Survey - Mental Component Summary
NCT00086190 (17) [back to overview]	Change in Short Form 36 Health Survey - Mental Health
NCT00086190 (17) [back to overview]	Change in Short Form 36 Health Survey - Role-Emotional
NCT00086190 (17) [back to overview]	Change in Snaith Clinical Anxiety Scale (CAS)
NCT00086190 (17) [back to overview]	Change in Unified Parkinson's Disease Rating Scale (UPDRS)
NCT00086190 (17) [back to overview]	Change in Unified Parkinson's Disease Rating Scale (UPDRS) - Bulbar
NCT00086190 (17) [back to overview]	Change in Unified Parkinson's Disease Rating Scale (UPDRS) - Motor
NCT00086190 (17) [back to overview]	Change in Unified Parkinson's Disease Rating Scale (UPDRS) - Tremor
NCT00086190 (17) [back to overview]	Change in Montgomery-Asberg Depression Rating Scale (MADRS)
NCT00086190 (17) [back to overview]	Change in Beck Depression Inventory II (BDI-II)
NCT00086190 (17) [back to overview]	Change in Brief Psychiatric Rating Scale (BPRS)
NCT00086190 (17) [back to overview]	Change in Geriatric Depression Rating Scale (GDS)
NCT00086190 (17) [back to overview]	Change in Hamilton Depression Rating Scale (HAM-D) Scores
NCT00086190 (17) [back to overview]	Change in Short Form 36 Health Survey - Vitality
NCT00086190 (17) [back to overview]	Change in Parkinson's Disease Questionnaire (PDQ) - 39 - Emotional Well-Being
NCT00113295 (5) [back to overview]	Depressive Symptoms, Montgomery-Asberg Depression Rating Scale (MADRS)
NCT00113295 (5) [back to overview]	The Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q).
NCT00113295 (5) [back to overview]	Hamilton Anxiety Scale (HAM-A) Score at Study Endpoint.
NCT00113295 (5) [back to overview]	Response, Clinical Global Impression of Improvement (CGI-I)
NCT00113295 (5) [back to overview]	Remission (HAM-A ≤ 7)
NCT00202449 (3) [back to overview]	Change in Global Trauma-related Symptom Severity and Functioning From the Clinical Global Impression of Change From Baseline to Week 12
NCT00202449 (3) [back to overview]	Change in Combat Trauma-related Nightmares From the Clinician Administered PTSD Scale (CAPS) Recurrent Distressing Dreams Item at Week 12
NCT00202449 (3) [back to overview]	Change in Sleep From the Pittsburgh Sleep Quality Index From Baseline to Week 12
NCT00218439 (5) [back to overview]	Plasma Epinephrine Concentration Response to Stress
NCT00218439 (5) [back to overview]	Plasma Norepinephrine Concentration Response to Stress
NCT00218439 (5) [back to overview]	Systolic Blood Pressure Response to Stress
NCT00218439 (5) [back to overview]	Heart Rate Response to Stress
NCT00218439 (5) [back to overview]	Diastolic Blood Pressure Response to Stress
NCT00246441 (3) [back to overview]	Drinking to Cope
NCT00246441 (3) [back to overview]	Alcohol Use, Quantity and Frequency
NCT00246441 (3) [back to overview]	Social Anxiety Severity
NCT00292370 (9) [back to overview]	Change in Mean Q-LES-Q Score From Baseline to Endpoint.
NCT00292370 (9) [back to overview]	Change in Mean Scores of Pittsburgh Sleep Quality Index (PSQI) From Baseline to Endpoint.
NCT00292370 (9) [back to overview]	Change in Mean PANSS Total and Subscores From Baseline to Endpoint
NCT00292370 (9) [back to overview]	Change in Clinician-Administered PTSD Scale for DSM-IV Total Score.
NCT00292370 (9) [back to overview]	Change in Mean Sheehan Disability Scale (SDS) Scores From Baseline to Endpoint.
NCT00292370 (9) [back to overview]	Change in CGI-I
NCT00292370 (9) [back to overview]	Change in Arizona Sexual Experience Scale (ASEX)
NCT00292370 (9) [back to overview]	Change in Total Mean Hamilton Rating Scale for Depression (HAMD) Scores
NCT00292370 (9) [back to overview]	Change in Total Mean Davidson Trauma Scale (DTS)
NCT00338962 (4) [back to overview]	Clinician-Administered PTSD Scale (CAPS)
NCT00338962 (4) [back to overview]	Hamilton Depression Rating Scale (HAM-D)
NCT00338962 (4) [back to overview]	Mean Number of Side Effects
NCT00338962 (4) [back to overview]	Mean Self-report Weekly Craving Via Obsessive Compulsive Drinking Scale (OCDS)
NCT00385762 (4) [back to overview]	Sperm Motility
NCT00385762 (4) [back to overview]	Sperm Concentration
NCT00385762 (4) [back to overview]	Sperm Morphology
NCT00385762 (4) [back to overview]	Semen Volume
NCT00403455 (1) [back to overview]	Clinician Administered PTSD Scale (CAPS)
NCT00420641 (23) [back to overview]	Mean Change From Randomization in the MADRS Total Score Over Week 8
NCT00420641 (23) [back to overview]	Mean Change From Randomization in the Motivation and Energy Inventory (MEI) 18-Item Short Form (SF) Total Score Over Week 10
NCT00420641 (23) [back to overview]	Change From Randomization at the End of the Treatment Phase (Week 10) in Bech Scale (6-item of 17-item Hamilton Depression Rating [HAMD-17] Scale) Score
NCT00420641 (23) [back to overview]	Number of Participants With Most Severe Suicidal Behaviour and Ideation in the Suicidal Behavior (SB) and Suicidal Ideation (SI) Subscales of the Columbia Suicide Severity Rating Scale (CSSRS) Over Week 10
NCT00420641 (23) [back to overview]	Percentage of Participants With Clinical Global Impression - Global Improvement (CGI-I) Over Week 10
NCT00420641 (23) [back to overview]	Percentage of Responders and Remitters of HAMD-17 Over Week 10
NCT00420641 (23) [back to overview]	Percentage of Responders and Remitters of IDS-CR Over Week 10
NCT00420641 (23) [back to overview]	Percentage of Responders and Remitters of MADRS Over Week 10
NCT00420641 (23) [back to overview]	Mean Change From Randomization at the End of the Treatment Phase (Week 10) in Inventory of Depressive Symptomatology-Clinician Rated (IDS-CR) Total Score
NCT00420641 (23) [back to overview]	Mean Change From Randomization at the End of the Treatment Phase in the MADRS Total Score
NCT00420641 (23) [back to overview]	Percentage of Participants Satisfied With Study Medication at Week 10
NCT00420641 (23) [back to overview]	Mean Change From Randomization at the End of the Treatment Phase (Week 10) in the HAMD-17 Total Score
NCT00420641 (23) [back to overview]	Mean Change From Randomization in IDS- Self-Rated Version (SR) Total Score Over Week 10
NCT00420641 (23) [back to overview]	Mean Change From Randomization in IDS-CR and IDS-SR 5 Item Subscale Over Week 10
NCT00420641 (23) [back to overview]	Mean Change From Randomization in IDS-CR Total Score Over Week 8
NCT00420641 (23) [back to overview]	Mean Change From Randomization in the 16-item Quick Inventory of Depressive Symptomatology-Clinician-rated Version (QIDS-CR16) Total Score Over Week 10
NCT00420641 (23) [back to overview]	Mean Change From Randomization in the 16-item Quick Inventory of Depressive Symptomatology-Self-rated Version (QIDS-SR16) Total Score Over Week 10
NCT00420641 (23) [back to overview]	Mean Change From Randomization in the Changes in Sexual Functioning Questionnaire 14-item Short Form (CSFQ-14SF) Over Week 10
NCT00420641 (23) [back to overview]	Mean Change From Randomization in the Clinical Global Impression-Severity of Illness (CGI-S) Scale Over Week 10
NCT00420641 (23) [back to overview]	Mean Change From Randomization in the HAMD-17 Scale Item 1 (Depressed Mood) Over Week 10
NCT00420641 (23) [back to overview]	Mean Change From Randomization in the IDS-CR Scale Item 5 (Feeling Sad) Over Week 10
NCT00420641 (23) [back to overview]	Mean Change From Randomization in the in Bech Scale (6-item of HAMD-17 Scale) Score Over Week 8
NCT00420641 (23) [back to overview]	Mean Change From Randomization in the MADRS Item 2 Score (Reported Sadness) Over Week 10
NCT00429169 (4) [back to overview]	Scale for Suicidal Ideation
NCT00429169 (4) [back to overview]	Occurrence of Suicidal Ideation or Acts Necessitating a Change in Treatment
NCT00429169 (4) [back to overview]	Go-No go Test
NCT00429169 (4) [back to overview]	Brain Activity Measured by BOLD Signal With fMRI During a Reward Processing Task.
NCT00445679 (7) [back to overview]	Clinical Global Impressions Scale-Severity of Illness (CGI-S) Scores
NCT00445679 (7) [back to overview]	Clinical Global Impressions Scale-Improvement (CGI-I) Scores
NCT00445679 (7) [back to overview]	Visual Analog Scale-pain Intensity (VAS-PI) Score Mean Change From Baseline
NCT00445679 (7) [back to overview]	Percentage of Responders With a 50% or Greater Decrease From Baseline on the Hamilton Rating Scale for Depression, 17-item (HAM-D17)
NCT00445679 (7) [back to overview]	Montgomery and Asberg Depression Rating Scale (MADRS) Total Score Mean Change From Baseline
NCT00445679 (7) [back to overview]	Hamilton Rating Scale for Depression, 6-item (HAM-D6) Score Mean Change From Baseline
NCT00445679 (7) [back to overview]	Covi Anxiety Scale Score Mean Change From Baseline
NCT00557622 (8) [back to overview]	Number of Participants With the Indicated Week 0 and Week 12 Z-scores for Regional Blood Flow Using Functional Magnetic Resonance Imaging (fMRI) in the Left Amygdala (LA), Right Amygdala (RA), and the Medial Prefrontal Cortex (MPFC)
NCT00557622 (8) [back to overview]	Number of Participants With the Indicated Change From Baseline in CGI (Clinical Global Impression) Severity of Illness Scores at Weeks 2, 4, 6, 8, 10, and 12
NCT00557622 (8) [back to overview]	Number of Participants With the Indicated Change From Baseline in CAPS-SX (Clinician-Administered Post Traumatic Stress Disorder [PTSD] Scale One Week Symptom Status Version) Total Score at Weeks 4 and 8
NCT00557622 (8) [back to overview]	Number of Participants With the Indicated Change From Baseline in CAPS-SX (Clinician-Administered Post Traumatic Stress Disorder [PTSD] Scale One Week Symptom Status Version) Relating Re-experiencing at Weeks 4, 8, and 12
NCT00557622 (8) [back to overview]	Number of Participants With the Indicated Change From Baseline in CAPS-SX (Clinician-Administered Post Traumatic Stress Disorder [PTSD] Scale One Week Symptom Status Version) Relating Increased Arousal Symptom at Weeks 4, 8, and 12
NCT00557622 (8) [back to overview]	Number of Participants With a Clinical Global Impression (CGI) Global Improvement of 4 at Week 12
NCT00557622 (8) [back to overview]	Number of Participants With the Indicated Change From Baseline in CAPS-SX (Clinician-Administered Post Traumatic Stress Disorder (PTSD) Scale One Week Symptom Status Version) Total Score at Week 12
NCT00557622 (8) [back to overview]	Number of Participants With the Indicated Change From Baseline in CAPS-SX (Clinician-Administered Post Traumatic Stress Disorder [PTSD] Scale One Week Symptom Status Version) Relating Avoidance and Numbing at Weeks 4, 8, and 12
NCT00560612 (4) [back to overview]	Change in Short PTSD Rating Interview Scores
NCT00560612 (4) [back to overview]	Change in Hospital Anxiety and Depression Scale Scores
NCT00560612 (4) [back to overview]	Change in Connor Davidson Resilience Scale Scores
NCT00560612 (4) [back to overview]	Change in Clinician Administered PTSD Scale (CAPS) Scores
NCT00666757 (25) [back to overview]	Change From Baseline in Brief Pain Inventory (BPI) Average 24-hour Pain Score, in Particpants With a Baseline BPI Average 24-hour Pain Score of 3 or Greater, at 12-Week Endpoint (Pain Measure)
NCT00666757 (25) [back to overview]	Change From Baseline in World Health Organization Health and Work Performance Questionnaire, Clinical Trials 7-Day Version (HPQ), Dollars of Income Lost Due to Work Absenteeism Score at Week-12 Endpoint
NCT00666757 (25) [back to overview]	Change From Baseline in World Health Organization Health and Work Performance Questionnaire, Clinical Trials 7-Day Version (HPQ), Dollars of Income Lost Due to Work Presenteeism (WP)Score, at Week-12 Endpoint
NCT00666757 (25) [back to overview]	Change From Baseline in BPI Average 24 Hour Pain Score at 12-Week Endpoint (Pain Measure)
NCT00666757 (25) [back to overview]	Change From Baseline in World Health Organization Health and Work Performance Questionnaire, Clinical Trials 7-Day Version (HPQ), Presenteeism Score, at Week-12 Endpoint
NCT00666757 (25) [back to overview]	Probability of Remission [16-item Quick Inventory of Depressive Symptomatology (QIDS-SR) Score Less Than or Equal to 5 at 12-Week Endpoint]
NCT00666757 (25) [back to overview]	Probability of Remission [17-item Hamilton Depression Rating Scale (HAMD-17) (Mood Measure) Less Than or Equal to 7 at 12-Week Endpoint]
NCT00666757 (25) [back to overview]	Change From Baseline in HAMD-17 Retardation Subscale Score at 12-Week Endpoint (Mood Measure)
NCT00666757 (25) [back to overview]	Probability of Response [HAMD-17 Total Score (Mood Measure) Greater Than Or Equal To 50 Percent Reduction From Baseline To 12 Week Endpoint]
NCT00666757 (25) [back to overview]	Change From Baseline in QIDS-SR Total Score at 12-Week Endpoint (Mood Measure)
NCT00666757 (25) [back to overview]	Probability of Response [QIDS-SR Total Score (Mood Measure) Greater Than Or Equal To 50 Percent Reduction From Baseline To 12 Week Endpoint]
NCT00666757 (25) [back to overview]	Change From Baseline in Diastolic Blood Pressure at Week-12 Endpoint
NCT00666757 (25) [back to overview]	Change From Baseline in HAMD-17 Anxiety/Somatization Subscale Score at 12-Week Endpoint (Mood Measure)
NCT00666757 (25) [back to overview]	Change From Baseline in HAMD-17 Bech Subscale Score at 12-Week Endpoint (Mood Measure)
NCT00666757 (25) [back to overview]	Change From Baseline in HAMD-17 Maier Subscale Score at 12-Week Endpoint (Mood Measure)
NCT00666757 (25) [back to overview]	Change From Baseline in HAMD-17 Sleep Subscale Score at 12-Week Endpoint (Mood Measure)
NCT00666757 (25) [back to overview]	Change From Baseline in HAMD-17 Total Score at 12-Week Endpoint (Mood Measure)
NCT00666757 (25) [back to overview]	Change From Baseline in Pulse Rate at Week-12 Endpoint
NCT00666757 (25) [back to overview]	Change From Baseline in SDS Social Item Score at 12-Week Endpoint (Functional Outcome Measure)
NCT00666757 (25) [back to overview]	Change From Baseline in SDS Work/School Item Score at 12-Week Endpoint (Functional Outcome Measure)
NCT00666757 (25) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) Family/Home Item Score at Week-12 Endpoint (Functional Outcome Measure)
NCT00666757 (25) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) Global Functional Impairment Score at 12-Week Endpoint (Functional Outcome Measure)
NCT00666757 (25) [back to overview]	Change From Baseline in Systolic Blood Pressure at Week-12 Endpoint
NCT00666757 (25) [back to overview]	Change From Baseline in Weight at Week-12 Endpoint
NCT00666757 (25) [back to overview]	Change From Baseline in World Health Organization Health and Work Performance Questionnaire, Clinical Trials 7-Day Version (HPQ), Absenteeism at 12-Week Endpoint
NCT00677352 (7) [back to overview]	Mean Change From Baseline in Panic and Agoraphobia Scale (PAS) Total Score at the End of Treatment Phase
NCT00677352 (7) [back to overview]	Mean Change From Baseline in Hamilton Anxiety Rating Scale Total Score at the End of Treatment Phase
NCT00677352 (7) [back to overview]	Summary of Adverse Events in Tapering Phase
NCT00677352 (7) [back to overview]	Mean Change From Baseline in Panic Attack at the End of Treatment Phase
NCT00677352 (7) [back to overview]	Percentage of Participants of Responder in Clinical Global Impression (CGI) - Improvement
NCT00677352 (7) [back to overview]	Number of Participants With Summary of Adverse Events in Treatment Phase
NCT00677352 (7) [back to overview]	Percentage of Participants With Deterioration in Antidepressant Discontinuation Scale During Tapering Phase
NCT00700999 (1) [back to overview]	Percent Change in Brain Response Measured by Functional Magnetic Resonance Imaging (fMRI)
NCT00786188 (11) [back to overview]	Proportion of Clinical Global Impression (CGI) Responders at Week 4 and Week 8
NCT00786188 (11) [back to overview]	Mean Change From Baseline in Hot Flash Frequency at Week 4 and Week 8
NCT00786188 (11) [back to overview]	Effect of Brisdelle (Paroxetine Mesylate) Capsules on Improvement of Hot Flash Interference at Week 4
NCT00786188 (11) [back to overview]	Asses the Effect of Brisdelle (Paroxetine Mesylate) Capsules on the Interference on Sexual Functioning at Week 8
NCT00786188 (11) [back to overview]	Effect of Brisdelle (Paroxetine Mesylate) Capsules on Mood at Week 4
NCT00786188 (11) [back to overview]	Effect of Brisdelle (Paroxetine Mesylate) Capsules on BMI at Week 4 and Week 8
NCT00786188 (11) [back to overview]	Proportion of Numerical Rating Scale (NRS) True Responders at Week 4 and Week 8
NCT00786188 (11) [back to overview]	Change From Baseline in Climacteric Symptoms at Week 8
NCT00786188 (11) [back to overview]	Mean Change From Baseline in Hot Flash Severity at Week 4 and Week 8
NCT00786188 (11) [back to overview]	Effect of Brisdelle (Paroxetine Mesylate) Capsules on Depression and Anxiety at Week 8
NCT00786188 (11) [back to overview]	Change From Baseline in Hot Flash Composite Score at Week 4 and Week 8
NCT00797966 (14) [back to overview]	Change From End of Phase A (Week 8 Visit) in Mean CGI-S Score for Every Study Week Visit in Phase B Other Than the Week 14 Visit.
NCT00797966 (14) [back to overview]	Change From End of Phase A (Week 8 Visit) in MADRS Total Score for Every Study Week Visit in Phase B Other Than the Week 14 Visit.
NCT00797966 (14) [back to overview]	Change From End of Phase A (Week 8 Visit) for Every Study Week Visit in Phase B in Inventory of Depressive Symptomatology (Self-Report) (IDS-SR) Total Score.
NCT00797966 (14) [back to overview]	Change From the End of Phase A (Week 8 Visit) to the End of Phase B (Week 14 Visit) in Montgomery Asberg Depression Rating Scale (MADRS) Total Score.
NCT00797966 (14) [back to overview]	Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Sheehan Disability Scale (SDS) Mean Score (the Mean of 3 Individual Item Scores).
NCT00797966 (14) [back to overview]	Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Q-LES-Q-SF Item 16 Score (Overall Life Satisfaction).
NCT00797966 (14) [back to overview]	Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Q-LES-Q-SF Item 15 Score (Satisfaction With Medication).
NCT00797966 (14) [back to overview]	Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Clinical Global Impression - Severity of Illness Scale (CGI-S) Score.
NCT00797966 (14) [back to overview]	Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Hamilton Depression Rating Scale (HAM-D17) Score.
NCT00797966 (14) [back to overview]	Percentage of Participants With MADRS Remission From End of Phase A (Week 8 Visit).
NCT00797966 (14) [back to overview]	Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Quality of Life, Enjoyment, and Satisfaction Questionnaire - Short Form (QLES-Q-SF) Subscale Score - the Overall General Subscore (Sum of First 14 Items).
NCT00797966 (14) [back to overview]	Percentage of Participants With MADRS Response From End of Phase A (Week 8 Visit).
NCT00797966 (14) [back to overview]	Percentage of Participants With CGI-I Response From End of Phase A (Week 8 Visit).
NCT00797966 (14) [back to overview]	Clinical Global Impression-Improvement Scale (CGI-I) Score at Each Study Week Visit in Phase B.
NCT00812812 (5) [back to overview]	Number of Clinical Global Impression - Global Improvement (CGI-GI) Responders at Weeks 1, 2, 3, 4, 6, and 8
NCT00812812 (5) [back to overview]	Change From Baseline in the Clinical Global Impression - Severity of Illness (CGI-SI) Score at Weeks 1, 2, 3, 4, 6, and 8
NCT00812812 (5) [back to overview]	Change From Baseline in the Children's Depression Rating Scale -Revised (CDRS-R) Total Score at Week 8
NCT00812812 (5) [back to overview]	Change From Baseline in the CDRS-R Total Score at Weeks 1, 2, 3, 4, and 6
NCT00812812 (5) [back to overview]	Plasma Paroxetine Concentrations at 12 Hours and 24 Hours After Administration of Study Drug at Week 8 or Withdrawal
NCT00841659 (3) [back to overview]	AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)
NCT00841659 (3) [back to overview]	Cmax - Maximum Observed Concentration (of Paroxetine in Plasma)
NCT00841659 (3) [back to overview]	AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)
NCT00841698 (3) [back to overview]	AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)
NCT00841698 (3) [back to overview]	AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)
NCT00841698 (3) [back to overview]	Cmax - Maximum Observed Concentration (of Paroxetine in Plasma)
NCT00866294 (6) [back to overview]	Mean Change From Baseline in the Clinical Global Impression-Severity of Illness (CGI-SI) Scores at Weeks 1, 2, 3, 4, 6, and 8
NCT00866294 (6) [back to overview]	Mean Change From Baseline in the HAM-D Total Score at Weeks 1, 2, 3, 4, 6, and 8
NCT00866294 (6) [back to overview]	Percentage of HAM-D Remitters at Weeks 4 and 8
NCT00866294 (6) [back to overview]	Percentage of HAM-D Responders at Weeks 4 and 8
NCT00866294 (6) [back to overview]	Percentage of Responders Based on the Clinical Global Impression-Global Improvement (CGI-GI) Scores at Weeks 4 and 8
NCT00866294 (6) [back to overview]	Adjusted Mean Change From Baseline in the Hamilton Depression Rating Scale (HAM-D; 17 Items) Total Score at Week 8
NCT01101841 (17) [back to overview]	Change in Frequency of Moderate to Severe Hot Flashes Frequency From Baseline (BMI ≥32 kg/m2, Week 4 and Week 12), Median
NCT01101841 (17) [back to overview]	Change in Severity of Moderate to Severe Hot Flashes From Baseline (BMI <32 kg/m2, At Week 4 and Week 12), Median
NCT01101841 (17) [back to overview]	Change in Severity of Moderate to Severe Hot Flashes From Baseline (BMI ≥32 kg/m2, Week 4 and Week 12), Median
NCT01101841 (17) [back to overview]	Effect of Brisdelle (Paroxetine Mesylate) Capsules on Anxiety and Depression
NCT01101841 (17) [back to overview]	Effect of Paroxetine Mesylate Capsules on Percent Improvement of Hot Flash Interference From Baseline at Week 4 and Week 12, Hot Flash Related Daily Interference Scale (HFRDIS)
NCT01101841 (17) [back to overview]	Mean Change From Baseline in Hot Flash Frequency at Week 4 and Week 12.
NCT01101841 (17) [back to overview]	Mean Change From Baseline in Hot Flash Severity at Week 4 and Week 12.
NCT01101841 (17) [back to overview]	Percent Responders Improvement in VMS From Baseline Using the Clinical Global Impression (CGI) Scale.
NCT01101841 (17) [back to overview]	Percentage of Responders
NCT01101841 (17) [back to overview]	Percent Daytime and Nighttime Responders, Numerical Rating Scale (NRS)
NCT01101841 (17) [back to overview]	Percent Persistence of Benefit, Statistically Significant Difference in Having 50% or More Reduction Compared to Baseline at Week 24.
NCT01101841 (17) [back to overview]	Assessment of Mood
NCT01101841 (17) [back to overview]	BMI Change From Baseline (kg/m2), Median
NCT01101841 (17) [back to overview]	Change From Baseline in Arizona Sexual Experience Scale (ASEX, Week 4 and Week 12) Total Score, Median
NCT01101841 (17) [back to overview]	Change From Baseline in Greene Climacteric Scale (GCS) at Week 4 and Week 12, Total Score, Median
NCT01101841 (17) [back to overview]	Change From Baseline in Total Number of Awakenings Due to Hot Flashes, Median
NCT01101841 (17) [back to overview]	Change in Frequency of Moderate to Severe Hot Flashes Frequency From Baseline (BMI <32 kg/m2, Week 4 and Week 12), Median
NCT01130103 (5) [back to overview]	Quality of Life Enjoyment and Satisfaction Scale Total Score at Week 0,5,10
NCT01130103 (5) [back to overview]	Treatment Response at Weeks 5 and 10
NCT01130103 (5) [back to overview]	Clinician Administered PTSD Scale (CAPS)
NCT01130103 (5) [back to overview]	Number of Participants Who Met Remission Criterion
NCT01130103 (5) [back to overview]	Hamilton Depression Scale 0 = no Depression Symptoms 40 = Extreme Depression Symptoms
NCT01254305 (3) [back to overview]	Change in Cognitive and Physical Functioning Questionnaire (CPFQ), Last Observation Carried Forward
NCT01254305 (3) [back to overview]	Change in Patient Global Impressions of Severity (PGI-S) for Fatigue Score
NCT01254305 (3) [back to overview]	Change in Clinical Global Impression of Severity (CGI-S) for Fatigue Score
NCT01339247 (3) [back to overview]	Cmin_ss
NCT01339247 (3) [back to overview]	Cmax_ss
NCT01339247 (3) [back to overview]	AUC_ss
NCT01354314 (32) [back to overview]	Change in CSF 3-nitrosylated Protein Levels Between Baseline and Week 24 - Per Protocol
NCT01354314 (32) [back to overview]	Neurocognitive Performance: Timed Gait - Per Protocol
NCT01354314 (32) [back to overview]	Neurocognitive Performance: CalCAP, Sequential - Per Protocol
NCT01354314 (32) [back to overview]	Change in CSF Ceramide Between Baseline and Week 24 (C18:0 Levels) - Intent to Treat
NCT01354314 (32) [back to overview]	Neurocognitive Performance: Trail Making B - Per Protocol
NCT01354314 (32) [back to overview]	Neurocognitive Performance: Trail Making B - Intent to Treat
NCT01354314 (32) [back to overview]	Neurocognitive Performance: Trail Making A - Per Protocol
NCT01354314 (32) [back to overview]	Neurocognitive Performance: Trail Making A - Intent to Treat
NCT01354314 (32) [back to overview]	Neurocognitive Performance: Timed Gait - Intent to Treat
NCT01354314 (32) [back to overview]	Neurocognitive Performance: Symbol-Digit Test - Per Protocol
NCT01354314 (32) [back to overview]	Neurocognitive Performance: Symbol-Digit Test - Intent to Treat
NCT01354314 (32) [back to overview]	Neurocognitive Performance: NPZ-8 - Per Protocol
NCT01354314 (32) [back to overview]	Neurocognitive Performance: NPZ-8 - Intent to Treat
NCT01354314 (32) [back to overview]	Neurocognitive Performance: Grooved Pegboard, Non-Dominant - Per Protocol
NCT01354314 (32) [back to overview]	Neurocognitive Performance: Grooved Pegboard, Non-Dominant - Intent to Treat
NCT01354314 (32) [back to overview]	Neurocognitive Performance: Grooved Pegboard, Dominant - Per Protocol
NCT01354314 (32) [back to overview]	Neurocognitive Performance: Grooved Pegboard, Dominant - Intent to Treat
NCT01354314 (32) [back to overview]	Neurocognitive Performance: CalCAP, Sequential - Intent to Treat
NCT01354314 (32) [back to overview]	Neurocognitive Performance: CalCAP, Choice - Per Protocol
NCT01354314 (32) [back to overview]	Neurocognitive Performance: CalCAP, Choice - Intent to Treat
NCT01354314 (32) [back to overview]	Change in CSF sCD14 Between Baseline and Week 24 - Per Protocol
NCT01354314 (32) [back to overview]	Change in CSF sCD14 Between Baseline and Week 24 - Intent to Treat
NCT01354314 (32) [back to overview]	Change in CSF Neurofilament Protein Light Chain (NFL) Between Baseline and Week 24 - Per Protocol
NCT01354314 (32) [back to overview]	Change in CSF Neurofilament Protein Light Chain (NFL) Between Baseline and Week 24 - Intent to Treat
NCT01354314 (32) [back to overview]	Change in CSF Neurofilament Protein Heavy Chain (pNFL) Between Baseline and Week 24 - Intent to Treat
NCT01354314 (32) [back to overview]	Change in CSF Neurofilament Protein Heavy Chain (pNFH) Between Baseline and Week 24 - Per Protocol
NCT01354314 (32) [back to overview]	Change in CSF Ceramide Between Baseline and Week 24 (C18:0 Levels) - Per Protocol
NCT01354314 (32) [back to overview]	Change in CSF CD163 Between Baseline and Week 24 - Per Protocol
NCT01354314 (32) [back to overview]	Change in CSF CD163 Between Baseline and Week 24 - Intent to Treat
NCT01354314 (32) [back to overview]	Change in CSF 3-nitrosylated Protein Levels Between Baseline and Week 24 - Intent to Treat
NCT01354314 (32) [back to overview]	Change in CES-D Score - Per Protocol
NCT01354314 (32) [back to overview]	Change in CES-D Score - Intent to Treat
NCT01360866 (5) [back to overview]	Mean Change From Baseline in Clinical Global Impression - Severity (CGI-S) of Illness Score
NCT01360866 (5) [back to overview]	Change From Baseline in the Inventory of Depressive Symptomatology - Self Report (IDS-SR) Total Score
NCT01360866 (5) [back to overview]	Adverse Events (AEs) - All Participants
NCT01360866 (5) [back to overview]	Summary of Mean Change From Baseline in Sheehan Disability Scale (SDS) Mean Score
NCT01360866 (5) [back to overview]	Change From Baseline in Mean Clinical Global Impression - Improvement (CGI-I) Score
NCT01361308 (18) [back to overview]	Change in Severity of Moderate to Severe Hot Flashes From Baseline (BMI ≥32 kg/m2, Week 4 and Week 12), Median
NCT01361308 (18) [back to overview]	Change From Baseline in Total Number of Awakenings Due to Hot Flashes, Median
NCT01361308 (18) [back to overview]	Change From Baseline in Greene Climacteric Scale (GCS) at Week 4 and Week 12, Total Score, Median
NCT01361308 (18) [back to overview]	BMI Change From Baseline (kg/m2), Median
NCT01361308 (18) [back to overview]	Percentage of Responders
NCT01361308 (18) [back to overview]	Percentage of Patient Global Improvement (PGI) Scale Responders (%)
NCT01361308 (18) [back to overview]	Percent Responders Improvement in VMS From Baseline Using the Clinical Global Impression (CGI) Scale.
NCT01361308 (18) [back to overview]	Assessment of Mood
NCT01361308 (18) [back to overview]	Percent Daytime and Nighttime Responders, Numerical Rating Scale (NRS)
NCT01361308 (18) [back to overview]	Mean Change in Frequency of Moderate to Severe VMS From Baseline at Week 4 and Week 12.
NCT01361308 (18) [back to overview]	Mean Change From Baseline in Hot Flash Severity at Week 4 and Week 12
NCT01361308 (18) [back to overview]	Effect of Paroxetine Mesylate Capsules on Percent Improvement of Hot Flash Interference From Baseline at Week 4 and Week 12, Hot Flash Related Daily Interference Scale (HFRDIS)
NCT01361308 (18) [back to overview]	Effect of Brisdelle (Paroxetine Mesylate) Capsules on Anxiety and Depression
NCT01361308 (18) [back to overview]	Clinical Meaningfulness Anchored to Patient Global Improvement (PGI-I) (%)
NCT01361308 (18) [back to overview]	Change in Frequency of Moderate to Severe Hot Flashes Frequency From Baseline (BMI <32 kg/m2, Week 4 and Week 12), Median
NCT01361308 (18) [back to overview]	Change in Severity of Moderate to Severe Hot Flashes From Baseline (BMI <32 kg/m2, At Week 4 and Week 12), Median
NCT01361308 (18) [back to overview]	Change in Frequency of Moderate to Severe Hot Flashes Frequency From Baseline (BMI ≥32 kg/m2, Week 4 and Week 12), Median
NCT01361308 (18) [back to overview]	Change From Baseline in Arizona Sexual Experience Scale (ASEX, Week 4 and Week 12) Total Score
NCT01608295 (4) [back to overview]	Hamilton Depression Rating Scale (HDRS)
NCT01608295 (4) [back to overview]	Changes in Proinflammatory Gene Expression From Baseline to Final Visit (up to 12 Weeks)
NCT01608295 (4) [back to overview]	UKU Side-effect Profile
NCT01608295 (4) [back to overview]	Neurocognitive Measure: The Rey-Osterrieth Complex Figure Test
NCT01681849 (2) [back to overview]	Change in Brain Blood Flow Assessed by Statistical Parametric Mapping (SPM)
NCT01681849 (2) [back to overview]	Mean Clinical Administered PTSD Scale for DSM-IV (CAPS) Score
NCT01748955 (2) [back to overview]	Percent Change in Contrast of Parameter Estimates (COPE)
NCT01748955 (2) [back to overview]	Change in Suicidal Ideation (SSI Score)
NCT01829919 (13) [back to overview]	Median t1/2 Single Dose Pharmacokinetics of Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg
NCT01829919 (13) [back to overview]	Mean t1/2 Single Dose Pharmacokinetics of Brisdelle™ (Paroxetine Mesylate) Capsules 7.5 mg
NCT01829919 (13) [back to overview]	Accumulation Index Multiple Dose Pharmacokinetics of Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg at Day 19
NCT01829919 (13) [back to overview]	Cavg,ss (ng/mL) Multiple Dose Pharmacokinetics of Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg
NCT01829919 (13) [back to overview]	Tmax (Hour) Multiple Dose Pharmacokinetics of Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg
NCT01829919 (13) [back to overview]	Cmax (ng/mL) Multiple Dose Pharmacokinetics of Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg
NCT01829919 (13) [back to overview]	AUC (Hour*ng/mL) Single Dose Pharmacokinetics of Brisdelle™ (Paroxetine Mesylate) Capsules 7.5 mg
NCT01829919 (13) [back to overview]	Ct (ng/mL) Multiple Dose Pharmacokinetics of Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg
NCT01829919 (13) [back to overview]	AUC (Hour*ng/mL) Multiple Dose Pharmacokinetics of Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg
NCT01829919 (13) [back to overview]	Cmin (ng/mL) Multiple Dose Pharmacokinetics of Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg
NCT01829919 (13) [back to overview]	Cmax (ng/mL) Single Dose Pharmacokinetics of Brisdelle™ (Paroxetine Mesylate) Capsules 7.5 mg
NCT01829919 (13) [back to overview]	Fluctuation Index (%) Multiple Dose Pharmacokinetics of Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg
NCT01829919 (13) [back to overview]	Kel (Hour^-1) Single Dose Pharmacokinetics of Brisdelle™ (Paroxetine Mesylate) Capsules 7.5 mg
NCT01916824 (1) [back to overview]	Money Earned
NCT02655354 (13) [back to overview]	Brief Pain Inventory
NCT02655354 (13) [back to overview]	Change From Baseline Alcohol Use Disorders Identification Over the Course of the Year After Injury
NCT02655354 (13) [back to overview]	Change From Baseline Patient Health Questionnaire 9 Item Depression Scale Over the Course of the Year After Injury
NCT02655354 (13) [back to overview]	Change From Baseline PTSD Checklist- Civilian (PCL-C) Over the Course of the Year After Injury
NCT02655354 (13) [back to overview]	Change From Baseline Short Form (SF)-12/36 Physical Function Over the Course of the Year After Injury
NCT02655354 (13) [back to overview]	Cognitive Impairment Scale
NCT02655354 (13) [back to overview]	Number of Participants Endorsing a Single Item That Assesses Marijuana Use
NCT02655354 (13) [back to overview]	Number of Participants Endorsing a Single Item That Assesses Stimulant Use
NCT02655354 (13) [back to overview]	Number of Participants With Suicidal Ideation
NCT02655354 (13) [back to overview]	SF-36 Quality of Life
NCT02655354 (13) [back to overview]	TSOS Patient Satisfaction: Mental Health Care
NCT02655354 (13) [back to overview]	TSOS Patient Satisfaction: Overall Health Care
NCT02655354 (13) [back to overview]	Number of Participants Endorsing a Single Item That Assesses Opioid Use
NCT02932904 (9) [back to overview]	Percentage of Participants Meeting Criteria for Sexual Dysfunction at Weeks 1, 2, 3, 4 and 5
NCT02932904 (9) [back to overview]	Change From Baseline in CSFQ-14 3 Phases of the Sexual Response Cycle (Desire, Arousal, and Orgasm/Completion) at Weeks 1, 2, 3, 4 and 5
NCT02932904 (9) [back to overview]	Change From Baseline in CSFQ-14 Total Score Difference for Vortioxetine Versus Placebo at Weeks 1, 2, 3, 4 and 5
NCT02932904 (9) [back to overview]	Change From Baseline in the CSFQ-14 Total Score Difference for Vortioxetine Versus Paroxetine at Week 5 in Modified Full Analysis Set 2 (mFAS2)
NCT02932904 (9) [back to overview]	Change From Baseline in the CSFQ-14 Total Score Difference for Vortioxetine Versus Paroxetine at Week 5 in Modified Full Analysis Set 1 (mFAS1)
NCT02932904 (9) [back to overview]	Change From Baseline in CSFQ-14 Total Score Difference for Paroxetine Versus Placebo at Weeks 1, 2, 3, 4 and 5
NCT02932904 (9) [back to overview]	Change From Baseline in CSFQ-14 Subscales 5 Dimensions at Weeks 1, 2, 3, 4 and 5
NCT02932904 (9) [back to overview]	Change From Baseline in the CSFQ-14 Total Score Difference for Vortioxetine Versus Paroxetine at Weeks 1, 2, 3 and 4
NCT02932904 (9) [back to overview]	Change From Baseline in the Changes in Sexual Functioning Questionnaire (CSFQ-14) Total Score Difference for Vortioxetine Versus Paroxetine at Week 5 in Full Analysis Set (FAS)
NCT03329573 (30) [back to overview]	Number of Participants With Hematology Laboratory Values Relative to PCI Criteria on Day 16 Under Fasting Condition
NCT03329573 (30) [back to overview]	Number of Participants With Non-SAE and SAEs Under Fasting Condition
NCT03329573 (30) [back to overview]	Number of Participants With Non-serious Adverse Events and Serious Adverse Events (SAEs) Under Fed Condition
NCT03329573 (30) [back to overview]	Number of Participants With Urinalysis Results by Dipstick Method Under Fasting Condition
NCT03329573 (30) [back to overview]	Number of Participants With Urinalysis Results by Dipstick Method Under Fed Condition
NCT03329573 (30) [back to overview]	Pulse Rate (PR) at Indicated Time-points Under Fasting Condition
NCT03329573 (30) [back to overview]	Pulse Rate (PR) at Indicated Time-points Under Fed Condition
NCT03329573 (30) [back to overview]	t1/2 of Paroxetine Following Single Oral Dose in Healthy Chinese Participants Under Fasting Condition
NCT03329573 (30) [back to overview]	Respiratory Rate (RR) at Indicated Time-point Under Fed Condition
NCT03329573 (30) [back to overview]	Maximum Observed Concentration (Cmax) of Paroxetine Following Single Oral Dose in Healthy Chinese Participants Under Fed Condition
NCT03329573 (30) [back to overview]	Lambda z of Paroxetine Following Single Oral Dose in Healthy Chinese Participants Under Fasting Condition
NCT03329573 (30) [back to overview]	Cmax of Paroxetine Following Single Oral Dose in Healthy Chinese Participants Under Fasting Condition
NCT03329573 (30) [back to overview]	AUC(0-t) of Paroxetine Following Single Oral Dose in Healthy Chinese Participants Under Fasting Condition
NCT03329573 (30) [back to overview]	AUC(0-infinity) of Paroxetine Following Single Oral Dose in Healthy Chinese Participants Under Fasting Condition
NCT03329573 (30) [back to overview]	Number of Participants With Hematology Laboratory Values Relative to PCI Criteria on Day 16 Under Fed Condition
NCT03329573 (30) [back to overview]	Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC[0-infinity]) of Paroxetine Following Single Oral Dose in Healthy Chinese Participants Under Fed Condition
NCT03329573 (30) [back to overview]	Number of Participants With Chemistry Laboratory Values Relative to Potential Clinical Importance (PCI) Criteria on Day 16 Under Fed Condition
NCT03329573 (30) [back to overview]	Area Under the Concentration-time Curve From Administration Extrapolated to the Last Time of Quantifiable Concentration (AUC[0-t]) of Paroxetine Following Single Oral Dose in Healthy Chinese Participants Under Fed Condition
NCT03329573 (30) [back to overview]	Number of Participants With Clinically Significant Abnormal Findings for Electrocardiogram (ECG) Parameters Under Fed Condition
NCT03329573 (30) [back to overview]	DBP and SBP at Indicated Time-points Under Fasting Condition
NCT03329573 (30) [back to overview]	Tmax of Paroxetine Following Single Oral Dose in Healthy Chinese Participants Under Fasting Condition
NCT03329573 (30) [back to overview]	Time to Reach Maximum Observed Concentration (Tmax) of Paroxetine Following Single Oral Dose in Healthy Chinese Participants Under Fed Condition
NCT03329573 (30) [back to overview]	Terminal Elimination Rate Constant (Lambda z) of Paroxetine Following Single Oral Dose in Healthy Chinese Participants Under Fed Condition
NCT03329573 (30) [back to overview]	Terminal Elimination Half-life (t1/2) of Paroxetine Following Single Oral Dose in Healthy Chinese Participants Under Fed Condition
NCT03329573 (30) [back to overview]	Temperature at Indicated Time-point Under Fed Condition
NCT03329573 (30) [back to overview]	Temperature at Indicated Time-point Under Fasting Condition
NCT03329573 (30) [back to overview]	Number of Participants With Chemistry Laboratory Values Relative to PCI Criteria on Day 16 Under Fasting Condition
NCT03329573 (30) [back to overview]	Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) at Indicated Time-points Under Fed Condition
NCT03329573 (30) [back to overview]	Number of Participants With Clinically Significant Abnormal Findings for ECG Parameters Under Fasting Condition
NCT03329573 (30) [back to overview]	RR at Indicated Time-point Under Fasting Condition
NCT04311463 (9) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Paroxetine
NCT04311463 (9) [back to overview]	Terminal Elimination Rate Constant (Kel) of Paroxetine
NCT04311463 (9) [back to overview]	Number of Participants With Abnormal Vital Signs
NCT04311463 (9) [back to overview]	Percentage of AUC (0 to Infinity) Obtained by Extrapolation (%AUCex) of Paroxetine
NCT04311463 (9) [back to overview]	Elimination Half-life (t1/2) of Paroxetine
NCT04311463 (9) [back to overview]	Area Under the Concentration-time Curve (AUC) From Time Zero to the Last Measurable Concentration (AUC[0-t]) of Paroxetine
NCT04311463 (9) [back to overview]	Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT04311463 (9) [back to overview]	Time of the Maximum Measured Plasma Concentration (Tmax) of Paroxetine
NCT04311463 (9) [back to overview]	Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of Paroxetine

Percent Responders

Percent of patients who had a 50% decrease in total HDRS at 8 weeks (NCT00062738)
Timeframe: 8 weeks

Intervention	percent of patients who were responders (Number)
Nortriptyline	53
Paroxetine	11
Placebo	24

Intervention	units on a scale (Mean)
Paroxetine Continuation	1.25
Paroxetine With CBT Augmentation	-0.02

Intervention	units on a scale (Mean)
Paroxetine Continuation	7.77
Paroxetine With CBT Augmentation	7.84

Intervention	units on a scale (Mean)
Paroxetine Continuation	0.25
Paroxetine With CBT Augmentation	-0.35

Intervention	units on a scale (Mean)
Paroxetine Continuation	2.75
Paroxetine With CBT Augmentation	5.83

Intervention	units on a scale (Mean)
Paroxetine Continuation	3.43
Paroxetine With CBT Augmentation	5.67

Intervention	Participants (Count of Participants)
	Responder Status72231809		Responder Status72231810	Remitter Status72231809	Remitter Status72231810
	Responder	Non-Responder
Paroxetine Continuation	17
Paroxetine With CBT Augmentation	28
Paroxetine Continuation	12
Paroxetine With CBT Augmentation	4
Paroxetine Continuation	3
Paroxetine With CBT Augmentation	11
Paroxetine Continuation	26
Paroxetine With CBT Augmentation	21

Intervention	units on a scale (Mean)
Paroxetine Continuation	1.13
Paroxetine With CBT Augmentation	3.91

Intervention	Change in PDQ-39 Emotional score (Mean)
Paroxetine	-21.4
Venlafaxine Extended Release	-20.7
Placebo	-10.9

Intervention	units on a scale (Mean)
	Baseline (Week 10)	Endpoint (Week 18)
Placebo Augmentation of Continued Paroxetine	12.36	11.64
Quetiapine, 25-400mg/Day Augmentation of Continued Paroxetine	11.45	10.27

Intervention	units on a scale (Mean)
	Baseline	Week 18	Change
Placebo Augmentation of Continued Paroxetine	15.82	15.55	-0.3
Quetiapine, 25-400mg/Day Augmentation of Continued Paroxetine	16.27	13.64	-2.6

Intervention	units on a scale (Least Squares Mean)
Nortriptyline	10.84
Paroxetine	12.45
Placebo	15.81

Intervention	pg / ml (Mean)
After 4 Weeks of Placebo	40.98
After 4 Weeks of Paroxetine	34.94

Intervention	pg / ml (Mean)
After 4 Weeks of Placebo	72.31
After 4 Weeks of Paroxetine	63.37

Intervention	mmHg (Mean)
After 4 Weeks of Placebo	16.85
After 4 Weeks of Paroxetine	11.71

Intervention	beats/minute (Mean)
After 4 Weeks of Placebo	20.39
After 4 Weeks of Paroxetine	20.02

Intervention	units on a scale (Mean)
	Baseline Q-LES-Q	Endpoint Q-LES-Q
Arm 2 OL Paroxetine + DB Placebo	37.85	38.22
Arm 3: OL Paroxetine + DB Quetiapine	40.44	41.06

Intervention	units on a scale (Mean)
	Baseline PSQI	Endpoint PSQI
Arm 2 OL Paroxetine + DB Placebo	11.60	8.70
Arm 3: OL Paroxetine + DB Quetiapine	12.69	13.19

Intervention	units on a scale (Mean)
	Baseline Total PANSS	Endpoint Total PANSS
Arm 2 OL Paroxetine + DB Placebo	46.63	43.92
Arm 3: OL Paroxetine + DB Quetiapine	47.76	42.24

Intervention	units on a scale (Mean)
	CAPS Total Baseline	CAPS Total Endpoint
Arm 2 OL Paroxetine + DB Placebo	72.15	67.90
Arm 3: OL Paroxetine + DB Quetiapine	68.78	51.52

Intervention	units on a scale (Mean)
	Baseline SDS-WS	Endpoint SDS-WS	Baseline SDS-SL	Endpoint SDS-SL	Baseline SDS-FL	Endpoint SDS-FL
Arm 2 OL Paroxetine + DB Placebo	5.07	4.58	6.67	5.92	5.85	5.39
Arm 3: OL Paroxetine + DB Quetiapine	4.44	4.66	5.64	4.95	4.72	4.61

Intervention	units on a scale (Mean)
	Baseline CGI-I	Endpoint CGI-I
Arm 2 OL Paroxetine + DB Placebo	3.56	2.61
Arm 3: OL Paroxetine + DB Quetiapine	3.36	2.22

paroxetine

Description

Cross-References

Synonyms (131)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (5)

Drug Classes (4)

Protein Targets (85)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (481)

Molecular Functions (149)

Ceullar Components (110)

Bioassays (316)

Research

Studies (3,996)

Market Indicators

Research Demand Index: 123.25

Study Types

Clinical Trials (215)

Trial Overview

Trial Outcomes

Percent Responders

Hamilton Depression Scale

Liebowitz Self-Report Disability Scale (LSRDS)

Liebowitz Social Anxiety Scale (LSAS)

Quality of Life Inventory (QOLI)

Social Phobia Scale (SPS)

Social Interaction Anxiety Scale (SIAS)

Clinical Global Impression Improvement Scale (CGI-I)

Brief Fear of Negative Evaluation Scale (BFNE)

Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS)

Change in Parkinson's Disease Questionnaire (PDQ) - 39 - Overall

Change in Pittsburgh Sleep Quality Index (PSQI)

Change in Short Form 36 Health Survey - Mental Component Summary

Change in Short Form 36 Health Survey - Mental Health

Change in Short Form 36 Health Survey - Role-Emotional

Change in Snaith Clinical Anxiety Scale (CAS)

Change in Unified Parkinson's Disease Rating Scale (UPDRS)

Change in Unified Parkinson's Disease Rating Scale (UPDRS) - Bulbar

Change in Unified Parkinson's Disease Rating Scale (UPDRS) - Motor

Change in Unified Parkinson's Disease Rating Scale (UPDRS) - Tremor

Change in Montgomery-Asberg Depression Rating Scale (MADRS)

Change in Beck Depression Inventory II (BDI-II)

Change in Brief Psychiatric Rating Scale (BPRS)

Change in Geriatric Depression Rating Scale (GDS)

Change in Hamilton Depression Rating Scale (HAM-D) Scores

Change in Short Form 36 Health Survey - Vitality

Change in Parkinson's Disease Questionnaire (PDQ) - 39 - Emotional Well-Being

Depressive Symptoms, Montgomery-Asberg Depression Rating Scale (MADRS)

The Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q).

Hamilton Anxiety Scale (HAM-A) Score at Study Endpoint.

Response, Clinical Global Impression of Improvement (CGI-I)

Remission (HAM-A ≤ 7)

Change in Global Trauma-related Symptom Severity and Functioning From the Clinical Global Impression of Change From Baseline to Week 12

Change in Combat Trauma-related Nightmares From the Clinician Administered PTSD Scale (CAPS) Recurrent Distressing Dreams Item at Week 12

Change in Sleep From the Pittsburgh Sleep Quality Index From Baseline to Week 12

Plasma Epinephrine Concentration Response to Stress

Plasma Norepinephrine Concentration Response to Stress

Systolic Blood Pressure Response to Stress

Heart Rate Response to Stress

Diastolic Blood Pressure Response to Stress

Drinking to Cope

Alcohol Use, Quantity and Frequency

Social Anxiety Severity

Change in Mean Q-LES-Q Score From Baseline to Endpoint.

Change in Mean Scores of Pittsburgh Sleep Quality Index (PSQI) From Baseline to Endpoint.

Change in Mean PANSS Total and Subscores From Baseline to Endpoint

Change in Clinician-Administered PTSD Scale for DSM-IV Total Score.

Intervention	units on a scale (Mean)
	Baseline ASEX	Endpoint ASEX
Arm 2 OL Paroxetine + DB Placebo	22.00	21.93
Arm 3: OL Paroxetine + DB Quetiapine	17.88	16.94

Intervention	units on a scale (Mean)
	Baseline HAMD	Endpoint HAMD
Arm 2 OL Paroxetine + DB Placebo	14.60	12.29
Arm 3: OL Paroxetine + DB Quetiapine	13.84	9.29

Intervention	units on a scale (Mean)
	Baseline DTS	Endpoint DTS
Arm 2 OL Paroxetine + DB Placebo	82.19	84.06
Arm 3: OL Paroxetine + DB Quetiapine	77.25	61.50

Intervention	units on a scale (Mean)
	Beginning of Treatment	End of Treatment
Desipramine and Naltrexone	62.500	26.751
Desipramine and Placebo	77.833	41.392
Paroxetine and Naltrexone	73.54	40.024
Paroxetine and Placebo	69.810	36.591

Intervention	side effects (Mean)
	Gastrointestinal symptoms	Emotional Symptoms	Neurological Symptoms	Cold Symptoms	Skin Symptoms	Sexual Symptoms	Cardiac Symptoms
Desipramine and Naltrexone	3.052	3.727	4.201	1.891	.591	.737	.389
Desipramine and Placebo	3.653	5.248	4.566	2.253	1.057	.736	.356
Paroxetine and Naltrexone	3.651	4.874	6.212	2.182	1.002	.877	.416
Paroxetine and Placebo	2.688	3.963	5.078	2.393	.859	.932	.474

Intervention	units on a scale (Mean)
	Week 1	Week 13
Desipramine and Naltrexone	18.500	4.296
Desipramine and Placebo	21.458	7.489
Paroxetine and Naltrexone	21.273	10.013
Paroxetine and Placebo	20.700	9.690

Intervention	Score on scale (Mean)
	Week 1	Week 2	Week 3	Week 4	Week 5	Week 6	Week 8
GSK372475	-2.8	-5.7	-7.3	-9.5	-11.9	-14.5	-17.3
Paroxetine	-2.8	-6.6	-10.1	-11.4	-14.9	-17.3	-19.1
Placebo	-2.9	-6.3	-9.7	-11.0	-12.0	-14.3	-15.1

Intervention	Score on scale (Mean)
	Week 1	Week 4	Week 10
GSK372475	5.7	15.4	31.8
Paroxetine	4.9	18.4	34.3
Placebo	3.8	16.1	29.8

Intervention	Participants (Count of Participants)
	SB, Score 00, Week 1	SB, Score 00, Week 2	SB, Score 00, Week 3	SB, Score 00, Week 4	SB, Score 00, Week 5	SB, Score 00, Week 6	SB, Score 00, Week 8	SB, Score 00, Week 10	SI, Score 00, Week 1	SI, Score 01, Week 1	SI, Score 02, Week 1	SI, Score 03, Week 1	SI, Score 04, Week 1	SI, Score 00, Week 2	SI, Score 01, Week 2	SI, Score 02, Week 2	SI, Score 03, Week 2	SI, Score 04, Week 2	SI, Score 00, Week 3	SI, Score 01, Week 3	SI, Score 02, Week 3	SI, Score 03, Week 3	SI, Score 00, Week 4	SI, Score 01, Week 4	SI, Score 02, Week 4	SI, Score 03, Week 4	SI, Score 00, Week 5	SI, Score 01, Week 5	SI, Score 02, Week 5	SI, Score 03, Week 5	SI, Score 00, Week 6	SI, Score 01, Week 6	SI, Score 02, Week 6	SI, Score 03, Week 6	SI, Score 00, Week 8	SI, Score 01, Week 8	SI, Score 03, Week 8	SI, Score 05, Week 8	SI, Score 00, Week 10	SI, Score 01, Week 10	SI, Score 02, Week 10
GSK372475	168	154	146	140	125	117	105	101	148	17	1	1	1	138	11	4	1	1	135	8	2	1	126	10	4	0	119	5	1	0	112	5	1	0	103	2	0	0	100	1	0
Paroxetine	166	154	151	148	141	136	133	130	156	8	1	1	0	148	3	2	1	0	145	4	1	1	143	2	2	1	137	2	1	1	134	1	0	2	130	3	0	1	128	1	1
Placebo	150	144	139	139	129	132	116	120	130	14	5	1	0	132	7	2	3	0	137	1	1	0	137	1	0	2	123	3	1	3	128	3	0	1	112	3	1	0	118	2	0

Intervention	Percentage of participants (Number)
	Responders, Week 1	Responders, Week 2	Responders, Week 3	Responders, Week 4	Responders, Week 5	Responders, Week 6	Responders, Week 8	Responders, Week 10	Remitters, Week 1	Remitters, Week 2	Remitters, Week 3	Remitters, Week 4	Remitters, Week 5	Remitters, Week 6	Remitters, Week 8	Remitters, Week 10
GSK372475	2	10	14	14	30	33	48	55	2	5	8	9	15	20	29	39
Paroxetine	4	14	25	32	42	54	62	72	2	9	15	16	26	40	45	52
Placebo	3	8	16	25	29	36	41	51	2	3	7	17	16	23	28	35